<SEC-DOCUMENT>0001213900-23-014358.txt : 20230224
<SEC-HEADER>0001213900-23-014358.hdr.sgml : 20230224
<ACCEPTANCE-DATETIME>20230224163026
ACCESSION NUMBER:		0001213900-23-014358
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		25
CONFORMED PERIOD OF REPORT:	20230224
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230224
DATE AS OF CHANGE:		20230224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40700
		FILM NUMBER:		23667884

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea174178-8k_abvcbio.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ABVC="http://abvcpharma.com/20230224">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_ABVC_abvcpharma.com_20230224 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20230224_20230224 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001173313 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityCentralIndexKey">0001173313</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abvc-20230224.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-02-24to2023-02-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-24</xbrli:startDate>
        <xbrli:endDate>2023-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, DC 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM <span id="xdx_905_edei--DocumentType_c20230224__20230224_zyOW80k9TCxl"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:DocumentType">8-K</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_90C_edei--DocumentPeriodEndDate_c20230224__20230224_zRrvHE7hZzh3"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February 24, 2023</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90D_edei--EntityRegistrantName_c20230224__20230224_zzLJt19vt0e9"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityRegistrantName">ABVC BIOPHARMA, INC.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20230224__20230224_zVEmKM0ZbXq8"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--EntityFileNumber_c20230224__20230224_z9m12hyIUERi"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityFileNumber">333-91436</ix:nonNumeric></span></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20230224__20230224_zzCr0bMQhyL3"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityTaxIdentificationNumber">26-0014658</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction<br />
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer<br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_907_edei--EntityAddressAddressLine1_c20230224__20230224_zv0T0TMfaASb"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityAddressAddressLine1">44370 Old Warm Springs Blvd.</ix:nonNumeric></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_908_edei--EntityAddressCityOrTown_c20230224__20230224_zbOqhK4svNGj"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityAddressCityOrTown">Fremont</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20230224__20230224_zdG5DMQ87Bbj"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></p></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20230224__20230224_z6ja1ujLFfci"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:EntityAddressPostalZipCode">94538</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number including area
code: (<span id="xdx_90A_edei--CityAreaCode_c20230224__20230224_z2psq0JudI8j"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:CityAreaCode">510</ix:nonNumeric></span>) <span id="xdx_909_edei--LocalPhoneNumber_c20230224__20230224_zKS4kvCib3Rd"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:LocalPhoneNumber">668-0881</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--WrittenCommunications_c20230224__20230224_z2OmDT7TxE73"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SolicitingMaterial_c20230224__20230224_zqHNG5GlLZp"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementTenderOffer_c20230224__20230224_zbcTUkTHSc7i"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20230224__20230224_zA9RVOKnfufi"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-size: 10pt">Title of Each Class</span></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-size: 10pt">Trading Symbol</span></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20230224__20230224_z2HPEKqL06ch"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20230224__20230224_zEnBfF6V2wRl"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" name="dei:TradingSymbol">ABVC</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_90E_edei--SecurityExchangeName_c20230224__20230224_zw8AY4tLh6Hd"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20230224__20230224_zlfi1wEsAGEe"><ix:nonNumeric contextRef="From2023-02-24to2023-02-24" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, ABVC BioPharma, Inc. (the
&#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with Lind Global
Fund II, LP (&#8220;Lind&#8221;), pursuant to which the Company would issue Lind a secured, convertible note in the principal amount of
$3,704,167 (the &#8220;Offering&#8221;), for a purchase price of $3,175,000 (the &#8220;Note&#8221;), that is convertible into shares
of the Company&#8217;s common stock at an initial conversion price of $1.05 per share, subject to adjustment (the &#8220;Note Shares&#8221;).
Lind will also receive a common stock purchase warrant (the &#8220;Warrant&#8221;) to purchase up to 5,291,667 shares of the Company&#8217;s
common stock at an initial exercise price of $1.05 per share, subject to adjustment (each, a &#8220;Warrant Share,&#8221; together with
the Note, Note Shares and Warrants, the &#8220;Securities&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Note does not carry any
interest. Beginning with the date that is six months from the issuance date of the Note and on each one (1) month anniversary thereafter,
the Company shall pay Lind an amount equal to $308,650.58, until the outstanding principal amount of the Note has been paid in full prior
to or on the Maturity Date or, if earlier, upon acceleration, conversion or redemption of the Note in accordance with the terms thereof
(the &#8220;Monthly Payments&#8221;). At the Company&#8217;s discretion, the Monthly Payments shall be made in (i) cash, (ii) shares of
the Company&#8217;s common stock, or (iii) a combination of cash and Shares; if made in shares, the number of shares shall be determined
by dividing (x) the principal amount being paid in shares by (y) 90% of the average of the 5 lowest daily VWAPs during the 20 trading
days prior to the applicable payment date. The Notes sets forth certain conditions that must be satisfied before the Company may make
any Monthly Payments in shares of common stock. If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash
premium of 5% of such Monthly Payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Upon the occurrence of any Event
of Default (as defined in the Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the
Note, in addition to any other remedies under the Note or the other Transaction Documents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Warrant may be exercised
via cashless exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Pursuant to the terms of the
Securities Purchase Agreement, if at any time prior to a date that is 18 months following the closing of the Offering, the Company proposes
to offer or sell any additional securities in a subsequent financing, the Company shall first offer Lind the opportunity to purchase up
to 10% of such new securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In connection with the Offering,
the Company and its subsidiaries: (i) Biokey, Inc., a California corporation (&#8220;BioKey&#8221;), (ii) Biolite Holding, Inc., a Nevada
corporation (&#8220;BioLite&#8221;), (iii) Biolite BVI, Inc., a British Virgin Islands corporation (&#8220;BioLite BVI&#8221;) and (iv)
American BriVision Corporation, a Delaware corporation (&#8220;American BriVision&#8221; and, collectively with the Company, BioKey, BioLite,
and BioLite BVI, the &#8220;Guarantors&#8221;), jointly and severally guaranteed all of the obligations of the Company in connection with
the Offering (the &#8220;Guaranty&#8221;) with certain collateral, as set forth in the related Transaction Documents (as hereinafter defined).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The sale of the Note and the terms of the Offering,
including the Guaranty are set forth in the Securities Purchase Agreement, the Note, the Warrant, a Security Agreement, Guarantor Security,
Guaranty, a Trademark Security Agreement with Rgene Corporation, a Trademark Security Agreement with BioFirst, a Patent Security Agreement,
a Copyright Security Agreement and a Stock Pledge Agreement (collectively, the &#8220;Transaction Documents&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Allele Capital Partners, LLC (&#8220;Allele&#8221;)
together with its executing broker dealer, Wilmington Capital Securities, LLC (together with its affiliates, &#8220;Wilmington&#8221;),
served as the exclusive placement agent (the &#8220;Placement Agent&#8221;) of the Offering. As a result of the Offering, the Company
will pay the Placement Agent (i) a cash fee of 6% of the gross proceeds from the sale of the Securities, and (ii) common stock purchase
warrants to purchase 6% of the number of shares of common stock issuable under the Note. We also agreed to pay certain expenses of the
placement agent in connection with the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Securities Purchase Agreement,
the Company agreed to register all of the Securities and the shares of common stock underlying the warrant issued to the placement agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Securities Purchase
Agreement also contains customary representation and warranties of the Company and the Investors, indemnification obligations of the Company,
termination provisions, and other obligations and rights of the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Transaction Documents
is qualified by reference to the full text of the forms of the Transaction Documents, which are filed as Exhibits hereto and incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither this Current Report on Form&#160;8-K,&#160;nor
any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure
does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company&#8217;s securities
in any state in which such offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under
the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable
exemption from the registration requirements under the Securities Act and applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>Item
3.02 Unregistered Sales of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained above under Item 1.01,
to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of Lind in the Securities
Purchase Agreement, the offering and sale of the Securities was made in reliance on the exemption afforded by Section 4(a)(2) of the Securities
Act and Rule&#160;506&#160;of&#160;Regulation D&#160;under the&#160;Securities Act&#160;and corresponding provisions of state securities
or &#8220;blue sky&#8221; laws. None of the Securities have been registered under the&#160;Securities Act&#160;or any state securities
laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration
requirements. The sale of the Securities did not involve a public offering and was made without general solicitation or general advertising.
The Company relied on this exemption from registration based in part on representations made by Lind.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither this Current Report on Form&#160;8-K&#160;nor
any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of common stock or other securities of the
Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>Item
8.01 Other Events.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued a press release on February
23, 2023 announcing the Offering. <span style="background-color: white">A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Exhibits.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 9%"><span style="font-size: 10pt">Exhibit <br />
    Number</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 90%"><span style="font-size: 10pt">Exhibit</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">4.1</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt"><a href="ea174178ex4-1_abvcbio.htm">Form of Placement Agent Warrant</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.1</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-1_abvcbio.htm"><span style="font-size: 10pt">Securities Purchase Agreement</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.2</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-2_abvcbio.htm"><span style="font-size: 10pt">Form of Note</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.3</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-3_abvcbio.htm"><span style="font-size: 10pt">Form of Warrant</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.4</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-4_abvcbio.htm"><span style="font-size: 10pt">Security Agreement</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.5</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-5_abvcbio.htm"><span style="font-size: 10pt">Guarantor Security Agreement</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.6</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-6_abvcbio.htm"><span style="font-size: 10pt">Guaranty</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.7</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-7_abvcbio.htm"><span style="font-size: 10pt">Trademark Security Agreement with Rgene Corporation</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.8</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-8_abvcbio.htm"><span style="font-size: 10pt">Trademark Security Agreement with BioFirst Corporation</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.9</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-9_abvcbio.htm"><span style="font-size: 10pt">Patent Security Agreement</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.10</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-10_abvcbio.htm">Copyright Security Agreement</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">10.11</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex10-11_abvcbio.htm">Stock Pledge Agreement</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">99.1 </span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea174178ex99-1_abvcbio.htm"><span style="font-size: 10pt">Press Release</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">104</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt">ABVC BioPharma, Inc.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">February 24, 2023</span></td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid">/s/ Howard Doong</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Howard Doong</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OsqfIvAyqYgsRCK63XKMJd2R2c3ykXrLViUaDgzDOd8cISZiSxtVIcNlladwwrqppEXIsURGfUOXSHb7GNzO8a6MZantcP7AhByDjllMg+XVGUO0VQaLGPxwFkZO4EfxPILsILzeT0iXqkBtlaxA6gIypoYVWsnd+OEk36Sp7oaqM7JRpGMIpv5ofyD0gxCO1MoX8cNAmibCmwzjiS3Ts+lrnsZSDesKa9dlRvQv7wsZV0lL -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea174178ex4-1_abvcbio.htm
<DESCRIPTION>FORM OF PLACEMENT AGENT WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS WARRANT HAS NOT BEEN REGISTERED WITH THE
SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">The number
of shares of common stock issuable upon exercise of this warrant may be less than the amounts set forth on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant is issued pursuant to that certain
Engagement Letter dated October 12, 2022, as amended on January 30, 2023 (the &ldquo;<U>Engagement Letter</U>&rdquo;) and that certain
Securities Purchase Agreement dated February 23, 2023 by and between the Company and the Holder (as defined below) (the &ldquo;<U>Purchase
Agreement</U>&rdquo;). Capitalized terms used and not otherwise defined herein shall have the meanings set forth for such terms in the
Purchase Agreement. Receipt of this Warrant by the Holder shall constitute acceptance and agreement to all of the terms contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No. PA-1</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ABVC
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>PLACEMENT AGENT </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COMMON STOCK PURCHASE WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABVC BioPharma, Inc., a Nevada
corporation (together with any corporation which shall succeed to or assume the obligations of ABVC BioPharma, Inc. hereunder, the &ldquo;<U>Company</U>&rdquo;),
hereby certifies that, for value received, [ ] (the &ldquo;<U>Holder</U>&rdquo;), is entitled, subject to the terms set forth below, to
purchase from the Company at any time during the Exercise Period (as defined in <U>Section 9</U>) up to 529,167<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
fully paid and non-assessable shares of Common Stock (as defined in <U>Section&nbsp;9</U>), at a purchase price per share equal to the
Exercise Price (as defined in <U>Section 9</U>). The number of shares of Common Stock for which this Placement Agent Common Stock Purchase
Warrant (this &ldquo;<U>Warrant</U>&rdquo;) is exercisable and the Exercise Price are subject to adjustment as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. <U>DEFINITIONS</U>.
Certain terms are used in this Warrant as specifically defined in <U>Section 9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. <U>EXERCISE
OF WARRANT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1. <U>Exercise</U>.
This Warrant may be exercised prior to its expiration pursuant to <U>Section 2.5</U> hereof by the Holder at any time or from time to
time during the Exercise Period, by submitting the form of subscription attached hereto (the &ldquo;<U>Exercise Notice</U>&rdquo;) duly
executed by the Holder, to the Company at its principal office, indicating whether the Holder is electing to purchase a specified number
of shares by paying the Aggregate Exercise Price as provided in <U>Section 2.2</U> or is electing to exercise this Warrant as to a specified
number of shares pursuant to the net exercise provisions of <U>Section 2.3</U>. On or before the first Trading Day following the date
on which the Company has received the Exercise Notice, the Company shall transmit by electronic mail an acknowledgement of confirmation
of receipt of the Exercise Notice. Subject to <U>Section 2.4</U>, this Warrant shall be deemed exercised for all purposes as of the close
of business on the day on which the Holder has delivered the Exercise Notice to the Company. The Aggregate Exercise Price, if any, shall
be paid by wire transfer to the Company within five (5) Business Days of the date of exercise and prior to the time the Company issues
the certificates evidencing the shares issuable upon such exercise. In the event this Warrant is not exercised in full, the Company may,
at its expense, require the Holder, after such partial exercise, to promptly return this Warrant to the Company and the Company will forthwith
issue and deliver to or upon the order of the Holder a new Warrant or Warrants of like tenor, in the name of the Holder or as the Holder
(upon payment by the Holder of any applicable transfer taxes) may request, calling in the aggregate on the face or faces thereof for the
number of shares of Common Stock equal (without giving effect to any adjustment therein) to the number of such shares called for on the
face of this Warrant minus the number of such shares (without giving effect to any adjustment therein) for which this Warrant shall have
been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
6% of aggregate securities sold in the Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2. <U>Payment
of Exercise Price by Wire Transfer</U>. If the Holder elects to purchase a specified number of shares by paying the Aggregate Exercise
Price, the Holder shall pay such amount by wire transfer of immediately available funds to the account designated by the Company in its
acknowledgement of receipt of such Exercise Notice pursuant to <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3. (a)
<U>Net Exercise</U>. If a registration statement covering the shares of Common Stock that are the subject of the Notice of Exercise (the
&ldquo;<U>Unavailable Warrant Shares</U>&rdquo;) is not available for the resale of such Unavailable Warrant Shares to the public or upon
exercise of this Warrant in connection with a Fundamental Transaction, the Holder may elect to exercise this Warrant by receiving shares
of Common Stock equal to the number of shares determined pursuant to the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">X = <U>Y (A - B)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">where,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">X =</TD><TD>the number of shares of Common Stock to be issued to Holder;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">Y =</TD><TD>the number of shares of Common Stock as to which this Warrant is to be exercised (as indicated on the Exercise Notice);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A =</TD><TD>VWAP for the Trading Day immediately preceding the date of exercise; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B =</TD><TD>the Exercise Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1in">(b) <U>Intentionally Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in">(c) <U>Prohibited Transactions</U>.
For the avoidance of doubt, in accordance with Section 5.9 of the Purchase Agreement, the Company agrees that will not to enter into any
Prohibited Transactions without the Holder&rsquo;s prior written consent while this Warrant remains outstanding and thereafter as provided
in such Section 5.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4. <U>Antitrust
Notification</U>. If the Holder determines, in its sole judgment upon the advice of counsel, that the issuance of any Warrant Shares pursuant
to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &ldquo;<U>HSR
Act</U>&rdquo;), the Company shall file as soon as practicable after the date on which the Company receives notice from the Holder of
the applicability of the HSR Act and a request to so file with the United States Federal Trade Commission and the United States Department
of Justice the notification and report form required to be filed by it pursuant to the HSR Act in connection with such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5. <U>Termination</U>.
This Warrant shall terminate upon the earlier to occur of (i) exercise in full or (ii) the expiration of the Exercise Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <U>REGISTRATION
RIGHTS</U>. The Holder of this Warrant has certain rights to require the Company to register its resale of the Warrant Shares under the
Securities Act and any blue sky or securities laws of any jurisdictions within the United States at the time and in the manner specified
in the Purchase Agreement for the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. <U>DELIVERY
OF STOCK CERTIFICATES ON EXERCISE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1. <U>Delivery
of Exercise Shares</U>. As soon as practicable after any exercise of this Warrant and in any event within three (3) Trading Days thereafter
(such date, the &ldquo;<U>Exercise Share Delivery Date</U>&rdquo;), the Company shall, at its expense (including the payment by it of
any applicable issue or stamp taxes), cause to be issued in the name of and delivered to the Holder, or as the Holder may direct, a certificate
or certificates evidencing the number of fully paid and non-assessable shares of Common Stock (which number shall be rounded down to the
nearest whole share in the event any fractional share may otherwise be issuable upon such exercise and the Company shall pay a cash adjustment
to the Holder in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price) to which the Holder
shall be entitled on such exercise, in such denominations as may be requested by the Holder, which certificate or certificates shall be
free of restrictive and trading legends (except for any such legends as may be required under the Securities Act). In lieu of delivering
physical certificates for the shares of Common Stock issuable upon any exercise of this Warrant, provided the Warrant Shares are not restricted
securities and the Company&rsquo;s transfer agent is participating in the Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;) Fast Automated
Securities Transfer program or a similar program, upon request of the Holder, the Company shall cause its transfer agent to electronically
transmit such shares of Common Stock issuable upon exercise of this Warrant to the Holder (or its designee), by crediting the account
of the Holder&rsquo;s (or such designee&rsquo;s) broker with DTC through its Deposit Withdrawal Agent Commission system (provided that
the same time periods herein as for stock certificates shall apply) as instructed by the Holder (or its designee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2. <U>Compensation
for Buy-In on Failure to Timely Deliver Exercise Shares</U>. In addition to any other rights available to the Holder, if the Company fails
to cause its transfer agent to transmit to the Holder Exercise Shares pursuant to an exercise on or before the Exercise Share Delivery
Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Exercise Shares which
the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (a) pay in cash to the Holder
the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Exercise Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation
was executed, and (b) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (a) of
the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure
to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3. <U>Charges,
Taxes and Expenses</U>. Issuance of Exercise Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Exercise Shares, all of which taxes and expenses shall be paid by the Company, and
such Exercise Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that in the event Exercise Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto (the &ldquo;<U>Assignment Form</U>&rdquo;) duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <U>CERTAIN
ADJUSTMENT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1. <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (a) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (b) subdivides outstanding shares of Common Stock into a larger number of shares, (c) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (d) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this <U>Section 5.1</U> shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2 <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to
the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the beneficial ownership
limitation provided for in <U>Section 10</U>, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the beneficial ownership limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3 <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (a) the Company effects any merger or consolidation of the Company
with or into another Person, (b) the Company effects any sale of all or substantially all of its assets in one or a series of related
transactions, (c) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders
of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (d) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into
or exchanged for other securities, cash or property (each, a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon the closing of
a Fundamental Transaction and payment of the exercise price therefore (including at the election of the Holder by cashless exercise),
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior
to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 10 on the
exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is
the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 10 on the exercise of this Warrant). For purposes of
any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based
on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company
shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be
received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental
Transaction the result of which is that in excess of 33% of the Company&rsquo;s outstanding equity shall be held by Persons differing
to those immediately prior to such Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the
Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the
date of the consummation of such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value this Warrant based
on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the final day of the Exercise Period, (B) an expected volatility equal to the greater of 100% and
the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the
sum of the price per share being offered in cash, if any, plus the value of any non- cash consideration, if any, being offered in such
Fundamental Transaction and (ii) the greater of (x) the last volume weighted average price immediately prior to the public announcement
of such Fundamental Transaction and (y) the last volume weighted average price immediately prior to the consummation of such Fundamental
Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the final day of the Exercise Period. The payment of the Black Scholes Value will be made by wire transfer of immediately
available funds within five Business Days of the Holder&rsquo;s election (or, if later, on the effective date of the Fundamental Transaction).
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in
accordance with the provisions of this 5.3 pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4 <U>Adjustment
to Exercise Price Upon Issuance of Common Stock</U>. If the Company shall, at any time after the Issue Date, issue or sell any shares
of Common Stock (other than in an Exempted Securities), whether directly or indirectly by way of Convertible Securities (&ldquo;<U>Additional
Shares of Common Stock</U>&rdquo;), without consideration or for consideration per share less than the Exercise Price in effect immediately
prior to such issuance or sale, then immediately upon such issuance or sale, the Exercise Price in effect immediately prior to such issuance
or sale shall be reduced (and in no event increased) to an Exercise Price equal to the consideration per share paid for such Additional
Shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5 <U>Calculations</U>.
All calculations under this <U>Section 5</U> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this <U>Section 5</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding at the close of the Trading
Day on or, if not applicable, most recently preceding, such given date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6 <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)  <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 5</U>, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring
such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)  <U>Notice
to Allow Exercise by Holder</U>. If (i) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock; (ii) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock; (iii) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights; (iv) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property;
or (v) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company;
then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register
of the Company, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a
record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the
mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. Subject to applicable law,
the Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event
triggering such notice. Notwithstanding the foregoing, the delivery of the notice described in this <U>Section 5.6</U> is not intended
to and shall not bestow upon the Holder any voting rights whatsoever with respect to outstanding unexercised Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. <U>NO
IMPAIRMENT</U>. The Company will not, by amendment of the Articles of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and
in taking all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment. Without
limiting the generality of the foregoing, the Company (a) will not increase the par value of any shares of Common Stock receivable on
the exercise of this Warrant above the amount payable therefor on such exercise and (b) will take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of stock on the exercise of
this Warrant from time to time outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <U>NOTICES
OF RECORD DATE</U>. In the event of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) any
taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock
of any class or any other securities or property, or to receive any other right;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) any
capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any transfer of
all or substantially all the assets of the Company to or any consolidation or merger of the Company with or into any other Person or any
other Change of Control; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) any
voluntary or involuntary dissolution, liquidation or winding-up of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then, and in each such event, the Company will
mail or cause to be mailed to the Holder a notice specifying (i) the date on which any such record is to be taken for the purpose of such
dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the date on which
any such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution, liquidation or winding-up is
anticipated to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock shall be entitled to
exchange their shares of Common Stock for securities or other property deliverable on such reorganization, reclassification, recapitalization,
transfer, consolidation, merger, dissolution, liquidation or winding-up. Such notice shall be mailed at least fifteen (15) days prior
to the date specified in such notice on which any such action is to be taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. <U>RESERVATION
OF STOCK ISSUABLE ON EXERCISE OF WARRANT; REGULATORY COMPLIANCE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1. <U>Reservation
of Stock Issuable on Exercise of Warrant</U>. The Company shall at all times while this Warrant shall be outstanding, reserve and keep
available out of its authorized but unissued Common Stock, such number of shares of Common Stock as shall from time to time be sufficient
to effect the exercise of all or any portion of the Warrant Shares (disregarding for this purpose any and all limitations of any kind
on such exercise). The Company shall, from time to time in accordance with the Delaware General Corporation Law, increase the authorized
number of shares of Common Stock or take other effective action if at any time the unissued number of authorized shares shall not be sufficient
to satisfy the Company&rsquo;s obligations under this <U>Section 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2. <U>Regulatory
Compliance</U>. If any shares of Common Stock to be reserved for the purpose of exercise of the Warrant Shares require registration or
listing with or approval of any Governmental Authority, stock exchange or other regulatory body under any federal or state law or regulation
or otherwise before such shares may be validly issued or delivered upon exercise, the Company shall, at its sole cost and expense, in
good faith and as expeditiously as possible, secure such registration, listing or approval, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. <U>DEFINITIONS</U>.
As used herein the following terms, unless the context otherwise requires, have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control
with, the Person specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Aggregate
Exercise Price</U></FONT>&rdquo; <FONT STYLE="font-size: 10pt">means, in connection with the exercise of this Warrant at any time, an
amount equal to the product obtained by multiplying (i) the Exercise Price times (ii) the number of shares of Common Stock for which this
Warrant is being exercised at such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Articles of Incorporation</U>&rdquo;
means the Company&rsquo;s Restated Articles of Incorporation as amended to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than a Saturday, Sunday or any other day on which banks are permitted or required to be closed in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Change of Control</U>&rdquo;
has the meaning set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means (i) the Company&rsquo;s Common Stock, $0.001 par value per share, and (ii) any other securities into which or for which any of the
securities described in clause (i) above have been converted or exchanged pursuant to a plan of recapitalization, reorganization, merger,
sale of assets or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Convertible Securities</U>&rdquo;
means any debt, equity or other securities that are, directly or indirectly, convertible into or exchangeable for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Period</U>&rdquo;
means the period commencing on the Issue Date and ending 11:59 P.M. (New York City time) on the date that is sixty (60) months from the
Issue Date or earlier closing of a Fundamental Transaction (other than a Fundamental Transaction of the type described in clause (d) of
the definition thereof resulting in the conversion into or exchange for another security of the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Price</U>&rdquo;
means $1.05 per share, as may be adjusted pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Shares</U>&rdquo;
means the shares of Common Stock for which this Warrant is then being exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fair Market Value</U>&rdquo;
means, with respect to any security or other property, the fair market value of such security or other property as determined by the Board
of Directors, acting in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Governmental Authority</U>&rdquo;
means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any
agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial,
taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the
European Union or the European Central Bank).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issue Date</U>&rdquo;
means February 23, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Note</U></FONT>&rdquo;
<FONT STYLE="font-size: 10pt">means the senior secured convertible promissory note issued by the Company to the Investor pursuant to the
Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Person</U></FONT>&rdquo;
<FONT STYLE="font-size: 10pt">means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means, as of any time of determination and with respect to any Person, any United States corporation, partnership, limited liability company
or limited liability partnership, all of the stock (or other equity interest) of every class of which, except directors&rsquo; qualifying
shares (or any equivalent), shall, at such time, be owned by such Person either directly or through Subsidiaries and of which such Person
or a Subsidiary shall have 100% control thereof, except directors&rsquo; qualifying shares. Unless the context otherwise clearly requires,
any reference to a &ldquo;Subsidiary&rdquo; is a reference to a Subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means whichever of the New York Stock Exchange, NYSE: Amex Exchange, or the Nasdaq Stock Market (including the Nasdaq Capital Market),
on which the Common Stock is listed or quoted for trading on the date in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, as of any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of one share of Common Stock trading in the ordinary course of
business on the applicable Trading Price for such date (or the nearest preceding date) on such Trading Market as reported by Bloomberg
Financial L.P.; (b) if the Common Stock is not then listed on a Trading Market and if the Common Stock is traded in the over-the-counter
market, as reported by the OTC Bulletin Board, the volume weighted average price of one share of Common Stock for such date (or the nearest
preceding date) on the OTC Bulletin Board, as reported by Bloomberg Financial L.P.; (c) if the Common Stock is not then listed or quoted
on the OTC Bulletin Board and if prices for the Common Stock is then reported in the &ldquo;Pink Sheets&rdquo; published by the Pink OTC
Markets Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price of one share
of Common Stock so reported, as reported by Bloomberg Financial L.P.; or (d) in all other cases, the fair market value of one share of
Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company (in
each case rounded to four decimal places).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Warrant
Shares</U></FONT>&rdquo; <FONT STYLE="font-size: 10pt">means collectively the shares of Common Stock of the Company issuable upon exercise
of the Warrant in accordance with its terms, as such number may be adjusted pursuant to the provisions thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. <U>LIMITATION
ON BENEFICIAL OWNERSHIP</U>. Notwithstanding anything to the contrary contained herein, the Holder shall not be entitled to receive shares
of Common Stock or other securities (together with Common Stock, &ldquo;<U>Equity Interests</U>&rdquo;) upon exercise of this Warrant
to the extent (but only to the extent) that such exercise or receipt would cause the Holder Group to become, directly or indirectly, a
&ldquo;beneficial owner&rdquo; (within the meaning of Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder)
of a number of Equity Interests of a class that is registered under the Exchange Act which exceeds the Maximum Percentage (as defined
below) of the Equity Interests of such class that are outstanding at such time. Any purported delivery of Equity Interests in connection
with the exercise of the Warrant prior to the termination of this restriction in accordance herewith shall be void and have no effect
to the extent (but only to the extent) that such delivery would result in the Holder Group becoming the beneficial owner of more than
the Maximum Percentage of the Equity Interests of a class that is registered under the Exchange Act that is outstanding at such time.
If any delivery of Equity Interests owed to the Holder following exercise of this Warrant is not made, in whole or in part, as a result
of this limitation, the Company&rsquo;s obligation to make such delivery shall not be extinguished and the Company shall deliver such
Equity Interests as promptly as practicable after the Holder gives notice to the Company that such delivery would not result in such limitation
being triggered or upon termination of the restriction in accordance with the terms hereof. To the extent limitations contained in this
<U>Section 10</U> apply, the determination of whether this Warrant is exercisable and of which portion of this Warrant is exercisable
shall be the sole responsibility and in the sole determination of the Holder, and the submission of an Exercise Notice shall be deemed
to constitute the Holder&rsquo;s determination that the issuance of the full number of Warrant Shares requested in the Exercise Notice
is permitted hereunder, and neither the Company nor any Warrant agent shall have any obligation to verify or confirm the accuracy of such
determination. For purposes of this <U>Section 10</U>, (i) the term &ldquo;<U>Maximum Percentage</U>&rdquo; shall mean 4.99%; provided,
that if at any time after the date hereof the Holder Group beneficially owns in excess of 4.99% of any class of Equity Interests in the
Company that is registered under the Exchange Act (excluding any Equity Interests deemed beneficially owned by virtue of this Warrant
or the Note), then the Maximum Percentage shall automatically increase to 9.99% so long as the Holder Group owns in excess of 4.99% of
such class of Equity Interests (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon the Holder Group ceasing to
own in excess of 4.99% of such class of Equity Interests); and (ii) the term &ldquo;<U>Holder Group</U>&rdquo; shall mean the Holder plus
any other Person with which the Holder is considered to be part of a group under Section 13 of the Exchange Act or with which the Holder
otherwise files reports under Sections 13 and/or 16 of the Exchange Act. In determining the number of Equity Interests of a particular
class outstanding at any point in time, the Holder may rely on the number of outstanding Equity Interests of such class as reflected in
(x) the Company&rsquo;s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission, as the case may be, (y) a more recent public announcement by the Company or (z) a more recent notice by the Company or its
transfer agent to the Holder setting forth the number of Equity Interests of such class then outstanding. For any reason at any time,
upon written or oral request of the Holder, the Company shall, within one (1) Trading Day of such request, confirm orally and in writing
to the Holder the number of Equity Interests of any class then outstanding. The provisions of this <U>Section 10</U> shall be construed,
corrected and implemented in a manner so as to effectuate the intended beneficial ownership limitation herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. <U>REGISTRATION
AND TRANSFER OF WARRANT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1. <U>Registration
of Warrant</U>. The Company shall register and record transfers, exchanges, reissuances and cancellations of this Warrant, upon the records
to be maintained by the Company for that purpose, in the name of the record holder hereof from time to time. The Company may deem and
treat the registered holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to
the Holder, and for all other purposes, absent actual notice to the contrary. The Company shall be entitled to rely, and held harmless
in acting or refraining from acting in reliance upon, any notices, instructions or documents it believes in good faith to be from an authorized
representative of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2 <U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form of assignment (the &ldquo;<U>Assignment Notice</U>&rdquo;) attached hereto duly executed by the Holder
or its agent or attorney. The Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the
transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of the transferred Warrant under the 1933 Act. Upon such surrender, the Company shall execute and deliver
a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified
in such Assignment Notice, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the
purchase of Exercise Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3. <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with <U>Section 11.2</U>, as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for this Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical
with this Warrant except as to the number of Exercise Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12. <U>LOSS,
THEFT, DESTRUCTION OR MUTILATION OF WARRANT</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Exercise Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13. <U>REMEDIES</U>.
The Company stipulates that the remedies at law of the Holder in the event of any default or threatened default by the Company in the
performance of or compliance with any of the terms of this Warrant are not and will not be adequate, and that such terms may be specifically
enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a violation of any of
the terms hereof or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. <U>NO
RIGHTS AS A STOCKHOLDER</U>. Except as otherwise specifically provided herein, the Holder, solely in such Person&rsquo;s capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for
any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity
as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Exercise
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15. <U>NOTICES</U>.
All notices, requests, demands and other communications that are required or may be given pursuant to the terms of this Warrant shall
be in writing and shall be deemed delivered (i) on the date of delivery when delivered by hand on a Business Day during normal business
hours or, if delivered on a day that is not a Business Day or after normal business hours, then on the next Business Day, (ii) on the
date of transmission when sent by facsimile transmission or email during normal business hours on a Business Day with telephone confirmation
of receipt or, if transmitted on a day that is not a Business Day or after normal business hours, then on the next Business Day, or (iii)
on the second Business Day after the date of dispatch when sent by a reputable courier service that maintains records of receipt. The
addresses for notice shall be as set forth in the Engagement Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16. <U>CONSENT
TO AMENDMENTS</U>. Any term of this Warrant may be amended, and the Company may take any action herein prohibited, or compliance therewith
may be waived, only if the Company shall have obtained the written consent (and not without such written consent) to such amendment, action
or waiver from the Holder. No course of dealing between the Company and the Holder nor any delay in exercising any rights hereunder shall
operate as a waiver of any rights of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17. <U>MISCELLANEOUS</U>.
In case any provision of this Warrant shall be invalid, illegal or unenforceable, or partially invalid, illegal or unenforceable, the
provision shall be enforced to the extent, if any, that it may legally be enforced and the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby. If any provision of this Warrant is found to conflict with
the Engagement Letter or Purchase Agreement, the provisions of this Warrant shall prevail. If any provision of this Warrant is found to
conflict with the Note, the provisions of the Note shall prevail. THIS WARRANT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND
THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE INTERNAL LAW OF THE STATE OF NEVADA EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE LAW
OF SUCH STATE THAT WOULD PERMIT THE APPLICATION OF THE LAWS OF A JURISDICTION OTHER THAN SUCH STATE. The headings in this Warrant are
for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Remainder of Page Intentionally Left Blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its duly authorized officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated as of February 23, 2023</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ABVC BIOPHARMA, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF SUBSCRIPTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be signed only on exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of Common Stock Purchase Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">TO:</TD><TD STYLE="text-align: justify">ABVC BioPharma, Inc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The
undersigned Holder of the attached Warrant hereby elects to exercise its purchase right under such Warrant to purchase shares of Common
Stock of ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), as follows (check one or more, as applicable):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">to exercise the Warrant to purchase __________ shares of Common Stock and to pay the Aggregate Exercise
Price therefor by wire transfer of United States funds to the account of the Company, which transfer has been made prior to or as of the
date of delivery of this Form of Subscription pursuant to the instructions of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">to exercise the Warrant with respect to ____________ shares of Common Stock pursuant to the net exercise
provisions specified in Section 2.3 of the Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. In
exercising this Warrant, the undersigned Holder hereby confirms and acknowledges that the shares of Common Stock are being acquired solely
for the account of the undersigned and not as a nominee for any other party, and for investment, and that the undersigned shall not offer,
sell or otherwise dispose of any such shares of Common Stock except under circumstances that will not result in a violation of the Securities
Act or any state securities laws. The undersigned hereby further confirms and acknowledges that it is an &ldquo;accredited investor&rdquo;,
as that term is defined under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. Please
issue a stock certificate or certificates representing the appropriate number of shares of Common Stock in the name of the undersigned
or in such other name(s) as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIN:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 7%">Dated:
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 13%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature must conform exactly to name of Holder as specified on the face of the Warrant)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be signed only on transfer of Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For value received, the undersigned
hereby sells, assigns, and transfers unto ________________ the right represented by the within Warrant to purchase ______________shares of Common Stock
of ABVC BioPharma, Inc., a Nevada corporation, to which the within Warrant relates, and appoints _________________ attorney to transfer
such right on the books of ABVC BioPharma, Inc., with full power of substitution in the premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[insert name of Holder]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Dated:____________________</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[insert address of Holder]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Signed in the presence of:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea174178ex10-1_abvcbio.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (as amended, supplemented, restated and/or modified from time to time, this &ldquo;<B>Agreement</B>&rdquo;) is entered into
as of February [&#9679;], 2023, by and between ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Lind
Global Fund II LP, a Delaware limited partnership (the &ldquo;<B>Investor</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BACKGROUND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A. The
board of directors (the &ldquo;<B>Board of Directors</B>&rdquo;) of the Company has authorized the issuance to Investor of the Note (as
defined below) and the Warrant (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B The
Investor desires to purchase the Note and the Warrant on the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW THEREFORE, in consideration
of the foregoing recitals and the covenants and agreements set forth herein, and intending hereby to be legally bound, the Company and
the Investor hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>1.
</B></FONT><B><U>DEFINITIONS</U></B>. As used in this Agreement, the following terms shall have the following meanings specified or indicated
below, and such meanings shall be equally applicable to the singular and plural forms of such defined terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>1933 Act</B>&rdquo;
means the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>1934 Act</B>&rdquo;
means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Acquisition</B>&rdquo;
means the acquisition by the Company or any direct or indirect Subsidiary of the Company of a majority of the Equity Interests or substantially
all of the assets and business of any Person, whether by direct purchase of Equity Interests, asset purchase, merger, consolidation or
like combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control
with, the Person specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Blue Sky Application</B>&rdquo;
has the meaning set forth in <U>Section 9.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Board of Directors</B>&rdquo;
has the meaning set forth in the recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
means any day other than a Saturday, Sunday or any other day on which banks are permitted or required to be closed in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Capital Stock</B>&rdquo;
means the Common Stock and any other classes of capital stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Change of Control</B>&rdquo;
means, with respect to the Company, on or after the date of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 34.9pt">(a)</TD><TD STYLE="text-align: justify">a change in the composition of the Board
                                            of Directors of the Company at a single shareholder meeting where a majority of the individuals
                                            that were directors of the Company immediately prior to the start of such shareholder meeting
                                            are no longer directors at the conclusion of such meeting, without prior written consent
                                            of the Investor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">a change, without prior written consent
                                            of the Investor, in the composition of the Board of Directors of the Company prior to the
                                            termination of this Agreement where a majority of the individuals that were directors as
                                            of the date of this Agreement cease to be directors of the Company prior to the termination
                                            of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">other than a shareholder that holds
                                            such a position at the date of this Agreement, if a Person comes to have beneficial ownership,
                                            control or direction over more than thirty-three percent (33%) of the voting rights attached
                                            to any class of voting securities of the Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">the sale or other disposition by the
                                            Company or any of its Subsidiaries in a single transaction, or in a series of transactions,
                                            of all or substantially all of their respective assets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing</B>&rdquo;
has the meaning set forth in <U>Section 2.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing Date</B>&rdquo;
has the meaning set forth in <U>Section 2.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commitment Fee</B>&rdquo;
means an amount equal to Four and One Half Percent (4.5%) of the applicable Funding Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common Stock</B>&rdquo;
means the common stock of the Company, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company</B>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Conversion Shares</B>&rdquo;
means the Common Stock issuable upon the full or any partial conversion of the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disclosure Letter</B>&rdquo;
has the meaning set forth in <U>Section 3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Effectiveness Period</B>&rdquo;
has the meaning set forth in <U>Section 9.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Equity Interests</B>&rdquo;
means and includes capital stock, membership interests and other similar equity securities, and shall also include warrants or options
to purchase capital stock, membership interests or other equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Event</B>&rdquo;
means any event, change, development, effect, condition, circumstance, matter, occurrence or state of facts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Event of Default</B>&rdquo;
has the meaning set forth in <U>Section 7.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exempted Securities</B>&rdquo;
means (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly
adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee
of non-employee directors established for such purpose for services rendered to the Company (&ldquo;<B>Equity Plan</B>&rdquo;), (b) securities
issued upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have
not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange
price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such
securities, or (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors
of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no
registration rights that require or permit the filing of any registration statement in connection therewith, and provided that any such
issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating
company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional
benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Form 8-K&rdquo;
</B>has the meaning set forth in <U>Section 5.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Funding Amount&rdquo;
</B>means an amount equal to Three Million Dollars ($3,175,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GAAP</B>&rdquo;
means United States generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>HSR Act</B>&rdquo;
has the meaning set forth in <U>Section 5.15</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor</B>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor Group</B>&rdquo;
shall mean the Investor plus any other Person with which the Investor is considered to be part of a group under Section 13 of the 1934
Act or with which the Investor otherwise files reports under Sections 13 and/or 16 of the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor Party</B>&rdquo;
has the meaning set forth in <U>Section 5.9(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U></U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor Shares</B>&rdquo;
means the Conversion Shares, the Warrant Shares and any other shares issued or issuable to the Investor pursuant to this Agreement, Note
or the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IP Rights</B>&rdquo;
has the meaning set forth in <U>Section 3.10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Law</B>&rdquo;
means any law, rule, regulation, order, judgment or decree, including, without limitation, any federal and state securities Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Legend Removal
Date</B>&rdquo; shall have the meaning set forth in <U>Section 5.1(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Losses</B>&rdquo;
has the meaning set forth in <U>Section 5.9(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Material Adverse
Effect</B>&rdquo; means any material adverse effect on (i) the businesses, properties, assets, prospects, operations, results of operations
or financial condition of the Company, or the Company and the Subsidiaries, taken as a whole, or (ii) the ability of the Company to consummate
the transactions contemplated by this Agreement or to perform its obligations hereunder or under the Note or the Warrant; <I>provided,
however</I>, that none of the following shall be deemed either alone or in combination to constitute, and none of the following shall
be taken into account in determining whether there has been or would be, a Material Adverse Effect: (a)&nbsp;any adverse effect resulting
from or arising out of general economic conditions; (b) any adverse effect resulting from or arising out of general conditions in the
industries in which the Company and the Subsidiaries operate; (c) any adverse effect resulting from any changes to applicable Law; or
(d)&nbsp;any adverse effect resulting from or arising out of any natural disaster or any acts of terrorism, sabotage, military action
or war or any escalation or worsening thereof; <I>provided</I>, <I>further</I>, that any event, occurrence, fact, condition or change
referred to in clauses (a) through (d) immediately above shall be taken into account in determining whether a Material Adverse Effect
has occurred or could reasonably be expected to occur to the extent that such event, occurrence, fact, condition or change has a disproportionate
effect on the Company and/or the Subsidiaries compared to other participants in the industries in which the Company and the Subsidiaries
operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Maximum Percentage</B>&rdquo;
means 4.99%; <I>provided</I>, that if at any time after the date hereof the Investor Group beneficially owns in excess of 4.99% of any
class of Equity Interests in the Company that is registered under the 1934 Act, then the Maximum Percentage shall automatically increase
to 9.99% so long as the Investor Group owns in excess of 4.99% of such class of Equity Interests (and shall, for the avoidance of doubt,
automatically decrease to 4.99% upon the Investor Group ceasing to own in excess of 4.99% of such class of Equity Interests).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Money Laundering
Laws</B>&rdquo; has the meaning set forth in <U>Section 3.25</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>New Securities</B>&rdquo;
means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to
purchase such equity securities, or securities of any type whatsoever that are, or may become convertible or exchangeable into or exercisable
for such equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Note</B>&rdquo;
has the meaning set forth in <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Notice Termination
Time&rdquo;</B> has the meaning set forth in <U>Section 10.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>OFAC</B>&rdquo;
has the meaning set forth in <U>Section 3.23</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Offer Notice</B>&rdquo;
has the meaning set forth in <U>Section 10.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment Amount</B>&rdquo;
means an amount in cash equal to five percent (5%) of the Outstanding Principal Amount set forth in a Prepayment Notice delivered to
the Investor pursuant to <U>Section 1.4</U> of the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment Notice</B>&rdquo;
has the meaning set forth in <U>Section 1.4</U> of the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment Right</B>&rdquo;
has the meaning set forth in <U>Section 2.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment Right
Date</B>&rdquo; means sixty (60) days following such date as Conversion Shares and the Warrant Shares, may be offered or sold pursuant
to an effective Registration Statement or in a transaction not subject to the registration requirements of the Securities Act and in
accordance with applicable State securities laws as evidenced by a legal opinion of counsel to the Company to such effect the substance
of which shall be reasonably acceptable to the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Press Release&rdquo;
</B>has the meaning set forth in <U>Section 5.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Principal Amount</B>&rdquo;
has the meaning set forth in <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Proceedings</B>&rdquo;
has the meaning set forth in <U>Section 3.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prohibited Transaction</B>&rdquo;
means a transaction with a third party or third parties in which the Company issues or sells (or arranges or agrees to issue or sell):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) any
debt, equity or equity-linked securities (including options or warrants) that are convertible into, exchangeable or exercisable for,
or include the right to receive shares of the Company&rsquo;s Capital Stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) at
a conversion, repayment, exercise or exchange rate or other price that is based on, and/or varies with, a discount to the future trading
prices of, or quotations for, shares of Common Stock; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) at
a conversion, repayment, exercise or exchange rate or other price that is subject to being reset at some future date after the initial
issuance of such debt, equity or equity-linked security or upon the occurrence of specified or contingent events (other than warrants
that may be repriced by the Company); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) any
securities in a capital or debt raising transaction or series of related transactions which grant to an investor the right to receive
additional securities based upon future transactions of the Company on terms more favorable than those granted to such investor in such
first transaction or series of related transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and are deemed to include transactions generally
referred to as at-the-market transactions (ATMs) or equity lines of credit and stand-by equity distribution agreements, and convertible
securities and loans having a similar effect. Notwithstanding the foregoing, and for the avoidance of doubt, rights issuances, shareholder
purchase plans, Equity Plans, or Common Stock Shares on the Trading Market but each at a fixed price per share, shall not be deemed to
be a Prohibited Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prospectus</B>&rdquo;
means the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with respect to
the terms of the offering of any portion of the Investor Shares covered by such Registration Statement and by all other amendments and
supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus, and
any &ldquo;free writing prospectus&rdquo; as defined in Rule 405 under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>register</B>,&rdquo;
&ldquo;<B>registered</B>&rdquo; and &ldquo;<B>registration</B>&rdquo; refer to a registration made by preparing and filing a Registration
Statement or similar document in compliance with the 1933 Act (as defined below), and the declaration or ordering of effectiveness of
such Registration Statement or document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registration Statement</B>&rdquo;
means any registration statement of the Company filed under the 1933 Act that covers the resale of any of the Investor Shares pursuant
to the provisions of this Agreement, including the Prospectus and amendments and supplements to such Registration Statement, and including
post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Required Minimum</B>&rdquo;
means, as of any date, 200% of the maximum aggregate number of shares of Common Stock then issued or potentially issuable in the future
pursuant to the Transaction Documents, including any Warrant Shares issuable upon exercise in full of the Warrant or Conversion Shares
issuable upon conversion in full of the Note, ignoring any conversion or exercise limits set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SEC</B>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SEC Documents</B>&rdquo;
has the meaning set forth in <U>Section 3.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities</B>&rdquo;
means the Note, the Warrant and the Investor Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities Termination
Event</B>&rdquo; means either of the following has occurred:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) trading
in securities generally in the United States has been suspended or limited for a consecutive period of greater than three (3) Business
Days; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) a
banking moratorium has been declared by the United States or the New York State authorities and is continuing for a consecutive period
of greater than three (3) Business Days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Security Agreement</B>&rdquo;
means a Security Agreement in the form attached hereto as <B><U>Exhibit C.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Shareholder Approval</B>&rdquo;
shall mean the approval of the holders of a majority of the Company&rsquo;s outstanding voting Common Stock: (a) if and to the extent
legally required, to amend the Company&rsquo;s Articles of Incorporation to increase the number of authorized shares of Common Stock
by at least the number of shares equal to the number of shares of Common Stock issuable under the Transaction Documents, or (b) to ratify
and approve all of the transactions contemplated by the Transaction Documents, including the issuance of all of the Investor Shares (as
such term is defined in each of such documents) issued and potentially issuable to the Investor thereunder, all as may be required by
the applicable rules and regulations of the Trading Market (or any successor entity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsequent Financing</B>&rdquo;
has the meaning set forth in <U>Section 10.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsidiaries</B>&rdquo;
and &ldquo;<B>Subsidiary</B>&rdquo; have the meaning set forth in <U>Section 3.4(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsidiary Guarantee</B>&rdquo;
means a Subsidiary Guarantee in the form attached hereto as <B><U>Exhibit D.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Trading Day&rdquo;
</B>means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading Market</B>&rdquo;
means whichever of the New York Stock Exchange, NYSE American, or the Nasdaq Stock Market (including the Nasdaq Capital Market), on which
the Common Stock is listed or quoted for trading on the date in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transaction Documents</B>&rdquo;
means this Agreement, the Note, the Warrant, the Security Agreement, the Subsidiary Guarantee, the Transfer Agent Instruction Letter
and any other documents or agreements executed or delivered in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer Agent</B>&rdquo;
shall mean Vstock Transfer, LLC having its address at 18 Lafayette Place, Woodmere, NY 11598, Oscar Williams, (212) 828-8436 ext. 112,
oscar@vstocktransfer.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer Agent
Instruction Letter</B>&rdquo; shall mean a letter of irrevocable instructions addressed by the Company to the Transfer Agent, acceptable
to the Investor in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>VWAP&rdquo;</B>
means, as of any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of one share of Common Stock trading in the ordinary course of
business at the applicable Trading Price for such date (or the nearest preceding date) on such Trading Market as reported by Bloomberg
Financial L.P.; (b) if the Common Stock is not then listed on a Trading Market and if the Common Stock traded in the over-the-counter
market, as reported by the OTCQX or OTCQB Markets, the volume weighted average price of one share of Common Stock for such date (or the
nearest preceding date) on the OTCQX or OTCQB Markets, as reported by Bloomberg Financial L.P.; (c) if the Common Stock is not then listed
or quoted on a Trading Market or on the OTCQX or OTCQB Markets and if prices for the Common Stock are then reported in the &ldquo;Pink
Sheets&rdquo; published by the OTC Markets Group (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price of one share of Common Stock so reported, as reported by Bloomberg Financial L.P.; or (d) in all other cases,
the fair market value of one share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and
reasonably acceptable to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Warrant&rdquo;
</B>has the meaning set forth in <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Warrant Shares</B>&rdquo;
means the shares of Common Stock issuable upon exercise of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>2.
</B></FONT><B><U>PURCHASE AND SALE OF THE NOTE AND THE WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.1 </B></FONT><U>Purchase
and Sale of the Note and the Warrant</U>. Subject to the terms and conditions set forth herein at the Closing, the Company shall issue
and sell to the Investor, and the Investor shall purchase from the Company, for the Funding Amount (a) a convertible promissory note,
in the form attached hereto as <U>Exhibit <B>A</B></U> (the <B>&ldquo;Note</B>&rdquo;), in the principal amount of Three Million Seven
Hundred Four Thousand One Hundred Sixty Seven Dollars ($3,704,167) (the <B>&ldquo;Principal Amount</B>&rdquo;) and (b) a Common Stock
purchase warrant, in the form attached hereto as <B><U>Exhibit B</U></B>, registered in the name of the Investor, pursuant to which the
Investor shall have the right to acquire 5,291,667 shares of Common Stock (the <B>&ldquo;Warrant&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.2 </B></FONT><U>Closing</U>.
The closing of the offer and sale of the Note and the Warrant shall take place remotely via the exchange of documents and signature and
shall occur no later than ten (10) Business Days following the execution and delivery of this Agreement, subject to satisfaction or waiver
of the conditions set forth in <U>Section 6</U>, or at such other time and place as the Company and the Investor agree upon, orally or
in writing (the &ldquo;<B>Closing</B>&rdquo;, and the date the Closing is completed being the <B>&ldquo;Closing Date&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.3 </B></FONT><U>Commitment
Fee</U>. At each Closing, as applicable, the Company shall pay to the Investor the Commitment Fee, in United States dollars and in immediately
available funds. The Commitment Fee shall be paid by being offset against the applicable Funding Amount payable by the Investor at the
Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.4 </B></FONT><U>Prepayment
Right.</U> As set forth in the Note, at any time following the Prepayment Right Date and upon giving the prior written notice set forth
in the Note , the Company will have the right to pre-pay the entire then-outstanding principal amount of the Note at any time (the &ldquo;<B>Prepayment
Right</B>&rdquo;); <I>provided</I>, that in the event that the Company elects to exercise its Prepayment Right, the Investor will have
the option to convert up to one-third (1/3) of the Principal Amount of the Note, at a price per share equal to the lesser of the Repayment
Share Price or the Conversion Price (as each such term is defined in the Note).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.5 </B></FONT><U>Senior
Obligation</U>. As an inducement for the Investor to enter into this Agreement and to purchase the Note, all obligations of the Company
pursuant to this Agreement and the Note shall be senior to all other existing Indebtedness and equity of the Company. Upon any Liquidation
Event (as defined in the Note), the Investor will be entitled to receive, before any distribution or payment is made upon, or set apart
with respect to, any Indebtedness of the Company or any class of capital stock of the Company, an amount equal to the Outstanding Principal
Amount (as defined in the Note).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>3.
</B></FONT><B><U>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</U></B>. The Company represents and warrants to the Investor and covenants
with the Investor that as of the Closing Date, except as is set forth in the Disclosure Letter being delivered to the Investor as of
the date hereof and updated and delivered to the Investor as of the Second Closing Date, as applicable (the <B>&ldquo;Disclosure Letter&rdquo;</B>),
the following representations and warranties are true and correct:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.1
</B></FONT><U>Organization and Qualification</U>. The Company is a corporation duly organized and validly existing in good standing under
the Laws of the State of Nevada and has the requisite corporate power and authority to own its properties and to carry on its business
as now being conducted. The Company is duly qualified to do business and is in good standing (if a good standing concept exists in such
jurisdiction) in every jurisdiction in which the ownership of its property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.2
</B></FONT><U>Authorization; Enforcement; Compliance with Other Instruments</U>. The Company has the requisite corporate power and authority
to execute the Transaction Documents, to issue and sell the Note and the Warrant pursuant hereto, and to perform its obligations under
the Transaction Documents, including issuing the Investor Shares on the terms set forth in this Agreement. The execution and delivery
of the Transaction Documents by the Company and the issuance and sale of the Securities pursuant hereto, including without limitation
the reservation of the Conversion Shares and the Warrant Shares for future insuance, have been duly and validly authorized by the Company&rsquo;s
Board of Directors and no further consent or authorization is required by the Company, its Board of Directors, its shareholders or any
other Person in connection therewith. The Transaction Documents have been duly and validly executed and delivered by the Company and
constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except
as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar Laws relating to, or affecting generally, the enforcement of creditors&rsquo; rights and remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.3
</B></FONT><U>No Conflicts</U>. The execution, delivery and performance of the Transaction Documents by the Company and the issuance
and sale of the Note and the Warrant hereunder will not (a) conflict with or result in a violation of the Company&rsquo;s Articles of
Incorporation or Bylaws, (b)&nbsp;conflict with, or constitute a material default (or an event which, with notice or lapse of time or
both, would become a material default) under, or give to others any right of termination, amendment, acceleration or cancellation of,
any material agreement to which the Company or any of the Subsidiaries is a party, or (c) subject to the making of the filings referred
to in <U>Section&nbsp; 5</U>, violate in any material respect any Law or any rule or regulation of the Trading Market applicable to the
Company or any of the Subsidiaries or by which any of their properties or assets are bound or affected. Assuming the accuracy of the
Investor&rsquo;s representations in <U>Section&nbsp;4</U> and subject to the making of the filings referred to in <U>Section&nbsp;5</U>,
(i) no approval or authorization will be required from any governmental authority or agency, regulatory or self-regulatory agency or
other third party (including the Trading Market) in connection with the issuance of the Note and the Warrant and the other transactions
contemplated by this Agreement (including the issuance of the Conversion Shares upon conversion of the Note and the Warrant Shares upon
the exercise of the Warrant) and (ii)&nbsp;the issuance of the Note and the Warrant, and the issuance of the Conversion Shares upon the
conversion of the Note and the Warrant Shares upon exercise of the Warrant will be exempt from the registration and qualification requirements
under the 1933 Act and all applicable state securities Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.4
</B></FONT><U>Capitalization and Subsidiaries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a) </FONT>The
authorized Capital Stock of the Company consists of 100,000,000 shares of Common Stock. As of the close of business on December 31, 2022,
32,857,329 shares of Common Stock were issued and outstanding; and since December 31, 2022, and through the date of this Agreement, the
Company has issued 223,411 additional shares of Common Stock. As of December 31, 2022, (i) an aggregate of 2,979,624 shares of Common
Stock are issuable upon exercise of options granted under the Amended and Restated 2016 Equity Incentive Plan, of which 2,587,104 shares
were exercisable as of December 31, 2022, and 392,160 additional shares are reserved for future issuance thereunder and (ii) 329,520
shares of Common Stock are reserved for issuance upon exercise of outstanding warrants with exercise prices ranging from $2 to $3 per
share. The Company has duly reserved up to 7,055,567 shares of Common Stock for issuance upon conversion of the Note and has duly reserved
up to 10,583,334 shares of Common Stock for issuance upon exercise of the Warrant. The Conversion Shares, when issued upon conversion
of the Note in accordance with their terms, and the Warrant Shares, if and when issued upon exercise of the Warrant in accordance with
their terms, will be validly issued, fully paid and non-assessable and free from all taxes, liens and charges with respect to the issuance
thereof. No shares of the Company&rsquo;s Capital Stock are subject to preemptive rights or any other similar rights or any liens or
encumbrances suffered or permitted by the Company. The Company&rsquo;s Articles of Incorporation and Bylaws on file on the SEC&rsquo;s
EDGAR website are true and correct copies of the Company&rsquo;s Articles of Incorporation and Bylaws as in effect as of the Closing
Date. The Company is not in violation of any provision of its Articles of Incorporation or Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b) </FONT><U>Schedule
3.4(b)</U> lists each direct and indirect subsidiary of the Company (each, a &ldquo;<B>Subsidiary</B>&rdquo; and collectively, the &ldquo;<B>Subsidiaries</B>&rdquo;).
The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary. No Subsidiary has any
outstanding stock options, warrants or other instruments pursuant to which such Subsidiary may at any time or under any circumstances
be obligated to issue any shares of its capital stock or other Equity Interests. Each Subsidiary is duly organized and validly existing
in good standing under the laws of its jurisdiction of formation (if a good standing concept exists in such jurisdiction) and has all
requisite power and authority to own its properties and to carry on its business as now being conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) Neither
the Company nor any Subsidiary is bound by any agreement or arrangement pursuant to which it is obligated to register the sale of any
securities under the 1933 Act. There are no outstanding securities of the Company or any of the Subsidiaries which contain any redemption
or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to redeem or purchase any security of the Company or any Subsidiary. There are no outstanding securities or instruments
containing anti-dilution or similar provisions that will be triggered by the issuance of the Note, the Warrant or the Investor Shares.
Neither the Company nor any Subsidiary has any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) The
issuance and sale of any of the Securities will not obligate the Company to issue shares of Common Stock or other securities, or to satisfy
any related contractual obligations, to any other Person and will not result in the adjustment of the exercise, conversion, exchange,
or reset price of any outstanding securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(e) </FONT>As
of the date of this Agreement, the Company has capacity under the rules and regulations of the Trading Market to issue up to 6,616,148
shares of Common Stock (or securities convertible into or exercisable for shares of Common Stock) without obtaining Shareholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.5
</B></FONT><U>SEC Documents; Financial Statements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a) </FONT>As
of the Closing Date, the Company has filed all reports, schedules, forms, statements and other documents required to be filed by it with
the SEC pursuant to the reporting requirements of the 1934 Act for the two years preceding the Closing Date (or such shorter period as
the Company was required by law or regulation to file such material) (all of the foregoing filed prior to the Closing Date and all exhibits
included therein and financial statements and schedules thereto and documents incorporated by reference therein being hereinafter referred
to as the &ldquo;<B>SEC Documents</B>&rdquo;). As of their respective filing dates, the SEC Documents complied in all material respects
with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents,
and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b) </FONT>As
of their respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial
statements have been prepared in accordance with International Financial Reporting Standards, and audited by a firm that is a member
a member of the Public Companies Accounting Oversight Board consistently applied, during the periods involved (except as may be otherwise
indicated in such financial statements or the notes thereto, or, in the case of unaudited interim statements, to the extent they may
exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the consolidated financial position
of the Company as of the dates thereof and the consolidated results of its operations and consolidated cash flows for the periods then
ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). No other written information provided by
or on behalf of the Company to the Investor in connection with the Investor&rsquo;s purchase of the Note and the Warrant which is not
included in the SEC Documents contains any untrue statement of a material fact or omits to state any material fact necessary to make
the statements therein, in the light of the circumstance under which they are or were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c) </FONT>The
Company and each of the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) reasonable
controls to safeguard assets are in place and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.6
</B></FONT><U>Litigation and Regulatory Proceedings</U>. There are no material actions, causes of action, suits, claims, proceedings,
inquiries or investigations (collectively, &ldquo;<B>Proceedings</B>&rdquo;) before or by any court, public board, government agency,
self-regulatory organization or body pending or, to the knowledge of the executive officers of Company or any of the Subsidiaries, threatened
against or affecting the Company or any of the Subsidiaries, the Common Stock or any other class of issued and outstanding shares of
the Company&rsquo;s Capital Stock, or any of the Company&rsquo;s or the Subsidiaries&rsquo; officers or directors in their capacities
as such and, to the knowledge of the executive officers of the Company, there is no reason to believe that there is any basis for any
such Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.7
</B></FONT><U>No Undisclosed Events, Liabilities or Developments</U>. No event, development or circumstance has occurred or exists, or
to the knowledge of the executive officers of the Company is reasonably anticipated to occur or exist that (a) would reasonably be anticipated
to have a Material Adverse Effect or (b) would be required to be disclosed by the Company under applicable securities Laws on a registration
statement filed with the SEC relating to an issuance and sale by the Company of its Common Stock and which has not been publicly announced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.8
</B></FONT><U>Compliance with Law</U>. The Company and each of the Subsidiaries have conducted and are conducting their respective businesses
in compliance in all material respects with all applicable Laws and are in compliance in all material respects with the rules and regulations
of the Trading Market. Except as set forth on Schedule 3.8, the Company is not aware of any facts which could reasonably be anticipated
to lead to have the effect of, delisting the Common Stock from the Trading Market, nor has the Company received any notification that
the Trading Market is currently contemplating terminating such listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.9
</B></FONT><U>Employee Relations</U>. Neither the Company nor any Subsidiary is involved in any union labor dispute nor, to the knowledge
of the Company, is any such dispute threatened. Neither the Company nor any Subsidiary is a party to any collective bargaining agreement.
No executive officer (as defined in Rule 501(f) of the 1933 Act) has notified the Company that such officer intends to leave the Company&rsquo;s
employ or otherwise terminate such officer&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.10
</B></FONT><U>Intellectual Property Rights</U>. The Company and each Subsidiary owns or possesses adequate rights or licenses to use
all trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights (collectively, &ldquo;<B>IP Rights</B>&rdquo;)
necessary to conduct their respective businesses as now conducted. None of the material IP Rights of the Company or any of the Subsidiaries
are expected to expire or terminate within three (3) years from the date of this Agreement. Neither the Company nor any Subsidiary is
infringing, misappropriating or otherwise violating any IP Rights of any other Person. No claim has been asserted, and no Proceeding
is pending, against the Company or any Subsidiary alleging that the Company or any Subsidiary is infringing, misappropriating or otherwise
violating the IP Rights of any other Person, and, to the Company&rsquo;s knowledge, no such claim or Proceeding is threatened, and the
Company is not aware of any facts or circumstances which might give rise to any such claim or Proceeding. The Company and the Subsidiaries
have taken commercially reasonable security measures to protect the secrecy, confidentiality and value of all of their material IP Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.11
</B></FONT><U>Environmental Laws</U>. Except, in each case, as would not be reasonably anticipated to have a Material Adverse Effect,
the Company and the Subsidiaries (a) are in compliance with any and all applicable Laws relating to the protection of human health and
safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants, (b) have received and hold all permits,
licenses or other approvals required of them under all such Laws to conduct their respective businesses and (c) are in compliance with
all terms and conditions of any such permit, license or approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.12
</B></FONT><U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title to all personal property owned by
them which is material to their respective businesses, in each case free and clear of all liens, encumbrances and defects. Any real property
and facilities held under lease by the Company or any Subsidiary are held under valid, subsisting and enforceable leases with such exceptions
as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and
the Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.13
</B></FONT><U>Insurance</U>. The Company and each of the Subsidiaries are insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as management of the Company reasonably believes to be prudent and customary in the
businesses in which the Company and the Subsidiaries are engaged. Neither the Company nor any of the Subsidiaries has been refused any
insurance coverage sought or applied for, and the Company has no reason to believe that it will not be able to renew all existing insurance
coverage as and when such coverage expires or to obtain similar coverage from similar insurers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.14
</B></FONT><U>Regulatory Permits</U>. The Company and the Subsidiaries have in full force and effect all certificates, approvals, authorizations
and permits from all regulatory authorities and agencies necessary to own, lease or operate their respective properties and assets and
conduct their respective businesses, and neither the Company nor any Subsidiary has received any notice of Proceedings relating to the
revocation or modification of any such certificate, approval, authorization or permit, except for such certificates, approvals, authorizations
or permits with respect to which the failure to hold would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.15
</B></FONT><U>No Materially Adverse Contracts, Etc</U>. Neither the Company nor any of the Subsidiaries is (a) subject to any charter,
corporate or other legal restriction, or any judgment, decree or order which in the judgment of the Company&rsquo;s officers has or is
expected in the future to have a Material Adverse Effect or (b) a party to any contract or agreement which in the judgment of the Company&rsquo;s
management has or would reasonably be anticipated to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.16
</B></FONT><U>Taxes</U>. The Company and the Subsidiaries each has made or filed, or caused to be made or filed, all United States federal
and other material tax returns, reports and declarations required by any jurisdiction to which it is subject and has paid all taxes and
other governmental assessments and charges that are material in amount, required to be paid by it, regardless of whether such amounts
are shown or determined to be due on such returns, reports and declarations, except those being contested in good faith by appropriate
proceedings and for which it has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent
to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due
by the taxing authority of any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.17 </B></FONT><U>Solvency</U>.
After giving effect to the receipt by the Company of the proceeds from the transactions contemplated by this Agreement (a) the Company&rsquo;s
fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing
debts and other liabilities (including known contingent liabilities) as they mature; and (b)&nbsp;the current cash flow of the Company,
together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated
uses of the cash, would be sufficient to pay all amounts on or in respect of its debt when such amounts are required to be paid. The
Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts
of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe
that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.18 </B></FONT><U>Investment
Company</U>. The Company is not, and is not an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment
Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.19
</B></FONT><U>Certain Transactions</U>. Other than as disclosed in the SEC Documents, there are no contracts, transactions, arrangements
or understandings between the Company or any of its Subsidiaries, on the one hand, and any director, officer or employee thereof on the
other hand, that would be required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC in the Company&rsquo;s
Form 10-K or proxy statement pertaining to an annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.20
</B></FONT><U>No General Solicitation</U>. Neither the Company, nor any of its Affiliates, nor any person acting on its behalf, has engaged
in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale
of the Note or the Warrant pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.21
</B></FONT><U>Acknowledgment Regarding the Investor&rsquo;s Purchase of the Note and the Warrant</U>. The Company&rsquo;s Board of Directors
has approved the execution of the Transaction Documents and the issuance and sale of the Note and the Warrant, based on its own independent
evaluation and determination that the terms of the Transaction Documents are reasonable and fair to the Company and in the best interests
of the Company and its stockholders. The Company is entering into this Agreement and is issuing and selling the each of the Note and
the Warrant voluntarily and without economic duress. The Company has had independent legal counsel of its own choosing review the Transaction
Documents and advise the Company with respect thereto. The Company acknowledges and agrees that the Investor is acting solely in the
capacity of an arm&rsquo;s length purchaser with respect to the Note and the Warrant and the transactions contemplated hereby and that
neither the Investor nor any person affiliated with the Investor is acting as a financial advisor to, or a fiduciary of, the Company
(or in any similar capacity) with respect to execution of the Transaction Documents or the issuance of the Note and the Warrant or any
other transaction contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.22
</B></FONT><U>No Brokers&rsquo;, Finders&rsquo; or Other Advisory Fees or Commissions</U>. Except as set forth on Schedule 3.22, No brokers,
finders or other similar advisory fees or commissions will be payable by the Company or any Subsidiary or by any of their respective
agents with respect to the issuance of the Note or any of the other transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.23 </B></FONT><U>OFAC</U>.
None of the Company nor any of the Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate
or person acting on behalf of the Company and/or any Subsidiary has been or is currently subject to any United States sanctions administered
by the Office of Foreign Assets Control of the United States Department of the Treasury (&ldquo;<B>OFAC</B>&rdquo;); and the Company
will not directly or indirectly use any proceeds received from the Investor, or lend, contribute or otherwise make available such proceeds
to its Subsidiaries or to any affiliated entity, joint venture partner or other person or entity, to finance any investments in, or make
any payments to, any country or person currently subject to any of the sanctions of the United States administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.24 </B></FONT><U>No
Foreign Corrupt Practices</U>. None of the Company or any of the Subsidiaries has, directly or indirectly: (a) made or authorized any
contribution, payment or gift of funds or property to any official, employee or agent of any governmental authority of any jurisdiction
except as otherwise permitted under applicable Law; or (b) made any contribution to any candidate for public office, in either case,
where either the payment or the purpose of such contribution, payment or gift was, is, or would be prohibited under the Foreign Corrupt
Practices Act or the rules and regulations promulgated thereunder or under any other legislation of any relevant jurisdiction covering
a similar subject matter applicable to the Company or its Subsidiaries and their respective operations and the Company has instituted
and maintained policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
with such legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.25 </B></FONT><U>Anti-Money
Laundering</U>. The operations of each of the Company and the Subsidiaries are and have been conducted at all times in compliance with
all applicable anti-money laundering laws, regulations, rules and guidelines in its jurisdiction of incorporation and in each other jurisdiction
in which such entity, as the case may be, conducts business (collectively, the &ldquo;<B>Money Laundering Laws</B>&rdquo;) and no action,
suit or proceeding by or before any court or governmental authority involving the Company or its Subsidiaries with respect to any of
the Money Laundering Laws is, to the knowledge of the Company, pending, threatened or contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.26 </B></FONT><U>Disclosure</U>.
The Company confirms that neither it, nor to its knowledge, any other Person acting on its behalf has provided the Investor or its agents
or counsel with any information that the Company believes constitutes material, non-public information. The Company understands and confirms
that the Investor will rely on the foregoing representations and covenants in effecting transactions in securities of the Company. All
disclosures provided to the Investor regarding the Company, its business and the transactions contemplated hereby, furnished by or on
behalf of the Company (including the Company&rsquo;s representations and warranties set forth in this Agreement) are true and correct
in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>4.
</B></FONT><B><U>REPRESENTATIONS AND WARRANTIES OF THE INVESTOR</U></B>. The Investor represents and warrants to the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.1
</B></FONT><U>Organization and Qualification</U>. The Investor is a limited partnership, duly formed and validly existing in good standing
under the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.2
</B></FONT><U>Authorization; Enforcement; Compliance with Other Instruments</U>. The Investor has the requisite power and authority to
enter into this Agreement, to purchase the Note and the Warrant and to perform its obligations under the Transaction Documents. The execution
and delivery of the Transaction Documents to which it is a party have been duly and validly authorized by the Investor&rsquo;s governing
body and no further consent or authorization is required. The Transaction Documents to which it is a party have been duly and validly
executed and delivered by the Investor and constitute valid and binding obligations of the Investor, enforceable against the Investor
in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors&rsquo;
rights and remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.3
</B></FONT><U>No Conflicts</U>. The execution, delivery and performance of the Transaction Documents to which it is a party by the Investor
and the purchase of the Note and the Warrant by the Investor will not (a) conflict with or result in a violation of the Investor&rsquo;s
organizational documents, (b) conflict with, or constitute a material default (or an event which, with notice or lapse of time or both,
would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any
material agreement, contract, indenture mortgage, indebtedness or instrument to which the Investor is a party, or (c) violate in any
material respect any Law applicable to the Investor or by which any of the Investor&rsquo;s properties or assets are bound or affected.
No approval or authorization will be required from any governmental authority or agency, regulatory or self-regulatory agency or other
third party in connection with the purchase of the Note and the Warrant and the other transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.4
</B></FONT><U>Investment Intent; Accredited Investor</U>. The Investor is purchasing the Note and the Warrant for its own account, for
investment purposes, and not with a view towards distribution. The Investor is an &ldquo;accredited investor&rdquo; as such term is defined
in Rule 501(a) of Regulation D of the 1933 Act. The Investor has, by reason of its business and financial experience, such knowledge,
sophistication and experience in financial and business matters and in making investment decisions of this type that it is capable of
(a) evaluating the merits and risks of an investment in the Note, the Warrant and the Investor Shares and making an informed investment
decision, (b) protecting its own interests and (c) bearing the economic risk of such investment for an indefinite period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.5 </B></FONT><U>No
Other Representations.</U> Except for the representations and warranties set forth in this Agreement and in other Transaction
Documents, the Investor makes no other representations or warranties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>5.
</B></FONT><B>OTHER AGREEMENTS OF THE PARTIES</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.1 </B></FONT><U>Legends,
etc</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) Securities
may only be disposed of pursuant to an effective registration statement under the 1933 Act, to the Company or pursuant to an available
exemption from or in a transaction not subject to the registration requirements of the 1933 Act, and in compliance with any applicable
state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) Certificates
evidencing the Securities will contain the following legend, so long as is required by this <U>Section 5.1(b)</U> or <U>Section 5.1(c)</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">[NEITHER THESE SECURITIES
NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED] [THESE SECURITIES HAVE NOT BEEN REGISTERED] WITH
THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. [THESE SECURITIES
AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES] [THESE SECURITIES] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges
and agrees that the Investor may from time to time pledge, and/or grant a security interest in some or all of the Securities, in accordance
with applicable securities laws, pursuant to a bona fide margin agreement in connection with a bona fide margin account and, if required
under the terms of such agreement or account, the Investor may transfer pledged or secured Securities to the pledgees or secured parties.
Such a pledge or transfer would not be subject to approval or consent of the Company and no legal opinion of legal counsel to the pledgee,
secured party or pledgor shall be required in connection with the pledge, but such legal opinion may be required in connection with a
subsequent transfer following default by the Investor transferee of the pledge. No notice shall be required of such pledge. At the Company&rsquo;s
expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably
request in connection with a pledge or transfer of the Securities including the preparation and filing of any required prospectus supplement
under Rule 424(b)(3) of the 1933 Act or other applicable provision of the 1933 Act to appropriately amend the list of selling stockholders
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) Certificates
evidencing the Investor Shares shall not contain any legend (including the legend set forth in <U>Section 5.1(b)</U>): (i) while a Registration
Statement is effective under the 1933 Act, (ii) following any sale of such Investor Shares pursuant to Rule 144, (iii) while such Investor
Shares are eligible for sale without restriction under Rule 144, or (iv) if such legend is not required under applicable requirements
of the 1933 Act (including judicial interpretations and pronouncements issued by the Staff of the SEC). The Company shall cause its counsel
to issue any legal opinion or instruction required by the Company&rsquo;s transfer agent to comply with the requirements set forth in
this Section. At such time as a legend is no longer required for the Investor Shares under this <U>Section 5.1(c)</U>, the Company will,
no later than three (3) Business Days following the delivery by the Investor to the Company or the Company&rsquo;s transfer agent of
a certificate representing Investor Shares containing a restrictive legend (such third Business Day, the &ldquo;<B>Legend Removal Date</B>&rdquo;),
deliver or cause to be delivered to the Investor a certificate representing such Investor Shares that is free from all restrictive and
other legends. In addition to any other remedies available to the Investor, the Company shall pay to the Investor, in cash, as partial
liquidated damages and not as a penalty, for each $1,000 of Investor Shares (based on the VWAP of the Common Stock on the date such Investor
Shares are submitted to the Company or the Company&rsquo;s transfer agent) delivered for removal of the restrictive or other legend,
$5 per Trading Day for each Trading Day after the Legend Removal Date until such Investor Shares are delivered without a legend.&nbsp;
The Company may not make any notation on its records or give instructions to any transfer agent of the Company that enlarge the restrictions
on transfer set forth in this Section except as it may reasonably determine are necessary or appropriate to comply or to ensure compliance
with those applicable laws that are enacted or modified after the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.2 </B></FONT><U>Furnishing
of Information</U>. As long as the Investor owns the Securities, the Company covenants to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to
the 1934 Act. As long as the Investor owns the Securities, if the Company is not required to file reports pursuant to such laws, it will
prepare and furnish to the Investor and make publicly available in accordance with Rule 144(c) such information as is required for the
Investor to sell the Investor Shares under Rule 144. The Company further covenants that it will take such further action as any holder
of the Securities may reasonably request, all to the extent required from time to time to enable such Person to sell such Investor Shares
without registration under the 1933 Act within the limitation of the exemptions provided by Rule 144 or other applicable exemptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.3 </B></FONT><U>Integration</U>.
The Company shall not, and shall use its best efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit
offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that will be integrated with
the offer or sale of the Securities in a manner that would require the registration under the 1933 Act of the sale of the Securities
to the Investor, or that will be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any
Trading Market that would require, under the rules of the Trading Market, the Shareholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.4 </B></FONT><U>Notification
of Certain Events</U>. The Company shall give prompt written notice to the Investor of (a)&nbsp;the occurrence or non-occurrence of any
Event, the occurrence or non-occurrence of which would render any representation or warranty of the Company contained in this Agreement
or any other Transaction Document, if made on or immediately following the date of such Event, untrue or inaccurate in any material respect,
(b)&nbsp;the occurrence of any Event that, individually or in combination with any other Events, has had or could reasonably be expected
to have a Material Adverse Effect, (c)&nbsp;any failure of the Company to comply with or satisfy any covenant or agreement to be complied
with or satisfied by it hereunder or any Event that would otherwise result in the nonfulfillment of any of the conditions to the Investor&rsquo;s
obligations hereunder, (d)&nbsp;any written notice or other written communication from any Person alleging that the consent of such Person
is or may be required in connection with the consummation of the transactions contemplated by this Agreement or any other Transaction
Document, or (e)&nbsp;any Proceeding pending or, to the Company&rsquo;s knowledge, threatened against a party relating to the transactions
contemplated by this Agreement or any other Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>5.5
</B></FONT><U>Available Stock</U>. The Company shall at all times keep authorized and reserved and available for issuance, free of preemptive
rights, such number of shares of Common Stock as are issuable upon repayment or conversion in full of the Note and exercise in full of
the Warrant at any time. If the Company determines at any time that it does not have a sufficient number of authorized Common Stock to
reserve and keep available for issuance as described in this <U>Section 5.5</U>, the Company shall use all commercially reasonable efforts
to increase the number of authorized Common Stock by seeking Shareholder Approval for the authorization of such additional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>5.6
</B></FONT><U>Use of Proceeds</U>. The Company will use the proceeds from the sale of the Note and the Warrant for general working capital
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.7 </B></FONT><U>Repayment
of Indebtedness</U>. The Company shall not make any voluntary cash prepayments on any Indebtedness at any time while any amounts are
owing under the Note other than cash payments the Company is required to make pursuant to the express terms thereof existing on the date
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.8 </B></FONT><U>Intercreditor
Agreement</U>. In the event that the Company or any Subsidiary incurs debt or issues convertible debt securities to a seller as partial
consideration paid to such seller in connection with an Acquisition, unless otherwise waived in writing by the Investor, as a condition
to consummation of such Acquisition, the holder of such debt or convertible debt securities shall enter into an intercreditor agreement
with the Company and the Investor on terms reasonably satisfactory to the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.9 </B></FONT><U>Prohibited
Transactions</U>. The Company hereby covenants and agrees not to enter into any Prohibited Transactions without the Investor&rsquo;s
prior written consent, until the later of (a) thirty (30) days after such time as the Note have been repaid in full, as applicable, and/or
have been converted into Conversion Shares and (b) the date on which the Investor ceases to hold any shares of Common Stock or have the
right to acquire any shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.10 </B></FONT><U>Securities
Laws Disclosure; Publicity</U>. The Company shall, by 9:00 a.m. (New York City time) on the Trading Day immediately following the date
hereof, issue a press release disclosing the material terms of the transactions contemplated hereby (the <B>&ldquo;Press Release&rdquo;</B>),
and shall, within four (4) business days following the date hereof, file a Report on Form 8-K (the <B>&ldquo;Form 8-K&rdquo;</B>) disclosing
the material terms of the transactions contemplated hereby and including this Agreement as an exhibit thereto; provided, that the Company
may not issue the Press Release without the Investor&rsquo;s prior written consent, which shall not be unreasonably withheld. The Company
shall provide a copy of the draft Form 8-K to the Investor for review prior to release and the Company shall incorporate the Investor&rsquo;s
reasonable comments. The Company shall not issue any press release nor otherwise make any such public statement regarding the Investor
or the Transaction Documents without the prior written consent of the Investor, except if such disclosure is made in a manner consistent
with the Press Release or Form 8-K, or is required by law, in which case the Company shall (a) ensure that such disclosure is restricted
and limited in content and scope to the maximum extent permitted by Law to meet the relevant disclosure requirement and (b) provide a
copy of the proposed disclosure to the Investor for review prior to release and the Company shall incorporate the Investor&rsquo;s reasonable
comments. Following the execution of this Agreement, the Investor and its Affiliates and/or advisors may place announcements on their
respective corporate websites and in financial and other newspapers and publications (including, without limitation, customary &ldquo;tombstone&rdquo;
advertisements) describing the Investor&rsquo;s relationship with the Company under this Agreement in a manner consistent with the Press
Release or Form 8-K and including the name and corporate logo of the Company. Notwithstanding anything herein to the contrary, to comply
with United States Treasury Regulations Section 1.6011-4(b)(3)(i), each of the Company and the Investor, and each employee, representative
or other agent of the Company or the Investor, may disclose to any and all persons, without limitation of any kind, the U.S. federal
and state income tax treatment, and the U.S. federal and state income tax structure, of the transactions contemplated hereby and all
materials of any kind (including opinions or other tax analyses) that are provided to such party relating to such tax treatment and tax
structure insofar as such treatment and/or structure relates to a U.S. federal or state income tax strategy provided to such recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.11 </B></FONT><U>Indemnification
of the Investor</U>. Subject to the provisions of this Section 5.11, the Company will indemnify and hold the Investor and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls the Investor (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members,
partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title) of such controlling persons (each, a &ldquo;<B>Investor Party</B>&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Investor Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents, (b) any action instituted against the Investor Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Investor Party, with respect to any of the transactions
contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Investor Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Investor Party may have with any such
stockholder or any violations by such Investor Party of state or federal securities laws or any conduct by such Investor Party which
is finally judicially determined to constitute fraud, gross negligence or willful misconduct), (c) any misrepresentation made by the
Company in any Transaction Document or in any SEC Document, (d) any omission to state any material fact necessary in order to make the
statements made in any SEC Document, in light of the circumstances under which they were made, not misleading, or (e) any Proceeding
before or by any court, public board, government agency, self-regulatory organization or body based upon, or resulting from the execution,
delivery, performance or enforcement of any of the Transaction Documents or the consummation of the transactions contemplated thereby,
and whether or not an Investor Party is party thereto by claim, counterclaim, crossclaim, as a defendant or otherwise, or if such Proceeding
is based upon, or results from, any of the items set forth in clauses (a) through (e) above. If any action shall be brought against any
Investor Party in respect of which indemnity may be sought pursuant to this Agreement, such Investor Party shall promptly notify the
Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Investor Party. Any Investor Party shall have the right to employ separate counsel in any such action and participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of such Investor Party except to the extent that (i) the employment
thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to
assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict
on any material issue between the position of the Company and the position of such Investor Party, in which case the Company shall be
responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Investor
Party under this Agreement (y) for any settlement by an Investor Party effected without the Company&rsquo;s prior written consent, which
shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is
attributable to any Investor Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by such Investor
Party in this Agreement or in the other Transaction Documents. The indemnification required by this <U>Section 5.11</U> shall be made
by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred.
The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Investor Party against
the Company or others and any liabilities the Company may be subject to pursuant to law. The provisions of this <U>Section 5.11</U> shall
survive the termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.12 </B></FONT><U>Non-Public
Information</U>. The Company covenants and agrees that neither it nor any other Person acting on its behalf will provide the Investor
or its agents or counsel with any information that the Company believes constitutes material, non-public information. To the extent the
Company provides the Investor with material, non-public information, the Company shall publicly disclose such information within forty
eight (48) hours of providing the information to the Investor; provided, however, in the event that such material non-public information
is provided to Investor pursuant to <U>Section 10</U>, the Company shall publicly disclose such information within five (5) Business
Days of providing the information to the Investor. The Company understands and confirms that the Investor shall be relying on the foregoing
representation in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.13 </B></FONT><U>Shareholder
Approval</U>. If required by the rules and regulations of the Trading Market or to otherwise fulfill any of its obligations under the
Transaction Documents, the Company shall hold a special meeting of shareholders (which may also be at the annual meeting of shareholders)
on or before the 60th calendar day following the date hereof for the purpose of obtaining the Shareholder Approval; provided, however,
such sixty (60) calendar days shall be increased to ninety (90) calendar days in the event the Company receives comments to its proxy
statement from the SEC, with the recommendation of the Board of Directors that such proposal be approved, and the Company shall solicit
proxies from its shareholders in connection therewith in the same manner as all other management proposals in such proxy statement and
all management-appointed proxyholders shall vote their proxies in favor of such proposal. If the Company does not obtain Shareholder
Approval at the first meeting, the Company shall call a meeting every four months thereafter to seek Shareholder Approval until the date
the Shareholder Approval is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.14 </B></FONT><U>Listing
of Securities</U>. The Company shall: (a) in the time and manner required by each Trading Market on which the Common Stock is listed,
prepare and file with such Trading Market a Listing of Additional Shares form covering the Investor Shares, (b)&nbsp;take all steps necessary
to cause such shares to be approved for listing on each Trading Market on which the Common Stock is listed as soon as possible thereafter,
(c) provide to the Investor evidence of such Trading Market&rsquo;s completion of review of the Listing of Additional Shares form, and
(d) maintain the listing of such shares on each such Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.15 </B></FONT><U>Antitrust
Notification</U>. If the Investor determines, in its sole judgment and upon the advice of counsel, that the issuance of the Note, the
Warrant or the Investor Shares pursuant to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended (the &ldquo;<B>HSR Act</B>&rdquo;), the Company shall file as soon as practicable after the date on which the
Company receives notice from the Investor of the applicability of the HSR Act and a request to so file with the United States Federal
Trade Commission and the United States Department of Justice the notification and report form required to be filed by it pursuant to
the HSR Act in connection with such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.16 </B></FONT><U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.17 </B></FONT><U>Share
Transfer Agent</U>. The Company has informed the Investor of the name of its share transfer agent and represents and warrants that the
transfer agent participates in the Depository Trust Company Fast Automated Securities Transfer program. The Company shall not change
its share transfer agent without the prior written consent of the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.18 </B></FONT><U>Tax
Treatment</U>. The Investor and the Company agree that for U.S. federal income tax purposes, and applicable state, local and non-U.S.
income tax purposes, the Note is not intended to be, and shall not be, treated as indebtedness. Neither the Investor nor the Company
shall take any contrary position on any tax return, or in any audit, claim, investigation, inquiry or proceeding in respect of taxes,
unless otherwise required pursuant to a final determination within the meaning of Section 1313 of the Internal Revenue Code of 1986,
as amended, or any analogous provision of applicable state, local or non-U.S. law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.19 </B></FONT><U>Set-Off</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) The
Investor may set off any of its obligations to the Company (whether or not due for payment), against any of the Company&rsquo;s obligations
to the Investor (whether or not due for payment) under this Agreement and/or any other Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) The
Investor may do anything necessary to effect any set-off undertaken in accordance with this <U>Section 5.16</U> (including varying the
date for payment of any amount payable by the Investor to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>6. </B></FONT><B>CLOSING
CONDITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.1 </B></FONT><U>Conditions
Precedent to the Obligations of the Investor</U>. The obligations of the Investor to fund the Note and acquire the Warrant are subject
to the satisfaction or waiver by the Investor, at or before the Closing of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) <U>Required
Documentation</U>. The Company must have delivered to the Investor (i) a duly executed certificate of an officer of the Company and each
Subsidiary appending thereto (A) copies of duly executed resolutions or consents, of the directors, members or manager, as applicable,
approving and consenting to such party&rsquo;s execution, performance of its obligations under the Transaction Documents and the transaction
contemplated thereby, (B) a certificate of good standing or equivalent document dated no more than five days prior to the date hereof,
in respect of such party, (C) true and correct copies of the organizational documents of such party, and (D) incumbency signatures of
such part, and (ii) copies of each Transaction Document, duly executed by the Company, the Subsidiaries or the Transfer Agent, as applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) <U>Consents
and Permits</U>. The Company must have obtained and delivered to the Investor copies of all necessary permits, approvals, and registrations
necessary to effect this Agreement, the Transaction Documents and any of the transactions contemplated hereby or thereby, including pursuant
to <U>Section 3.14</U> of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) <U>Trading
Market Approval</U>. The Company shall have either (i) obtained and delivered to the Investor copies of all necessary Trading Market
approvals for the issuance of the Note, the Warrant, and, upon the conversion of the Note, the Conversion Shares, and upon exercise of
the Warrant, the Warrant Shares, or (ii) submitted a Listing of Additional Shares Notification Form with the Trading Market relating
to the issuance of the Note, the Warrant, and, upon conversion of the Note, the Conversion Shares, and upon exercise of the Warrant,
the applicable Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) <U>No
Event(s) of Default</U>. The Investor must be of the reasonable opinion that no Event of Default has occurred and no Event of Default
would result from the execution of this Agreement or any of the Transaction Documents or the transactions contemplated hereby or thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e) <U>Representations
and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct in all material respects
as of the date when made and as of the Closing Date as though made on and as of such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f) <U>Performance</U>.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required
by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g) <U>No
Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h) <U>No
Suspensions of Trading in Common Stock; Listing</U>. Trading in the Common Stock shall not have been suspended by the SEC or any Trading
Market (except for any suspensions of trading of not more than one day on which the Trading Market is open solely to permit dissemination
of material information regarding the Company) at any time since the date of execution of this Agreement, and the Common Stock shall
have been at all times since such date listed for trading on a Trading Market;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) <U>Limitation
on Beneficial Ownership</U>. The issuance of the Note and the Warrant shall not cause the Investor Group to become, directly or indirectly,
a &ldquo;beneficial owner&rdquo; (within the meaning of Section 13(d) of the 1934 Act and the rules and regulations promulgated thereunder)
of a number of Equity Interests of a class that is registered under the 1934 Act which exceeds the Maximum Percentage of the Equity Interests
of such class that are outstanding at such time; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j) <U>Funds
Flow Request</U>. The Company shall have delivered to the Investor a flow of funds request, substantially in the form set out in <B><U>Exhibit
E</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.2 </B></FONT><U>Conditions
Precedent to the Obligations of the Company</U>. The obligations of the Company to issue the Note and the Warrant are subject to the
satisfaction or waiver by the Company, at or before the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) <U>Representations
and Warranties</U>. The representations and warranties of the Investor contained herein shall be true and correct in all material respects
as of the date when made and as of the Closing Date as though made on and as of such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) <U>Performance</U>.
The Investor shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required
by the Transaction Documents to be performed, satisfied or complied with by the Investor at or prior to the Closing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) <U>No
Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>7. </B></FONT><B><U>EVENTS
OF DEFAULT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.1 </B></FONT><U>Events
of Default</U>. The occurrence of any of the following events shall be an &ldquo;<B>Event of Default</B>&rdquo; under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) an
Event of Default (as defined in the Note);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) any
of the representations or warranties made by the Company or any of its agents, officers, directors, employees or representatives in any
Transaction Document or public filing being inaccurate, false or misleading in any material respect, as of the date as of which it is
made or deemed to be made, including as of the Closing Date, or any certificate or financial or other written statements furnished by
or on behalf of the Company to the Investor or any of its representatives, is inaccurate, false or misleading, in any material respect,
as of the date as of which it is made or deemed to be made, including as of the Closing Date; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) a
failure by the Company to comply with any of its covenants or agreements set forth in this Agreement, including those set forth in <U>Section
9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.2 </B></FONT><U>Investor
Right to Investigate an Event of Default</U>. If in the Investor&rsquo;s reasonable opinion, an Event of Default has occurred, or is
or may be continuing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) the
Investor may notify the Company that is wishes to investigate such purported Event of Default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) the
Company shall cooperate with the Investor in such investigation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) the
Company shall comply with all reasonable requests made by the Investor to the Company in connection with any investigation by the Investor
and shall (i) provide all information requested by the Investor in relation to the Event of Default to the Investor; provided that the
Investor agrees that any materially price sensitive information and/or non-public information will be subject to confidentiality, and
(ii) provide all such requested information within three (3) Business Days of such request; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) the
Company shall pay all reasonable costs incurred by the Investor in connection with any such investigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.3 </B></FONT><U>Remedies
Upon an Event of Default</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) If
an Event of Default occurs pursuant to <U>Section 7.1(a)</U>, the Investor shall have such remedies as are set forth in the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) If
an Event of Default occurs pursuant to <U>Section 7.1(b)</U> or <U>Section&nbsp;7.1(c)</U> and is not remedied within (i) two (2) Business
Days for an Event of Default occurring by the Company&rsquo;s failure to comply with <U>Section 7.1(c)</U>, or (ii) five (5) Business
Days for an Event of Default occurring pursuant to <U>Section 7.1(b)</U>, the Investor may declare, by notice to the Company, effective
immediately, all outstanding obligations by the Company under the Transaction Documents to be immediately due and payable in immediately
available funds and the Investor shall have no obligation to consummate the Closing or to accept the conversion of the Note into Conversion
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>8. </B></FONT><B><U>TERMINATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.1 </B></FONT><U>Events
of Termination</U>. Prior to the occurrence of the Closing, this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) may
be terminated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i) by
the Investor on the occurrence or existence of a Securities Termination Event or a Change of Control; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii) by
either Party, by written notice to the other Party, effective immediately, if the Closing has not occurred within ten (10) Business Days
of the date specified by this Agreement or such later date as the Company and the Investor agree in writing, provided that the right
to terminate this Agreement under this <U>Section 8.1(a)(ii)</U> is not available to any party that is in material breach of or material
default under this Agreement or whose failure to fulfill any obligation under this Agreement has been the principal cause of, or has
resulted in the failure of the Closing to occur; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iii) by the Investor, in
accordance with <U>Section 7.3(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.2 </B></FONT><U>Effect
of Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) Subject
to <U>Section 8.2(b)</U>, each party&rsquo;s right of termination under <U>Section 8.1</U> is in addition to any other rights it may
have under this Agreement or otherwise, and the exercise of a right of termination will not be an election of remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) If
the Investor terminates this Agreement under <U>Section 8.1(a)(i)</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i) the
Investor may declare, by notice to the Company, all outstanding obligations by the Company under the Transaction Documents to be due
and payable without presentment, demand, protest or any other notice of any kind all of which are expressly waived by the Company, anything
to the contrary contained in this Agreement or in any other Transaction Document notwithstanding; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) Nothing
in this Agreement will be deemed to release the Purchaser from any liability for any breach by such party of the terms and provisions
of this Agreement or to impair the right of any party to compel specific performance by any other Party of its obligations under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>9. </B></FONT><B>REGISTRATION
RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.1 </B></FONT><U>Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) <U>Registration
Statement</U>. Promptly, but in any event no later than sixty (60) days from the date of this Agreement, the Company shall prepare and
file with the SEC a Registration Statement covering the resale of all of the Investor Shares. The foregoing Registration Statement shall
be filed on Form S-1 or any successor forms thereto. The Registration Statement (and each amendment or supplement thereto, and each request
for acceleration of effectiveness thereof) shall be provided to the Investor and its counsel at least five (5) Business Days prior to
its filing or other submission and the Company shall incorporate all reasonable comments provided by the Investor or its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) <U>Expenses</U>.
Except as otherwise expressly provided herein, the Company will pay all fees and expenses incident to the performance of or compliance
with this <U>Section 9</U>, including all fees and expenses associated with effecting the registration of the Investor Shares, including
all filing and printing fees, the Company&rsquo;s counsel and accounting fees and expenses, costs associated with clearing the Investor
Shares for sale under applicable state securities laws, listing fees, fees and expenses of one counsel to the Investor and the Investor&rsquo;s
reasonable expenses in connection with the registration, but excluding discounts, commissions, fees of underwriters, selling brokers,
dealer managers or similar securities industry professionals with respect to the Investor Shares being sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) <U>Effectiveness</U>.
The Company shall use its best efforts to have the Registration Statement declared effective as soon as practicable after filing thereof
but in no event later than the date that is ninety (90) days following the Closing Date; provided, however, that such date will be extended
for an additional 15 days in the event that the Company receives comments to the Registration Statement from the SEC. The Company shall
notify the Investor by e-mail as promptly as practicable, and in any event, within twenty-four (24) hours, after the Registration Statement
is declared effective and shall simultaneously provide the Investor with copies of any related Prospectus to be used in connection with
the sale or other disposition of the securities covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) <U>Piggyback
Registration Rights</U>. If the Company at any time determines to file a registration statement under the 1933 Act to register the offer
and sale, by the Company, of Common Stock (other than (x) on Form S-4 or Form S-8 under the 1933 Act or any successor forms thereto,
(y) an at-the-market offering, or (z) a registration of securities solely relating to an offering and sale to employees or directors
of the Company pursuant to any employee stock plan or other employee benefit plan arrangement), the Company shall, as soon as reasonably
practicable, give written notice to the Investor of its intention to so register the offer and sale of Common Stock and, upon the written
request, given within five (5) Business Days after delivery of any such notice by the Company, of the Investor to include in such registration
the Investor Shares (which request shall specify the number of Investor Shares proposed to be included in such registration), the Company
shall cause all such Investor Shares to be included in such registration statement on the same terms and conditions as the Common Stock
otherwise being sold pursuant to such registered offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.2 </B></FONT><U>Company
Obligations</U>. The Company will use its best efforts to effect the registration of the Investor Shares in accordance with the terms
hereof, and pursuant thereto the Company will, as expeditiously as possible:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) use
its commercially reasonable efforts to cause the Registration Statement to become effective and to remain continuously effective for
a period that will terminate upon the first date on which all Investor Shares are either covered by the Registration Statement or may
be sold without restriction, including volume or manner-of-sale restrictions, pursuant to Rule 144 or have been sold by the Investor
(the &ldquo;<B>Effectiveness Period</B>&rdquo;) and advise the Investor in writing when the Effectiveness Period has expired;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) prepare
and file with the SEC such amendments and post-effective amendments and supplements to the Registration Statement and the Prospectus
as may be necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the provisions of the
1933 Act and the 1934 Act with respect to the distribution of all of the Investor Shares covered thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) provide
copies to and permit counsel designated by the Investor to review all amendments and supplements to the Registration Statement no fewer
than three (3) Business Days prior to its filing with the SEC and not file any document to which such counsel reasonably objects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) furnish
to the Investor and its legal counsel, without charge, (i) promptly after the same is prepared and publicly distributed, filed with the
SEC, or received by the Company (but not later than two (2) Business Days after the filing date, receipt date or sending date, as the
case may be) one copy of the Registration Statement and any amendment thereto, each preliminary prospectus and Prospectus and each amendment
or supplement thereto, and each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence
from the SEC or the staff of the SEC, in each case relating to the Registration Statement (other than any portion of any thereof which
contains information for which the Company has sought confidential treatment), and (ii) such number of copies of a Prospectus, including
a preliminary prospectus, and all amendments and supplements thereto and such other documents as the Investor may reasonably request
in order to facilitate the disposition of the Investor Shares that are covered by the related Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e) immediately
notify the Investor of any request by the SEC for the amending or supplementing of the Registration Statement or Prospectus or for additional
information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f) use
its commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such
order is issued, obtain the withdrawal of any such order at the earliest possible moment and notify the Company of the issuance of any
such order and the resolution thereof, or its receipt of notice of the initiation or threat of any proceeding for such purpose;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g) prior
to any public offering of Investor Shares, use its commercially reasonable efforts to register or qualify or cooperate with the Investor
and its counsel in connection with the registration or qualification of such Investor Shares for offer and sale under the securities
or blue sky laws of such jurisdictions requested by the Investor and do any and all other commercially reasonable acts or things necessary
or advisable to enable the distribution in such jurisdictions of the Investor covered by the Registration Statement and the Company shall
promptly notify the Investor of any notification with respect to the suspension of the registration or qualification of any of such Investor
Shares for sale under the securities or blue sky laws of such jurisdictions or its receipt of notice of the initiation or threat of any
proceeding for such purpose;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h) immediately
notify the Investor, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon the happening of any event
as a result of which, the Registration Statement or Prospectus includes an untrue statement of a material fact or omits to state any
material fact required to be stated therein or necessary to make the statements therein not misleading (in the case of the Prospectus,
in light of the circumstances in which they were made), and promptly prepare, file with the SEC and furnish to such holder a supplement
to or an amendment of such Registration Statement or Prospectus as may be necessary so that such Registration Statement or Prospectus
shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading (in the case of such Prospectus, in light of the circumstances in which they were made);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) otherwise
use its commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the 1933 Act and the 1934
Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j) hold
in confidence and not make any disclosure of information concerning the Investor provided to the Company unless (i) disclosure of such
information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to complete
the Registration Statement or to avoid or correct a misstatement or omission in the Registration Statement, (iii) the release of such
information is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental body of competent jurisdiction,
or (iv) such information has been made generally available to the public other than by disclosure in violation of this Agreement or any
other agreement, and upon learning that disclosure of such information concerning the Investor is sought in or by a court or governmental
body of competent jurisdiction or through other means, give prompt written notice to the Investor and allow the Investor, at the Investor&rsquo;s
expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(k) take
all other reasonable actions necessary to expedite and facilitate disposition by the Investor of all Investor Shares pursuant to the
Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.3 </B></FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) <U>Indemnification
by the Company</U>. The Company will indemnify and hold harmless the Investor Parties, from and against any Losses to which they may
become subject under the 1933 Act or otherwise, arising out of, relating to or based upon: (i) any untrue statement or alleged untrue
statement of any material fact contained in any Registration Statement, any preliminary Prospectus, final Prospectus or other document,
including any Blue Sky Application (as defined below), or any amendment or supplement thereof or any omission or alleged omission of
a material fact required to be stated therein or, in the case of the Registration Statement, necessary to make the statements therein
not misleading or, in the case of any preliminary Prospectus, final Prospectus or other document, necessary to make the statements therein,
in light of the circumstances in which they were made, not misleading; (ii) any Blue Sky Application or other document executed by the
Company specifically for that purpose or based upon written information furnished by the Company filed in any state or other jurisdiction
in order to qualify any or all of the Investor Shares under the securities laws thereof (any such application, document or information
herein called a &ldquo;<B>Blue Sky Application</B>&rdquo;); (iii) any violation or alleged violation by the Company or its agents of
the 1933 Act, the 1934 Act or any similar federal or state law or any rule or regulation promulgated thereunder applicable to the Company
or its agents and relating to any action or inaction required of the Company in connection with the registration or the offer or sale
of the Investor Shares pursuant to any Registration Statement; or (iv) any failure to register or qualify the Investor Shares included
in any such Registration Statement in any state where the Company or its agents has affirmatively undertaken or agreed in writing that
the Company will undertake such registration or qualification on the Investor&rsquo;s behalf and will reimburse the Investor Indemnified
Parties for any legal or other expenses reasonably incurred by them in connection with investigating, preparing or defending any such
Losses; <U>provided</U>, <U>however</U>, that the Company will not be liable in any such case if and to the extent, but only to the extent,
that any such Losses arise out of or are based upon an untrue statement or alleged untrue statement or omission or alleged omission so
made in conformity with information furnished by the Investor or any such controlling Person in writing specifically for use in such
Registration Statement or Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) <U>Conduct
of Indemnification Proceedings</U>. Any Person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying
party of any claim, action, suit or proceeding with respect to which it seeks indemnification following such Person&rsquo;s receipt of,
or such Person otherwise become aware of, the commencement of such claim, action, suit or proceeding and (ii) permit such indemnifying
party to assume the defense of such claim, action, suit or proceeding with counsel reasonably satisfactory to the indemnified party;
<U>provided</U>, <U>however</U>, that any Person entitled to indemnification hereunder shall have the right to employ separate counsel
and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such Person unless
(A) the indemnifying party has agreed to pay such fees or expenses, (B) the indemnifying party shall have failed to assume the defense
of such claim and employ counsel reasonably satisfactory to such Person or (C) in the reasonable judgment of any such Person, based upon
written advice of its counsel, a conflict of interest exists between such Person and the indemnifying party with respect to such claims
(in which case, if the Person notifies the indemnifying party in writing that such Person elects to employ separate counsel at the expense
of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such Person);
and <U>provided</U>, <U>further</U>, that the failure or delay of any indemnified party to give notice as provided herein shall not relieve
the indemnifying party of its obligations hereunder, except to the extent that such failure or delay to give notice shall materially
adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party
shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm
of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party,
consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) <U>Contribution</U>.
If for any reason the indemnification provided for in the preceding paragraph (a) is unavailable to an indemnified party or insufficient
to hold it harmless, other than as expressly specified therein, the indemnifying party shall contribute to the amount paid or payable
by the indemnified party as a result of such Losses in such proportion as is appropriate to reflect the relative fault of the indemnified
party and the indemnifying party, as well as any other relevant equitable considerations. No Person guilty of fraudulent misrepresentation
within the meaning of Section 11(f) of the 1933 Act shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation.
The indemnity and contribution agreements contained in this Section are in addition to any other rights or remedies that any indemnified
party may have under applicable law, by separate agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.4 </B></FONT><U>Effect
of Failure to File and Maintain Effectiveness of any Registration Statement</U>. In addition to any other remedies provided under the
Transaction Documents, if (i) the Registration Statement covering the resale of all of the Investor Shares required to be covered thereby
and required to be filed by the Company pursuant to Section 9.1 is not filed with the SEC on or before the Filing Deadline (a &ldquo;<B>Filing
Failure</B>&rdquo;), (ii) on any day after the effective date of a Registration Statement sales of all of the Registrable Securities
required to be included on such Registration Statement cannot be made pursuant to such Registration Statement (including, without limitation,
because of a failure to keep such Registration Statement effective, a failure to disclose such information as is necessary for sales
to be made pursuant to such Registration Statement, a suspension or delisting of (or a failure to timely list) the shares of Common Stock
on a Trading Market, or a failure to register a sufficient number of shares of Common Stock or by reason of a stop order) or the prospectus
contained therein is not available for use for any reason (a &ldquo;Maintenance Failure&rdquo;), other than the period of time where
the Registration Statement is not effective due to a post-effective amendment filing to the Registration Statement after an Annual Report
on Form 10-K is filed, or (iii) if the Company fails to file with the SEC any required reports under Section 13 or 15(d) of the 1934
Act such that it is not in compliance with Rule 144(c)(1) (or Rule 144(i)(2), if applicable) (a &ldquo;Current Public Information Failure&rdquo;)
as a result of which the Investor is unable to sell those Investor Shares included in such Registration Statement without restriction
under Rule 144 (including, without limitation, volume restrictions), then, as partial relief for the damages to any holder by reason
of any such delay in, or reduction of, its ability to sell the underlying shares of Common Stock (which remedy shall not be exclusive
of any other remedies available at law or in equity), the Company shall pay to each holder of Investor Shares relating to such Registration
Statement an amount in cash equal to two percent (2.0%) of the Outstanding Principal Amount (I) on the date of such Filing Failure, Maintenance
Failure or Current Public Information Failure, as applicable, and (2) on every thirty (30) day anniversary of (I) a Filing Failure until
such Filing Failure is cured; (II) a Maintenance Failure until such Maintenance Failure is cured; and (III) a Current Public Information
Failure until the earlier of (i) the date such Current Public Information Failure is cured and (ii) such time that such public information
is no longer required pursuant to Rule 144 (in each case, pro rated for periods totaling less than thirty (30) days). The payments to
which a holder of Investor Shares shall be entitled pursuant to this Section 9.4 are referred to herein as &ldquo;Registration Delay
Payments.&rdquo; Following the initial Registration Delay Payment for any particular event or failure (which shall be paid on the date
of such event or failure, as set forth above), without limiting the foregoing, if an event or failure giving rise to the Registration
Delay Payments is cured prior to any thirty (30) day anniversary of such event or failure, then such Registration Delay Payment shall
be made on the third (3rd) Trading Day after such cure. Notwithstanding the foregoing, (i) no single event or failure with respect to
a particular Registration Statement shall give rise to more than one type of Registration Delay Payment with respect to such Registration
Statement, (ii) no Registration Delay Payments shall be owed to the Investor (with respect to any period during which all of Investor
Shares may be sold by the Investor without restriction under Rule 144 (including, without limitation, volume restrictions) and without
the need for current public information required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable), and (iii) with respect to any
Investor Shares excluded from a Registration Statement by election of the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>10. </B></FONT><B>RIGHTS
TO FUTURE STOCK ISSUANCES.</B> Subject to the terms and conditions of this <U>Section 10</U> and applicable securities laws, if at any
time prior to date that is eighteen months following the Closing, the Company proposes to offer or sell any New Securities (a <B>&ldquo;Subsequent
Financing&rdquo;</B>), the Company shall first offer the Investor the opportunity to purchase up to ten percent (10%) of such New Securities.
The Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate
among itself and&nbsp;its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.1 </B></FONT>The
Company shall give notice (the &ldquo;<B>Offer Notice</B>&rdquo;) to the Investor, stating (a) its bona fide intention to offer such
New Securities, (b) the number of such New Securities to be offered, and (c) the price and terms, if any, upon which it proposes to offer
such New Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.2 </B></FONT>By
notification to the Company within one (1) business day after the date the Offer Notice is given (the <B>&ldquo;Notice Termination Time&rdquo;</B>),
the Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to ten percent
(10%) of such New Securities. If the Company receives no such notice from the Investor as of such Notice Termination Time, the Investor
shall be deemed to have notified the Company that it does not elect to participate in such Subsequent Financing. The closing of any sale
pursuant to this <U>Section 9</U> shall occur within five (5) days of the date that the Offer Notice is given and the date of initial
sale of New Securities pursuant to <U>Section&nbsp;10.3.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.3 </B></FONT>The
Company may, during the five (5) day period following the expiration of the period provided in <U>Section 10.2</U>, offer and sell the
remaining portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree
than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within
such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall
be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this
<U>Section 10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.4 </B></FONT>The
right of first offer in this <U>Section 10</U> shall not be applicable to Exempted Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>11. </B></FONT><B><U>GENERAL
PROVISIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.1
</B></FONT><U>Fees and Expenses</U>. Prior to the date of this Agreement, the Company has paid Lucosky Brookman LLP $25,000. At the Closing,
the Company shall reimburse the Investor up to an additional $50,000 of due diligence costs and reasonable fees and disbursements of
Lucosky Brookman LLP in connection with the preparation of the Transaction Documents, it being understood that Lucosky Brookman LLP has
not rendered any legal advice to the Company in connection with the transactions contemplated hereby and that the Company has relied
for such matters on the advice of its own counsel. Except as specified above, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of the Transaction Documents. The Company shall pay all stamp and other taxes and duties levied in
connection with the sale of the Note and the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.2 </B></FONT><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via email
at the email address specified in this Section prior to 5:00 p.m. (New York time) on a Business Day, (b) the next Business Day after
the date of transmission, if such notice or communication is delivered via email at the email address specified in this Section on a
day that is not a Business Day or later than 5:00 p.m. (New York time) on any date and earlier than 11:59 p.m. (New York time) on such
date, (c) the Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (d) upon
actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">ABVC BioPharma, Inc.,<BR>
44370 Old Warm Springs Blvd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">Fremont, CA 94538</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">Telephone:<BR>
Email: howard.doong@ambrivis.com<BR>
Attention: Howard Doong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">If to the Investor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">Lind Global Fund II LP<BR>
Telephone:<BR>
Email:<BR>
Attention: Jeff Easton</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">With a copy (which shall not constitute
notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">Lucosky Brookman LLP<BR>
101 Wood Avenue South<BR>
Fifth Floor<BR>
Woodbridge, NJ<BR>
Telephone: (732) 395-4400<BR>
Email: sbrookman@lucbro.com<BR>
Attention: Seth Brookman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other address as may be designated in
writing hereafter, in the same manner, by such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.3
</B></FONT><U>Severability</U>. If any provision of this Agreement is held by a court of competent jurisdiction to be excessive in scope
or otherwise invalid or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable to
the maximum extent possible, and the validity and enforceability of the remaining provisions of this Agreement will not in any way be
affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.4
</B></FONT><U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the Laws of the State of Nevada,
without reference to principles of conflict of laws or choice of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.5
</B></FONT><U>Jurisdiction and Venue</U>. Any action, proceeding or claim arising out of, or relating in any way to this Agreement shall
be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District
of New York. The Company and the Investor irrevocably submit to the jurisdiction of such courts, which jurisdiction shall be exclusive,
and hereby waive any objection to such exclusive jurisdiction or that such courts represent an inconvenient forum. The prevailing party
in any such action shall be entitled to recover its reasonable and documented attorneys&rsquo; fees and out-of-pocket expenses relating
to such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.6
</B></FONT><U>WAIVER OF RIGHT TO JURY TRIAL</U>. THE COMPANY AND THE INVESTOR HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED
BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE OTHER
TRANSACTION DOCUMENTS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.7 </B></FONT><U>Survival</U>.
The representations, warranties, agreements and covenants contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.8
</B></FONT><U>Entire Agreement</U>. The Transaction Documents, together with the Exhibits and Schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with
respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.9
</B></FONT><U>Amendments; Waivers</U>. No provision of this Agreement may be waived or amended except in a written instrument signed
by the Company and the Investor. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition
or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise
of any such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.10 </B></FONT><U>Construction</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted
jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement or any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.11
</B></FONT><U>Successors and Assigns</U>. This Agreement shall be binding upon, and inure to the benefit of and be enforceable by, the
Company and the Investor and their respective successors and assigns. The Company may not assign this Agreement or any rights or obligations
hereunder without the prior written consent of the Investor. The Investor may assign any or all of its rights under this Agreement to
any Person to whom the Investor assigns or transfers any Securities, provided such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions hereof that apply to the &ldquo;Investor&rdquo; and such transferee is an accredited
investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.12 </B></FONT><U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.13
</B></FONT><U>Further Assurances</U>. Each party hereto shall do and perform, or cause to be done and performed, all such further acts
and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.14
</B></FONT><U>Counterparts</U>. This Agreement may be executed in two identical counterparts, both of which shall be considered one and
the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. Signature
pages delivered by facsimile or e-mail shall have the same force and effect as an original signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.15 </B></FONT><U>Specific
Performance</U>. The Company acknowledges that monetary damages alone would not be adequate compensation to the Investor for a breach
by the Company of this Agreement and the Investor may seek an injunction or an order for specific performance from a court of competent
jurisdiction if (a) the Company fails to comply or threatens not to comply with this Agreement or (b) the Investor has reason to believe
that the Company will not comply with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have executed this Securities Purchase Agreement as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><B>COMPANY:</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>INVESTOR:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">ABVC BIOPHARMA, INC.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">Lind GLOBAL FUND II LP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 35%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify; width: 20%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify"> Howard Doong</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify"> Jeff Easton</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;Managing Member of Lind Global</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Partners II LLC, General Partner</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page of Securities
Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FORM OF NOTE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[See attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FORM OF WARRANT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[See attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FORM OF SECURITY AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[See attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT D</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FORM OF SUBSIDIARY GUARANTEE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[See attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT E</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FLOW OF FUNDS REQUEST</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABVC BioPharma, Inc. &ndash; Securities Purchase Agreement &ndash;
Flow of Funds Request</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Securities Purchase Agreement,
dated February [&#9679;], 2023 (the &ldquo;Agreement&rdquo;) between ABVC BioPharma, Inc. (the &ldquo;Company&rdquo;) and Lind Global
Fund II LP (the &ldquo;Investor&rdquo;), the Company irrevocably authorizes the Investor to distribute such funds as set out below, in
the manner set out below, at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Capitalized terms used but not otherwise defined in this letter will
have the meaning given to such terms in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">Item</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; width: 88%">Closing </TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 1%">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; width: 9%">[&#9679;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 1%">]</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Commitment Fee</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">[&#9679;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">]</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;[&#9679;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">]</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please transfer the net amount of US $[&#9679;] due at the Closing,
to the following bank account:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 25%">Routing #:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: left; width: 72%">[&#9679;]</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Account #</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">[&#9679;]</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>FBO:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">[&#9679;]</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">[&#9679;]</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">[&#9679;]</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Bank:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">[&#9679;]</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">[&#9679;]</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>[&#9679;]</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Yours sincerely,</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>ABVC BIOPHARMA, INC.</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:&nbsp;</TD>
    <TD>Howard Doong</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ea174178ex10-2_abvcbio.htm
<DESCRIPTION>FORM OF NOTE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[THIS NOTE HAS NOT BEEN REGISTERED WITH THE
SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS NOTE AND
THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ABVC BIOPHARMA, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Senior<BR>
Convertible Promissory<BR>
Note due August 23, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Note No. L-1</FONT></TD>
    <TD STYLE="text-align: right; width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">$3,704,167</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">Dated: February 23, 2023 (the &ldquo;<U>Issuance Date</U>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For value received, ABVC BioPharma,
Inc., a Nevada corporation (the &ldquo;<U>Maker</U>&rdquo; or the &ldquo;<U>Company</U>&rdquo;), hereby promises to pay to the order of
Lind Global Fund II LP, a Delaware limited partnership (together with its successors and representatives, the &ldquo;<U>Holder</U>&rdquo;),
in accordance with the terms hereinafter provided, the principal amount of THREE MILLION SEVEN HUNDRED FOUR THOUSAND ONE HUNDRED SIXTY
SEVEN DOLLARS ($3,704,167.00) (the &ldquo;<U>Principal Amount</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All payments under or pursuant
to this Convertible Promissory Note (this &ldquo;<U>Note</U>&rdquo;) shall be made in United States Dollars in immediately available funds
to the Holder at the address of the Holder set forth in the Purchase Agreement (as hereinafter defined) or at such other place as the
Holder may designate from time to time in writing to the Maker or by wire transfer of funds to the Holder&rsquo;s account, instructions
for which are attached hereto as <U>Exhibit A</U>. The outstanding principal balance of this Note shall be due and payable on August 23,
2024 (the &ldquo;<U>Maturity Date</U>&rdquo;) or at such earlier time as provided herein; provided, that the Holder, in its sole discretion,
may extend the Maturity Date to any date after the original Maturity Date. In the event that the Maturity Date shall fall on Saturday
or Sunday, such Maturity Date shall be the next succeeding Business Day. All calculations made pursuant to this Note shall be rounded
down to three decimal places.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1 <U>Purchase
Agreement</U>. This Note has been executed and delivered pursuant to the Securities Purchase Agreement, dated as of February 23, 2023
(as the same may be amended from time to time, the &ldquo;<U>Purchase Agreement</U>&rdquo;), by and between the Maker and the Holder.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth for such terms in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2 <U>Interest</U>.
Other than as set forth in <U>Section 2.2</U> herein, this Note shall not bear interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3 <U>Principal
Installment Payments</U>. Commencing on the date that is six months from the Issuance Date, the Maker shall pay to the Holder the Outstanding
Principal Amount hereunder in twelve (12) consecutive monthly installments, on such date and each one (1) month anniversary thereof (each,
a &ldquo;<U>Payment Date</U>&rdquo; and collectively the &ldquo;<U>Monthly Payments</U>&rdquo;), an amount equal to Three Hundred Eight
Thousand Six Hundred Eighty and 58/10 Dollars ($308,680.58), until the Outstanding Principal Amount has been paid in full prior to or
on the Maturity Date or, if earlier, upon acceleration, conversion or redemption of this Note in accordance with the terms herein. The
Monthly Payments shall, at the Maker&rsquo;s option, be made in (i) cash, (ii) Repayment Shares, or (iii) a combination of cash and Repayment
Shares; provided that the number of Repayment Shares shall be determined by dividing the Principal Amount being paid in shares of Common
Stock by the Repayment Share Price; provided, however, that no portion of the Principal Amount may be paid in Repayment Shares unless
such Repayment Shares (A) may be immediately resold under Rule 144 without restriction on the number of shares to be sold or manner of
sale, or (B) are registered for resale under the 1933 Act and the registration statement is in effect and lawfully usable to effect immediate
sales of such Repayment Shares. Any Monthly Payment elected to be paid in a cash shall be required to paid with an additional cash premium
of five percent (5%) of such Monthly Payment, which such premium shall not be counted towards the Outstanding Principal Amount and shall
be in addition to any other amounts owing hereunder. The Company must provide advance written notice to the Holder of whether it will
elect to pay a Monthly Payment in cash, Repayment Shares or a combination thereof as follows: (i) with respect to the first Monthly Payment,
at least thirty (30) days before the Payment Date, and (ii) with respect to each Monthly Payment thereafter, within three (3) Business
Days of the prior Payment Date; provided, however, that if no such notice is provided within the timeframes set forth above, such Monthly
Payments shall be made in Repayment Shares. Notwithstanding the foregoing, the Holder may elect with respect to no more than two of the
Monthly Payments to increase the amount of such Monthly Payments up to one million dollars ($1,000,000.00) each. In respect of any particular
Monthly Payment elected to be increased by the Holder, the Holder may provide one or more notices to the Maker of its election to increase
such Monthly Payment at any time prior or following the applicable Payment Date; provided that such notices shall be provided to the Company
prior to the next succeeding Payment Date and that the amounts of the increases elected in such notices shall not cause the amount of
such Monthly Payment to exceed in the aggregate $1,000,000.00. Following any such increased Monthly Payment, the amount of such increase
shall be deducted from the amount of the last Monthly Payment owing hereunder until such Monthly Payment is reduced to zero and each Monthly
Payment immediately preceding such Monthly Payment in reverse chronological order until such preceding Monthly Payment is also reduced
to zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4 <U>Prepayment.</U>
The Maker may repay all, but not less than all, of the then Outstanding Principal Amount on any date following the Prepayment Right
Date; provided that the Maker shall have given no less than ten (10) day&rsquo;s written notice to the Holder of such intended
prepayment (the &ldquo;<U>Prepayment Notice</U>&rdquo;). If the Maker elects to prepay this Note pursuant to this <U>Section
1.4</U>, the Holder shall have the right (a &ldquo;<U>Prepayment Conversion Notice</U>&rdquo;) within five (5) Business Days of the
Holder&rsquo;s receipt of a Prepayment Notice, to convert up to one third (1/3) of the Principal Amount (the &ldquo;<U>Maximum
Amount</U>&rdquo;) at the lesser of the Repayment Share Price or the Conversion Price (each as defined below), in accordance with
the provisions of Article 3, specifying the Principal Amount (up to the Maximum Amount) that the Holder will convert. Upon delivery
of a Prepayment Notice, the Maker irrevocably and unconditionally agrees to, within five (5) Business Days of receiving a Prepayment
Conversion Notice, and if no Prepayment Conversion Notice is received, within ten (10) Business Days of delivery of a Prepayment
Notice: (i) repay the amount of the Outstanding Principal Amount <U>plus</U> the Prepayment Amount <U>minus</U> the Principal Amount
set forth in the Prepayment Conversion Notice and (ii) issue the applicable Conversion Shares to the Holder in accordance with
Article 3, as applicable. The foregoing notwithstanding, the Maker may not deliver a Prepayment Notice with respect to any
Outstanding Principal Amount that is subject to a Conversion Notice delivered by the Holder in accordance with Article 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.5 <U>Delisting
from a Trading Market.</U> If at any time the Common Stock ceases to be listed on a Trading Market, (i) the Holder may deliver a demand
for payment to the Company and, if such a demand is delivered, the Company shall, within ten (10) Business Days following receipt of the
demand for payment from the Holder, pay all of the Outstanding Principal Amount or (ii) the Holder may, at its election, at any time following
the Issuance Date, upon notice to the Company in accordance with <U>Section&nbsp;5.1</U>, convert all or a portion of the Outstanding
Principal Amount and the Conversion Price shall be adjusted to the lower of (A) the then-current Conversion Price and (A) eighty percent
(80%) of the average of the three (3) lowest daily VWAPs during the twenty (20) Trading Days prior to delivery by the Holder of its notice
of conversion pursuant to this <U>Section 1.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.6 <U>Payment
on Non-Business Days</U>. Whenever any payment to be made shall be due on a day which is not a Business Day, such payment may be due on
the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.7 <U>Transfer</U>.
This Note may be transferred or sold, subject to the provisions of <U>Section 5.8</U> of this Note, or pledged, hypothecated or otherwise
granted as security by the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.8 <U>Replacement</U>.
Upon receipt of a duly executed and notarized written statement from the Holder with respect to the loss, theft or destruction of this
Note (or any replacement hereof), or, in the case of a mutilation of this Note, upon surrender and cancellation of such Note, the Maker
shall issue a new Note, of like tenor and amount, in lieu of such lost, stolen, destroyed or mutilated Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.9 <U>Use
of Proceeds</U>. The Maker shall use the proceeds of this Note as set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.10 <U>Status
of Note</U>. The obligations of the Maker under this Note shall be senior to all other existing Indebtedness and equity of the Company.
Upon any Liquidation Event (as hereinafter defined), the Holder will be entitled to receive, before any distribution or payment is made
upon, or set apart with respect to, any Indebtedness of the Maker or any class of capital stock of the Maker, an amount equal to the Outstanding
Principal Amount. For purposes of this Note, &ldquo;<U>Liquidation Event</U>&rdquo; means a liquidation pursuant to a filing of a petition
for bankruptcy under applicable law or any other insolvency or debtor&rsquo;s relief, an assignment for the benefit of creditors, or a
voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Maker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.11 <U>Tax
Treatment</U>. The Maker and the Holder agree that for U.S. federal income tax purposes, and applicable state, local and non-U.S. income
tax purposes, this Note is not intended to be, and shall not be, treated as indebtedness. Neither the Maker nor the Holder shall take
any contrary position on any tax return, or in any audit, claim, investigation, inquiry or proceeding in respect of Taxes, unless otherwise
required pursuant to a final determination within the meaning of Section 1313 of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;),
or any analogous provision of applicable state, local or non-U.S. law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 <U>Events
of Default</U>. An &ldquo;<U>Event of Default</U>&rdquo; under this Note shall mean the occurrence of any of the events defined in the
Purchase Agreement, and any of the additional events described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(a) any
default in the payment of (i) the Principal Amount or any accrued and unpaid interest hereunder when due, or any principal or interest
owing under any other Note; or (ii)&nbsp;liquidated damages in respect of this Note or any other Note as and when the same shall become
due and payable (whether on the Maturity Date or by acceleration or otherwise);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(b) the
Maker shall fail to observe or perform any other covenant, condition or agreement contained in this Note or any Transaction Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(c) the
Maker&rsquo;s notice to the Holder, including by way of public announcement, at any time, of its inability to comply (including for any
of the reasons described in <U>Section 3.6(a)</U> hereof) or its intention not to comply with proper requests for conversion of this Note
into Common Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(d) the
Maker shall fail to (i) timely deliver the shares of Common Stock as and when required in <U>Section 3.2</U>; or (ii) make the payment
of any fees and/or liquidated damages under this Note, the Purchase Agreement or the other Transaction Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(e) default
shall be made in the performance or observance of any material covenant, condition or agreement contained in the Purchase Agreement or
any other Transaction Document that is not covered by any other provisions of this <U>Section 2.1</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(f) at
any time the Maker shall fail to have 200% of a sufficient number of shares of Common Stock authorized, reserved and available for issuance
to satisfy the potential conversion in full (disregarding for this purpose any and all limitations of any kind on such conversion) of
this Note or upon exercise of the Warrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(g) any
representation or warranty made by the Maker or any of its Subsidiaries herein or in the Purchase Agreement, the Note, the Warrant or
any other Transaction Document shall prove to have been false or incorrect or breached in a material respect on the date as of which made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(h) unless
otherwise approved in writing in advance by the Holder, the Maker shall, or shall announce an intention to pursue or consummate a Change
of Control, or a Change of Control shall be consummated, or the Maker shall negotiate, propose or enter into any agreement, understanding
or arrangement with respect to any Change of Control;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(i) the
Maker or any of its Subsidiaries shall (A) default in any payment of any amount or amounts of principal of or interest (if any) on any
Indebtedness (other than the Indebtedness hereunder), the aggregate principal amount of which Indebtedness is in excess of $100,000 or
(B) default in the observance or performance of any other agreement or condition relating to any such Indebtedness or contained in any
instrument or agreement evidencing, securing or relating thereto, or any other event shall occur or condition exist, the effect of which
default or other event or condition is to cause, or to permit the holder or holders or beneficiary or beneficiaries of such Indebtedness
to cause with the giving of notice if required, such Indebtedness to become due prior to its stated maturity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(j) the
Maker or any of its Subsidiaries shall: (i) apply for or consent to the appointment of, or the taking of possession by, a receiver, custodian,
trustee or liquidator of itself or of all or a substantial part of its property or assets; (ii) make a general assignment for the benefit
of its creditors; (iii) commence a voluntary case under the United States Bankruptcy Code (as now or hereafter in effect) or under the
comparable laws of any jurisdiction (foreign or domestic); (iv) file a petition seeking to take advantage of any bankruptcy, insolvency,
moratorium, reorganization or other similar law affecting the enforcement of creditors&rsquo; rights generally; (v) acquiesce in writing
to any petition filed against it in an involuntary case under United States Bankruptcy Code (as now or hereafter in effect) or under the
comparable laws of any jurisdiction (foreign or domestic); (vi) issue a notice of bankruptcy or winding down of its operations or issue
a press release regarding same; or (vii)&nbsp;take any action under the laws of any jurisdiction (foreign or domestic) analogous to any
of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(k) a
proceeding or case shall be commenced in respect of the Maker or any of its Subsidiaries, without its application or consent, in any court
of competent jurisdiction, seeking: (i) the liquidation, reorganization, moratorium, dissolution, winding up, or composition or readjustment
of its debts; (ii) the appointment of a trustee, receiver, custodian, liquidator or the like of it or of all or any substantial part of
its assets in connection with the liquidation or dissolution of the Maker or any of its Subsidiaries; or (iii) similar relief in respect
of it under any law providing for the relief of debtors, and such proceeding or case described in clause (i), (ii) or (iii) shall continue
undismissed, or unstayed and in effect, for a period of forty-five (45) days or any order for relief shall be entered in an involuntary
case under United States Bankruptcy Code (as now or hereafter in effect) or under the comparable laws of any jurisdiction (foreign or
domestic) against the Maker or any of its Subsidiaries or action under the laws of any jurisdiction (foreign or domestic) analogous to
any of the foregoing shall be taken with respect to the Maker or any of its Subsidiaries and shall continue undismissed, or unstayed and
in effect for a period of forty-five (45) days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(l) one
or more final judgments or orders for the payment of money aggregating in excess of $100,000 (or its equivalent in the relevant currency
of payment) are rendered against one or more of the Company and its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(m) the
failure of the Maker to instruct the Transfer Agent to remove any legends from shares of Common Stock and issue such unlegended certificates
to the Holder within three (3) Trading Days of the Holder&rsquo;s request so long as the Holder has provided reasonable assurances to
the Maker that such shares of Common Stock can be sold pursuant to Rule 144 or any other applicable exemption;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(n) the
Maker&rsquo;s Common Stock is no longer publicly traded or ceases to be listed on the Trading Market or, after the six month anniversary
of the Issuance Date, any Investor Shares may not be immediately resold under Rule 144 without restriction on the number of shares to
be sold or manner of sale, unless such Investor Shares have been registered for resale under the 1933 Act and may be sold without restriction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(o) the
Maker proposes to or does consummate a &ldquo;going private&rdquo; transaction as a result of which the Common Stock will no longer be
registered under Sections 12(b) or 12(g) of the 1934 Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(p) there
shall be any SEC or judicial stop trade order or trading suspension stop-order or any restriction in place with the Transfer Agent restricting
the trading of such Common Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(q) the
Depository Trust Company places any restrictions on transactions in the Common Stock or the Common Stock are no longer tradeable through
the Depository Trust Company Fast Automated Securities Transfer program;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(r) the
Company&rsquo;s Market Capitalization is below $12,500,000 for ten (10) consecutive days; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(s) the
occurrence of a Material Adverse Effect in respect of the Maker, or the Maker and its Subsidiaries taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">For the avoidance of doubt,
any default pursuant to clause (i) above shall not be subject to any cure periods pursuant to the instrument governing such Indebtedness
or this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2 <U>Remedies
Upon an Event of Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(a) Upon
the occurrence of any Event of Default , the Maker shall be obligated to pay to the Holder the Mandatory Default Amount, which Mandatory
Default Amount shall be earned by the Holder on the date the Event of Default giving rise thereto occurs and shall be due and payable
on the earlier to occur of the Maturity Date, upon conversion, redemption or prepayment of this Note or the date on which all amounts
owing hereunder have been accelerated in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(b) Upon
the occurrence of any Event of Default, the Maker shall, as promptly as possible but in any event within one (1) Business Day of such
Event of Default, notify the Holder of the occurrence of such Event of Default, describing the event or factual situation giving rise
to the Event of Default and specifying the relevant subsection or subsections of <U>Section 2.1</U> hereof under which such Event of Default
has occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(c) Upon
the occurrence and during the continuance of an Event of Default<U>,</U> the Holder may at any time at its option (1) declare the Mandatory
Default Amount due and payable, and thereupon, the same shall be accelerated and so due and payable, without presentment, demand, protest
or notice, all of which are hereby expressly unconditionally and irrevocably waived by the Maker and (2) exercise all other rights and
remedies available to it under the Transaction Documents; <I>provided, however</I>, that (x) upon the occurrence of an Event of Default
described above or an event which with the passage of time may result in an Event of Default, the Holder, in its sole and absolute discretion
(without the obligation to provide notice of such Event of Default or potential Event of Default), may: (a) from time-to-time demand that
all or a portion of the Outstanding Principal Amount be converted into shares of Common Stock at the lower of (i) the then-current Conversion
Price and (ii) eighty-percent (80%) of the average of the three (3) lowest daily VWAPs during the twenty (20) Trading Days prior to the
delivery by the Holder of the applicable notice of conversion or (b) exercise or otherwise enforce any one or more of the Holder&rsquo;s
rights, powers, privileges, remedies and interests under this Note, the Purchase Agreement, the other Transaction Documents or applicable
law and (y) upon the occurrence of an Event of Default described in <U>Section 2.1(k)</U> above, the Mandatory Default Amount shall become
immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Maker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(d) No
course of delay on the part of the Holder shall operate as a waiver thereof or otherwise prejudice the rights of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(e) No
remedy conferred hereby shall be exclusive of any other remedy referred to herein or now or hereafter available at law, in equity, by
statute or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
3</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1 <U>Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(a) <U>Conversion</U>.
At any time following the Issuance Date, this Note shall be convertible (in whole or in part), at the option of the Holder, into such
number of fully paid and non-assessable Common Stock as is determined by dividing (x) that portion of the Outstanding Principal Amount
that the Holder elects to convert (the &ldquo;<U>Conversion Amount</U>&rdquo;) by (y) the Conversion Price then in effect on the date
on which the Holder delivers a notice of conversion, in substantially the form attached hereto as <U>Exhibit B</U> (the &ldquo;<U>Conversion
Notice</U>&rdquo;), in accordance with the instructions set forth in <U>Section 5.1</U> to the Maker. The Holder shall deliver this Note
to the Maker at the address designated in the Purchase Agreement at such time that this Note is fully converted. With respect to partial
conversions of this Note, the Maker shall keep written records of the amount of this Note converted as of the date of such conversion
(each, a &ldquo;<U>Conversion Date</U>&rdquo;). Any amounts of the Outstanding Principal Amount converted hereunder shall be credited
to the next scheduled Monthly Payment, or if any amount of the Outstanding Principal Amount converted hereunder exceeds the next scheduled
Monthly Payment, future Monthly Payments shall be credited, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(b) <U>Conversion
Price</U>. The &ldquo;<U>Conversion Price</U>&rdquo; means $1.05, and shall be subject to adjustment as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2 <U>Delivery
of Conversion Shares</U>. As soon as practicable after the occurrence of any event requiring the issuance of Common Stock issuable upon
conversion of this Note (&ldquo;<U>Conversion Shares</U>&rdquo;), and in any event within two (2) Business Days thereafter (such date,
the &ldquo;<U>Share Delivery Date</U>&rdquo;), the Maker shall, at its expense, cause to be issued in the name of and delivered to the
Holder, or as the Holder may direct, a certificate or certificates evidencing the number of fully paid and nonassessable Common Stock
to which the Holder shall be entitled, in such denominations as may be requested by the Holder, which certificate or certificates shall
be free of restrictive and trading legends, except for any such legends as may be required under the Securities Act. In lieu of delivering
physical certificates for the shares of Common Stock issuable upon the occurrence of any event requiring the issuance of Conversion Shares
in accordance with this Note, provided the Transfer Agent is participating in the Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;)
Fast Automated Securities Transfer program or a similar program, upon request of the Holder, the Company shall cause the Transfer Agent
to electronically transmit such Conversion Shares so issuable to the Holder (or its designee), by crediting the account of the Holder&rsquo;s
(or such designee&rsquo;s) broker with DTC through its Deposit and Withdrawal At Custodian (&ldquo;<U>DWAC</U>&rdquo;) system (provided
that the same time periods herein as for stock certificates shall apply) as instructed by the Holder (or its designee); provided, that
such issuance shall only be made through DTC&rsquo;s DWAC system if such Conversion Shares will be issued free of restrictive legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3
<U>Ownership Cap</U>. Notwithstanding anything to the contrary contained herein, the Holder shall not be entitled to receive shares representing
Equity Interests upon conversion of this Note to the extent (but only to the extent) that such exercise or receipt would cause the Holder
Group (as defined below) to become, directly or indirectly, a &ldquo;beneficial owner&rdquo; (within the meaning of Section 13(d) of the
1934 Act and the rules and regulations promulgated thereunder) of a number of Equity Interests of a class that is registered under the
1934 Act which exceeds the Maximum Percentage (as defined in the Purchase Agreement) of the Equity Interests of such class that are outstanding
at such time. Any purported delivery of Equity Interests in connection with the conversion of this Note prior to the termination of this
restriction in accordance herewith shall be void and have no effect to the extent (but only to the extent) that such delivery would result
in the Holder Group becoming the beneficial owner of more than the Maximum Percentage of the Equity Interests of a class that is registered
under the 1934 Act that is outstanding at such time. If any delivery of Equity Interests owed to the Holder following conversion of this
Note is not made, in whole or in part, as a result of this limitation, the Company&rsquo;s obligation to make such delivery shall not
be extinguished and the Company shall deliver such Equity Interests as promptly as practicable after the Holder gives notice to the Company
that such delivery would not result in such limitation being triggered or upon termination of the restriction in accordance with the terms
hereof. To the extent limitations contained in this <U>Section 3.3</U> apply, the determination of whether this Note is convertible and
of which portion of this Note is convertible shall be the sole responsibility and in the sole determination of the Holder, and the submission
of a notice of conversion shall be deemed to constitute the Holder&rsquo;s determination that the issuance of the full number of Conversion
Shares requested in the notice of conversion is r hereunder, and the Company shall not have any obligation to verify or confirm the accuracy
of such determination. For purposes of this <U>Section 3.2</U>, (i)&nbsp;the term &ldquo;<U>Maximum Percentage</U>&rdquo; shall mean 4.99%;
provided, that if at any time after the date hereof the Holder Group beneficially owns in excess of 4.99% of any class of Equity Interests
in the Company that is registered under the 1934 Act, then the Maximum Percentage shall automatically increase to 9.99% so long as the
Holder Group owns in excess of 4.99% of such class of Equity Interests (and shall, for the avoidance of doubt, automatically decrease
to 4.99% upon the Holder Group ceasing to own in excess of 4.99% of such class of Equity Interests); and (ii) the term &ldquo;<U>Holder
Group</U>&rdquo; shall mean the Holder plus any other Person with which the Holder is considered to be part of a group under Section 13
of the 1934 Act or with which the Holder otherwise files reports under Sections&nbsp;13 and/or 16 of the 1934 Act. In determining the
number of Equity Interests of a particular class outstanding at any point in time, the Holder may rely on the number of outstanding Equity
Interests of such class as reflected in (x) the Company&rsquo;s most recent Annual Report on Form 20-F filed with the Securities and Exchange
Commission, as the case may be, (y) a more recent public announcement by the Company or (z) a more recent notice by the Company or the
Transfer Agent to the Holder setting forth the number of Equity Interests of such class then outstanding. For any reason at any time,
upon written or oral request of the Holder, the Company shall, within one (1) Business Day of such request, confirm orally and in writing
to the Holder the number of Equity Interests of any class then outstanding. The provisions of this <U>Section 3.3</U> shall be construed,
corrected and implemented in a manner so as to effectuate the intended beneficial ownership limitation herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4 <U>Adjustment
of Conversion Price</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(a) Until
the Note has been paid in full or converted in full, the Conversion Price shall be subject to adjustment from time to time as follows
(but shall not be increased, other than pursuant to <U>Section 3.4(a)(i)</U> hereof):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) <U>Adjustments
for Stock Splits and Combinations</U>. If the Maker shall at any time or from time to time after the Closing Date (but whether before
or after the Issuance Date) effect a split or other subdivision of the outstanding Common Stock, the applicable Conversion Price in effect
immediately prior to the stock split shall be proportionately decreased. If the Maker shall at any time or from time to time after the
Closing Date (but whether before or after the Issuance Date), combine the outstanding Common Stock, the applicable Conversion Price in
effect immediately prior to the combination shall be proportionately increased. Any adjustments under this <U>Section 3.4(a)(i)</U> shall
be effective at the close of business on the date the stock split or combination occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) <U>Adjustments
for Certain Dividends and Distributions</U>. If the Maker shall at any time or from time to time after the Closing Date (but whether before
or after the Issuance Date) make or issue or set a record date for the determination of holders of Common Stock entitled to receive a
dividend or other distribution payable in Common Stock, then, and in each event, the applicable Conversion Price in effect immediately
prior to such event shall be decreased as of the time of such issuance or, in the event such record date shall have been fixed, as of
the close of business on such record date, by multiplying the applicable Conversion Price then in effect by a fraction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(1) the
numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance
or the close of business on such record date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(2) the
denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or
distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) <U>Adjustment
for Other Dividends and Distributions</U>. If the Maker shall at any time or from time to time after the Closing Date (but whether before
or after the Issuance Date) make or issue or set a record date for the determination of holders of Common Stock entitled to receive a
dividend or other distribution payable in other than Common Stock, then, and in each event, an appropriate revision to the applicable
Conversion Price shall be made and provision shall be made (by adjustments of the Conversion Price or otherwise) so that the Holder of
this Note shall receive upon conversions thereof, in addition to the number of shares of Common Stock receivable thereon, the number of
securities of the Maker or other issuer (as applicable) or cash or other property that it would have received had this Note been converted
into shares of Common Stock in full (without regard to any conversion limitations herein) on the date of such event and had thereafter,
during the period from the date of such event to and including the Conversion Date, retained such securities (together with any distributions
payable thereon during such period) or assets, giving application to all adjustments called for during such period under this <U>Section
3.4(a)(iii)</U> with respect to the rights of the holders of this Note; <I>provided, however</I>, that if such record date shall have
been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Conversion Price
shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends or distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv) <U>Adjustments
for Reclassification, Exchange or Substitution</U>. If the shares of Common Stock at any time or from time to time after the Closing Date
(but whether before or after the Issuance Date) shall be changed to the same or different number of shares or other securities of any
class or classes of stock or other property, whether by reclassification, exchange, substitution or otherwise (other than by way of a
stock split or combination of shares or stock dividends provided for in <U>Sections 3.4(a)(i), (ii) and (iii)</U> hereof, or a reorganization,
merger, consolidation, or sale of assets provided for in <U>Section 3.4(a)(vii)</U> hereof), then, and in each event, an appropriate revision
to the Conversion Price shall be made and provisions shall be made (by adjustments of the Conversion Price or otherwise) so that the Holder
shall have the right thereafter to convert this Note into the kind and amount of shares of stock or other securities or other property
receivable upon reclassification, exchange, substitution or other change, by holders of the number of shares of Common Stock into which
such Note might have been converted immediately prior to such reclassification, exchange, substitution or other change, all subject to
further adjustment as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v) <U>Adjustments
for Issuance of Additional Shares of Common Stock</U>. In the event the Maker shall at any time or from time to time after the Closing
Date (but whether before or after the Issuance Date) issue or sell any additional Common Stock (&ldquo;<U>Additional Common Stock</U>&rdquo;),
other than (A) as provided in this Note (including the foregoing subsections (i) through (iv) of this <U>Section 3.4(a)</U>), pursuant
to any Equity Plan (including pursuant to Common Stock Equivalents granted or issued under any Equity Plan), (B) pursuant to Common Stock
Equivalents (as defined below) granted or issued prior to the Closing Date, (C) Exempted Securities, or (D) pursuant to the terms of this
Note, in any case, at an effective price per share that is <B><I>less </I></B>than the Conversion Price then in effect or without consideration,
then the Conversion Price upon each such issuance shall be reduced to a price equal to the consideration per share paid for such Additional
Common Stock. For purposes of clarification, the amount of consideration received for such Additional Common Stock shall not include the
value of any additional securities or other rights received in connection with such issuance of Additional Common Stock (i.e., warrants,
rights of first refusal or other similar rights).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi) <U>Issuance,
Amendment or Adjustment of Common Stock Equivalents</U>. Except for Exempted Securities, if (x) the Maker, at any time after the Closing
Date (but whether before or after the Issuance Date), shall issue any securities convertible into or exercisable or exchangeable for,
directly or indirectly, Common Stock (&ldquo;<U>Convertible Securities</U>&rdquo;), or any rights or warrants or options to purchase any
such Common Stock or Convertible Securities, other than Common Stock Equivalents granted or issued under any Equity Plan (collectively
with the Convertible Securities, the &ldquo;<U>Common Stock Equivalents</U>&rdquo;) and the price per share for which Common Stock may
be issuable pursuant to any such Common Stock Equivalent shall be <B><I>less </I></B>than the applicable Conversion Price then in effect,
or (y) the price per share for which Common Stock may be issuable under any Common Stock Equivalents is amended or adjusted, pursuant
to the terms of such Common Stock Equivalents or otherwise, and such price as so amended or adjusted shall be less than the applicable
Conversion Price in effect at the time of such amendment or adjustment, then, in each such case (x) or (y), the applicable Conversion
Price upon each such issuance or amendment or adjustment shall be adjusted as provided in subsection (vi) of this <U>Section 3.4(a)</U>
as if the maximum number of shares of Common Stock issuable upon conversion, exercise or exchange of such Common Stock Equivalents had
been issued on the date of such issuance or amendment or adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii) <U>Consideration
for Stock</U>. In case any Common Stock or any Common Stock Equivalents shall be issued or sold:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(1) in
connection with any merger or consolidation in which the Maker is the surviving corporation (other than any consolidation or merger in
which the previously outstanding Common Stock of the Maker shall be changed to or exchanged for the stock or other securities of another
corporation), the amount of consideration therefor shall be deemed to be the fair value, as determined reasonably and in good faith by
the Board of Directors of the Maker and approved by the Holder, of such portion of the assets and business of the nonsurviving corporation
as such Board of Directors may determine to be attributable to such shares of Common Stock, Convertible Securities, rights or warrants
or options, as the case may be; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(2) in
the event of any consolidation or merger of the Maker in which the Maker is not the surviving corporation or in which the previously outstanding
Common Stock of the Maker shall be changed into or exchanged for the stock or other securities of another corporation or other property,
or in the event of any sale of all or substantially all of the assets of the Maker for stock or other securities or other property of
any corporation, the Maker shall be deemed to have issued shares of Common Stock, at a price per share equal to the valuation of the Maker&rsquo;s
Common Stock based on the actual exchange ratio on which the transaction was predicated, as applicable, and the fair market value on the
date of such transaction of all such stock or securities or other property of the other corporation. If any such calculation results in
adjustment of the applicable Conversion Price, or the number of shares of Common Stock issuable upon conversion of the Note, the determination
of the applicable Conversion Price or the number of shares of Common Stock issuable upon conversion of the Note immediately prior to such
merger, consolidation or sale, shall be made after giving effect to such adjustment of the number of shares of Common Stock issuable upon
conversion of the Note. In the event shares of Common Stock are issued with other shares or securities or other assets of the Maker for
consideration which covers both, the consideration computed as provided in this <U>Section 3.4(a)(vii)</U> shall be allocated among such
securities and assets as determined in good faith by the Board of Directors of the Maker, and approved by the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii) <U>Record
Date</U>. In case the Maker shall take record of the holders of its Common Stock for the purpose of entitling them to subscribe for or
purchase shares of Common Stock or Convertible Securities, then the date of the issue or sale of the shares of Common Stock shall be deemed
to be such record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(b) <U>No
Impairment</U>. The Maker shall not, by amendment of its Articles of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms to be observed or performed hereunder by the Maker, but will at all times in good faith assist in the
carrying out of all the provisions of this <U>Section 3.4</U> and in the taking of all such action as may be necessary or appropriate
in order to protect the conversion rights of the Holder against impairment. In the event the Holder shall elect to convert this Note as
provided herein, the Maker cannot refuse conversion based on any claim that the Holder or anyone associated or affiliated with the Holder
has been engaged in any violation of law, violation of an agreement to which the Holder is a party or for any reason whatsoever, unless,
an injunction from a court, or notice, restraining and or adjoining conversion of this Note shall have issued and the Maker posts a surety
bond for the benefit of the Holder in an amount equal to one hundred fifty percent (150%) of the Principal Amount of the Note the Holder
has elected to convert, which bond shall remain in effect until the completion of arbitration/litigation of the dispute and the proceeds
of which shall be payable to the Holder (as liquidated damages) in the event it obtains judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(c) <U>Certificates
as to Adjustments</U>. Upon occurrence of each adjustment or readjustment of the Conversion Price or number of shares of Common Stock
issuable upon conversion of this Note pursuant to this <U>Section 3.4</U>, the Maker at its expense shall promptly compute such adjustment
or readjustment in accordance with the terms hereof and furnish to the Holder a certificate setting forth such adjustment and readjustment,
showing in detail the facts upon which such adjustment or readjustment is based. The Maker shall, upon written request of the Holder,
at any time, furnish or cause to be furnished to the Holder a like certificate setting forth such adjustments and readjustments, the applicable
Conversion Price in effect at the time, and the number of shares of Common Stock and the amount, if any, of other securities or property
which at the time would be received upon the conversion of this Note. Notwithstanding the foregoing, the Maker shall not be obligated
to deliver a certificate unless such certificate would reflect an increase or decrease of at least one percent (1%) of such adjusted amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(d) <U>Issue
Taxes</U>. The Maker shall pay any and all issue and other taxes, excluding federal, state or local income taxes, that may be payable
in respect of any issue or delivery of shares of Common Stock on conversion of this Note pursuant thereto; <I>provided, however</I>, that
the Maker shall not be obligated to pay any transfer taxes resulting from any transfer requested by the Holder in connection with any
such conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(e) <U>Fractional
Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of this Note. In lieu of any fractional shares to which
the Holder would otherwise be entitled, the Maker shall pay cash equal such fractional shares multiplied by the Conversion Price then
in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(f) <U>Reservation
of Shares of Common Stock</U>. The Maker shall at all times while this Note shall be outstanding, reserve and keep available out of its
authorized but unissued Common Stock, 200% of such number of shares of Common Stock as shall from time to time be sufficient to effect
the conversion of this Note (disregarding for this purpose any and all limitations of any kind on such conversion). The Maker shall, from
time to time, use all commercially reasonable efforts to increase the authorized number of shares of Common Stock or take other effective
action if at any time the unissued number of authorized shares shall not be sufficient to satisfy the Maker&rsquo;s obligations under
this <U>Section&nbsp;3.4(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(g) <U>Regulatory
Compliance</U>. If any shares of Common Stock to be reserved for the purpose of conversion of this Note require registration or listing
with or approval of any governmental authority, stock exchange or other regulatory body under any federal or state law or regulation or
otherwise before such shares may be validly issued or delivered upon conversion, the Maker shall, at its sole cost and expense, in good
faith and as expeditiously as possible, secure such registration, listing or approval, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(h) <U>Effect
of Events Prior to the Issuance Date</U>. If the Issuance Date of this Note is after the Closing Date, then, if the Conversion Price or
any other right of the Holder of this Note would have been adjusted or modified by operation of any provision of this Note had this Note
been issued on the Closing Date, such adjustment or modification shall be deemed to apply to this Note as of the Issuance Date as if this
Note had been issued on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5 <U>Prepayment
Following a Change of Control</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(a) <U>Mechanics
of Prepayment at Option of Holder in Connection with a Change of Control</U>. No sooner than fifteen (15) days prior to entry into an
agreement for a Change of Control nor later than ten (10) days prior to the consummation of a Change of Control, but not prior to the
public announcement of such Change of Control, the Maker shall deliver written notice (&ldquo;<U>Notice of Change of Control</U>&rdquo;)
to the Holder. At any time after receipt of a Notice of Change of Control (or, in the event a Notice of Change of Control is not delivered
at least ten (10) days prior to a Change of Control, at any time within ten (10) days prior to a Change of Control), the Holder may require
the Maker to prepay, effective immediately prior to the consummation of such Change of Control, an amount equal to the Outstanding Principal
Amount <U>plus</U> five percent (5%) of the Outstanding Principal Amount (the &ldquo;<U>COC Repayment Price</U>&rdquo;), by delivering
written notice thereof (&ldquo;<U>Notice of Prepayment at Option of Holder Upon Change of Control</U>&rdquo;) to the Maker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(b) <U>Payment
of COC Repayment Price</U>. Upon the Maker&rsquo;s receipt of a Notice(s) of Prepayment at Option of Holder Upon Change of Control from
the Holder, the Maker shall deliver the COC Repayment Price to the Holder immediately prior to the consummation of the Change of Control;
provided that the Holder&rsquo;s original Note shall have been so delivered to the Maker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6 <U>Inability
to Fully Convert</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(a) <U>Holder&rsquo;s
Option if Maker Cannot Fully Convert</U>. If, upon the Maker&rsquo;s receipt of a Conversion Notice or as otherwise required under this
Note, including with respect to repayment of principal in Common Stock as permitted under this Note, the Maker cannot issue Common Stock
for any reason, including, without limitation, because the Maker (x) does not have a sufficient number of shares of Common Stock authorized
and available or (y) is otherwise prohibited by applicable law or by the rules or regulations of any stock exchange, interdealer quotation
system or other self-regulatory organization with jurisdiction over the Maker or any of its securities from issuing all of the shares
of Common Stock which are to be issued to the Holder pursuant to this Note, then the Maker shall issue as many shares of Common Stock
as it is able to issue and, with respect to the unconverted portion of this Note or with respect to any shares of Common Stock not timely
issued in accordance with this Note, the Holder, solely at Holder&rsquo;s option, can elect to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) require
the Maker to prepay that portion of this Note for which the Maker is unable to issue Common Stock or for which shares of Common Stock
were not timely issued (the &ldquo;<U>Mandatory Prepayment</U>&rdquo;) at a price equal to the number of shares of Common Stock that the
Maker is unable to issue multiplied by the VWAP on the date of the Conversion Notice (the &ldquo;<U>Mandatory Prepayment Price</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) void
its Conversion Notice and retain or have returned, as the case may be, this Note that was to be converted pursuant to the Conversion Notice
(provided that the Holder&rsquo;s voiding its Conversion Notice shall not affect the Maker&rsquo;s obligations to make any payments which
have accrued prior to the date of such notice); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) defer
issuance of the applicable Conversion Shares until such time as the Maker can legally issue such shares; provided, that the Principal
Amount underlying such Conversion Shares shall remain outstanding until the delivery of such Conversion Shares; provided, further, that
if the Holder elects to defer the issuance of the Conversion Shares, it may exercise its rights under either clause (i) or (ii) above
at any time prior to the issuance of the Conversion Shares upon two (2) Business Days&rsquo; notice to the Maker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(b) <U>Mechanics
of Fulfilling Holder&rsquo;s Election</U>. The Maker shall immediately send to the Holder, upon receipt of a Conversion Notice from the
Holder, which cannot be fully satisfied as described in <U>Section 3.6(a)</U> above, a notice of the Maker&rsquo;s inability to fully
satisfy the Conversion Notice (the &ldquo;<U>Inability to Fully Convert Notice</U>&rdquo;). Such Inability to Fully Convert Notice shall
indicate (i) the reason why the Maker is unable to fully satisfy the Holder&rsquo;s Conversion Notice; and (ii) the amount of this Note
which cannot be converted. The Holder shall notify the Maker of its election pursuant to <U>Section 3.6(a)</U> above by delivering written
notice to the Maker (&ldquo;<U>Notice in Response to Inability to Convert</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(c) <U>Payment
of Mandatory Prepayment Price</U>. If the Holder shall elect to have its Note prepaid pursuant to <U>Section 3.6(a)(i)</U> above, the
Maker shall pay the Mandatory Prepayment Price to the Holder within five (5) Business Days of the Maker&rsquo;s receipt of the Holder&rsquo;s
Notice in Response to Inability to Convert; provided that prior to the Maker&rsquo;s receipt of the Holder&rsquo;s Notice in Response
to Inability to Convert the Maker has not delivered a notice to the Holder stating, to the satisfaction of the Holder, that the event
or condition resulting in the Mandatory Prepayment has been cured and all Conversion Shares issuable to the Holder can and will be delivered
to the Holder in accordance with the terms of this Note. If the Maker shall fail to pay the applicable Mandatory Prepayment Price to the
Holder on the date that is one (1) Business Day following the Maker&rsquo;s receipt of the Holder&rsquo;s Notice in Response to Inability
to Convert, in addition to any remedy the Holder may have under this Note and the Purchase Agreement, such unpaid amount shall bear interest
at the rate of two percent (2%) per month (prorated for partial months) until paid in full. Until the full Mandatory Prepayment Price
is paid in full to the Holder, the Holder may (i) void the Mandatory Prepayment with respect to that portion of the Note for which the
full Mandatory Prepayment Price has not been paid and (ii) receive back such Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(d) <U>No
Rights as Stockholder</U>. Nothing contained in this Note shall be construed as conferring upon the Holder, prior to the conversion of
this Note, the right to vote or to receive dividends or to consent or to receive notice as a stockholder in respect of any meeting of
stockholders for the election of directors of the Maker or of any other matter, or any other rights as a stockholder of the Maker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.7 <U>Compensation
for Buy-In on Failure to Timely Deliver Conversion Shares</U>.&nbsp; In addition to any other rights available to the Holder, if the Company
fails to cause the Transfer Agent to transmit to the Holder Conversion Shares or any other shares pursuant to a conversion on or before
the Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Conversion Shares which the Holder anticipated receiving upon such conversion (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall
(a) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Conversion Shares
that the Company was required to deliver to the Holder in connection with the conversion at issue times (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (b) at the option of the Holder, either reinstate the portion of the Note
and equivalent number of Conversion Shares for which such conversion was not honored (in which case such conversion shall be deemed rescinded)
or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its conversion
and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000
to cover a Buy-In with respect to an attempted conversion of shares of Common Stock with an aggregate sale price giving rise to such purchase
obligation of $10,000, under clause (a) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000.
The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and evidence
of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue a decree of specific performance and/or injunctive
relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon conversion of the Note as required pursuant
to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
4</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1 <U>Covenants</U>.
For so long as any Note is outstanding, without the prior written consent of the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(a) <U>Compliance
with Transaction Documents</U>. The Maker shall, and shall cause its Subsidiaries to, comply with its obligations under this Note and
the other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(b) <U>Payment
of Taxes, Etc</U>. The Maker shall, and shall cause each of its Subsidiaries to, promptly pay and discharge, or cause to be paid and discharged,
when due and payable, all lawful taxes, assessments and governmental charges or levies imposed upon the income, profits, property or business
of the Maker and the Subsidiaries, except for such failures to pay that, individually or in the aggregate, have not had and would not
reasonably be expected to have a Material Adverse Effect; provided, however, that any such tax, assessment, charge or levy need not be
paid if the validity thereof shall currently be contested in good faith by appropriate proceedings and if the Maker or such Subsidiaries
shall have set aside on its books reserves with respect thereto in accordance with generally accepted accounting principles, and provided,
further, that the Maker and such Subsidiaries will pay all such taxes, assessments, charges or levies forthwith upon the commencement
of proceedings to foreclose any lien which may have attached as security therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(c) <U>Corporate
Existence</U>. The Maker shall, and shall cause each of its Subsidiaries to, maintain in full force and effect its corporate existence,
rights and franchises (other than the existence, rights and franchises of the Subsidiaries of the Maker that the board of directors of
the Maker determine are no longer necessary or useful to the operation of the Maker&rsquo;s business) and all licenses and other rights
to use property owned or possessed by it and reasonably deemed to be necessary to the conduct of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(d) <U>Investment
Company Act</U>. The Maker shall conduct its businesses in a manner so that it will not become subject to, or required to be registered
under, the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(e) <U>Prohibited
Transactions</U>. The Company hereby covenants and agrees not to enter into any Prohibited Transactions until thirty (30) days after such
time as this Note has been converted into Conversion Shares or repaid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(f) <U>Repayment
of This Note</U>. If the Company or any Subsidiary issues any debt, including any subordinated debt or convertible debt (other than the
Note or any other &ldquo;Note&rdquo; as defined in the Purchase Agreement), or any Equity Interests, other than Exempted Securities, in
one or more transactions, unless otherwise waived in writing by and at the discretion of the Holder, the Company will immediately utilize
the proceeds of such issuance to repay this Note, and if the Company issues any Equity Interests other than Exempted Securities for aggregate
proceeds of more than five million dollars ($5,000,000), unless otherwise waived in writing by and at the discretion of the Holder, the
Company will direct unless otherwise waived in writing by and at the discretion of the Investor, the Company will direct twenty-five percent
(25%) of the proceeds from such issuance to repay this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2 <U>Set-Off</U>.
This Note shall be subject to the set-off provisions set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
5</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1 <U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via email
at the email address specified in this Section prior to 5:00 p.m. (New York time) on a Business Day, (b) the next Business Day after the
date of transmission, if such notice or communication is delivered via email at the email address specified in this Section on a day that
is not a Business Day or later than 5:00 p.m. (New York time) on any date and earlier than 11:59 p.m. (New York time) on such date, (c)
the Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (d) upon actual receipt
by the party to whom such notice is required to be given. The addresses for such notices and communications shall be as set forth in the
Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2 <U>Governing
Law</U>. This Agreement shall be governed by and construed in accordance with the Laws of the State of Nevada, without reference to principles
of conflict of laws or choice of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3 <U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Note and shall not be deemed to limit or affect any of
the provisions hereof. The language used in this Note will be deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party. This Note shall be construed as if drafted jointly by the
parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions
of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4 <U>Remedies,
Characterizations, Other Obligations, Breaches and Injunctive Relief</U>. The remedies provided in this Note shall be cumulative and in
addition to all other remedies available under this Note, at law or in equity (including, without limitation, a decree of specific performance
and/or other injunctive relief), no remedy contained herein shall be deemed a waiver of compliance with the provisions giving rise to
such remedy and nothing herein shall limit the Holder&rsquo;s right to pursue actual damages for any failure by the Maker to comply with
the terms of this Note. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation
thereof) shall be the amounts to be received by the holder thereof and shall not, except as expressly provided herein, be subject to any
other obligation of the Maker (or the performance thereof). The Maker acknowledges that a breach by it of its obligations hereunder will
cause irreparable and material harm to the Holder and that the remedy at law for any such breach would be inadequate. Therefore, the Maker
agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available rights
and remedies, at law or in equity, to equitable relief, including but not limited to an injunction restraining any such breach or threatened
breach, without the necessity of showing economic loss and without any bond or other security being required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5 <U>Enforcement
Expenses</U>. The Maker agrees to pay all costs and expenses of enforcement of this Note, including, without limitation, attorneys&rsquo;
fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6 <U>Binding
Effect</U>. The obligations of the Maker and the Holder set forth herein shall be binding upon the successors and assigns of each such
party, whether or not such successors or assigns are permitted by the terms herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7 <U>Amendments;
Waivers</U>. No provision of this Note may be waived or amended except in a written instrument signed by the Company and the Holder. No
waiver of any default with respect to any provision, condition or requirement of this Note shall be deemed to be a continuing waiver in
the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay
or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8 <U>Compliance
with Securities Laws</U>. The Holder of this Note acknowledges that this Note is being acquired solely for the Holder&rsquo;s own account
and not as a nominee for any other party, and for investment, and that the Holder shall not offer, sell or otherwise dispose of this Note
in violation of securities laws. This Note and any Note issued in substitution or replacement therefor shall be stamped or imprinted with
a legend in substantially the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">&ldquo;THIS NOTE HAS NOT BEEN REGISTERED WITH
THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9 <U>Jurisdiction;
Venue</U>. Any action, proceeding or claim arising out of, or relating in any way to this Note shall be brought and enforced in the New
York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York. The Company and
the Holder irrevocably submit to the jurisdiction of such courts, which jurisdiction shall be exclusive, and hereby waive any objection
to such exclusive jurisdiction or that such courts represent an inconvenient forum. The prevailing party in any such action shall be entitled
to recover its reasonable and documented attorneys&rsquo; fees and out-of-pocket expenses relating to such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10 <U>Parties
in Interest</U>. This Note shall be binding upon, inure to the benefit of and be enforceable by the Maker, the Holder and their respective
successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11 <U>Failure
or Indulgence Not Waiver</U>. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder
shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12 <U>Maker
Waivers</U>. Except as otherwise specifically provided herein, the Maker and all others that may become liable for all or any part of
the obligations evidenced by this Note, hereby waive presentment, demand, notice of nonpayment, protest and all other demands and notices
in connection with the delivery, acceptance, performance and enforcement of this Note, and do hereby consent to any number of renewals
of extensions of the time or payment hereof and agree that any such renewals or extensions may be made without notice to any such persons
and without affecting their liability herein and do further consent to the release of any person liable hereon, all without affecting
the liability of the other persons, firms or Maker liable for the payment of this Note, AND DO HEREBY WAIVE TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(a) No
delay or omission on the part of the Holder in exercising its rights under this Note, or course of conduct relating hereto, shall operate
as a waiver of such rights or any other right of the Holder, nor shall any waiver by the Holder of any such right or rights on any one
occasion be deemed a waiver of the same right or rights on any future occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(b) THE
MAKER ACKNOWLEDGES THAT THE TRANSACTION OF WHICH THIS NOTE IS A PART IS A COMMERCIAL TRANSACTION, AND TO THE EXTENT ALLOWED BY APPLICABLE
LAW, HEREBY WAIVES ITS RIGHT TO NOTICE AND HEARING WITH RESPECT TO ANY PREJUDGMENT REMEDY WHICH THE HOLDER OR ITS SUCCESSORS OR ASSIGNS
MAY DESIRE TO USE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13 <U>Definitions</U>.
Capitalized terms used herein and not defined shall have the meanings set forth in the Purchase Agreement. For the purposes hereof, the
following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(a) &ldquo;<U>Convertible
Securities</U>&rdquo; means any securities convertible into or exercisable or exchangeable for, directly or indirectly, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(b) &ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any rights or warrants or options to purchase any Common Stock or Convertible Securities, other than
rights or warrants or options to purchase any Common Stock or Convertible Securities granted or issued under any Equity Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(c) &ldquo;<U>Indebtedness</U>&rdquo;
means: (a) all obligations for borrowed money; (b) all obligations evidenced by bonds, debentures, notes, or other similar instruments
and all reimbursement or other obligations in respect of letters of credit, bankers acceptances, current swap agreements, interest rate
hedging agreements, interest rate swaps, or other financial products; (c) all capital lease obligations that exceed $150,000 in the aggregate
in any fiscal year; (d) all obligations or liabilities secured by a lien or encumbrance on any asset of the Maker, irrespective of whether
such obligation or liability is assumed; (e) all obligations for the deferred purchase price of assets, together with trade debt and other
accounts payable that exceed $150,000 in the aggregate in any fiscal year; (f) all synthetic leases; (g) any obligation guaranteeing or
intended to guarantee (whether directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse) any of the foregoing
obligations of any other person; (h) trade debt; and (i) endorsements for collection or deposit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(d)
&ldquo;<U>Mandatory Default Amount</U>&rdquo; means an amount equal to one hundred twenty percent (120%) of the Outstanding Principal
Amount of this Note on the date on which the first Event of Default has occurred hereunder and any other amounts owing under this Note
or the other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(e) &ldquo;<U>Market
Capitalization</U>&rdquo; means, as of any date of determination, the product of (a) the number of issued and outstanding shares of Common
Stock as of such date (exclusive of any shares of Common Stock issuable upon the exercise of options or warrants or conversion of any
convertible securities), multiplied by (b) the closing price of the Common Stock on the Trading Market on the date of determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(f) &ldquo;<U>Outstanding
Principal Amount</U>&rdquo; means, at the time of determination, the Principal Amount outstanding after giving effect to any adjustments,
conversions or prepayments pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(g) &ldquo;<U>Repayment
Shares</U>&rdquo; means shares of Common Stock issued to the Holder by the Maker as payment for interest and/or the Principal Amount,
pursuant to <U>Section 1.3</U> of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(h) &ldquo;<U>Repayment
Share Price</U>&rdquo; means ninety percent (90%) of the average of the five (5) lowest daily VWAPs during the twenty (20) Trading Days
prior to the Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(i)
&ldquo;<U>Trading Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">(j) &ldquo;<U>VWAP</U>&rdquo;
means, as of any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of one share of Common Stock trading in the ordinary course of
business on the applicable Trading Price for such date (or the nearest preceding date) on such Trading Market as reported by Bloomberg
Financial L.P.; (b) if the Common Stock is not then listed on a Trading Market and if the Common Stock is traded in the over-the-counter
market, as reported by the OTCQX or OTCQB markets, the volume weighted average price of one share of Common Stock for such date (or the
nearest preceding date) on the OTCQX or OTCQB markets, as reported by Bloomberg Financial L.P.; (c) if the Common Stock is not then listed
or quoted on a Trading Market or on the OTCQX or OTCBQ markets and if prices for the Common Stock is then reported in the &ldquo;Pink
Sheets&rdquo; published by the OTC Markets Group (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price of one share of Common Stock so reported, as reported by Bloomberg Financial L.P.; or (d) in all other cases,
the fair market value of one share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and
reasonably acceptable to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Pages Follow]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Maker has caused
this Note to be duly executed by its duly authorized officer as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ABVC BIOPHARMA, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">[<FONT>&#9679;</FONT>]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">[&#9679;]</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>WIRE INSTRUCTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">Name of Bank:</FONT></TD>
    <TD STYLE="width: 85%"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Routing #:</FONT></TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">For credit to:</FONT></TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Account #:</FONT></TD>
    <TD></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF CONVERSION NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be Executed by the Registered Holder in order
to Convert the Note)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The undersigned hereby irrevocably
elects to convert $ ________________ of the principal amount of the above Note No. ___ into Common Stock of ABVC BioPharma, Inc., a Nevada
corporation (the &ldquo;<U>Maker</U>&rdquo;) according to the conditions hereof, as of the date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.8pt 0pt 12.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Date of Conversion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Conversion Price:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Number of Shares of Common Stock beneficially owned or deemed
beneficially owned by the Holder on the Conversion Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">[HOLDER]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Address:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>ea174178ex10-3_abvcbio.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS WARRANT HAS NOT BEEN REGISTERED WITH THE
SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">The number
of shares of common stock issuable upon exercise of this warrant may be less than the amounts set forth on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant is issued pursuant to that certain
Securities Purchase Agreement dated February 23, 2023 by and between the Company and the Holder (as defined below) (the &ldquo;<U>Purchase
Agreement</U>&rdquo;). Capitalized terms used and not otherwise defined herein shall have the meanings set forth for such terms in the
Purchase Agreement. Receipt of this Warrant by the Holder shall constitute acceptance and agreement to all of the terms contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No. WL-1 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ABVC
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COMMON STOCK PURCHASE WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABVC BioPharma, Inc., a Nevada
corporation (together with any corporation which shall succeed to or assume the obligations of ABVC BioPharma, Inc. hereunder, the &ldquo;<U>Company</U>&rdquo;),
hereby certifies that, for value received, Lind Global Fund II LP, a Delaware limited partnership (the &ldquo;<U>Holder</U>&rdquo;), is
entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period (as defined in <U>Section
9</U>) up to 5,291,667 fully paid and non-assessable shares of Common Stock (as defined in <U>Section&nbsp;9</U>), at a purchase price
per share equal to the Exercise Price (as defined in <U>Section 9</U>). The number of shares of Common Stock for which this Common Stock
Purchase Warrant (this &ldquo;<U>Warrant</U>&rdquo;) is exercisable and the Exercise Price are subject to adjustment as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>DEFINITIONS</U>. Certain terms are used in this Warrant as specifically defined in <U>Section 9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>EXERCISE OF WARRANT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise</U>.
This Warrant may be exercised prior to its expiration pursuant to <U>Section 2.5</U> hereof by the Holder at any time or from time to
time during the Exercise Period, by submitting the form of subscription attached hereto (the &ldquo;<U>Exercise Notice</U>&rdquo;) duly
executed by the Holder, to the Company at its principal office, indicating whether the Holder is electing to purchase a specified number
of shares by paying the Aggregate Exercise Price as provided in <U>Section 2.2</U> or is electing to exercise this Warrant as to a specified
number of shares pursuant to the net exercise provisions of <U>Section 2.3</U>. On or before the first Trading Day following the date
on which the Company has received the Exercise Notice, the Company shall transmit by electronic mail an acknowledgement of confirmation
of receipt of the Exercise Notice. Subject to <U>Section 2.4</U>, this Warrant shall be deemed exercised for all purposes as of the close
of business on the day on which the Holder has delivered the Exercise Notice to the Company. The Aggregate Exercise Price, if any, shall
be paid by wire transfer to the Company within five (5) Business Days of the date of exercise and prior to the time the Company issues
the certificates evidencing the shares issuable upon such exercise. In the event this Warrant is not exercised in full, the Company may,
at its expense, require the Holder, after such partial exercise, to promptly return this Warrant to the Company and the Company will forthwith
issue and deliver to or upon the order of the Holder a new Warrant or Warrants of like tenor, in the name of the Holder or as the Holder
(upon payment by the Holder of any applicable transfer taxes) may request, calling in the aggregate on the face or faces thereof for the
number of shares of Common Stock equal (without giving effect to any adjustment therein) to the number of such shares called for on the
face of this Warrant minus the number of such shares (without giving effect to any adjustment therein) for which this Warrant shall have
been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
of Exercise Price by Wire Transfer</U>. If the Holder elects to purchase a specified number of shares by paying the Aggregate Exercise
Price, the Holder shall pay such amount by wire transfer of immediately available funds to the account designated by the Company in its
acknowledgement of receipt of such Exercise Notice pursuant to <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
<U>Net Exercise</U>. If a registration statement covering the shares of Common Stock that are the subject of the Notice of Exercise (the
&ldquo;<U>Unavailable Warrant Shares</U>&rdquo;) is not available for the resale of such Unavailable Warrant Shares to the public or upon
exercise of this Warrant in connection with a Fundamental Transaction, the Holder may elect to exercise this Warrant by receiving shares
of Common Stock equal to the number of shares determined pursuant to the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">X = <U>Y (A - B)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">A&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.15pt">where,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">X =</TD><TD>the number of shares of Common Stock to be issued to Holder;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">Y =</TD><TD STYLE="text-align: justify">the number of shares of Common Stock as to which this Warrant is to be exercised (as indicated on the Exercise Notice);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A =</TD><TD STYLE="text-align: justify">VWAP for the Trading Day immediately preceding the date of exercise; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B =</TD><TD>the Exercise Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) <U>Intentionally Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) <U>Prohibited Transactions</U>.
For the avoidance of doubt, in accordance with Section 5.9 of the Purchase Agreement, the Company agrees that will not to enter into any
Prohibited Transactions without the Holder&rsquo;s prior written consent while this Warrant remains outstanding and thereafter as provided
in such Section 5.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Antitrust
Notification</U>. If the Holder determines, in its sole judgment upon the advice of counsel, that the issuance of any Warrant Shares pursuant
to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &ldquo;<U>HSR
Act</U>&rdquo;), the Company shall file as soon as practicable after the date on which the Company receives notice from the Holder of
the applicability of the HSR Act and a request to so file with the United States Federal Trade Commission and the United States Department
of Justice the notification and report form required to be filed by it pursuant to the HSR Act in connection with such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
This Warrant shall terminate upon the earlier to occur of (i) exercise in full or (ii) the expiration of the Exercise Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>REGISTRATION RIGHTS</U>. The Holder of this Warrant has certain rights to require the Company to register its resale of the Warrant
Shares under the Securities Act and any blue sky or securities laws of any jurisdictions within the United States at the time and in
the manner specified in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>DELIVERY OF STOCK CERTIFICATES ON EXERCISE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Exercise Shares</U>. As soon as practicable after any exercise of this Warrant and in any event within three (3) Trading Days thereafter
(such date, the &ldquo;<U>Exercise Share Delivery Date</U>&rdquo;), the Company shall, at its expense (including the payment by it of
any applicable issue or stamp taxes), cause to be issued in the name of and delivered to the Holder, or as the Holder may direct, a certificate
or certificates evidencing the number of fully paid and non-assessable shares of Common Stock (which number shall be rounded down to the
nearest whole share in the event any fractional share may otherwise be issuable upon such exercise and the Company shall pay a cash adjustment
to the Holder in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price) to which the Holder
shall be entitled on such exercise, in such denominations as may be requested by the Holder, which certificate or certificates shall be
free of restrictive and trading legends (except for any such legends as may be required under the Securities Act). In lieu of delivering
physical certificates for the shares of Common Stock issuable upon any exercise of this Warrant, provided the Warrant Shares are not restricted
securities and the Company&rsquo;s transfer agent is participating in the Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;) Fast Automated
Securities Transfer program or a similar program, upon request of the Holder, the Company shall cause its transfer agent to electronically
transmit such shares of Common Stock issuable upon exercise of this Warrant to the Holder (or its designee), by crediting the account
of the Holder&rsquo;s (or such designee&rsquo;s) broker with DTC through its Deposit Withdrawal Agent Commission system (provided that
the same time periods herein as for stock certificates shall apply) as instructed by the Holder (or its designee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Exercise Shares</U>. In addition to any other rights available to the Holder, if the Company fails
to cause its transfer agent to transmit to the Holder Exercise Shares pursuant to an exercise on or before the Exercise Share Delivery
Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Exercise Shares which
the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (a) pay in cash to the Holder
the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Exercise Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation
was executed, and (b) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (a) of
the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure
to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Exercise Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Exercise Shares, all of which taxes and expenses shall be paid by the Company, and
such Exercise Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that in the event Exercise Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto (the &ldquo;<U>Assignment Form</U>&rdquo;) duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>CERTAIN ADJUSTMENT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (a) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (b) subdivides outstanding shares of Common Stock into a larger number of shares, (c) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (d) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this <U>Section 5.1</U> shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to
the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the beneficial ownership
limitation provided for in <U>Section 10</U>, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the beneficial ownership limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (a) the Company effects any merger or consolidation of the Company
with or into another Person, (b) the Company effects any sale of all or substantially all of its assets in one or a series of related
transactions, (c) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders
of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (d) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into
or exchanged for other securities, cash or property (each, a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon the closing of
a Fundamental Transaction and payment of the exercise price therefore (including at the election of the Holder by cashless exercise),
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior
to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 10 on the
exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is
the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 10 on the exercise of this Warrant). For purposes of
any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based
on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company
shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be
received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental
Transaction the result of which is that in excess of 33% of the Company&rsquo;s outstanding equity shall be held by Persons differing
to those immediately prior to such Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the
Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the
date of the consummation of such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value this Warrant based
on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the final day of the Exercise Period, (B) an expected volatility equal to the greater of 100% and
the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the
sum of the price per share being offered in cash, if any, plus the value of any non- cash consideration, if any, being offered in such
Fundamental Transaction and (ii) the greater of (x) the last volume weighted average price immediately prior to the public announcement
of such Fundamental Transaction and (y) the last volume weighted average price immediately prior to the consummation of such Fundamental
Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the final day of the Exercise Period. The payment of the Black Scholes Value will be made by wire transfer of immediately
available funds within five Business Days of the Holder&rsquo;s election (or, if later, on the effective date of the Fundamental Transaction).
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in
accordance with the provisions of this 5.3 pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price Upon Issuance of Common Stock</U>. If the Company shall, at any time after the Issue Date, issue or sell any shares
of Common Stock (other than in an Exempted Securities), whether directly or indirectly by way of Convertible Securities (&ldquo;<U>Additional
Shares of Common Stock</U>&rdquo;), without consideration or for consideration per share less than the Exercise Price in effect immediately
prior to such issuance or sale, then immediately upon such issuance or sale, the Exercise Price in effect immediately prior to such issuance
or sale shall be reduced (and in no event increased) to an Exercise Price equal to the consideration per share paid for such Additional
Shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Calculations</U>.
All calculations under this <U>Section 5</U> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may
be. For purposes of this <U>Section 5</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding at the
close of the Trading Day on or, if not applicable, most recently preceding, such given date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 5</U>, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring
such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (i) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock; (ii) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock; (iii) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights; (iv) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property;
or (v) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company;
then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register
of the Company, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a
record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the
mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. Subject to applicable law,
the Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event
triggering such notice. Notwithstanding the foregoing, the delivery of the notice described in this <U>Section 5.6</U> is not intended
to and shall not bestow upon the Holder any voting rights whatsoever with respect to outstanding unexercised Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>NO
IMPAIRMENT</U>. The Company will not, by amendment of the Articles of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and
in taking all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment. Without
limiting the generality of the foregoing, the Company (a) will not increase the par value of any shares of Common Stock receivable on
the exercise of this Warrant above the amount payable therefor on such exercise and (b) will take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of stock on the exercise of
this Warrant from time to time outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>NOTICES
OF RECORD DATE</U>. In the event of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock
of any class or any other securities or property, or to receive any other right;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any transfer of
all or substantially all the assets of the Company to or any consolidation or merger of the Company with or into any other Person or any
other Change of Control; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
voluntary or involuntary dissolution, liquidation or winding-up of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then, and in each such event, the Company will
mail or cause to be mailed to the Holder a notice specifying (i) the date on which any such record is to be taken for the purpose of such
dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the date on which
any such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution, liquidation or winding-up is
anticipated to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock shall be entitled to
exchange their shares of Common Stock for securities or other property deliverable on such reorganization, reclassification, recapitalization,
transfer, consolidation, merger, dissolution, liquidation or winding-up. Such notice shall be mailed at least fifteen (15) days prior
to the date specified in such notice on which any such action is to be taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>RESERVATION
OF STOCK ISSUABLE ON EXERCISE OF WARRANT; REGULATORY COMPLIANCE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Stock Issuable on Exercise of Warrant</U>. The Company shall at all times while this Warrant shall be outstanding, reserve and keep
available out of its authorized but unissued Common Stock, such number of shares of Common Stock as shall from time to time be sufficient
to effect the exercise of all or any portion of the Warrant Shares (disregarding for this purpose any and all limitations of any kind
on such exercise). The Company shall, from time to time in accordance with the Delaware General Corporation Law, increase the authorized
number of shares of Common Stock or take other effective action if at any time the unissued number of authorized shares shall not be sufficient
to satisfy the Company&rsquo;s obligations under this <U>Section 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Compliance</U>. If any shares of Common Stock to be reserved for the purpose of exercise of the Warrant Shares require registration or
listing with or approval of any Governmental Authority, stock exchange or other regulatory body under any federal or state law or regulation
or otherwise before such shares may be validly issued or delivered upon exercise, the Company shall, at its sole cost and expense, in
good faith and as expeditiously as possible, secure such registration, listing or approval, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DEFINITIONS</U>.
As used herein the following terms, unless the context otherwise requires, have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control
with, the Person specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Aggregate
Exercise Price</U></FONT>&rdquo; <FONT STYLE="font-size: 10pt">means, in connection with the exercise of this Warrant at any time, an
amount equal to the product obtained by multiplying (i) the Exercise Price times (ii) the number of shares of Common Stock for which this
Warrant is being exercised at such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Articles of Incorporation</U>&rdquo;
means the Company&rsquo;s Restated Articles of Incorporation as amended to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than a Saturday, Sunday or any other day on which banks are permitted or required to be closed in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Change of Control</U>&rdquo;
has the meaning set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means (i) the Company&rsquo;s Common Stock, $0.001 par value per share, and (ii) any other securities into which or for which any of the
securities described in clause (i) above have been converted or exchanged pursuant to a plan of recapitalization, reorganization, merger,
sale of assets or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Convertible Securities</U>&rdquo;
means any debt, equity or other securities that are, directly or indirectly, convertible into or exchangeable for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Period</U>&rdquo;
means the period commencing on the Issue Date and ending 11:59 P.M. (New York City time) on the date that is sixty (60) months from the
Issue Date or earlier closing of a Fundamental Transaction (other than a Fundamental Transaction of the type described in clause (d) of
the definition thereof resulting in the conversion into or exchange for another security of the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Price</U>&rdquo;
means $1.05 per share, as may be adjusted pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Shares</U>&rdquo;
means the shares of Common Stock for which this Warrant is then being exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fair Market Value</U>&rdquo;
means, with respect to any security or other property, the fair market value of such security or other property as determined by the Board
of Directors, acting in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Governmental Authority</U>&rdquo;
means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any
agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial,
taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the
European Union or the European Central Bank).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issue Date</U>&rdquo;
means February 23, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Note</U></FONT>&rdquo;
<FONT STYLE="font-size: 10pt">means the senior secured convertible promissory note issued by the Company to the Holder pursuant to the
Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Person</U></FONT>&rdquo;
<FONT STYLE="font-size: 10pt">means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means, as of any time of determination and with respect to any Person, any United States corporation, partnership, limited liability company
or limited liability partnership, all of the stock (or other equity interest) of every class of which, except directors&rsquo; qualifying
shares (or any equivalent), shall, at such time, be owned by such Person either directly or through Subsidiaries and of which such Person
or a Subsidiary shall have 100% control thereof, except directors&rsquo; qualifying shares. Unless the context otherwise clearly requires,
any reference to a &ldquo;Subsidiary&rdquo; is a reference to a Subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means whichever of the New York Stock Exchange, NYSE: Amex Exchange, or the Nasdaq Stock Market (including the Nasdaq Capital Market),
on which the Common Stock is listed or quoted for trading on the date in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, as of any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of one share of Common Stock trading in the ordinary course of
business on the applicable Trading Price for such date (or the nearest preceding date) on such Trading Market as reported by Bloomberg
Financial L.P.; (b) if the Common Stock is not then listed on a Trading Market and if the Common Stock is traded in the over-the-counter
market, as reported by the OTC Bulletin Board, the volume weighted average price of one share of Common Stock for such date (or the nearest
preceding date) on the OTC Bulletin Board, as reported by Bloomberg Financial L.P.; (c) if the Common Stock is not then listed or quoted
on the OTC Bulletin Board and if prices for the Common Stock is then reported in the &ldquo;Pink Sheets&rdquo; published by the Pink OTC
Markets Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price of one share
of Common Stock so reported, as reported by Bloomberg Financial L.P.; or (d) in all other cases, the fair market value of one share of
Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company (in
each case rounded to four decimal places).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Warrant
Shares</U></FONT>&rdquo; <FONT STYLE="font-size: 10pt">means collectively the shares of Common Stock of the Company issuable upon exercise
of the Warrant in accordance with its terms, as such number may be adjusted pursuant to the provisions thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>LIMITATION
ON BENEFICIAL OWNERSHIP</U>. Notwithstanding anything to the contrary contained herein, the Holder shall not be entitled to receive shares
of Common Stock or other securities (together with Common Stock, &ldquo;<U>Equity Interests</U>&rdquo;) upon exercise of this Warrant
to the extent (but only to the extent) that such exercise or receipt would cause the Holder Group to become, directly or indirectly, a
&ldquo;beneficial owner&rdquo; (within the meaning of Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder)
of a number of Equity Interests of a class that is registered under the Exchange Act which exceeds the Maximum Percentage (as defined
below) of the Equity Interests of such class that are outstanding at such time. Any purported delivery of Equity Interests in connection
with the exercise of the Warrant prior to the termination of this restriction in accordance herewith shall be void and have no effect
to the extent (but only to the extent) that such delivery would result in the Holder Group becoming the beneficial owner of more than
the Maximum Percentage of the Equity Interests of a class that is registered under the Exchange Act that is outstanding at such time.
If any delivery of Equity Interests owed to the Holder following exercise of this Warrant is not made, in whole or in part, as a result
of this limitation, the Company&rsquo;s obligation to make such delivery shall not be extinguished and the Company shall deliver such
Equity Interests as promptly as practicable after the Holder gives notice to the Company that such delivery would not result in such limitation
being triggered or upon termination of the restriction in accordance with the terms hereof. To the extent limitations contained in this
<U>Section 10</U> apply, the determination of whether this Warrant is exercisable and of which portion of this Warrant is exercisable
shall be the sole responsibility and in the sole determination of the Holder, and the submission of an Exercise Notice shall be deemed
to constitute the Holder&rsquo;s determination that the issuance of the full number of Warrant Shares requested in the Exercise Notice
is permitted hereunder, and neither the Company nor any Warrant agent shall have any obligation to verify or confirm the accuracy of such
determination. For purposes of this <U>Section 10</U>, (i) the term &ldquo;<U>Maximum Percentage</U>&rdquo; shall mean 4.99%; provided,
that if at any time after the date hereof the Holder Group beneficially owns in excess of 4.99% of any class of Equity Interests in the
Company that is registered under the Exchange Act (excluding any Equity Interests deemed beneficially owned by virtue of this Warrant
or the Note), then the Maximum Percentage shall automatically increase to 9.99% so long as the Holder Group owns in excess of 4.99% of
such class of Equity Interests (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon the Holder Group ceasing to
own in excess of 4.99% of such class of Equity Interests); and (ii) the term &ldquo;<U>Holder Group</U>&rdquo; shall mean the Holder plus
any other Person with which the Holder is considered to be part of a group under Section 13 of the Exchange Act or with which the Holder
otherwise files reports under Sections 13 and/or 16 of the Exchange Act. In determining the number of Equity Interests of a particular
class outstanding at any point in time, the Holder may rely on the number of outstanding Equity Interests of such class as reflected in
(x) the Company&rsquo;s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission, as the case may be, (y) a more recent public announcement by the Company or (z) a more recent notice by the Company or its
transfer agent to the Holder setting forth the number of Equity Interests of such class then outstanding. For any reason at any time,
upon written or oral request of the Holder, the Company shall, within one (1) Trading Day of such request, confirm orally and in writing
to the Holder the number of Equity Interests of any class then outstanding. The provisions of this <U>Section 10</U> shall be construed,
corrected and implemented in a manner so as to effectuate the intended beneficial ownership limitation herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>REGISTRATION
AND TRANSFER OF WARRANT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
of Warrant</U>. The Company shall register and record transfers, exchanges, reissuances and cancellations of this Warrant, upon the records
to be maintained by the Company for that purpose, in the name of the record holder hereof from time to time. The Company may deem and
treat the registered holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to
the Holder, and for all other purposes, absent actual notice to the contrary. The Company shall be entitled to rely, and held harmless
in acting or refraining from acting in reliance upon, any notices, instructions or documents it believes in good faith to be from an authorized
representative of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form of assignment (the &ldquo;<U>Assignment Notice</U>&rdquo;) attached hereto duly executed by the Holder
or its agent or attorney. The Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the
transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of the transferred Warrant under the 1933 Act. Upon such surrender, the Company shall execute and deliver
a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified
in such Assignment Notice, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the
purchase of Exercise Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with <U>Section 11.2</U>, as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for this Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical
with this Warrant except as to the number of Exercise Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>LOSS,
THEFT, DESTRUCTION OR MUTILATION OF WARRANT</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Exercise Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>REMEDIES</U>.
The Company stipulates that the remedies at law of the Holder in the event of any default or threatened default by the Company in the
performance of or compliance with any of the terms of this Warrant are not and will not be adequate, and that such terms may be specifically
enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a violation of any of
the terms hereof or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>NO
RIGHTS AS A STOCKHOLDER</U>. Except as otherwise specifically provided herein, the Holder, solely in such Person&rsquo;s capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for
any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity
as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Exercise
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>NOTICES</U>.
All notices, requests, demands and other communications that are required or may be given pursuant to the terms of this Warrant shall
be in writing and shall be deemed delivered (i) on the date of delivery when delivered by hand on a Business Day during normal business
hours or, if delivered on a day that is not a Business Day or after normal business hours, then on the next Business Day, (ii) on the
date of transmission when sent by facsimile transmission or email during normal business hours on a Business Day with telephone confirmation
of receipt or, if transmitted on a day that is not a Business Day or after normal business hours, then on the next Business Day, or (iii)
on the second Business Day after the date of dispatch when sent by a reputable courier service that maintains records of receipt. The
addresses for notice shall be as set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>CONSENT
TO AMENDMENTS</U>. Any term of this Warrant may be amended, and the Company may take any action herein prohibited, or compliance therewith
may be waived, only if the Company shall have obtained the written consent (and not without such written consent) to such amendment, action
or waiver from the Holder. No course of dealing between the Company and the Holder nor any delay in exercising any rights hereunder shall
operate as a waiver of any rights of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>MISCELLANEOUS</U>.
In case any provision of this Warrant shall be invalid, illegal or unenforceable, or partially invalid, illegal or unenforceable, the
provision shall be enforced to the extent, if any, that it may legally be enforced and the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby. If any provision of this Warrant is found to conflict with
the Purchase Agreement, the provisions of this Warrant shall prevail. If any provision of this Warrant is found to conflict with the Note,
the provisions of the Note shall prevail. THIS WARRANT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND THE RIGHTS OF THE PARTIES
SHALL BE GOVERNED BY, THE INTERNAL LAW OF THE STATE OF NEVADA EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE LAW OF SUCH STATE THAT WOULD PERMIT
THE APPLICATION OF THE LAWS OF A JURISDICTION OTHER THAN SUCH STATE. The headings in this Warrant are for purposes of reference only,
and shall not limit or otherwise affect any of the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Remainder of Page Intentionally Left Blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its duly authorized officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated as of February 23, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>ABVC BIOPHARMA, INC.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF SUBSCRIPTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be signed only on exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of Common Stock Purchase Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO: ABVC BioPharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned Holder of the attached Warrant hereby elects to exercise its purchase right under such Warrant to purchase shares of Common
Stock of ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), as follows (check one or more, as applicable):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">to exercise the Warrant to purchase __________ shares of Common Stock and to pay the Aggregate Exercise
Price therefor by wire transfer of United States funds to the account of the Company, which transfer has been made prior to or as of the
date of delivery of this Form of Subscription pursuant to the instructions of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">to exercise the Warrant with respect to ____________ shares of Common Stock pursuant to the net exercise
provisions specified in Section 2.3 of the Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
exercising this Warrant, the undersigned Holder hereby confirms and acknowledges that the shares of Common Stock are being acquired solely
for the account of the undersigned and not as a nominee for any other party, and for investment, and that the undersigned shall not offer,
sell or otherwise dispose of any such shares of Common Stock except under circumstances that will not result in a violation of the Securities
Act or any state securities laws. The undersigned hereby further confirms and acknowledges that it is an &ldquo;accredited investor&rdquo;,
as that term is defined under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
issue a stock certificate or certificates representing the appropriate number of shares of Common Stock in the name of the undersigned
or in such other name(s) as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding-bottom: 3pt; text-align: left; width: 10%; vertical-align: top">Name:</TD>
    <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 3pt; text-align: left; vertical-align: top">Address:</TD>
    <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 3pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 3pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 3pt; text-align: left; vertical-align: top">TIN:</TD>
    <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">Dated: </TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>(Signature must conform exactly to name of Holder as specified on the
    face of the Warrant)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be signed only on transfer of Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For value received, the undersigned
hereby sells, assigns, and transfers unto ________________ the right represented by the within Warrant to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
shares of Common Stock of ABVC BioPharma, Inc., a Nevada corporation, to which the within Warrant relates, and appoints _________________
attorney to transfer such right on the books of ABVC BioPharma, Inc., with full power of substitution in the premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">[insert name of Holder]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%">Dated:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 40%">&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 40%">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">[insert address of Holder]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Signed in the presence of:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>ea174178ex10-4_abvcbio.htm
<DESCRIPTION>SECURITY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SECURITY AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>SECURITY AGREEMENT</B>
(this &ldquo;<U>Agreement</U>&rdquo;), dated as of February 23, 2023, by and between <FONT STYLE="text-transform: uppercase"><B>ABVC BIOPHARMA,
INC.</B></FONT><B>, </B>a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), and <B>LIND GLOBAL FUND II LP</B> (the &ldquo;<U>Secured
Party</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
(a) and the Secured Party have entered into that certain Securities Purchase Agreement dated as of the date hereof (as amended and in
effect from time to time, the &ldquo;<U>SPA</U>&rdquo;) and (b) issued to the Secured Party that certain Senior Convertible Promissory Note
dated the date hereof (as amended and in effect from time to time, the &ldquo;<U>Note</U>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, it is a condition
precedent to the Secured Party agreeing to make loans or otherwise extend credit to the Company under the SPA and the Note that the Company
execute and deliver to the Secured Party a security agreement in substantially the form hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
wishes to grant security interests in favor of the Secured Party as herein provided;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>1. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All capitalized terms used herein without definitions shall have the respective meanings provided therefor in the SPA. All terms defined
in the Uniform Commercial Code of the State (as hereinafter defined) and used herein shall have the same definitions herein as specified
therein, however, if a term is defined in Article 9 of the Uniform Commercial Code of the State differently than in another Article of
the Uniform Commercial Code of the State, the term has the meaning specified in Article 9, and the following terms shall have the following
meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Event of Default</U>&rdquo;
means the occurrence of any &ldquo;Event of Default&rdquo; under and as defined in each of the SPA and the Note, or the failure of the Company
to comply with any term or covenant of any Transaction Document (including this Agreement) to which it is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Guarantors</U>&rdquo;
means, collectively, each subsidiary of the Company which provides a guarantee of all or any portion of the Obligations of the Company
to the Secured Party, including, without limitation, American BriVision Corp., BioKey, Inc., BioLite Holding, Inc. and BioLite BVI, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lien</U>&rdquo; means
any mortgage, charge, pledge, hypothecation, security interest, assignment by way of security, lien (statutory or otherwise), encumbrance,
conditional sale agreement, capital lease, financing lease, deposit arrangement, title retention agreement, and any other agreement, trust
or arrangement that in substance secures payment or performance of an obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Obligations</U>&rdquo;
means, collectively, (a) all debts, liabilities and obligations, present or future, direct or indirect, absolute or contingent, matured
or unmatured, at any time or from time to time due or accruing, due and owing by or otherwise payable by the Company or any Guarantor
to the Secured Party, in any currency, under, in connection with or pursuant to any Transaction Document (including, without limitation,
this Agreement), and whether incurred by the Company or any Guarantor alone or jointly with another or others and whether as principal,
guarantor or surety and in whatever name or style and (b) all expenses, costs and charges incurred by or on behalf of the Secured Party
in connection with any Transaction Document (including this Agreement) or the Collateral, including all legal fees, court costs, receiver&rsquo;s
or agent&rsquo;s remuneration and other expenses of taking possession of, repairing, protecting, insuring, preparing for disposition,
realizing, collecting, selling, transferring, delivering or obtaining payment for the Collateral, and of taking, defending or participating
in any action or proceeding in connection with any of the foregoing matters or otherwise in connection with the Secured Party&rsquo;s interest
in any Collateral, whether or not directly relating to the enforcement of this Agreement or any other Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted Lien</U>&rdquo;
means any of the following: (a) mechanics and materialman Liens and other statutory Liens (including Liens for taxes, fees, assessments
and other governmental charges or levies) in respect of any amount (i) which is not at the time overdue or (ii) which may be overdue but
the validity of which is being contested at the time in good faith by appropriate proceedings, in each case so long as the holder of such
Lien has not taken any action to foreclose or otherwise exercise any remedies with respect to such Lien; (b) Liens under $150,000 to support
the working capital of the Company so long as the Company has complied with the terms provided for in the Transaction Documents relating
thereto (including, without limitation, entering into an intercreditor agreement acceptable to the Secured Party) and (c) Liens which
are permitted in writing by the Secured Party in its sole and absolute discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>State</U>&rdquo; means
the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction Documents</U>&rdquo;
has the meaning provided for in the SPA, provided, however, for purposes of this Agreement, upon the indefeasible repayment in full, in
cash, of the Note and all obligations owing thereunder, such term shall thereafter not include the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>2. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Grant
of Security Interest</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>2.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Grant;
Collateral Description</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company hereby grants
to the Secured Party, to secure the payment and performance in full of all of the Obligations, a security interest in and pledges and
assigns to the Secured Party the following properties, assets and rights of the Company, wherever located, whether now owned or hereafter
acquired or arising, and all proceeds and products thereof (all of the same being hereinafter called the &ldquo;<U>Collateral</U>&rdquo;):
all personal and fixture property of every kind and nature including all goods (including inventory, equipment and any accessions thereto),
instruments (including promissory notes), documents (whether tangible or electronic), accounts (including health-care-insurance receivables),
chattel paper (whether tangible or electronic), deposit accounts, letter-of-credit rights (whether or not the letter of credit is evidenced
by a writing), commercial tort claims, securities and all other investment property, supporting obligations, any other contract rights
or rights to the payment of money, insurance claims and proceeds, and all general intangibles (including all payment intangibles). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>2.2. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Commercial
Tort Claims</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Secured Party acknowledges that
the attachment of its security interest in any commercial tort claim as original collateral is subject to the Company&rsquo;s compliance with
&sect;4.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>3. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization
to File Financing Statements</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company hereby
irrevocably authorizes the Secured Party at any time and from time to time to file in any filing office which the Secured Party deems
necessary in any Uniform Commercial Code jurisdiction any initial financing statements and amendments thereto that (a) indicate the Collateral
(i) as all assets of the Company, or words of similar effect, regardless of whether any particular asset comprised in the Collateral falls
within the scope of Article 9 of the Uniform Commercial Code of the State or such jurisdiction, or (ii) as being of an equal or lesser
scope or with greater detail, and (b) provide any other information required by part 5 of Article 9 of the Uniform Commercial Code of
the State or such other jurisdiction for the sufficiency or filing office acceptance of any financing statement or amendment, including
whether the Company is an organization, the type of organization and any organizational identification number issued to the Company. The
Company agrees to furnish any such information to the Secured Party promptly upon the Secured Party&rsquo;s reasonable request. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>4. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
Actions</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Further to insure the attachment, perfection
and first priority of, and the ability of the Secured Party to enforce, the Secured Party&rsquo;s security interest in the Collateral, the Company
agrees, in each case at the Company&rsquo;s expense, to take the following actions with respect to the following Collateral and without limitation
on the Company&rsquo;s other obligations contained in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Promissory
Notes and Tangible Chattel Paper</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>.</I> If the
Company shall, now or at any time hereafter, hold or acquire any promissory notes or tangible chattel paper with an aggregate value for
all such promissory notes or tangible chattel paper in excess of $150,000, the Company shall forthwith endorse, assign and deliver the
same to the Secured Party, accompanied by such instruments of transfer or assignment duly executed in blank as the Secured Party may from
time to time specify.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.2. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Deposit
Accounts</U>. </FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For each deposit account that the Company,
now or at any time hereafter, opens or maintains, the Company shall, within thirty days of the date hereof, or for any such deposit account
opened following the date hereof, the date of opening such deposit account, unless waived in writing by the Secured Party, pursuant to
an agreement in form and substance reasonably satisfactory to the Secured Party, either (a) cause the depositary bank to agree to comply
without further consent of the Company, at any time with instructions from the Secured Party to such depositary bank directing the disposition
of funds from time to time credited to such deposit account, or (b) arrange for the Secured Party to become the customer of the depositary
bank with respect to the deposit account, with the Company being permitted, only with the consent of the Secured Party, to exercise rights
to withdraw funds from such deposit account. The Secured Party agrees with the Company that the Secured Party shall not give any such
instructions or withhold any withdrawal rights from the Company, unless an Event of Default has occurred and is continuing, or, if effect
were given to any withdrawal not otherwise permitted by the Transaction Documents, would occur. The provisions of this paragraph shall
not apply to any deposit accounts specially and exclusively used (i) for payroll, payroll taxes and other employee wage and benefit payments
to or for the benefit of the Company&rsquo;s salaried employees, (ii) in cases where the Company acts as custodian, trust, fiduciary or escrow
agent for the benefit of a third party in transactions permitted by the Transaction Documents, and (iii) as petty cash accounts that collectively
have an average daily balance at any time of less than $25,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.3. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investment
Property</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>.</I> If the Company shall, now or
at any time hereafter, hold or acquire any certificated securities, the Company shall forthwith endorse, assign and deliver the same to
the Secured Party, accompanied by such instruments of transfer or assignment duly executed in blank as the Secured Party may from time
to time specify. If any securities now or hereafter acquired by the Company are uncertificated and are issued to the Company or its nominee
directly by the issuer thereof, the Company shall promptly (but in any event within five Business Days) notify the Secured Party thereof
and, at the Secured Party&rsquo;s request and option, pursuant to an agreement in form and substance reasonably satisfactory to the Secured
Party, either (a) cause the issuer to agree to comply without further consent of the Company or such nominee, at any time with instructions
from the Secured Party as to such securities, or (b) arrange for the Secured Party to become the registered owner of the securities. If
any securities, whether certificated or uncertificated, or other investment property now or hereafter acquired by the Company are held
by the Company or its nominee through a securities intermediary or commodity intermediary, the Company shall promptly (but in any event
within five Business Days) notify the Secured Party thereof and, at the Secured Party&rsquo;s request and option, pursuant to an agreement in
form and substance reasonably satisfactory to the Secured Party, either (i) cause such securities intermediary or (as the case may be)
commodity intermediary to agree to comply, in each case without further consent of the Company or such nominee, at any time with entitlement
orders or other instructions from the Secured Party to such securities intermediary as to such securities or other investment property,
or (as the case may be) to apply any value distributed on account of any commodity contract as directed by the Secured Party to such commodity
intermediary, or (ii) in the case of financial assets or other investment property held through a securities intermediary, arrange for
the Secured Party to become the entitlement holder with respect to such investment property, with the Company being permitted, only with
the consent of the Secured Party, to exercise rights to withdraw or otherwise deal with such investment property. The Secured Party agrees
with the Company that the Secured Party shall not give any such entitlement orders or instructions or directions to any such issuer, securities
intermediary or commodity intermediary, and shall not withhold its consent to the exercise of any withdrawal or dealing rights by the
Company, unless an Event of Default has occurred and is continuing, or, after giving effect to any such investment and withdrawal rights
not otherwise permitted by the Transaction Documents, would occur. The provisions of this paragraph shall not apply to any financial assets
credited to a securities account for which the Secured Party is the securities intermediary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.4. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Collateral
in the Possession of a Bailee</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>.</I> If any
Collateral with an aggregate value in excess of $150,000 is, now or at any time hereafter, in the possession of a bailee, the Company
shall promptly notify the Secured Party thereof and, at the Secured Party&rsquo;s reasonable request and option, shall promptly obtain an acknowledgement
from the bailee, in form and substance reasonably satisfactory to the Secured Party, that the bailee holds such Collateral for the benefit
of the Secured Party and such bailee&rsquo;s agreement to comply, without further consent of the Company, at any time with instructions of the
Secured Party as to such Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.5. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Electronic
Chattel Paper, Electronic Documents and Transferable Records</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If the Company, now or at any time hereafter, holds or acquires an interest in any Collateral that is electronic chattel paper, any electronic
document or any &ldquo;transferable record,&rdquo; as that term is defined in Section 201 of the federal Electronic Signatures in Global
and National Commerce Act, or in &sect;16 of the Uniform Electronic Transactions Act as in effect in any relevant jurisdiction, the Company
shall promptly notify the Secured Party thereof and, at the request and option of the Secured Party, shall take such action as the Secured
Party may reasonably request to vest in the Secured Party control, under &sect;9-105 of the Uniform Commercial Code of the State or any
other relevant jurisdiction, of such electronic chattel paper, control, under &sect;7-106 of the Uniform Commercial Code of the State
or any other relevant jurisdiction, of such electronic document or control, under Section 201 of the federal Electronic Signatures in
Global and National Commerce Act or, as the case may be, &sect;16 of the Uniform Electronic Transactions Act, as so in effect in such
jurisdiction, of such transferable record. The Secured Party agrees with the Company that the Secured Party will arrange, pursuant to
procedures satisfactory to the Secured Party and so long as such procedures will not result in the Secured Party&rsquo;s loss of control, for
the Company to make alterations to the electronic chattel paper, electronic document or transferable record permitted under UCC &sect;9-105,
UCC &sect;7-106, or, as the case may be, Section 201 of the federal Electronic Signatures in Global and National Commerce Act or &sect;16
of the Uniform Electronic Transactions Act for a party in control to make without loss of control, unless an Event of Default has occurred
and is continuing or would occur after taking into account any action by the Company with respect to such electronic chattel paper, electronic
document or transferable record. The provisions of this &sect;4.5 relating to electronic documents and &ldquo;control&rdquo; under UCC &sect;7-106
apply in the event that the 2003 revisions to Article 7, with amendments to Article 9, of the Uniform Commercial Code, in substantially
the form approved by the American Law Institute and the National Conference of Commissioners on Uniform State Laws, are now or hereafter
adopted and become effective in the State or in any other relevant jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.6. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Letter-of-Credit
Rights</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. If the Company is, now or at any time
hereafter, a beneficiary under a letter of credit with a stated amount in excess of $25,000, or if the Company is a beneficiary under
letters of credit not assigned to the Secured Party with an aggregate stated amount in excess of $150,000, the Company shall promptly
notify the Secured Party thereof and, at the request and option of the Secured Party, the Company shall, pursuant to an agreement in form
and substance reasonably satisfactory to the Secured Party, either (a) arrange for the issuer and any confirmer of such letter of credit
to consent to an assignment to the Secured Party of the proceeds of the letter of credit or (b) arrange for the Secured Party to become
the transferee beneficiary of the letter of credit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.7. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Commercial
Tort Claims</U><I>.</I></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> If the Company shall, now
or at any time hereafter, hold or acquire a commercial tort claim, the Company shall promptly notify the Secured Party in a writing signed
by the Company of the particulars thereof and grant to the Secured Party in such writing a security interest therein and in the proceeds
thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to the Secured Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.8. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
Actions as to any and all Collateral</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company
further agrees, upon the request of the Secured Party and at the Secured Party&rsquo;s option, to take any and all other actions as the Secured
Party may determine to be necessary or useful for the attachment, perfection and first priority of, and the ability of the Secured Party
to enforce, the Secured Party&rsquo;s security interest in any and all of the Collateral, including (a) executing, delivering and, where appropriate,
filing financing statements and amendments relating thereto under the Uniform Commercial Code of any relevant jurisdiction, to the extent,
if any, that the Company&rsquo;s signature thereon is required therefor, (b) causing the Secured Party&rsquo;s name to be noted as secured party on
any certificate of title for a titled good if such notation is a condition to attachment, perfection or priority of, or ability of the
Secured Party to enforce, the Secured Party&rsquo;s security interest in such Collateral, (c) complying with any provision of any statute, regulation
or treaty of the United States as to any Collateral if compliance with such provision is a condition to attachment, perfection or priority
of, or ability of the Secured Party to enforce, the Secured Party&rsquo;s security interest in such Collateral, (d) obtaining governmental and
other third party waivers, consents and approvals, in form and substance reasonably satisfactory to the Secured Party, including any consent
of any licensor, lessor or other Person obligated on Collateral, (e) obtaining waivers from mortgagees and landlords of the Company&rsquo;s
primary place of business or any other location where the aggregate value of the Collateral at such location exceeds $150,000, in form
and substance reasonably satisfactory to the Secured Party and (f) taking all actions under any earlier versions of the Uniform Commercial
Code or under any other law, as reasonably determined by the Secured Party to be applicable in any relevant Uniform Commercial Code or
other jurisdiction, including any foreign jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>5. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
and Warranties Concerning a Company&rsquo;s Legal Status</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company has, on the date hereof, delivered to the Secured Party a certificate signed by the Company and entitled &ldquo;Perfection
Certificate&rdquo; (the &ldquo;<U>Perfection Certificate</U>&rdquo;). The Company represents and warrants to the Secured Party as follows:
as of the date hereof (a) the Company&rsquo;s exact legal name is that indicated on the Perfection Certificate and on the signature page hereof,
(b) the Company is an organization of the type, and is organized in the jurisdiction, set forth in the Perfection Certificate, (c) the
Perfection Certificate accurately sets forth the Company&rsquo;s organizational identification number or accurately states that the Company
has none, (d) the Perfection Certificate accurately sets forth the Company&rsquo;s place of business or, if more than one, its chief executive
office, as well as the Company&rsquo;s mailing address, if different, (e) all other information set forth on the Perfection Certificate pertaining
to the Company is accurate and complete, and (f) there has been no material change in any of such information since the date on which
the Perfection Certificate was signed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>6. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants
Concerning Company&rsquo;s Legal Status</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company
covenants with the Secured Party as follows: (a) without providing at least fifteen (15) days prior written notice to the Secured Party,
the Company will not change its name, its place of business or, if more than one, chief executive office, or its mailing address or organizational
identification number if it has one, (b) if the Company does not have an organizational identification number and later obtains one, the
Company will forthwith notify the Secured Party of such organizational identification number, and (c) the Company will not change its
type of organization, jurisdiction of organization or other legal structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>7. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
and Warranties Concerning Collateral, Etc</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The
Company further represents and warrants to the Secured Party as follows: (a) the Company is the owner of or has other rights in or power
to transfer the Collateral, free from any right or claim of any Person or any adverse lien, except for the security interest created by
this Agreement and the Permitted Liens, (b) none of the account debtors or other Persons obligated on any of the Collateral is a governmental
authority covered by the Federal Assignment of Claims Act or like federal, state or local statute or rule in respect of such Collateral,
(c) the Company holds no commercial tort claim except as indicated on the Company&rsquo;s Perfection Certificate, (d) all other information
set forth on the Company&rsquo;s Perfection Certificate pertaining to the Collateral is accurate and complete, and (e) there has been no material
change in any of such information since the date on which the Company&rsquo;s Perfection Certificate was signed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>8. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants
Concerning Collateral, Etc</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company further
covenants with the Secured Party as follows: (a) other than inventory sold in the ordinary course of business consistent with past practices,
the Collateral, to the extent not delivered to the Secured Party pursuant to &sect;4, will be kept at those locations listed on the Perfection
Certificate and the Company will not remove the Collateral from such locations, without providing at least ten (10) Business Days prior
written notice to the Secured Party, (b) except for the security interest herein granted, the Company shall be the owner of or have other
rights in the Collateral free from any right or claim of any other Person or any Lien (other than Permitted Liens), and the Company shall
defend the same against all claims and demands of all Persons at any time claiming the same or any interests therein adverse to the Secured
Party, (c) other than in favor of the Secured Party or with respect to any Permitted Lien, the Company shall not pledge, mortgage or create,
or suffer to exist any right of any Person in or claim by any Person to the Collateral, or any Lien in the Collateral in favor of any
Person, or become bound (as provided in Section 9-203(d) of the Uniform Commercial Code of the State or any other relevant jurisdiction
or otherwise) by a security agreement in favor of any Person as secured party, (d) the Company will permit the Secured Party, or its designee,
upon advance written notice to the Company to inspect the Collateral during normal business hours, wherever located, provided, if any
Event of Default has occurred and is continuing, no advance written notice to the Company shall be required and any such inspection shall
be permitted at any reasonable time, (e) the Company will pay promptly when due all taxes, assessments, governmental charges and levies
upon the Collateral or incurred in connection with the use or operation of the Collateral or incurred in connection with this Agreement,
and (f) the Company will not sell or otherwise dispose, or offer to sell or otherwise dispose, of the Collateral, or any interest therein
except for, so long as no Event of Default has occurred and is continuing, dispositions of obsolete or worn-out property, the granting
of non-exclusive licenses in the ordinary course of business, and the sale of inventory in the ordinary course of business consistent
with past practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>9. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Collateral
Protection Expenses; Preservation of Collateral</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>9.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses
Incurred by Secured Party</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. In the Secured Party&rsquo;s
discretion, the Secured Party may discharge taxes and other encumbrances at any time levied or placed on any of the Collateral, and pay
any necessary filing fees or insurance premiums, in each case if the Company fails to do so. The Company agrees to reimburse the Secured
Party on demand for all expenditures so made. The Secured Party shall have no obligation to the Company to make any such expenditures,
nor shall the making thereof be construed as a waiver or cure of any Event of Default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>9.2. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Secured
Party&rsquo;s Obligations and Duties</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Anything herein
to the contrary notwithstanding, the Company shall remain obligated and liable under each contract or agreement comprised in the Collateral
to be observed or performed by the Company thereunder. The Secured Party shall not have any obligation or liability under any such contract
or agreement by reason of or arising out of this Agreement or the receipt by the Secured Party of any payment relating to any of the Collateral,
nor shall the Secured Party be obligated in any manner to perform any of the obligations of the Company under or pursuant to any such
contract or agreement, to make inquiry as to the nature or sufficiency of any payment received by the Secured Party in respect of the
Collateral or as to the sufficiency of any performance by any party under any such contract or agreement, to present or file any claim,
to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to the Secured Party
or to which the Secured Party may be entitled at any time or times. The Secured Party&rsquo;s sole duty with respect to the custody, safe keeping
and physical preservation of the Collateral in its possession, under &sect;9-207 of the Uniform Commercial Code of the State or otherwise,
shall be to deal with such Collateral in the same manner as the Secured Party deals with similar property for its own account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>10. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Securities
and Deposits</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Secured Party may at any time
following and during the continuance of a payment default or an Event of Default<I>,</I> at its option, transfer to itself or any nominee
any securities constituting Collateral, receive any income thereon and hold such income as additional Collateral or apply it to the Obligations.
Whether or not any Obligations are due, the Secured Party may, following and during the continuance of a payment default or an Event of
Default demand, sue for, collect, or make any settlement or compromise which it deems desirable with respect to the Collateral. Regardless
of the adequacy of Collateral or any other security for the Obligations, any deposits or other sums at any time credited by or due from
the Secured Party to the Company may at any time be applied to or set off against any of the Obligations then due and owing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>11. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notification
to Account Debtors and Other Persons Obligated on Collateral</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If an Event of Default shall have occurred and be continuing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)
the Company shall, at the request and option of the Secured Party, notify account debtors and other Persons obligated on any of the Collateral
of the security interest of the Secured Party in any account, chattel paper, general intangible, instrument or other Collateral and that
payment thereof is to be made directly to the Secured Party or to any financial institution designated by the Secured Party as the Secured
Party&rsquo;s agent therefor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)
the Secured Party may itself, without notice to or demand upon the Company, so notify account debtors and other Persons obligated on Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)
after the making of such a request or the giving of any such notification, the Company shall hold any proceeds of collection of accounts,
chattel paper, general intangibles, instruments and other Collateral received by the Company as trustee for the Secured Party, for the
benefit of the Secured Party, without commingling the same with other funds of the Company and shall turn the same over to the Secured
Party in the identical form received, together with any necessary endorsements or assignments; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d) the
Secured Party shall apply the proceeds of collection of accounts, chattel paper, general intangibles, instruments and other Collateral
and received by the Secured Party to the payment of the Obligations, such proceeds to be immediately credited after final payment in cash
or other immediately available funds of the items giving rise to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>12. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Power
of Attorney</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>12.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Appointment
and Powers of Secured Party</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company hereby
irrevocably constitutes and appoints the Secured Party and any officer or agent thereof, with full power of substitution, as its true
and lawful attorneys-in-fact with full irrevocable power and authority in the place and stead of the Company or in the Secured Party&rsquo;s
own name, for the purpose of carrying out the terms of this Agreement, to take any and all appropriate action and to execute any and all
documents and instruments that may be necessary or useful to accomplish the purposes of this Agreement and, without limiting the generality
of the foregoing, hereby gives said attorneys the power and right, on behalf of the Company, without notice to or assent by the Company,
to do the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(a) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
the occurrence and during the continuance of an Event of Default, generally to sell, transfer, pledge, make any agreement with respect
to or otherwise dispose of or deal with any of the Collateral in such manner as is consistent with the Uniform Commercial Code of the
State or any other relevant jurisdiction and as fully and completely as though the Secured Party were the absolute owner thereof for all
purposes, and to do, at the Company&rsquo;s expense, at any time, or from time to time, all acts and things which the Secured Party deems necessary
or useful to protect, preserve or realize upon the Collateral and the Secured Party&rsquo;s security interest therein, in order to effect the
intent of this Agreement, all no less fully and effectively as the Company might do, including (i) upon written notice to the Company,
the exercise of voting rights with respect to voting securities, which rights may be exercised, if the Secured Party so elects, with a
view to causing the liquidation of assets of the issuer of any such securities and (ii) the execution, delivery and recording, in connection
with any sale or other disposition of any Collateral, of the endorsements, assignments or other instruments of conveyance or transfer
with respect to such Collateral; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(b) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
the extent that the Company&rsquo;s authorization given in &sect;3 is not sufficient, to file such financing statements with respect hereto,
with or without the Company&rsquo;s signature, or a photocopy of this Agreement in substitution for a financing statement, as the Secured Party
may deem appropriate and to execute in the Company&rsquo;s name such financing statements and amendments thereto and continuation statements
which may require the Company&rsquo;s signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>12.2. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Ratification
by Company</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. To the extent permitted by law, the
Company hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue hereof. This power of attorney is a power
coupled with an interest and is irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>12.3. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Duty on Secured Party</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The powers conferred on
the Secured Party hereunder are solely to protect the interests of the Secured Party in the Collateral and shall not impose any duty upon
the Secured Party to exercise any such powers. The Secured Party shall be accountable only for the amounts that it actually receives as
a result of the exercise of such powers, and neither it nor any of its officers, directors, employees or agents shall be responsible to
the Company for any act or failure to act, except for the Secured Party&rsquo;s own gross negligence or willful misconduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>13. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rights
and Remedies</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>13.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If an Event of Default shall have occurred and be continuing, the Secured Party, without any other notice to or demand upon the Company,
shall have in any jurisdiction in which enforcement hereof is sought, in addition to all other rights and remedies, the rights and remedies
of a secured party under the Uniform Commercial Code of the State or any other relevant jurisdiction and any additional rights and remedies
as may be provided to a secured party in any jurisdiction in which Collateral is located, including the right to take possession of the
Collateral, and for that purpose the Secured Party may, so far as the Company can give authority therefor, enter upon any premises on
which the Collateral may be situated and remove the same therefrom. The Secured Party may in its discretion require the Company to assemble
all or any part of the Collateral at such location or locations within the jurisdiction(s) of the Company&rsquo;s principal office(s) or at
such other locations as the Secured Party may reasonably designate. Unless the Collateral is perishable or threatens to decline speedily
in value or is of a type customarily sold on a recognized market, the Secured Party shall give to the Company at least ten (10) Business
Days prior written notice of the time and place of any public sale of Collateral or of the time after which any private sale or any other
intended disposition is to be made. The Company hereby acknowledges that ten (10) Business Days prior written notice of such sale or sales
shall be reasonable notice. In addition, the Company waives any and all rights that it may have to a judicial hearing in advance of the
enforcement of any of the Secured Party&rsquo;s rights and remedies hereunder, including its right following an Event of Default to take immediate
possession of the Collateral and to exercise its rights and remedies with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>14. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Standards
for Exercising Rights and Remedies</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. To the extent
that applicable law imposes duties on the Secured Party to exercise remedies in a commercially reasonable manner, the Company acknowledges
and agrees that it is not commercially unreasonable for the Secured Party (a) to fail to incur expenses reasonably deemed significant
by the Secured Party to prepare Collateral for disposition or otherwise to fail to complete raw material or work in process into finished
goods or other finished products for disposition, (b) to fail to obtain third party consents for access to Collateral to be disposed of,
or to obtain or, if not required by other law, to fail to obtain governmental or third party consents for the collection or disposition
of Collateral to be collected or disposed of, (c) to fail to exercise collection remedies against account debtors or other Persons obligated
on Collateral or to fail to remove Liens on or any adverse claims against Collateral, (d) to exercise collection remedies against account
debtors and other Persons obligated on the Collateral directly or through the use of collection agencies and other collection specialists,
(e) to advertise dispositions of the Collateral through publications or media of general circulation, whether or not the Collateral is
of a specialized nature, (f) to contact other Persons, whether or not in the same business as the Company, for expressions of interest
in acquiring all or any portion of the Collateral, (g) to hire one or more professional auctioneers to assist in the disposition of the
Collateral, whether or not the collateral is of a specialized nature, (h) to dispose of the Collateral by utilizing Internet sites that
provide for the auction of assets of the types included in the Collateral or that have the reasonable capability of doing so, or that
match buyers and sellers of assets, (i) to dispose of assets in wholesale rather than retail markets, (j) to disclaim disposition warranties,
(k) to purchase insurance or credit enhancements to insure the Secured Party against risks of loss, collection or disposition of the Collateral
or to provide to the Secured Party a guaranteed return from the collection or disposition of such Collateral, or (l) to the extent deemed
appropriate by the Secured Party, to obtain the services of brokers, investment bankers, consultants and other professionals to assist
the Secured Party in the collection or disposition of any of the Collateral. The Company acknowledges that the purpose of this &sect;14
is to provide non-exhaustive indications of what actions or omissions by the Secured Party would fulfill the Secured Party&rsquo;s duties under
the Uniform Commercial Code of the State or any other relevant jurisdiction in the Secured Party&rsquo;s exercise of remedies against the Collateral
and that other actions or omissions by the Secured Party shall not be deemed to fail to fulfill such duties solely on account of not being
indicated in this &sect;14. Without limitation upon the foregoing, nothing contained in this &sect;14 shall be construed to grant any
rights to the Company or to impose any duties on the Secured Party that would not have been granted or imposed by this Agreement or by
applicable law in the absence of this &sect;14. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>15. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Waiver by Secured Party, etc</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Secured Party
shall not be deemed to have waived any of its rights and remedies in respect of the Obligations or the Collateral unless such waiver shall
be in writing and signed by the Secured Party. No delay or omission on the part of the Secured Party in exercising any right or remedy
shall operate as a waiver of such right or remedy or any other right or remedy. A waiver on any one occasion shall not be construed as
a bar to or waiver of any right or remedy on any future occasion. All rights and remedies of the Secured Party with respect to the Obligations
or the Collateral, whether evidenced hereby or by any other instrument or papers, shall be cumulative and may be exercised singularly,
alternatively, successively or concurrently at such time or at such times as the Secured Party deems expedient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>16. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Suretyship
Waivers by Company</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company waives demand,
notice, protest, notice of acceptance of this Agreement, notice of loans made, credit extended, Collateral received or delivered or other
action taken in reliance hereon and all other demands and notices of any description. With respect to both the Obligations and the Collateral,
the Company assents to any extension or postponement of the time of payment or any other indulgence, to any substitution, exchange or
release of or failure to perfect any security interest in any such Collateral, to the addition or release of any party or Person primarily
or secondarily liable, to the acceptance of partial payment thereon and the settlement, compromising or adjusting of any thereof, all
in such manner and at such time or times as the Secured Party may deem advisable. The Secured Party shall have no duty as to the collection
or protection of the Collateral or any income therefrom, the preservation of rights against prior parties, or the preservation of any
rights pertaining thereto beyond the safe custody thereof as set forth in &sect;9.2. The Company further waives any and all other suretyship
defenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>17. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Marshaling</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Secured Party shall not be required to marshal any present or future collateral security (including but not limited to the Collateral)
for, or other assurances of payment of, the Obligations or any of them or to resort to such collateral security or other assurances of
payment in any particular order, and all of the rights and remedies of the Secured Party hereunder and of the Secured Party in respect
of such collateral security and other assurances of payment shall be cumulative and in addition to all other rights and remedies, however
existing or arising. To the extent that it lawfully may, the Company hereby agrees that it will not invoke any law relating to the marshaling
of collateral which might cause delay in or impede the enforcement of the Secured Party&rsquo;s rights and remedies under this Agreement or
under any other instrument creating or evidencing any of the Obligations or under which any of the Obligations is outstanding or by which
any of the Obligations is secured or payment thereof is otherwise assured, and, to the extent that it lawfully may, the Company hereby
irrevocably waives the benefits of all such laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>18. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Proceeds
of Dispositions; Expenses</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company shall
pay to the Secured Party on demand any and all documented expenses, including reasonable attorneys&rsquo; fees and disbursements, actually incurred
or paid by the Secured Party in protecting or preserving the Secured Party&rsquo;s rights and remedies under or in respect of any of the Obligations
or any of the Collateral and any such expenses actually incurred in releasing any security interest granted hereunder and, in addition,
the Company shall pay to the Secured Party on demand any and all expenses, including attorneys&rsquo; fees and disbursements, incurred or paid
by the Secured Party in enforcing the Secured Party&rsquo;s rights and remedies under or in respect of any of the Obligations or any of the
Collateral. After deducting all of said expenses, the residue of any proceeds of collection or sale or other disposition of Collateral
shall, to the extent actually received in cash, be applied to the payment of the Obligations in such order or preference as is provided
in the SPA, proper allowance and provision being made for any Obligations not then due. Upon the final payment and satisfaction in full
of all of the Obligations and after making any payments required by Sections 9-608(a)(1)(C) or 9-615(a)(3) of the Uniform Commercial Code
of the State, any excess shall be returned to the Company. In the absence of final payment and satisfaction in full of all of the Obligations,
the Company shall remain liable for any deficiency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>19. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overdue
Amounts</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Until paid, all amounts due and payable
by the Company hereunder shall be a debt secured by the Collateral and shall bear, whether before or after judgment, interest at the rate
of interest for overdue principal set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>20. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing
Law; Consent to Jurisdiction</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. <FONT STYLE="text-transform: uppercase"><B>This
Agreement IS A contract UNDER the laws of the state of NEVADA and shall for all purposes be construed in accordance with and governed
by the laws of SAID state of NEVADA. The Company and THE SECURED PARTY EACH agree that any suit for the enforcement of this agreement
or any other action brought by SUCH PERSON arising hereunder or in any way related to this agreement </B></FONT><B>SHALL BE BROUGHT IN
THE COURTS OF THE STATE OF NEW YORK IN THE BOROUGH OF MANHATTAN OR ANY FEDERAL COURT SITTING THEREIN AND CONSENTS TO THE NONEXCLUSIVE
JURISDICTION OF SUCH COURT AND SERVICE OF PROCESS IN ANY SUCH SUIT BEING MADE UPON SUCH PERSON BY MAIL AT THE ADDRESS SPECIFIED ON THE
SIGNATURE PAGE OF EACH PARTY HERETO. <FONT STYLE="text-transform: uppercase">the Company AND THE SECURED PARTY EACH hereby waive any objection
that it may now or hereafter have to the venue of any suit BROUGHT IN the state of new york or any court SITTING THEREIN or that A suit
BROUGHT THEREIN is brought in an inconvenient court.</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>21. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waiver
of Jury Trial</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. THE COMPANY AND THE SECURED PARTY
WAIVES ITS RIGHT TO A JURY TRIAL WITH RESPECT TO ANY ACTION OR CLAIM ARISING OUT OF ANY DISPUTE IN CONNECTION WITH THIS AGREEMENT, ANY
RIGHTS OR OBLIGATIONS HEREUNDER OR THE PERFORMANCE OR ENFORCEMENT OF ANY SUCH RIGHTS OR OBLIGATIONS. Except as prohibited by law, the
Company waives any right which it may have to claim or recover in any litigation referred to in the preceding sentence any special, exemplary,
punitive or consequential damages or any damages other than, or in addition to, actual damages. The Company (a) certifies that neither
the Secured Party nor any representative, agent or attorney of the Secured Party has represented, expressly or otherwise, that the Secured
Party would not, in the event of litigation, seek to enforce the foregoing waivers or other waivers contained in this Agreement and (b)
acknowledges that, in entering into this Agreement and any other Transaction Document to which the Secured Party is a party, the Secured
Party is relying upon, among other things, the waivers and certifications contained in this &sect;21.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>22. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All notices, requests and other communications hereunder shall be made in the manner set forth in the SPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>23. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The headings of each section of this Agreement are for convenience only and shall not define or limit the provisions thereof. This Agreement
and all rights and obligations hereunder shall be binding upon the Company and its successors and assigns, and shall inure to the benefit
of the Secured Party and its successors and assigns. If any term of this Agreement shall be held to be invalid, illegal or unenforceable,
the validity of all other terms hereof shall in no way be affected thereby, and this Agreement shall be construed and be enforceable as
if such invalid, illegal or unenforceable term had not been included herein. The Company acknowledges receipt of a copy of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>24.&#9;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Release
of Collateral; Reinstatement</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. (a)&#9;Upon any
sale, transfer or other disposition of any Collateral which is permitted by the Transaction Documents, upon receipt by the Secured Party
of any proceeds thereof which the Company is required to pay to the Secured Party pursuant to the terms of the Transaction Documents,
such Collateral (but not the proceeds thereof) shall automatically be released from the Liens created hereby, and the Secured Party agrees
that, at the request and sole expense of the Company, it shall promptly execute and deliver to the Company all releases or other documents
reasonably necessary for the release of such Lien on such Collateral. In addition, the Secured Party agrees that upon the indefeasible
repayment in full, in cash, of all Obligations owing under the Transaction Documents (other than (a) contingent obligations not due and
owing, and, (b) so long as the Company is in compliance with all of its obligations under the Warrant, the Company&rsquo;s obligations under
the Warrant) and the termination of any commitments pursuant to the terms of the Transaction Documents, the security interests granted
hereby shall, subject to the Secured Party&rsquo;s rights of reinstatement set forth herein or in any other Transaction Document, automatically
terminate, all rights to the Collateral shall revert to the Company without further action from any Person and the Secured Party agrees
that, at the request and sole expense of the Company, it shall promptly execute and deliver to the Company all releases or other documents
reasonably necessary for the release of the Liens on the Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Notwithstanding
anything to the contrary contained herein, the Company acknowledges and agrees its obligations and liabilities under the Transaction Documents
(and all security interests and other Liens granted hereunder) shall be deemed to have continued in existence and shall be reinstated
with full force and effect if, at any time on or after the payment of any Obligations under the Transaction Documents, all or any portion
of the Obligations or any other amounts applied by the Secured Party to any of the Obligations is voided or rescinded or must otherwise
be returned by the Secured Party to the Company upon the Company&rsquo;s insolvency, bankruptcy or reorganization or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>[Signature pages to follow]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
intending to be legally bound, the Company has caused this Agreement to be duly executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABVC BIOPHARMA, INC.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44370 Old Warm Springs Blvd</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fremont, CA 94538</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accepted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LIND GLOBAL FUND II LP<BR>
By: Lind Global Partners II LLC, its general partner </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT>&nbsp;</TD>
    <TD STYLE="width: 31%">Jeff Easton, Managing Member</TD>
    <TD STYLE="width: 60%">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CERTIFICATE OF ACKNOWLEDGMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMONWEALTH OR STATE OF _________________</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">) ss.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COUNTY OF ____________________________________</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before me, the undersigned,
a Notary Public in and for the county aforesaid, on this __ day of February, 2023, personally appeared __________________ to me known
personally, and who, being by me duly sworn, deposes and says that he/she is the _____________ of ABVC BioPharma, Inc. and that said instrument
was signed and sealed on behalf of said corporation by authority of its Board of Directors, and said ______________ acknowledged said
instrument to be the free act and deed of said corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(official signature and seal of notary)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">My commission expires:</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>ea174178ex10-5_abvcbio.htm
<DESCRIPTION>GUARANTOR SECURITY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.5</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">GUARANTOR SECURITY
AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>GUARANTOR SECURITY AGREEMENT
</B>(this &ldquo;<U>Agreement</U>&rdquo;), dated as of February 23, 2023, by and among <B>AMERICAN BRIVISION CORPORATION</B>, a Delaware
corporation (&ldquo;<U>American BriVision</U>&rdquo;), <B>BIOKEY, INC.</B>, a California corporation (&ldquo;<U>BioKey</U>&rdquo;), <B>BIOLITE
HOLDING, INC.</B>, a Nevada corporation (&ldquo;<U>BioLite</U>&rdquo;), <B>BIOLITE BVI, INC.</B>, a British Virgin Islands corporation
(&ldquo;<U>BioLite BVI</U>&rdquo; and, collectively with American BriVision, BioKey and BioLite, the &ldquo;<U>Companies</U>&rdquo;,
and each, individually, a &ldquo;<U>Company</U>&rdquo;), and <B>LIND GLOBAL FUND II LP</B> (the &ldquo;<U>Secured Party</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Companies
have executed and delivered to the Secured Party that certain Guaranty dated as of the date hereof (as amended and in effect from time
to time, the &ldquo;<U>Guaranty</U>&rdquo;) pursuant to which the Companies have jointly and severally guaranteed all of the obligations
of ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<U>Parent</U>&rdquo;), owing to the Secured Party pursuant to the SPA, the
Note and the Borrower Security Agreement (as each such term is defined in the Guaranty); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, it is a condition
precedent to the Secured Party agreeing to make loans or otherwise extend credit to the Parent under the SPA and the Note that the Companies
execute and deliver to the Secured Party a security agreement in substantially the form hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, each Company
wishes to grant security interests in favor of the Secured Party as herein provided;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>1.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All capitalized terms used herein without definitions shall have the respective meanings provided therefor in the SPA. All terms defined
in the Uniform Commercial Code of the State (as hereinafter defined) and used herein shall have the same definitions herein as specified
therein, however, if a term is defined in Article 9 of the Uniform Commercial Code of the State differently than in another Article of
the Uniform Commercial Code of the State, the term has the meaning specified in Article 9, and the following terms shall have the following
meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Event of Default</U>&rdquo;
means the occurrence of any &ldquo;Event of Default&rdquo; under and as defined in each of the SPA and the Note, or the failure of the
Parent or any Company to comply with any term or covenant of any Transaction Document (including this Agreement) to which it is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Guarantors</U>&rdquo;
means, collectively, each subsidiary of the Company which provides a guarantee of all or any portion of the Obligations of the Parent
to the Secured Party, including, without limitation, the Companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lien</U>&rdquo;
means any mortgage, charge, pledge, hypothecation, security interest, assignment by way of security, lien (statutory or otherwise), encumbrance,
conditional sale agreement, capital lease, financing lease, deposit arrangement, title retention agreement, and any other agreement,
trust or arrangement that in substance secures payment or performance of an obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Obligations</U>&rdquo;
means, collectively, (a) all debts, liabilities and obligations, present or future, direct or indirect, absolute or contingent, matured
or unmatured, at any time or from time to time due or accruing due and owing by or otherwise payable by the Parent or any Guarantor (including,
without limitation, any Company) to the Secured Party in any currency, under, in connection with or pursuant to the any Transaction Document
(including, without limitation, this Agreement), and whether incurred by the Parent or any Guarantor (including, without limitation,
any Company) alone or jointly with another or others and whether as principal, guarantor or surety and in whatever name or style and
(b) all expenses, costs and charges incurred by or on behalf of the Secured Party in connection with any Transaction Document (including
this Agreement) or the Collateral, including all legal fees, court costs, receiver&rsquo;s or agent&rsquo;s remuneration and other expenses
of taking possession of, repairing, protecting, insuring, preparing for disposition, realizing, collecting, selling, transferring, delivering
or obtaining payment for the Collateral, and of taking, defending or participating in any action or proceeding in connection with any
of the foregoing matters or otherwise in connection with the Secured Party&rsquo;s interest in any Collateral, whether or not directly
relating to the enforcement of this Agreement or any other Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted Lien</U>&rdquo;
means any of the following: (a) mechanics and materialman Liens and other statutory Liens (including Liens for taxes, fees, assessments
and other governmental charges or levies) in respect of any amount (i) which is not at the time overdue or (ii) which may be overdue
but the validity of which is being contested at the time in good faith by appropriate proceedings, in each case so long as the holder
of such Lien has not taken any action to foreclose or otherwise exercise any remedies with respect to such Lien; and (b) Liens which
are permitted in writing by the Secured Party in its sole and absolute discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>State</U>&rdquo;
means the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction Documents</U>&rdquo;
has the meaning provided for in the SPA, provided, however, for purposes of this Agreement, upon the indefeasible repayment in full,
in cash, of the Note and all obligations owing thereunder, such term shall thereafter not include the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>2.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Grant of Security Interest</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>2.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Grant;
Collateral Description</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Each Company hereby
grants to the Secured Party, to secure the payment and performance in full of all of the Obligations, a security interest in and pledges
and assigns to the Secured Party the following properties, assets and rights of such Company, wherever located, whether now owned or
hereafter acquired or arising, and all proceeds and products thereof (all of the same being hereinafter called the &ldquo;<U>Collateral</U>&rdquo;):
all personal and fixture property of every kind and nature including all goods (including inventory, equipment and any accessions thereto),
instruments (including promissory notes), documents (whether tangible or electronic), accounts (including health-care-insurance receivables),
chattel paper (whether tangible or electronic), deposit accounts, letter-of-credit rights (whether or not the letter of credit is evidenced
by a writing), commercial tort claims, securities and all other investment property, supporting obligations, any other contract rights
or rights to the payment of money, insurance claims and proceeds, and all general intangibles (including all payment intangibles). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>2.2. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Commercial
Tort Claims</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Secured Party acknowledges
that the attachment of its security interest in any commercial tort claim as original collateral is subject to each Company&rsquo;s compliance
with &sect;4.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>3.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization to File Financing Statements</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Each Company hereby irrevocably authorizes the Secured Party at any time and from time to time to file in any filing office which the
Secured Party deems necessary in any Uniform Commercial Code jurisdiction any initial financing statements and amendments thereto that
(a) indicate the Collateral (i) as all assets of such Company or words of similar effect, regardless of whether any particular asset
comprised in the Collateral falls within the scope of Article 9 of the Uniform Commercial Code of the State or such jurisdiction, or
(ii) as being of an equal or lesser scope or with greater detail, and (b) provide any other information required by part 5 of Article
9 of the Uniform Commercial Code of the State or such other jurisdiction for the sufficiency or filing office acceptance of any financing
statement or amendment, including whether such Company is an organization, the type of organization and any organizational identification
number issued to such Company. Each Company agrees to furnish any such information to the Secured Party promptly upon the Secured Party&rsquo;s
reasonable request. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>4.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other Actions</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Further to insure the attachment, perfection and first priority of, and the ability of the Secured Party to enforce, the Secured Party&rsquo;s
security interest in the Collateral, each Company agrees, in each case at such Company&rsquo;s expense, to take the following actions
with respect to the following Collateral and without limitation on the Company&rsquo;s other obligations contained in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Promissory
Notes and Tangible Chattel Paper</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>.</I> If
a Company shall, now or at any time hereafter, hold or acquire any promissory notes or tangible chattel paper with an aggregate value
for all such promissory notes or tangible chattel paper in excess of $150,000, such Company shall forthwith endorse, assign and deliver
the same to the Secured Party, accompanied by such instruments of transfer or assignment duly executed in blank as the Secured Party
may from time to time specify.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.2. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Deposit
Accounts</U>. </FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For each deposit account that a Company,
now or at any time hereafter, opens or maintains, such Company shall, within thirty days of the date hereof, or for any such deposit
account opened following the date hereof, the date of opening such deposit account, unless waived in writing by the Secured Party, pursuant
to an agreement in form and substance reasonably satisfactory to the Secured Party, either (a) cause the depositary bank to agree to
comply without further consent of such Company, at any time with instructions from the Secured Party to such depositary bank directing
the disposition of funds from time to time credited to such deposit account, or (b) arrange for the Secured Party to become the customer
of the depositary bank with respect to the deposit account, with such Company being permitted, only with the consent of the Secured Party,
to exercise rights to withdraw funds from such deposit account. The Secured Party agrees with each Company that the Secured Party shall
not give any such instructions or withhold any withdrawal rights from such Company, unless an Event of Default has occurred and is continuing,
or, if effect were given to any withdrawal not otherwise permitted by the Transaction Documents, would occur. The provisions of this
paragraph shall not apply to any deposit accounts specially and exclusively used (i) for payroll, payroll taxes and other employee wage
and benefit payments to or for the benefit of a Company&rsquo;s salaried employees, (ii) in cases where a Company acts as custodian,
trust, fiduciary or escrow agent for the benefit of a third party in transactions permitted by the Transaction Documents, and (iii) as
petty cash accounts that collectively have an average daily balance at any time of less than $25,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.3. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investment
Property</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>.</I> If any Company shall, now or
at any time hereafter, hold or acquire any certificated securities, such Company shall forthwith endorse, assign and deliver the same
to the Secured Party, accompanied by such instruments of transfer or assignment duly executed in blank as the Secured Party may from
time to time specify. If any securities now or hereafter acquired by a Company are uncertificated and are issued to such Company or its
nominee directly by the issuer thereof, such Company shall promptly (but in any event within five Business Days) notify the Secured Party
thereof and, at the Secured Party&rsquo;s request and option, pursuant to an agreement in form and substance reasonably satisfactory
to the Secured Party, either (a) cause the issuer to agree to comply without further consent of such Company or such nominee, at any
time with instructions from the Secured Party as to such securities, or (b) arrange for the Secured Party to become the registered owner
of the securities. If any securities, whether certificated or uncertificated, or other investment property now or hereafter acquired
by a Company are held by a Company or its nominee through a securities intermediary or commodity intermediary, such Company shall promptly
(but in any event within five Business Days) notify the Secured Party thereof and, at the Secured Party&rsquo;s request and option, pursuant
to an agreement in form and substance reasonably satisfactory to the Secured Party, either (i) cause such securities intermediary or
(as the case may be) commodity intermediary to agree to comply, in each case without further consent of such Company or such nominee,
at any time with entitlement orders or other instructions from the Secured Party to such securities intermediary as to such securities
or other investment property, or (as the case may be) to apply any value distributed on account of any commodity contract as directed
by the Secured Party to such commodity intermediary, or (ii) in the case of financial assets or other investment property held through
a securities intermediary, arrange for the Secured Party to become the entitlement holder with respect to such investment property, with
such Company being permitted, only with the consent of the Secured Party, to exercise rights to withdraw or otherwise deal with such
investment property. The Secured Party agrees with each Company that the Secured Party shall not give any such entitlement orders or
instructions or directions to any such issuer, securities intermediary or commodity intermediary, and shall not withhold its consent
to the exercise of any withdrawal or dealing rights by such Company, unless an Event of Default has occurred and is continuing, or, after
giving effect to any such investment and withdrawal rights not otherwise permitted by the Transaction Documents, would occur. The provisions
of this paragraph shall not apply to any financial assets credited to a securities account for which the Secured Party is the securities
intermediary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.4. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Collateral
in the Possession of a Bailee</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>.</I> If any
Collateral with an aggregate value in excess of $150,000 is, now or at any time hereafter, in the possession of a bailee, the applicable
Company shall promptly notify the Secured Party thereof and, at the Secured Party&rsquo;s reasonable request and option, shall promptly
obtain an acknowledgement from the bailee, in form and substance reasonably satisfactory to the Secured Party, that the bailee holds
such Collateral for the benefit of the Secured Party and such bailee&rsquo;s agreement to comply, without further consent of such Company,
at any time with instructions of the Secured Party as to such Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.5. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Electronic
Chattel Paper, Electronic Documents and Transferable Records</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If a Company, now or at any time hereafter, holds or acquires an interest in any Collateral that is electronic chattel paper, any electronic
document or any &ldquo;transferable record,&rdquo; as that term is defined in Section 201 of the federal Electronic Signatures in Global
and National Commerce Act, or in &sect;16 of the Uniform Electronic Transactions Act as in effect in any relevant jurisdiction, such
Company shall promptly notify the Secured Party thereof and, at the request and option of the Secured Party, shall take such action as
the Secured Party may reasonably request to vest in the Secured Party control, under &sect;9-105 of the Uniform Commercial Code of the
State or any other relevant jurisdiction, of such electronic chattel paper, control, under &sect;7-106 of the Uniform Commercial Code
of the State or any other relevant jurisdiction, of such electronic document or control, under Section 201 of the federal Electronic
Signatures in Global and National Commerce Act or, as the case may be, &sect;16 of the Uniform Electronic Transactions Act, as so in
effect in such jurisdiction, of such transferable record. The Secured Party agrees with each Company that the Secured Party will arrange,
pursuant to procedures satisfactory to the Secured Party and so long as such procedures will not result in the Secured Party&rsquo;s
loss of control, for the applicable Company to make alterations to the electronic chattel paper, electronic document or transferable
record permitted under UCC &sect;9-105, UCC &sect;7-106, or, as the case may be, Section 201 of the federal Electronic Signatures in
Global and National Commerce Act or &sect;16 of the Uniform Electronic Transactions Act for a party in control to make without loss of
control, unless an Event of Default has occurred and is continuing or would occur after taking into account any action by the applicable
Company with respect to such electronic chattel paper, electronic document or transferable record. The provisions of this &sect;4.5 relating
to electronic documents and &ldquo;control&rdquo; under UCC &sect;7-106 apply in the event that the 2003 revisions to Article 7, with
amendments to Article 9, of the Uniform Commercial Code, in substantially the form approved by the American Law Institute and the National
Conference of Commissioners on Uniform State Laws, are now or hereafter adopted and become effective in the State or in any other relevant
jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.6. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Letter-of-Credit
Rights</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. If a Company is, now or at any time
hereafter, a beneficiary under a letter of credit with a stated amount in excess of $150,000, or if a Company is a beneficiary under
letters of credit not assigned to the Secured Party with an aggregate stated amount in excess of $150,000, such Company shall promptly
notify the Secured Party thereof and, at the request and option of the Secured Party, such Company shall, pursuant to an agreement in
form and substance reasonably satisfactory to the Secured Party, either (a) arrange for the issuer and any confirmer of such letter of
credit to consent to an assignment to the Secured Party of the proceeds of the letter of credit or (b) arrange for the Secured Party
to become the transferee beneficiary of the letter of credit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.7. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Commercial
Tort Claims</U><I>.</I></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> If a Company shall, now
or at any time hereafter, hold or acquire a commercial tort claim, the Company shall promptly notify the Secured Party in a writing signed
by such Company of the particulars thereof and grant to the Secured Party in such writing a security interest therein and in the proceeds
thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to the Secured Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>4.8. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
Actions as to any and all Collateral</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Each Company
further agrees, upon the request of the Secured Party and at the Secured Party&rsquo;s option, to take any and all other actions as the
Secured Party may determine to be necessary or useful for the attachment, perfection and first priority of, and the ability of the Secured
Party to enforce, the Secured Party&rsquo;s security interest in any and all of the Collateral, including (a) executing, delivering and,
where appropriate, filing financing statements and amendments relating thereto under the Uniform Commercial Code of any relevant jurisdiction,
to the extent, if any, that such Company&rsquo;s signature thereon is required therefor, (b) causing the Secured Party&rsquo;s name to
be noted as secured party on any certificate of title for a titled good if such notation is a condition to attachment, perfection or
priority of, or ability of the Secured Party to enforce, the Secured Party&rsquo;s security interest in such Collateral, (c) complying
with any provision of any statute, regulation or treaty of the United States as to any Collateral if compliance with such provision is
a condition to attachment, perfection or priority of, or ability of the Secured Party to enforce, the Secured Party&rsquo;s security
interest in such Collateral, (d) obtaining governmental and other third party waivers, consents and approvals, in form and substance
reasonably satisfactory to the Secured Party, including any consent of any licensor, lessor or other Person obligated on Collateral,
(e) obtaining waivers from mortgagees and landlords of such Company&rsquo;s primary place of business or any other location where the
aggregate value of the Collateral at such location exceeds $150,000, in form and substance reasonably satisfactory to the Secured Party
and (f) taking all actions under any earlier versions of the Uniform Commercial Code or under any other law, as reasonably determined
by the Secured Party to be applicable in any relevant Uniform Commercial Code or other jurisdiction, including any foreign jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>5.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties Concerning
a Company&rsquo;s Legal Status</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Each Company
has, on the date hereof, delivered to the Secured Party a certificate signed by such Company and entitled &ldquo;Perfection Certificate&rdquo;
(each, a &ldquo;<U>Perfection Certificate</U>&rdquo;). Each Company represents and warrants to the Secured Party as follows: as of the
date hereof (a) such Company&rsquo;s exact legal name is that indicated on its Perfection Certificate and on the signature page hereof,
(b) such Company is an organization of the type, and is organized in the jurisdiction, set forth in its Perfection Certificate, (c) its
Perfection Certificate accurately sets forth such Company&rsquo;s organizational identification number or accurately states that such
Company has none, (d) its Perfection Certificate accurately sets forth such Company&rsquo;s place of business or, if more than one, its
chief executive office, as well as such Company&rsquo;s mailing address, if different, (e) all other information set forth on its Perfection
Certificate pertaining to such Company is accurate and complete, and (f) there has been no material change in any of such information
since the date on which its Perfection Certificate was signed by such Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>6.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants Concerning Company&rsquo;s Legal
Status</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Each Company covenants with the Secured
Party as follows: (a) without providing at least fifteen (15) days prior written notice to the Secured Party, such Company will not change
its name, its place of business or, if more than one, chief executive office, or its mailing address or organizational identification
number if it has one, (b) if such Company does not have an organizational identification number and later obtains one, such Company will
forthwith notify the Secured Party of such organizational identification number, and (c) such Company will not change its type of organization,
jurisdiction of organization or other legal structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>7.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties Concerning
Collateral, Etc</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Each Company further represents
and warrants to the Secured Party as follows: (a) such Company is the owner of or has other rights in or power to transfer the Collateral
of such Company, free from any right or claim of any Person or any adverse lien, except for the security interest created by this Agreement
and the Permitted Liens, (b) none of the account debtors or other Persons obligated on any of the Collateral is a governmental authority
covered by the Federal Assignment of Claims Act or like federal, state or local statute or rule in respect of such Collateral, (c) such
Company holds no commercial tort claim except as indicated on such Company&rsquo;s Perfection Certificate, (d) all other information
set forth on such Company&rsquo;s Perfection Certificate pertaining to the Collateral is accurate and complete, and (e) there has been
no material change in any of such information since the date on which such Company&rsquo;s Perfection Certificate was signed by such
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>8.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants Concerning Collateral, Etc</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Each Company further covenants with the Secured Party as follows: (a) other than inventory sold in the ordinary course of business consistent
with past practices, the Collateral, to the extent not delivered to the Secured Party pursuant to &sect;4, will be kept at those locations
listed on such Company&rsquo;s Perfection Certificate and such Company will not remove the Collateral from such locations, without providing
at least ten (10) Business Days prior written notice to the Secured Party, (b) except for the security interest herein granted, such
Company shall be the owner of or have other rights in the Collateral free from any right or claim of any other Person or any Lien (other
than Permitted Liens), and such Company shall defend the same against all claims and demands of all Persons at any time claiming the
same or any interests therein adverse to the Secured Party, (c) other than in favor of the Secured Party or with respect to any Permitted
Lien, such Company shall not pledge, mortgage or create, or suffer to exist any right of any Person in or claim by any person to the
Collateral, or any Lien in the Collateral in favor of any Person, or become bound (as provided in Section 9-203(d) of the Uniform Commercial
Code of the State or any other relevant jurisdiction or otherwise) by a security agreement in favor of any Person as secured party, (d)
such Company will permit the Secured Party, or its designee, upon advance written notice to the Company to inspect the Collateral during
normal business hours, wherever located, provided, if any Event of Default has occurred and is continuing, no advance written notice
to such Company shall be required and any such inspection shall be permitted at any reasonable time, (e) such Company will pay promptly
when due all taxes, assessments, governmental charges and levies upon the Collateral or incurred in connection with the use or operation
of the Collateral or incurred in connection with this Agreement, and (f) such Company will not sell or otherwise dispose, or offer to
sell or otherwise dispose, of the Collateral, or any interest therein except for, so long as no Event of Default has occurred and is
continuing, dispositions of obsolete or worn-out property, the granting of non-exclusive licenses in the ordinary course of business,
and the sale of inventory in the ordinary course of business consistent with past practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>9.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Collateral Protection Expenses; Preservation
of Collateral</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>9.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses
Incurred by Secured Party</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. In the Secured Party&rsquo;s
discretion, the Secured Party may discharge taxes and other encumbrances at any time levied or placed on any of the Collateral, and pay
any necessary filing fees or insurance premiums, in each case if a Company fails to do so. Each Company agrees to reimburse the Secured
Party on demand for all expenditures so made. The Secured Party shall have no obligation to any Company to make any such expenditures,
nor shall the making thereof be construed as a waiver or cure of any Event of Default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>9.2. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Secured
Party&rsquo;s Obligations and Duties</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Anything
herein to the contrary notwithstanding, each Company shall remain obligated and liable under each contract or agreement comprised in
the Collateral to be observed or performed by such Company thereunder. The Secured Party shall not have any obligation or liability under
any such contract or agreement by reason of or arising out of this Agreement or the receipt by the Secured Party of any payment relating
to any of the Collateral, nor shall the Secured Party be obligated in any manner to perform any of the obligations of any Company under
or pursuant to any such contract or agreement, to make inquiry as to the nature or sufficiency of any payment received by the Secured
Party in respect of the Collateral or as to the sufficiency of any performance by any party under any such contract or agreement, to
present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been
assigned to the Secured Party or to which the Secured Party may be entitled at any time or times. The Secured Party&rsquo;s sole duty
with respect to the custody, safe keeping and physical preservation of the Collateral in its possession, under &sect;9-207 of the Uniform
Commercial Code of the State or otherwise, shall be to deal with such Collateral in the same manner as the Secured Party deals with similar
property for its own account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>10.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Securities and Deposits</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Secured Party may at any time following and during the continuance of a payment default or an Event of Default<I>,</I> at its option,
transfer to itself or any nominee any securities constituting Collateral, receive any income thereon and hold such income as additional
Collateral or apply it to the Obligations. Whether or not any Obligations are due, the Secured Party may, following and during the continuance
of a payment default or an Event of Default demand, sue for, collect, or make any settlement or compromise which it deems desirable with
respect to the Collateral. Regardless of the adequacy of Collateral or any other security for the Obligations, any deposits or other
sums at any time credited by or due from the Secured Party to the Company may at any time be applied to or set off against any of the
Obligations then due and owing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>11.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notification to Account Debtors and Other
Persons Obligated on Collateral</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. If an Event
of Default shall have occurred and be continuing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a) each Company
shall, at the request and option of the Secured Party, notify account debtors and other Persons obligated on any of the Collateral of
the security interest of the Secured Party in any account, chattel paper, general intangible, instrument or other Collateral and that
payment thereof is to be made directly to the Secured Party or to any financial institution designated by the Secured Party as the Secured
Party&rsquo;s agent therefor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b) the Secured Party
may itself, without notice to or demand upon any Company, so notify account debtors and other Persons obligated on Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c) after the making
of such a request or the giving of any such notification, each Company shall hold any proceeds of collection of accounts, chattel paper,
general intangibles, instruments and other Collateral received by such Company as trustee for the Secured Party, for the benefit of the
Secured Party, without commingling the same with other funds of such Company and shall turn the same over to the Secured Party in the
identical form received, together with any necessary endorsements or assignments; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d) the Secured Party
shall apply the proceeds of collection of accounts, chattel paper, general intangibles, instruments and other Collateral and received
by the Secured Party to the payment of the Obligations, such proceeds to be immediately credited after final payment in cash or other
immediately available funds of the items giving rise to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>12.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Power of Attorney</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>12.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Appointment
and Powers of Secured Party</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Each Company hereby
irrevocably constitutes and appoints the Secured Party and any officer or agent thereof, with full power of substitution, as its true
and lawful attorneys-in-fact with full irrevocable power and authority in the place and stead of such Company or in the Secured Party&rsquo;s
own name, for the purpose of carrying out the terms of this Agreement, to take any and all appropriate action and to execute any and
all documents and instruments that may be necessary or useful to accomplish the purposes of this Agreement and, without limiting the
generality of the foregoing, hereby gives said attorneys the power and right, on behalf of such Company, without notice to or assent
by such Company, to do the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(a) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
the occurrence and during the continuance of an Event of Default, generally to sell, transfer, pledge, make any agreement with respect
to or otherwise dispose of or deal with any of the Collateral in such manner as is consistent with the Uniform Commercial Code of the
State or any other relevant jurisdiction and as fully and completely as though the Secured Party were the absolute owner thereof for
all purposes, and to do, at such Company&rsquo;s expense, at any time, or from time to time, all acts and things which the Secured Party
deems necessary or useful to protect, preserve or realize upon the Collateral and the Secured Party&rsquo;s security interest therein,
in order to effect the intent of this Agreement, all no less fully and effectively as such Company might do, including (i) upon written
notice to such Company, the exercise of voting rights with respect to voting securities, which rights may be exercised, if the Secured
Party so elects, with a view to causing the liquidation of assets of the issuer of any such securities and (ii) the execution, delivery
and recording, in connection with any sale or other disposition of any Collateral, of the endorsements, assignments or other instruments
of conveyance or transfer with respect to such Collateral; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(b) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
the extent that such Company&rsquo;s authorization given in &sect;3 is not sufficient, to file such financing statements with respect
hereto, with or without such Company&rsquo;s signature, or a photocopy of this Agreement in substitution for a financing statement, as
the Secured Party may deem appropriate and to execute in such Company&rsquo;s name such financing statements and amendments thereto and
continuation statements which may require such Company&rsquo;s signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>12.2. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Ratification
by Company</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. To the extent permitted by law,
each Company hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue hereof. This power of attorney is
a power coupled with an interest and is irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>12.3. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Duty on Secured Party</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The powers conferred
on the Secured Party hereunder are solely to protect the interests of the Secured Party in the Collateral and shall not impose any duty
upon the Secured Party to exercise any such powers. The Secured Party shall be accountable only for the amounts that it actually receives
as a result of the exercise of such powers, and neither it nor any of its officers, directors, employees or agents shall be responsible
to each Company for any act or failure to act, except for the Secured Party&rsquo;s own gross negligence or willful misconduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>13.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rights and Remedies</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>13.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If an Event of Default shall have occurred and be continuing, the Secured Party, without any other notice to or demand upon any Company,
shall have in any jurisdiction in which enforcement hereof is sought, in addition to all other rights and remedies, the rights and remedies
of a secured party under the Uniform Commercial Code of the State or any other relevant jurisdiction and any additional rights and remedies
as may be provided to a secured party in any jurisdiction in which Collateral is located, including the right to take possession of the
Collateral, and for that purpose the Secured Party may, so far as such Company can give authority therefor, enter upon any premises on
which the Collateral may be situated and remove the same therefrom. The Secured Party may in its discretion require each Company to assemble
all or any part of the Collateral at such location or locations within the jurisdiction(s) of such Company&rsquo;s principal office(s)
or at such other locations as the Secured Party may reasonably designate. Unless the Collateral is perishable or threatens to decline
speedily in value or is of a type customarily sold on a recognized market, the Secured Party shall give to such Company at least ten
(10) Business Days prior written notice of the time and place of any public sale of Collateral or of the time after which any private
sale or any other intended disposition is to be made. Each Company hereby acknowledges that ten (10) Business Days prior written notice
of such sale or sales shall be reasonable notice. In addition, each Company waives any and all rights that it may have to a judicial
hearing in advance of the enforcement of any of the Secured Party&rsquo;s rights and remedies hereunder, including its right following
an Event of Default to take immediate possession of the Collateral and to exercise its rights and remedies with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>14.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Standards for Exercising Rights and Remedies</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
To the extent that applicable law imposes duties on the Secured Party to exercise remedies in a commercially reasonable manner, each
Company acknowledges and agrees that it is not commercially unreasonable for the Secured Party (a) to fail to incur expenses reasonably
deemed significant by the Secured Party to prepare Collateral for disposition or otherwise to fail to complete raw material or work in
process into finished goods or other finished products for disposition, (b) to fail to obtain third party consents for access to Collateral
to be disposed of, or to obtain or, if not required by other law, to fail to obtain governmental or third party consents for the collection
or disposition of Collateral to be collected or disposed of, (c) to fail to exercise collection remedies against account debtors or other
Persons obligated on Collateral or to fail to remove Liens on or any adverse claims against Collateral, (d) to exercise collection remedies
against account debtors and other Persons obligated on the Collateral directly or through the use of collection agencies and other collection
specialists, (e) to advertise dispositions of the Collateral through publications or media of general circulation, whether or not the
Collateral is of a specialized nature, (f) to contact other Persons, whether or not in the same business as the Company, for expressions
of interest in acquiring all or any portion of the Collateral, (g) to hire one or more professional auctioneers to assist in the disposition
of the Collateral, whether or not the collateral is of a specialized nature, (h) to dispose of the Collateral by utilizing Internet sites
that provide for the auction of assets of the types included in the Collateral or that have the reasonable capability of doing so, or
that match buyers and sellers of assets, (i) to dispose of assets in wholesale rather than retail markets, (j) to disclaim disposition
warranties, (k) to purchase insurance or credit enhancements to insure the Secured Party against risks of loss, collection or disposition
of the Collateral or to provide to the Secured Party a guaranteed return from the collection or disposition of such Collateral, or (l)
to the extent deemed appropriate by the Secured Party, to obtain the services of brokers, investment bankers, consultants and other professionals
to assist the Secured Party in the collection or disposition of any of the Collateral. Each Company acknowledges that the purpose of
this &sect;14 is to provide non-exhaustive indications of what actions or omissions by the Secured Party would fulfill the Secured Party&rsquo;s
duties under the Uniform Commercial Code of the State or any other relevant jurisdiction in the Secured Party&rsquo;s exercise of remedies
against the Collateral and that other actions or omissions by the Secured Party shall not be deemed to fail to fulfill such duties solely
on account of not being indicated in this &sect;14. Without limitation upon the foregoing, nothing contained in this &sect;14 shall be
construed to grant any rights to any Company or to impose any duties on the Secured Party that would not have been granted or imposed
by this Agreement or by applicable law in the absence of this &sect;14. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>15.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Waiver by Secured Party, etc</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Secured Party shall not be deemed to have waived any of its rights and remedies in respect of the Obligations or the Collateral unless
such waiver shall be in writing and signed by the Secured Party. No delay or omission on the part of the Secured Party in exercising
any right or remedy shall operate as a waiver of such right or remedy or any other right or remedy. A waiver on any one occasion shall
not be construed as a bar to or waiver of any right or remedy on any future occasion. All rights and remedies of the Secured Party with
respect to the Obligations or the Collateral, whether evidenced hereby or by any other instrument or papers, shall be cumulative and
may be exercised singularly, alternatively, successively or concurrently at such time or at such times as the Secured Party deems expedient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>16.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Suretyship Waivers by Company</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Each Company waives demand, notice, protest, notice of acceptance of this Agreement, notice of loans made, credit extended, Collateral
received or delivered or other action taken in reliance hereon and all other demands and notices of any description. With respect to
both the Obligations and the Collateral, each Company assents to any extension or postponement of the time of payment or any other indulgence,
to any substitution, exchange or release of or failure to perfect any security interest in any such Collateral, to the addition or release
of any party or Person primarily or secondarily liable, to the acceptance of partial payment thereon and the settlement, compromising
or adjusting of any thereof, all in such manner and at such time or times as the Secured Party may deem advisable. The Secured Party
shall have no duty as to the collection or protection of the Collateral or any income therefrom, the preservation of rights against prior
parties, or the preservation of any rights pertaining thereto beyond the safe custody thereof as set forth in &sect;9.2. Each Company
further waives any and all other suretyship defenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>17.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Marshaling</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Secured Party shall not be required to marshal any present or future collateral security (including but not limited to the Collateral)
for, or other assurances of payment of, the Obligations or any of them or to resort to such collateral security or other assurances of
payment in any particular order, and all of the rights and remedies of the Secured Party hereunder and of the Secured Party in respect
of such collateral security and other assurances of payment shall be cumulative and in addition to all other rights and remedies, however
existing or arising. To the extent that it lawfully may, each Company hereby agrees that it will not invoke any law relating to the marshaling
of collateral which might cause delay in or impede the enforcement of the Secured Party&rsquo;s rights and remedies under this Agreement
or under any other instrument creating or evidencing any of the Obligations or under which any of the Obligations is outstanding or by
which any of the Obligations is secured or payment thereof is otherwise assured, and, to the extent that it lawfully may, each Company
hereby irrevocably waives the benefits of all such laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>18.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Proceeds of Dispositions; Expenses</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Each Company shall pay to the Secured Party on demand any and all documented expenses, including reasonable attorneys&rsquo; fees and
disbursements, actually incurred or paid by the Secured Party in protecting or preserving the Secured Party&rsquo;s rights and remedies
under or in respect of any of the Obligations or any of the Collateral and any such expenses actually incurred in releasing any security
interest granted hereunder and, in addition, such Company shall pay to the Secured Party on demand any and all expenses, including attorneys&rsquo;
fees and disbursements, incurred or paid by the Secured Party in enforcing the Secured Party&rsquo;s rights and remedies under or in
respect of any of the Obligations or any of the Collateral. After deducting all of said expenses, the residue of any proceeds of collection
or sale or other disposition of Collateral shall, to the extent actually received in cash, be applied to the payment of the Obligations
in such order or preference as is provided in the SPA, proper allowance and provision being made for any Obligations not then due. Upon
the final payment and satisfaction in full of all of the Obligations and after making any payments required by Sections 9-608(a)(1)(C)
or 9-615(a)(3) of the Uniform Commercial Code of the State, any excess shall be returned to the applicable Company. In the absence of
final payment and satisfaction in full of all of the Obligations, each Company shall remain jointly and severally liable for any deficiency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>19.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overdue Amounts</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Until paid, all amounts due and payable by a Company hereunder shall be a debt secured by the Collateral and shall bear, whether before
or after judgment, interest at the rate of interest for overdue principal set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>20.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing Law; Consent to Jurisdiction</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
<FONT STYLE="text-transform: uppercase"><B>This Agreement IS A contract UNDER the laws of the state of NEVADA and shall for all purposes
be construed in accordance with and governed by the laws of SAID state of NEVADA. each Company and THE SECURED PARTY EACH agree that
any suit for the enforcement of this agreement or any other action brought by SUCH PERSON arising hereunder or in any way related to
this agreement </B></FONT><B>SHALL BE BROUGHT IN THE COURTS OF THE STATE OF NEW YORK IN THE BOROUGH OF MANHATTAN OR ANY FEDERAL COURT
SITTING THEREIN AND CONSENTS TO THE NONEXCLUSIVE JURISDICTION OF SUCH COURT AND SERVICE OF PROCESS IN ANY SUCH SUIT BEING MADE UPON SUCH
PERSON BY MAIL AT THE ADDRESS SPECIFIED ON THE SIGNATURE PAGE OF EACH PARTY HERETO. <FONT STYLE="text-transform: uppercase">each Company
AND THE SECURED PARTY EACH hereby waive any objection that it may now or hereafter have to the venue of any suit BROUGHT IN the state
of new york or any court SITTING THEREIN or that A suit BROUGHT THEREIN is brought in an inconvenient court.</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>21.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waiver of Jury Trial</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
EACH COMPANY AND THE SECURED PARTY WAIVES ITS RIGHT TO A JURY TRIAL WITH RESPECT TO ANY ACTION OR CLAIM ARISING OUT OF ANY DISPUTE IN
CONNECTION WITH THIS AGREEMENT, ANY RIGHTS OR OBLIGATIONS HEREUNDER OR THE PERFORMANCE OR ENFORCEMENT OF ANY SUCH RIGHTS OR OBLIGATIONS.
Except as prohibited by law, each Company waives any right which it may have to claim or recover in any litigation referred to in the
preceding sentence any special, exemplary, punitive or consequential damages or any damages other than, or in addition to, actual damages.
Each Company (a) certifies that neither the Secured Party nor any representative, agent or attorney of the Secured Party has represented,
expressly or otherwise, that the Secured Party would not, in the event of litigation, seek to enforce the foregoing waivers or other
waivers contained in this Agreement and (b) acknowledges that, in entering into this Agreement and any other Transaction Document to
which the Secured Party is a party, the Secured Party is relying upon, among other things, the waivers and certifications contained in
this &sect;21.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>22.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All notices, requests and other communications hereunder shall be made in the manner set forth in the SPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>23.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The headings of each section of this Agreement are for convenience only and shall not define or limit the provisions thereof. This Agreement
and all rights and obligations hereunder shall be binding upon each Company and its successors and assigns, and shall inure to the benefit
of the Secured Party and its successors and assigns. If any term of this Agreement shall be held to be invalid, illegal or unenforceable,
the validity of all other terms hereof shall in no way be affected thereby, and this Agreement shall be construed and be enforceable
as if such invalid, illegal or unenforceable term had not been included herein. Each Company acknowledges receipt of a copy of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>24. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Release
of Collateral; Reinstatement</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. (a) Upon
any sale, transfer or other disposition of any Collateral which is permitted by the Transaction Documents, upon receipt by the
Secured Party of any proceeds thereof which the Parent or the applicable Company is required to pay to the Secured Party pursuant to
the terms of the Transaction Documents, such Collateral (but not the proceeds thereof) shall automatically be released from the
Liens created hereby, and the Secured Party agrees that, at the request and sole expense of such Company, it shall promptly execute
and deliver to such Company all releases or other documents reasonably necessary for the release of such Lien on such Collateral. In
addition, the Secured Party agrees that upon the indefeasible repayment in full, in cash, of all Obligations owing under the
Transaction Documents (other than (a) contingent obligations not due and owing, and, (b) so long as the Parent is in compliance with
all of its obligations under the Warrant, the Parent&rsquo;s obligations under the Warrant) and the termination of any commitments
pursuant to the terms of the Transaction Documents, the security interests granted hereby shall, subject to the Secured
Party&rsquo;s rights of reinstatement set forth herein or in any other Transaction Document, automatically terminate, all rights to
the Collateral shall revert to the applicable Company without further action from any Person and the Secured Party agrees that, at
the request and sole expense of a Company, it shall promptly execute and deliver to such Company all releases or other documents
reasonably necessary for the release of the Liens on the Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Notwithstanding anything
to the contrary contained herein, each Company acknowledges and agrees its obligations and liabilities under the Transaction Documents
(and all security interests and other Liens granted hereunder) shall be deemed to have continued in existence and shall be reinstated
with full force and effect if, at any time on or after the payment of any Obligations under the Transaction Documents, all or any portion
of the Obligations or any other amounts applied by the Secured Party to any of the Obligations is voided or rescinded or must otherwise
be returned by the Secured Party to the Parent or any Company upon the Parent&rsquo;s or any Company&rsquo;s insolvency, bankruptcy or
reorganization or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><I>[Signature pages to follow]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
intending to be legally bound, each Company has caused this Agreement to be duly executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>AMERICAN BRIVISION CORPORATION</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BIOKEY, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BIOLITE HOLDING, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BIOLITE BVI, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: justify">Accepted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.5in 0pt 0; text-align: justify"><B>LIND GLOBAL FUND II LP<BR>
By: Lind Global Partners II LLC, its general partner </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.5in 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-size: 10pt">Jeff Easton, Managing Member</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.5in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF ACKNOWLEDGMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMMONWEALTH OR STATE OF _________________)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 3in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) ss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COUNTY OF ____________________________________)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before me, the undersigned,
a Notary Public in and for the county aforesaid, on this __ day of February, 2023, personally appeared __________________ to me known
personally, and who, being by me duly sworn, deposes and says that he/she is the _____________ of AMERICAN BRIVISION CORPORATION and
that said instrument was signed and sealed on behalf of said corporation by authority of its Board of Directors, and said ______________
acknowledged said instrument to be the free act and deed of said corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">(official signature and seal of notary)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">My commission expires:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF ACKNOWLEDGMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMMONWEALTH OR STATE OF _________________)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 3in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) ss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COUNTY OF ____________________________________)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before me, the undersigned,
a Notary Public in and for the county aforesaid, on this __ day of February, 2023, personally appeared __________________ to me known
personally, and who, being by me duly sworn, deposes and says that he/she is the _____________ of BIOKEY, INC. and that said instrument
was signed and sealed on behalf of said limited liability company by authority of its managers, and said ______________ acknowledged
said instrument to be the free act and deed of said limited liability company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">(official signature and seal of notary)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">My commission expires:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF ACKNOWLEDGMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMMONWEALTH OR STATE OF _________________)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 3in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) ss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COUNTY OF ____________________________________)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before me, the undersigned,
a Notary Public in and for the county aforesaid, on this __ day of February, 2023, personally appeared __________________ to me known
personally, and who, being by me duly sworn, deposes and says that he/she is the _____________ of BIOLITE HOLDING, INC. and that said
instrument was signed and sealed on behalf of said limited liability company by authority of its managers, and said ______________ acknowledged
said instrument to be the free act and deed of said limited liability company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">(official signature and seal of notary)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">My commission expires:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF ACKNOWLEDGMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMMONWEALTH OR STATE OF _________________)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 3in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) ss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COUNTY OF ____________________________________)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before me, the undersigned,
a Notary Public in and for the county aforesaid, on this __ day of February, 2023, personally appeared __________________ to me known
personally, and who, being by me duly sworn, deposes and says that he/she is the _____________ of BIOLITE BVI, INC. and that said instrument
was signed and sealed on behalf of said limited liability company by authority of its managers, and said ______________ acknowledged
said instrument to be the free act and deed of said limited liability company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">(official signature and seal of notary)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">My commission expires:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">16</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>8
<FILENAME>ea174178ex10-6_abvcbio.htm
<DESCRIPTION>GUARANTY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: capitalize; text-align: right">Exhibit 10.6</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: capitalize; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">GUARANTY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>GUARANTY</B> (the &ldquo;<U>Guaranty</U>&rdquo;),
dated as of February 23, 2023, by <B>AMERICAN BRIVISION CORPORATION</B>, a Delaware corporation (&ldquo;<U>American BriVision</U>&rdquo;),
<B>BIOKEY, INC.</B>, a California corporation (&ldquo;<U>BioKey</U>&rdquo;), <B>BIOLITE HOLDINGS, INC.</B>, a Nevada corporation (&ldquo;<U>BioLite</U>&rdquo;),
and <B>BIOLITE BVI, INC.</B>, a British Virgin Islands corporation (&ldquo;<U>BioLite BVI</U>&rdquo; and, collectively with American BriVision,
BioKey and BioLite, the &ldquo;<U>Guarantors</U>&rdquo;, and each, a &ldquo;<U>Guarantor</U>&rdquo;), in favor of <B>LIND GLOBAL FUND
II LP </B>(the &ldquo;<U>Lender</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, ABVC BioPharma,
Inc., a Nevada corporation (the &ldquo;<U>Borrower</U>&rdquo;), is the holder of 100% of the equity interests of American BriVision, BioKey
and BioLite, and Borrower is the holder of 73% of the equity interests of BioLite BVI; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, (a) the Borrower
and the Lender have entered into that certain Securities Purchase Agreement dated as of the date hereof (as amended and in effect from
time to time, the &ldquo;<U>SPA</U>&rdquo;); (b) the Borrower has issued to the Lender that certain Senior Convertible Promissory Note
dated the date hereof (as amended and in effect from time to time, the &ldquo;<U>Note</U>&rdquo;); and (c) the Borrower and the Lender
are parties to that certain Security Agreement dated as of the date hereof (as amended and in effect from time to time, the &ldquo;<U>Borrower
Security Agreement</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Borrower
and the Guarantors are members of a group of related entities, the success of any one of which is dependent in part on the success of
the other members of such group;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Guarantors
expect to receive substantial direct and indirect benefits from the transactions contemplated by the SPA and the Note (including, without
limitation, the extensions of credit to the Borrower by the Lender pursuant to the SPA and the Note) (which benefits are hereby acknowledged);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, it is a condition
precedent to the Lender&rsquo;s willingness to enter into the SPA and the Note and make the loans to the Borrower thereunder that the
Guarantors execute and deliver to the Lender a guaranty substantially in the form hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Guarantors
wish to jointly and severally guaranty the Borrower&rsquo;s, the other Guarantors&rsquo;, and any other Person&rsquo;s obligations to
the Lender under or in respect of the SPA, the Note and the other Transaction Documents (as such term is defined in the SPA) as provided
herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, the
Guarantors hereby agree with the Lender as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>1. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The term (a) &ldquo;Obligations&rdquo; means, collectively, all debts, liabilities and obligations (including, without limitation, any
expenses, costs and charges incurred by or on behalf of the Lender in connection with any Transaction Document), present or future, direct
or indirect, absolute or contingent, matured or unmatured, at any time or from time to time due or accruing due and owing by or otherwise
payable by the Borrower, the Guarantors, or any other &ldquo;Guarantor&rdquo; (as such term is defined in the Borrower Security Agreement)
(the &ldquo;Other Guarantors&rdquo;) to the Lender in any currency, under, in connection with or pursuant to any Transaction Document
(including, without limitation, this Guaranty), and whether incurred by the Borrower, any Guarantor or any Other Guarantor alone or jointly
with another or others and whether as principal, guarantor or surety and in whatever name or style; and (b) &ldquo;Transaction Documents&rdquo;
means, collectively, this Guaranty and the &ldquo;Transaction Documents&rdquo; as defined in the SPA. All other capitalized terms used
herein without definition shall have the respective meanings provided therefor in the SPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>2. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Guaranty
of Payment and Performance</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Guarantors hereby
jointly and severally guarantee to the Lender the full and punctual payment when due (whether at stated maturity, by required pre-payment,
by acceleration or otherwise), as well as the performance, of all of the Obligations, including all such payments which would become due
but for the operation of the automatic stay pursuant to &sect;362(a) of the Federal Bankruptcy Code and the operation of &sect;&sect;502(b)
and 506(b) of the Federal Bankruptcy Code in a bankruptcy or other insolvency proceeding of the Borrower. This Guaranty is an absolute,
unconditional and continuing guaranty of the full and punctual payment and performance of all of the Obligations and not of their collectibility
only and is in no way conditioned upon any requirement that the Lender first attempt to collect any of the Obligations from the Borrower
or any other Person or resort to any collateral security or other means of obtaining payment. Should the Borrower default in the payment
or performance of any of the Obligations, the joint and several obligations of the Guarantors hereunder with respect to such Obligations
in default shall, upon demand by the Lender, become immediately due and payable to the Lender, without demand or notice of any nature,
all of which are expressly waived by the Guarantors. Payments by the Guarantors hereunder may be required by the Lender on any number
of occasions. All payments by the Guarantors hereunder shall be made to the Lender, in the manner and at the place of payment specified
therefor in the Note, for the account of the Lender. Each Guarantor shall make all payments hereunder without setoff or counterclaim and
free and clear of and without deduction for any taxes, levies, imposts, duties, charges, fees, deductions, withholdings, compulsory loans,
restrictions or conditions of any nature now or hereafter imposed or levied by any jurisdiction or any political subdivision thereof or
taxing or other authority therein unless such Guarantor is compelled by law to make such deduction or withholding. If any such obligation
is imposed upon such Guarantor with respect to any amount payable by it hereunder, such Guarantor will pay to the Lender on the date on
which such amount is due and payable hereunder, such additional amount in U.S. dollars as shall be necessary to enable the Lender to receive
the same net amount which the Lender would have received on such due date had no such obligation been imposed upon such Guarantor. Each
Guarantor will deliver promptly to the Lender certificates or other valid vouchers for all taxes or other charges deducted from or paid
with respect to payments made by such Guarantor hereunder. The obligations of each Guarantor under this paragraph shall survive the payment
in full of the Obligations and termination of this Guaranty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>3. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Guarantors&rsquo;
Agreement to Pay Enforcement Costs, etc</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Each
Guarantor further agrees, as the principal obligor and not as a guarantor only, to pay to the Lender, on demand, all out-of-pocket costs
and expenses (including court costs and legal expenses) incurred or expended by the Lender in connection with the Obligations, this Guaranty
and the enforcement thereof, together with interest on amounts recoverable under this &sect;3 from the time when such amounts become due
until payment, whether before or after judgment, at the rate of interest for overdue principal set forth in the Note, provided that if
such interest exceeds the maximum amount permitted to be paid under applicable law, then such interest shall be reduced to such maximum
permitted amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>4. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waivers
by Guarantors; Lender&rsquo;s Freedom to Act</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Each Guarantor agrees that the Obligations will be paid and performed strictly in accordance with their respective terms to the maximum
extent permitted by applicable law, regulation or order now or hereafter in effect in any jurisdiction affecting any of such terms or
the rights of the Lender with respect thereto. Each Guarantor waives promptness, diligence, presentment, demand, protest, notice of acceptance,
notice of any Obligations incurred and all other notices of any kind, all defenses which may be available by virtue of any valuation,
stay, moratorium law or other similar law now or hereafter in effect, any right to require the marshalling of assets the Borrower or any
other entity or other person primarily or secondarily liable with respect to any of the Obligations, and all suretyship defenses generally.
Without limiting the generality of the foregoing, each Guarantor agrees to the provisions of any instrument evidencing, securing or otherwise
executed in connection with any Obligation and agrees that the joint and several obligations of the Guarantors hereunder shall not be
released or discharged, in whole or in part, or otherwise affected by (a) the failure of the Lender to assert any claim or demand or to
enforce any right or remedy against the Borrower or any other entity or other person primarily or secondarily liable with respect to any
of the Obligations; (b) any extensions, compromise, refinancing, consolidation or renewals of any Obligation; (c) any change in the time,
place or manner of payment of any of the Obligations or any rescissions, waivers, compromise, refinancing, consolidation or other amendments
or modifications of any of the terms or provisions of the SPA, the Note, the other Transaction Documents or any other agreement evidencing,
securing or otherwise executed in connection with any of the Obligations; (d) the addition, substitution or release of any entity or other
person primarily or secondarily liable for any Obligation; (e) the adequacy of any rights which the Lender may have against any collateral
security or other means of obtaining repayment of any of the Obligations; (f) the impairment of any collateral securing any of the Obligations,
including without limitation the failure to perfect or preserve any rights which the Lender might have in such collateral security or
the substitution, exchange, surrender, release, loss or destruction of any such collateral security; or (g) any other act or omission
which might in any manner or to any extent vary the risk of the Guarantors or otherwise operate as a release or discharge of any Guarantor,
all of which may be done without notice to the Guarantors. To the fullest extent permitted by law, each Guarantor hereby expressly waives
any and all rights or defenses arising by reason of (i) any &ldquo;one action&rdquo; or &ldquo;anti-deficiency&rdquo; law which would
otherwise prevent the Lender from bringing any action, including any claim for a deficiency, or exercising any other right or remedy (including
any right of set-off), against the Guarantor before or after the Lender&rsquo;s commencement or completion of any foreclosure action,
whether judicially, by exercise of power of sale or otherwise, or (ii) any other law which in any other way would otherwise require any
election of remedies by the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>5. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Unenforceability
of Obligations Against Borrower</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. If for any reason
the Borrower, any other Guarantor or any Other Guarantor has no legal existence or is under no legal obligation to discharge any of the
Obligations, or if any of the Obligations have become irrecoverable from the Borrower, any Guarantor or any Other Guarantor by reason
of the Borrower&rsquo;s, such other Guarantor&rsquo;s or such Other Guarantor&rsquo;s insolvency, bankruptcy or reorganization or by other
operation of law or for any other reason, this Guaranty shall nevertheless be binding on the Guarantors to the same extent as if each
Guarantor at all times had been the principal obligor on all such Obligations. In the event that acceleration of the time for payment
of any of the Obligations is stayed upon the insolvency, bankruptcy or reorganization of the Borrower, any Guarantor or any Other Guarantor,
or for any other reason, all such amounts otherwise subject to acceleration under the terms of the SPA, the Note, the other Transaction
Documents or any other agreement evidencing, securing or otherwise executed in connection with any Obligation shall be immediately due
and payable by the Guarantors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>6. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subrogation;
Subordination</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>6.1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waiver
of Rights Against Borrower</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Until the final payment
and performance in full of all of the Obligations, the Guarantors shall not exercise, and each Guarantor hereby waives, any rights against
the Borrower arising as a result of payment by such Guarantor hereunder, by way of subrogation, reimbursement, restitution, contribution
or otherwise, and will not prove any claim in competition with the Lender in respect of any payment hereunder in any bankruptcy, insolvency
or reorganization case or proceedings of any nature; the Guarantors will not claim any setoff, recoupment or counterclaim against the
Borrower in respect of any liability of a Guarantor to the Borrower; and each Guarantor waives any benefit of and any right to participate
in any collateral security which may be held by the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>6.2. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subordination</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
The payment of any amounts due with respect to any indebtedness of the Borrower for money borrowed or credit received now or hereafter
owed to any Guarantor is hereby subordinated to the prior payment in full of all of the Obligations. Each Guarantor agrees that, after
the occurrence and during the continuance of any default in the payment of any of the Obligations or upon the occurrence and continuation
of any other Event of Default, such Guarantor will not demand, sue for or otherwise attempt to collect any such indebtedness of the Borrower
to such Guarantor until all of the Obligations shall have been paid in full. If, notwithstanding the foregoing sentence, any Guarantor
shall collect, enforce or receive any amounts in respect of such indebtedness while any Obligations are still outstanding, such amounts
shall be collected, enforced and received by such Guarantor as trustee for the Lender and be paid over to the Lender on account of the
Obligations without affecting in any manner the liability of the Guarantors under the other provisions of this Guaranty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>6.3. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Provisions
Supplemental</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The provisions of this &sect;6
shall be supplemental to and not in derogation of any rights and remedies of the Lender under any separate subordination agreement which
the Lender may at any time and from time to time enter into with any Guarantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>7. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Security;
Setoff</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Each Guarantor grants to the Lender,
as security for the full and punctual payment and performance of all of such Guarantor&rsquo;s obligations hereunder, a continuing lien
on and security interest in all securities or other property belonging to such Guarantor now or hereafter held by the Lender and in all
deposits (general or special, time or demand, provisional or final) and other sums credited by or due from the Lender to such Guarantor
or subject to withdrawal by such Guarantor. Regardless of the adequacy of any collateral security or other means of obtaining payment
of any of the Obligations, the Lender is hereby authorized at any time and from time to time, without notice to any Guarantor (any such
notice being expressly waived by each Guarantor) and to the fullest extent permitted by law, to set off and apply such deposits and other
sums against the obligations of each Guarantor under this Guaranty, whether or not the Lender shall have made any demand under this Guaranty
and although such obligations may be contingent or unmatured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>8. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Further
Assurances</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Each Guarantor agrees that it will
from time to time, at the request of the Lender, do all such things and execute all such documents as the Lender may reasonably request
and consider necessary or desirable to give full effect to this Guaranty and to perfect and preserve the rights and powers of the Lender
hereunder. Each Guarantor acknowledges and confirms that such Guarantor itself has established its own adequate means of obtaining from
the Borrower on a continuing basis all information desired by such Guarantor concerning the financial condition of the Borrower and that
such Guarantor will look to the Borrower and not to the Lender in order for such Guarantor to keep adequately informed of changes in the
Borrower&rsquo;s financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>9. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination;
Reinstatement</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> This Guaranty shall remain in
full force and effect until the Lender is given written notice of a Guarantor&rsquo;s intention to discontinue this Guaranty with respect
to such Guarantor, notwithstanding any intermediate or temporary payment or settlement of the whole or any part of the Obligations (and
to the extent such notice is given by a Guarantor, this Guaranty shall remain in full force and effect against each other Guarantor).
No such notice shall be effective unless received and acknowledged by an officer of the Lender at the address of Lender for notices set
forth in the SPA. No such notice shall affect any rights of the Lender hereunder, including without limitation the rights set forth in
&sect;&sect;4 and 6, with respect to any Obligations incurred or accrued prior to the receipt of such notice or any Obligations incurred
or accrued pursuant to any contract or commitment in existence prior to such receipt. This Guaranty shall continue to be effective or
be reinstated, notwithstanding any such notice, if at any time any payment made or value received with respect to any Obligation is rescinded
or must otherwise be returned by the Lender upon the insolvency, bankruptcy or reorganization of the Borrower, or otherwise, all as though
such payment had not been made or value received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>10. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Successors
and Assigns</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> This Guaranty shall be binding upon
each Guarantor, its successors and assigns, and shall inure to the benefit of the Lender and its successors, transferees and assigns.
Without limiting the generality of the foregoing sentence, the Lender may assign or otherwise transfer any Transaction Document or any
other agreement or note held by it evidencing, securing or otherwise executed in connection with the Obligations, or sell participations
in any interest therein, to any other entity or other person, and such other entity or other person shall thereupon become vested, to
the extent set forth in the agreement evidencing such assignment, transfer or participation, with all the rights in respect thereof granted
to the Lender herein, all in accordance with, and subject to, the SPA and the Note. The Guarantors may not assign any of their obligations
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>11. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendments
and Waivers</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> No amendment or waiver of any provision
of this Guaranty nor consent to any departure by any Guarantor therefrom shall be effective unless the same shall be in writing and signed
by the Lender. No failure on the part of the Lender to exercise, and no delay in exercising, any right hereunder shall operate as a waiver
thereof; nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise
of any other right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>12. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
All notices and other communications called for hereunder shall be made in writing and, unless otherwise specifically provided herein,
shall be deemed to have been duly made or given when made or given in accordance with the procedures set forth in the SPA and addressed
as follows: if to any Guarantor, at the address set forth beneath its signature hereto, and if to the Lender, at the address for notices
to the Lender set forth in the SPA, or at such address as either party may designate in writing to the other.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>13. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing
Law; Consent to Jurisdiction</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> THIS GUARANTY SHALL
BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEVADA. Each Guarantor agrees that any suit for the enforcement
of this Guaranty may be brought in the courts of the STATE OF NEW YORK sitting in the Borough of Manhattan or, to the extent permitted
by applicable law, any federal court for the Southern District of New York (and appellate courts thereof) and consents to the nonexclusive
jurisdiction of such court and to service of process in any such suit being made upon such Guarantor by mail at the address specified
by reference in &sect;12. Each Guarantor hereby waives any objection that it may now or hereafter have to the venue of any such suit or
any such court or that such suit was brought in an inconvenient court.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>14. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waiver
of Jury Trial</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> EACH GUARANTOR HEREBY WAIVES ITS
RIGHT TO A JURY TRIAL WITH RESPECT TO ANY ACTION OR CLAIM ARISING OUT OF ANY DISPUTE IN CONNECTION WITH THIS GUARANTY, ANY RIGHTS OR OBLIGATIONS
HEREUNDER OR THE PERFORMANCE OF ANY OF SUCH RIGHTS OR OBLIGATIONS. Except as prohibited by law, each Guarantor hereby waives any right
which it may have to claim or recover in any litigation referred to in the preceding sentence any special, exemplary, punitive or consequential
damages or any damages other than, or in addition to, actual damages. Each Guarantor (i) certifies that neither the Lender nor any representative,
agent or attorney of the Lender has represented, expressly or otherwise, that the Lender would not, in the event of litigation, seek to
enforce the foregoing waivers and (ii) acknowledges that, in entering into the SPA, the Note and the other Transaction Documents to which
the Lender is a party, the Lender is relying upon, among other things, the waivers and certifications contained in this &sect;14.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>15. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
This Guaranty constitutes the entire agreement of the Guarantors with respect to the matters set forth herein. The rights and remedies
herein provided are cumulative and not exclusive of any remedies provided by law or any other agreement, and this Guaranty shall be in
addition to any other guaranty of or collateral security for any of the Obligations. The invalidity or unenforceability of any one or
more sections of this Guaranty shall not affect the validity or enforceability of its remaining provisions. Captions are for the ease
of reference only and shall not affect the meaning of the relevant provisions. The meanings of all defined terms used in this Guaranty
shall be equally applicable to the singular and plural forms of the terms defined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>16. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Contribution</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
To the extent any Guarantor makes a payment hereunder in excess of the aggregate amount of the benefit received by such Guarantor in respect
of the extensions of credit under the Transaction Documents (the &ldquo;<U>Benefit Amount</U>&rdquo;), then such Guarantor, after the
payment in full, in cash, of all of the Obligations, shall be entitled to recover from each other guarantor of the Obligations such excess
payment, <U>pro rata</U>, in accordance with the ratio of the Benefit Amount received by each such other guarantor to the total Benefit
Amount received by all guarantors of the Obligations, and the right to such recovery shall be deemed to be an asset and property of such
Guarantor so funding; <U>provided</U>, that all such rights to recovery shall be subordinated and junior in right of payment to the final
and undefeasible payment in full in cash of all of the Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>17. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effectiveness</U>.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Delivery of an executed signature page of this Guaranty by facsimile transmission or by email with a PDF attachment shall be effective
as delivery of a manually executed counterpart hereof. This Guaranty and the other Transaction Documents constitute the entire contract
among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written,
relating to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,</B>
the Guarantor has caused this Guaranty to be executed and delivered as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMERICAN BRIVISION CORPORATION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOKEY, INC.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOLITE HOLDING, INC.</B></FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOLITE BVI, INC.</B></FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-7-</P></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>9
<FILENAME>ea174178ex10-7_abvcbio.htm
<DESCRIPTION>TRADEMARK SECURITY AGREEMENT WITH RGENE CORPORATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>TRADEMARK SECURITY AGREEMENT </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This TRADEMARK SECURITY AGREEMENT (this &ldquo;<U>Trademark
Security Agreement</U>&rdquo;) is entered into as of February 23, 2023 by and between <FONT STYLE="text-transform: uppercase"><B>ABVC BIOPHARMA,
INC.</B>,</FONT> a Nevada corporation (&ldquo;<U>ABVC</U>&rdquo;), <B>Rgene Corporation</B>, a company incorporated under the laws of Taiwan
(&ldquo;<U>Rgene</U>&rdquo; and, together with ABVC, each a &ldquo;Grantor&rdquo; and together, the &ldquo;Grantors&rdquo;), and <B>LIND
GLOBAL FUND II LP </B>(the &ldquo;<U>Lender</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, pursuant to
that Certain Securities Purchase Agreement dated as of the date hereof by and between the Grantor and the Lender (as amended and in effect
from time to time, the &ldquo;<U>SPA</U>&rdquo;) and that certain Senior Convertible Promissory Note dated the date hereof from the Grantor
in favor of the Lender (as amended and in effect from time to time, the &ldquo;<U>Note</U>&rdquo;), the Lender has agreed to make certain
financial accommodations available to the Grantor pursuant to the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Lender
is willing to make the financial accommodations to the Grantor as provided for in the SPA and the Note, but only upon the condition, among
others, that the Grantor shall have executed and delivered to the Lender that certain Security Agreement, dated as of the date hereof
(as from time to time amended, restated, amended and restated, supplemented or otherwise modified, the &ldquo;<U>Security Agreement</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, pursuant to
the Security Agreement, the Grantor has pledged and granted to the Lender a security interest in the Trademark Collateral (as defined
below); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, in connection
with the Security Agreement, the Grantor has agreed to execute and deliver this Trademark Security Agreement in order to record the security
interest granted to the Lender with the United States Patent and Trademark Office;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Grantor hereby agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 1. <U>Defined Terms.</U>
Unless otherwise defined herein, capitalized terms defined in the Security Agreement and used herein have the meaning given to them in
the Security Agreement. The term &ldquo;<U>Trademarks</U>&rdquo; means, collectively, (a) all of the trademarks, service marks, designs,
logos, indicia, trade names, corporate names, company names, business names, fictitious business names, trade styles, elements of package
or trade dress, and other source and product or service identifiers, used or associated with or appurtenant to the products, services
and businesses of the Grantor, that (i) are set forth on <U>Schedule</U>&nbsp;<U>I</U> hereto, or (ii) have been adopted, acquired, owned,
held or used by the Grantor or are now owned, held or used by the Grantor, in the Grantor&rsquo;s business, or with the Grantor&rsquo;s products and
services, or in which the Grantor has any right, title or interest, or (iii) are in the future adopted, acquired, owned, held and used
by the Grantor in the Grantor&rsquo;s business or with the Grantor&rsquo;s products and services, or in which the Grantor in the future acquires any
right, title or interest, (b) all past, present or future rights in, to and associated with the foregoing throughout the world, whether
arising under federal law, state law, common law, foreign law or otherwise, including the following: all such rights arising out of or
associated with the registrations of the foregoing items set forth in clause (a), the right (but not the obligation) to register claims
under any state, federal or foreign trademark law or regulation; the right (but not the obligation) to sue or bring opposition or cancellation
proceedings in the name of the Grantor or the Lender for any and all past, present and future infringements or dilution of or any other
damages or injury to the foregoing or any associated goodwill, and the rights to damages or profits due or accrued arising out of or in
connection with any such past, present or future infringement, dilution, damage or injury; and (c) any license rights related to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 2. <U>Grant of Security
Interest in Trademark Collateral.</U> The Grantor hereby pledges, collaterally assigns and grants to the Lender, for the benefit of the
Lender, to secure the prompt and complete payment and performance of the Obligations, a security interest (referred to in this Trademark
Security Agreement as the &ldquo;<U>Security Interest</U>&rdquo;) in all of the Grantor&rsquo;s right, title and interest in, to and under the
following, whether now owned or hereafter acquired or arising (collectively, the &ldquo;<U>Trademark Collateral</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(a) all
of its Trademarks and licenses with respect to Trademarks to which it is a party including those referred to on Schedule I;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(b) all
goodwill of the business connected with the use of, and symbolized by, each Trademark and each license with respect to Trademarks; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(c) all
products and proceeds (as that term is defined in the UCC) of the foregoing, including any claim by the Grantor against third parties
for past, present or future (i) infringement or dilution of any Trademark or any Trademarks exclusively licensed under any license, including
right to receive any damages, (ii) injury to the goodwill associated with any Trademark, or (iii) right to receive license fees, royalties,
and other compensation under any license with respect to Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3. <U>Security for
Obligations.</U> This Trademark Security Agreement and the Security Interest created hereby secures the payment and performance of the
Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Trademark Security Agreement
secures the payment of all amounts which constitute part of the Obligations and would be owed by the Grantor to the Lender, whether or
not they are unenforceable or not allowable due to the existence of an insolvency proceeding involving the Grantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 4. <U>Security Agreement.</U>
The Security Interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interests granted
to the Lender, for the benefit of the Lender, pursuant to the Security Agreement. The Grantor hereby acknowledges and affirms that the
rights and remedies of the Lender with respect to the Security Interest in the Trademark Collateral made and granted hereby are more fully
set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.
To the extent there is any inconsistency between this Trademark Security Agreement and the Security Agreement, the Security Agreement
shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 5. <U>Authorization
to Supplement.</U> If the Grantor shall obtain rights to any new Trademarks, the provisions of this Trademark Security Agreement shall
automatically apply thereto. The Grantor hereby authorizes the Lender unilaterally to modify this Trademark Security Agreement by amending
<U>Schedule I</U> to include any such new trademark rights of the Grantor. Notwithstanding the foregoing, no failure to so modify this
Trademark Security Agreement or amend <U>Schedule I</U> shall in any way affect, invalidate or detract from the Lender&rsquo;s continuing
security interest in all Collateral (including the Trademark Collateral), whether or not listed on <U>Schedule I</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 6. <U>Counterparts.</U>
This Trademark Security Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument,
and any party here to may execute this Trademark Security Agreement by signing and delivering one or more counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 7. <U>Governing Law.</U>
This Trademark Security Agreement and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based
upon, arising out of or relating to this Trademark Security Agreement and the transactions contemplated hereby shall be governed by, and
construed in accordance with, the law of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>[signature pages follow] </U></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each Grantor
has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 1.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GRANTOR: </B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>ABVC BIOPHARMA, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 1.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GRANTOR: </B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>RGENE</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and Agreed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LIND GLOBAL FUND II LP, as Lender</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>By: Lind Global Partners II LLC, its general
partner </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Jeff Easton</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-size: 10pt">Managing Member</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>SCHEDULE I<BR>
</U>to<BR>
<U>TRADEMARK SECURITY AGREEMENT<BR>
TRADEMARK REGISTRATIONS AND TRADEMARK APPLICATIONS </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trademark</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration No.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration Date</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>10
<FILENAME>ea174178ex10-8_abvcbio.htm
<DESCRIPTION>TRADEMARK SECURITY AGREEMENT WITH BIOFIRST CORPORATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TRADEMARK SECURITY AGREEMENT </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This TRADEMARK SECURITY AGREEMENT (this &quot;<U>Trademark
Security Agreement</U>&quot;) is entered into as of February 23, 2023 by and between <FONT STYLE="text-transform: uppercase"><B>ABVC BIOPHARMA,
INC.</B>,</FONT> a Nevada corporation (&ldquo;ABVC&rdquo;), <B>BioFirst Corporation</B>, a company incorporated under the laws of Taiwan
(&ldquo;<U>BioFirst</U>&rdquo; and, together with ABVC, each a &ldquo;Grantor&rdquo; and together, the &ldquo;Grantors&rdquo;) and <B>LIND
GLOBAL FUND II LP </B>(the &ldquo;<U>Lender</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, pursuant to
that Certain Securities Purchase Agreement dated as of the date hereof by and between the Grantor and the Lender (as amended and in effect
from time to time, the &ldquo;<U>SPA</U>&rdquo;) and that certain Senior Convertible Promissory Note dated the date hereof from the Grantor
in favor of the Lender (as amended and in effect from time to time, the &ldquo;<U>Note</U>&rdquo;), the Lender has agreed to make certain
financial accommodations available to the Grantor pursuant to the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Lender
is willing to make the financial accommodations to the Grantor as provided for in the SPA and the Note, but only upon the condition, among
others, that the Grantor shall have executed and delivered to the Lender that certain Security Agreement, dated as of the date hereof
(as from time to time amended, restated, amended and restated, supplemented or otherwise modified, the &ldquo;<U>Security Agreement</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, pursuant to
the Security Agreement, the Grantor has pledged and granted to the Lender a security interest in the Trademark Collateral (as defined
below); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, in connection
with the Security Agreement, the Grantor has agreed to execute and deliver this Trademark Security Agreement in order to record the security
interest granted to the Lender with the United States Patent and Trademark Office;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Grantor hereby agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 1. <U>Defined Terms.</U>
Unless otherwise defined herein, capitalized terms defined in the Security Agreement and used herein have the meaning given to them in
the Security Agreement. The term &quot;<U>Trademarks</U>&quot; means, collectively, (a) all of the trademarks, service marks, designs,
logos, indicia, trade names, corporate names, company names, business names, fictitious business names, trade styles, elements of package
or trade dress, and other source and product or service identifiers, used or associated with or appurtenant to the products, services
and businesses of the Grantor, that (i) are set forth on <U>Schedule</U>&nbsp;<U>I</U> hereto, or (ii) have been adopted, acquired, owned,
held or used by the Grantor or are now owned, held or used by the Grantor, in the Grantor's business, or with the Grantor's products and
services, or in which the Grantor has any right, title or interest, or (iii) are in the future adopted, acquired, owned, held and used
by the Grantor in the Grantor's business or with the Grantor's products and services, or in which the Grantor in the future acquires any
right, title or interest, (b) all past, present or future rights in, to and associated with the foregoing throughout the world, whether
arising under federal law, state law, common law, foreign law or otherwise, including the following: all such rights arising out of or
associated with the registrations of the foregoing items set forth in clause (a), the right (but not the obligation) to register claims
under any state, federal or foreign trademark law or regulation; the right (but not the obligation) to sue or bring opposition or cancellation
proceedings in the name of the Grantor or the Lender for any and all past, present and future infringements or dilution of or any other
damages or injury to the foregoing or any associated goodwill, and the rights to damages or profits due or accrued arising out of or in
connection with any such past, present or future infringement, dilution, damage or injury; and (c) any license rights related to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 2. <U>Grant of Security
Interest in Trademark Collateral.</U> The Grantor hereby pledges, collaterally assigns and grants to the Lender, for the benefit of the
Lender, to secure the prompt and complete payment and performance of the Obligations, a security interest (referred to in this Trademark
Security Agreement as the &quot;<U>Security Interest</U>&quot;) in all of the Grantor's right, title and interest in, to and under the
following, whether now owned or hereafter acquired or arising (collectively, the &quot;<U>Trademark Collateral</U>&quot;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(a) all
of its Trademarks and licenses with respect to Trademarks to which it is a party including those referred to on Schedule I;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(b) all
goodwill of the business connected with the use of, and symbolized by, each Trademark and each license with respect to Trademarks; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(c) all
products and proceeds (as that term is defined in the UCC) of the foregoing, including any claim by the Grantor against third parties
for past, present or future (i) infringement or dilution of any Trademark or any Trademarks exclusively licensed under any license, including
right to receive any damages, (ii) injury to the goodwill associated with any Trademark, or (iii) right to receive license fees, royalties,
and other compensation under any license with respect to Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3. <U>Security for
Obligations.</U> This Trademark Security Agreement and the Security Interest created hereby secures the payment and performance of the
Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Trademark Security Agreement
secures the payment of all amounts which constitute part of the Obligations and would be owed by the Grantor to the Lender, whether or
not they are unenforceable or not allowable due to the existence of an insolvency proceeding involving the Grantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 4. <U>Security Agreement.</U>
The Security Interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interests granted
to the Lender, for the benefit of the Lender, pursuant to the Security Agreement. The Grantor hereby acknowledges and affirms that the
rights and remedies of the Lender with respect to the Security Interest in the Trademark Collateral made and granted hereby are more fully
set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.
To the extent there is any inconsistency between this Trademark Security Agreement and the Security Agreement, the Security Agreement
shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 5. <U>Authorization
to Supplement.</U> If the Grantor shall obtain rights to any new Trademarks, the provisions of this Trademark Security Agreement shall
automatically apply thereto. The Grantor hereby authorizes the Lender unilaterally to modify this Trademark Security Agreement by amending
<U>Schedule I</U> to include any such new trademark rights of the Grantor. Notwithstanding the foregoing, no failure to so modify this
Trademark Security Agreement or amend <U>Schedule I</U> shall in any way affect, invalidate or detract from the Lender&rsquo;s continuing
security interest in all Collateral (including the Trademark Collateral), whether or not listed on <U>Schedule I</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 6. <U>Counterparts.</U>
This Trademark Security Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument,
and any party hereto may execute this Trademark Security Agreement by signing and delivering one or more counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 7. <U>Governing Law.</U>
This Trademark Security Agreement and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based
upon, arising out of or relating to this Trademark Security Agreement and the transactions contemplated hereby shall be governed by, and
construed in accordance with, the law of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>[signature pages follow]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U></U></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each Grantor
has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GRANTOR: </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ABVC BIOPHARMA, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 15%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 30%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GRANTOR: </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>BIOFIRST</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and Agreed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>LIND GLOBAL FUND II LP, as Lender</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>By:&nbsp;&nbsp;Lind Global Partners II LLC, its general partner</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jeff Easton</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: &nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Managing Member </FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE I<BR>
</U>to<BR>
<U>TRADEMARK SECURITY AGREEMENT<BR>
TRADEMARK REGISTRATIONS AND TRADEMARK APPLICATIONS </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trademark</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration No.</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration Date</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>11
<FILENAME>ea174178ex10-9_abvcbio.htm
<DESCRIPTION>PATENT SECURITY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><B>Exhibit 10.9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B><U>PATENT SECURITY AGREEMENT </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">This PATENT SECURITY AGREEMENT (this &ldquo;<U>Patent
Security Agreement</U>&rdquo;) is entered into as of February 23, 2023 by and between <B>ABVC BIOPHARMA, INC.</B>, a Nevada corporation
(the &ldquo;<U>Grantor</U>&rdquo;) and <B>LIND GLOBAL FUND II LP</B> (the &ldquo;<U>Lender</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">W I T N E S S E T H:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to that
certain Securities Purchase Agreement dated as of the date hereof, by and between the Grantor and the Lender (as amended and in effect
from time to time, the &ldquo;<U>SPA</U>&rdquo;), and that certain Senior Convertible Promissory Note, dated the date hereof, from the
Grantor in favor of the Lender (as amended and in effect from time to time, the &ldquo;<U>Note</U>&rdquo;), the Lender has agreed to make
certain financial accommodations available to the Grantor pursuant to the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Lender is willing
to make the financial accommodations to the Grantor as provided for in the SPA and the Note, but only upon the condition, among others,
that the Grantor shall have executed and delivered to the Lender that certain Security Agreement, dated as of the date hereof (as from
time to time amended, restated, amended and restated, supplemented or otherwise modified, the &ldquo;<U>Security Agreement</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to the Security
Agreement, the Grantor has pledged and granted to the Lender a security interest in the Patent Collateral (as defined below); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">WHEREAS, in connection with
the Security Agreement, the Grantor has agreed to execute and deliver this Patent Security Agreement in order to record the security interest
granted to the Lender with the United States Patent and Trademark Office;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Grantor hereby agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">SECTION 1. <U>Defined Terms.</U>
Unless otherwise defined herein, capitalized terms defined in the Security Agreement and used herein have the meaning given to them in
the Security Agreement. The term &ldquo;<U>Patents</U>&rdquo; means, collectively, (a) all of the patent and patent applications, whether
United States or foreign, that are owned by the Grantor, or in which the Grantor has any right, title or interest, now or in the future,
including but not limited to (i) the patents and patent applications listed on Schedule I hereto (as the same may be amended pursuant
hereto from time to time), (ii) all letters patent of the United States or any other country, and all applications for letters patent
of the United States or any other country; (iii) all re-issues, continuations, divisions, continuations-in-part, renewals or extensions
thereof; (iv) the inventions disclosed or claimed therein, including the right to make, use, practice and/or sell (or license or otherwise
transfer or dispose of) the inventions disclosed or claimed therein; and (v) the right (but not the obligation) to make and prosecute
applications for such patents, (b) all past, present or future rights in, to and associated with the foregoing throughout the world, whether
arising under federal law, state law, common law, foreign law or otherwise, including the following: all such rights arising out of or
associated with the registrations of the foregoing items set forth in clause (a), the right (but not the obligation) to register claims
under any state, federal or foreign patent law or regulation; the right (but not the obligation) to sue or bring opposition or cancellation
proceedings in the name of the Grantor or the Lender for any and all past, present and future infringements or dilution of or any other
damages or injury to the foregoing or any associated goodwill, and the rights to damages or profits due or accrued arising out of or in
connection with any such past, present or future infringement, dilution, damage or injury; and (c) any license rights related to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">SECTION 2. <U>Grant of Security
Interest in Patent Collateral.</U> The Grantor hereby pledges, collaterally assigns and grants to the Lender to secure the prompt and
complete payment and performance of the Obligations, a security interest (referred to in this Patent Security Agreement as the &ldquo;<U>Security
Interest</U>&rdquo;) in all of the Grantor&rsquo;s right, title and interest in, to and under the following, whether now owned or hereafter
acquired or arising (collectively, the &ldquo;<U>Patent Collateral</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">all of its Patents and licenses with respect to Patents to which
it is a party including those referred to on Schedule I;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">each license with respect to Patents; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">all products and proceeds (as that term is defined in the UCC)
of the foregoing, including any claim by the Grantor against third parties for past, present or future (i) infringement or dilution of
any Patent or any Patents exclusively licensed under any license, including right to receive any damages, or (ii) right to receive license
fees, royalties, and other compensation under any license with respect to Patents.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">SECTION 3. <U>Security
for Obligations.</U> This Patent Security Agreement and the Security Interest created hereby secures the payment and performance of the
Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement
secures the payment of all amounts which constitute part of the Obligations and would be owed by the Grantor to Lender, whether or not
they are unenforceable or not allowable due to the existence of an insolvency proceeding involving the Grantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">SECTION 4. <U>Security
Agreement.</U> The Security Interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interests
granted to the Lender pursuant to the Security Agreement. The Grantor hereby acknowledges and affirms that the rights and remedies of
the Lender with respect to the Security Interest in the Patent Collateral made and granted hereby are more fully set forth in the Security
Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is
any inconsistency between this Patent Security Agreement and the Security Agreement, the Security Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">SECTION 5. <U>Authorization
to Supplement.</U> If the Grantor shall obtain rights to any new Patents, the provisions of this Patent Security Agreement shall automatically
apply thereto. The Grantor hereby authorizes the Lender unilaterally to modify this Patent Security Agreement by amending <U>Schedule
I</U> to include any such new patent rights of the Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security
Agreement or amend <U>Schedule I</U> shall in any way affect, invalidate or detract from the Lender&rsquo;s continuing security interest
in all Collateral (including the Patent Collateral), whether or not listed on <U>Schedule I</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">SECTION 6. <U>Counterparts.</U>
This Patent Security Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument,
and any party hereto may execute this Patent Security Agreement by signing and delivering one or more counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">SECTION 7. <U>Governing Law.</U>
This Patent Security Agreement and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based
upon, arising out of or relating to this Patent Security Agreement and the transactions contemplated hereby shall be governed by, and
construed in accordance with, the law of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><U>[signature pages follow]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Grantor
has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GRANTOR:</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ABVC BIOPHARMA, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 36%"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Accepted and Agreed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>LIND GLOBAL FUND II LP</B><BR>
as Lender</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>By: LIND GLOBAL PARTNERS II LLC, its </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>general partner</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp; </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jeff Easton</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Managing Member</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><U>SCHEDULE I<BR>
</U>to<BR>
<U>PATENT SECURITY AGREEMENT<BR>
PATENT REGISTRATIONS AND PATENT APPLICATIONS </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B><U>
Registrations:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
    No.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
    Date</B></FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B><U>Applications:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
    Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>12
<FILENAME>ea174178ex10-10_abvcbio.htm
<DESCRIPTION>COPYRIGHT SECURITY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.10</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COPYRIGHT SECURITY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This COPYRIGHT SECURITY AGREEMENT (this &ldquo;<U>Patent
Security Agreement</U>&rdquo;) is entered into as of February 23, 2023 by and between <B>ABVC BIOPHARMA, INC.</B>, a Nevada corporation
(the &ldquo;<U>Grantor</U>&rdquo;) and <B>LIND GLOBAL FUND II LP</B> (the &ldquo;<U>Lender</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">W I T N E S S E T H:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to that
certain Securities Purchase Agreement dated as of the date hereof by and between the Grantor and the Lender (as amended and in effect
from time to time, the &ldquo;<U>SPA</U>&rdquo;) and that certain Senior Convertible Promissory Note dated as of the date hereof from the
Grantor in favor of the Lender (as amended and in effect from time to time, the &ldquo;<U>Note</U>&rdquo;), the Lender has agreed to make
certain financial accommodations available to the Grantor pursuant to the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Lender is willing
to make the financial accommodations to the Grantor as provided for in the SPA and the Note, but only upon the condition, among others,
that the Grantor shall have executed and delivered to the Lender that certain Security Agreement, dated as of the date hereof (as from
time to time amended, restated, amended and restated, supplemented or otherwise modified, the &ldquo;<U>Security Agreement</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to the Security
Agreement, the Grantor has pledged and granted to the Lender a security interest in the Copyright Collateral (as defined below); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, in connection with
the Security Agreement, the Grantor has agreed to execute and deliver this Copyright Security Agreement in order to record the security
interest granted to the Lender with the United States Copyright Office;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Grantor hereby agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 1. <U>Defined Terms.</U>
Unless otherwise defined herein, capitalized terms defined in the Security Agreement and used herein have the meaning given to them in
the Security Agreement. The term &ldquo;<U>Copyrights</U>&rdquo; means, collectively, (a) the copyrights and all other rights in and to
the works identified in Part I of <U>Schedule I</U> attached hereto, (b) the copyrights and all other rights in and to the copyrighted
or copyrightable works identified in Part II of <U>Schedule I</U> attached hereto, (c) the copyrights and all other rights in and to all
other copyrighted or copyrightable works of the Grantor now or hereafter existing or now owned or hereafter acquired, whether or not identified
by a title and/or United States Copyright Office registration number, whether or not identified on <U>Schedule I</U> attached hereto,
and whether or not registered with the United States Copyright Office, and (d) all proceeds from the sale, exchange, license, lease or
other transfer or disposition or collection of any of the foregoing (in whole or in part) or of any right or interest therein, and all
proceeds or other value received and attributable (in whole or in part) to the ownership, possession or use of any of the foregoing (including
without limitation any amounts recovered or recoverable on account of any infringement or misappropriation thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 2. <U>Grant of Security
Interest in Copyright Collateral.</U> The Grantor hereby pledges, collaterally assigns and grants to the Lender to secure the prompt and
complete payment and performance of the Obligations, a security interest (referred to in this Copyright Security Agreement as the &ldquo;<U>Security
Interest</U>&rdquo;) in all of the Grantor&rsquo;s right, title and interest in, to and under the following, whether now owned or hereafter acquired
or arising (collectively, the &ldquo;<U>Copyright Collateral</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(a) all
of its Copyrights and licenses with respect to Copyrights to which it is a party including those referred to on Schedule I; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(b) all
products and proceeds (as that term is defined in the UCC) of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3. <U>Security for
Obligations.</U> This Copyright Security Agreement and the Security Interest created hereby secures the payment and performance of the
Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Copyright Security Agreement
secures the payment of all amounts which constitute part of the Obligations and would be owed by the Grantor to Lender, whether or not
they are unenforceable or not allowable due to the existence of an insolvency proceeding involving the Grantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 4. <U>Security Agreement.</U>
The Security Interest granted pursuant to this Copyright Security Agreement is granted in conjunction with the security interests granted
to the Lender pursuant to the Security Agreement. The Grantor hereby acknowledges and affirms that the rights and remedies of the Lender
with respect to the Security Interest in the Copyright Collateral made and granted hereby are more fully set forth in the Security Agreement,
the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency
between this Copyright Security Agreement and the Security Agreement, the Security Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 5. <U>Authorization
to Supplement.</U> If the Grantor shall obtain rights to any new Copyrights, the provisions of this Copyright Security Agreement shall
automatically apply thereto. The Grantor hereby authorizes the Lender unilaterally to modify this Copyright Security Agreement by amending
<U>Schedule I</U> to include any such new Copyrights of the Grantor. Notwithstanding the foregoing, no failure to so modify this Copyright
Security Agreement or amend <U>Schedule I</U> shall in any way affect, invalidate or detract from the Lender&rsquo;s continuing security
interest in all Collateral (including the Copyright Collateral), whether or not listed on <U>Schedule I</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 6. <U>Counterparts.</U>
This Copyright Security Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument,
and any party here to may execute this Copyright Security Agreement by signing and delivering one or more counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 7. <U>Governing Law.</U>
This Copyright Security Agreement and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based
upon, arising out of or relating to this Copyright Security Agreement and the transactions contemplated hereby shall be governed by, and
construed in accordance with, the law of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[signature pages follow]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each Grantor
has caused this Copyright Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>GRANTOR:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: uppercase">ABVC BIOPHARMA, INC.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: uppercase">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD></TR>
  </TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Accepted and Agreed:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>LIND GLOBAL FUND II LP </B>as Lender</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>By: Lind Global Partners II LLC, its general partner</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff Easton</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Member</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>SCHEDULE I<BR>
</U>to<BR>
<U>COPYRIGHT SECURITY AGREEMENT </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>COPYRIGHT REGISTRATIONS AND COPYRIGHT APPLICATIONS</U></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD COLSPAN="7" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Part I</U></FONT></TD></TR>
  <TR>
    <TD COLSPAN="7" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD COLSPAN="7" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Copyrights Registered with U.S. Copyright Office</U></FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Copyright
    </FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Author(s)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Part II</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Copyrights Not Registered</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 49%">Title</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 49%">Author(s)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>13
<FILENAME>ea174178ex10-11_abvcbio.htm
<DESCRIPTION>STOCK PLEDGE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>STOCK PLEDGE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This <B>PLEDGE AGREEMENT</B>
(this &ldquo;<U>Agreement</U>&rdquo;) is made as of February 23, 2023, by and between <B>ABVC Biopharma, Inc.</B>, a Nevada corporation
(the &ldquo;<U>Company</U>&rdquo;), and <B>LIND GLOBAL FUND II LP</B> (the &ldquo;<U>Secured Party</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
and the Secured Party are parties to that certain Security Agreement dated as of the date hereof (as amended and in effect from time to
time, the &ldquo;<U>Security Agreement</U>&rdquo;), pursuant to which the Company has granted to the Secured Party a security interest in
substantially all of its assets to secure (i) its obligations under that certain convertible promissory note (the &ldquo;<U>Note&rdquo;)</U>,
issued to the Secured Party pursuant to the terms of that certain Securities Purchase Agreement, dated as of February 23, 2023 (the &ldquo;<U>SPA</U>&rdquo;),
between the Company and the Secured Party, and (ii) its obligations under each related Transaction Document; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
is the direct legal and beneficial owner of one hundred percent (100%) of the issued and outstanding shares of each class of the capital
stock of <B>AMERICAN BRIVISION CORPORATION</B>, a Delaware corporation (&ldquo;<U>American BriVision</U>&rdquo;), <B>BIOKEY, INC.</B>,
a California corporation (&ldquo;<U>BioKey</U>&rdquo;), <B>BIOLITE HOLDINGS, INC.</B>, a Nevada corporation (&ldquo;<U>BioLite</U>&rdquo;),
and seventy-three percent (73%) of the issued and outstanding shares of each class of the capital stock of <B>BIOLITE BVI, INC.</B>, a
British Virgin Islands corporation (&ldquo;<U>BioLite BVI</U>&rdquo; and, collectively with American BriVision, BioKey and BioLite, the
&ldquo;<U>Subsidiaries</U>&rdquo; and each, a &ldquo;<U>Subsidiary</U>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, it is a condition
precedent to the Secured Party agreeing to make loans or otherwise extend credit to the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Company under the SPA and the Note that the Company
execute and deliver to the Secured Party a pledge agreement in substantially the form hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1. <U>Pledge.</U> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>1.1. <U>Pledge
of Securities</U>. </B> (a) The Company hereby ratifies and affirms the grant of security interests made pursuant to the Security
Agreement, and (b) in addition, the Company hereby pledges, assigns, grants a security interest in, and delivers to the Secured
Party, all of the shares of capital stock or other units of equity ownership of every class of each Subsidiary now owned or
hereafter acquired by the Company, as more fully described on <U>Annex</U>&nbsp;<U>A </U>hereto, hereto, including without
limitation, (i) all payments or distributions, whether in cash, property or otherwise, at any time owing or payable to the Company
on account of its interest as a shareholder in a Subsidiary, (ii) all of the Company&rsquo;s rights and interest under the
organizational documents of a Subsidiary, including all voting and management rights and rights to grant or withhold consents or
approvals; (iii) all rights of access and inspection to and use of all books and records, including computer software and computer
software programs, of each Subsidiary, (iv) all other rights, interests, property or claims to which the Company may be entitled in
its capacity as a stockholder of a Subsidiary, and (v) all proceeds, income from, increases in and products of any of the foregoing.
The certificates for such shares, accompanied by stock powers or other appropriate instruments of assignment thereof duly executed
in blank by the Company, have been delivered to the Secured Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>1.2. <U>Additional
Securities</U>.</B> Each Subsidiary agrees that it shall not authorize or issue any additional shares of capital stock or other interests
of such Subsidiary after the date hereof without the prior written consent of the Secured Party, and the Company agrees it will not permit
any Subsidiary to authorize or issue any additional shares of capital stock equity interests after the date hereof without the prior
written consent of the Secured Party. In case the Company shall acquire any additional shares of capital stock or other equity interests
of any Subsidiary or any corporation or other entity which is the successor of a Subsidiary, or any securities exchangeable for or convertible
into shares of capital stock or such other equity interests of any class of a Subsidiary, whether by purchase, dividend, split or otherwise,
or any other Person which becomes a subsidiary, then such shares or other securities shall be subject to the pledge, assignment and security
interest granted to the Secured Party under this Agreement and the Company shall deliver to the Secured Party forthwith any certificates
therefor, accompanied by stock powers or other appropriate instruments of assignment duly executed by the Company in blank. The Company
agrees that the Secured Party may from time to time attach as <U>Annex</U>&nbsp;<U>A</U> hereto an updated list of the shares of capital
stock or securities at the time pledged with the Secured Party hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>1.3. <U>Pledge
of any account into which cash collateral is held</U>. </B>The Company also hereby pledges, assigns, grants a security interest in,
and delivers to the Secured Party, any account into which any Cash Collateral is deposited and all of the Cash Collateral as such
terms are hereinafter defined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2. <U>Definitions</U>. </B>The
term &ldquo;<U>Obligations</U>&rdquo; and all other capitalized terms used herein without definition shall have the respective
meanings provided therefor in the Security Agreement. Terms used herein and not defined in the Security Agreement or otherwise
defined herein that are defined in the Uniform Commercial Code of the State of Nevada (the &ldquo;<U>NV UCC</U>&rdquo;) have such
defined meanings herein (with terms used in Article 9 controlling over terms used in another Article), unless the context otherwise
indicated or requires, and the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Cash Collateral</U>. See
&sect;4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Event of Default</U>. Means
the occurrence of any of the following: (a) an Event of Default as defined in the SPA, (b) an Event of Default as defined in the Note,
(c) an Event of Default as defined in the Security Agreement, or (d) any other default under any other Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Securities</U>. Includes
the shares of stock, membership interests and other equity interests described in <U>Annex</U>&nbsp;<U>A</U> attached hereto and any additional
shares of stock, membership interests or other equity interests at the time pledged with the Lender hereunder and the interests described
in clauses (b)(i) through (v) of &sect;1.1 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Securities Act</U>. See
&sect;7.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Securities Collateral</U>.
The property at any time pledged to the Secured Party hereunder (whether described herein or not) and all income therefrom, increases
therein and proceeds thereof, including, without limitation, that which is included in Cash Collateral. The term does not include any
income, increases or proceeds received by the Company to the extent expressly permitted by &sect;6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Transaction Documents</U>.
The SPA, the Note, the Security Agreement, the Guaranty and the other &ldquo;Transaction Documents&rdquo; as defined in the SPA, provided,
however, for purposes of this Agreement, upon the indefeasible repayment in full, in cash, of the Note and all obligations owing thereunder,
such term shall thereafter not include the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3. <U>Security for
Obligations</U>. </B>This Agreement and the security interest in and pledge of the Securities Collateral hereunder are made with and
granted to the Secured Party as security for the payment and performance in full of all the Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4. <U>Liquidation,
Recapitalization, etc</U>. </B>Any sums or other property paid or distributed upon or with respect to any of the Securities, whether
by dividend or redemption or upon the liquidation or dissolution of the issuer thereof or otherwise, shall, except to the limited
extent provided in &sect;6, be paid over and delivered to the Secured Party to be held by the Secured Party as security for the
payment and performance in full of all of the Obligations. To the extent any such property paid or distributed pursuant to the
immediately preceding sentence is in the form of money, the Secured Party shall have the right (but not the obligation) to deposit
such money in a deposit account with a depository satisfactory to the Secured Party and any such funds may be invested in such items
as the Secured Party may elect, and the Secured Party shall have a perfected security interest in all such sums or other property so
paid or distributed and all proceeds thereof (and any interest earned shall continue to be held by the Secured Party as security for
the payment and performance in full of all of the Obligations). Any money so received by the Secured Party pursuant to this &sect;4,
any account into which it shall be deposited and all proceeds thereof shall be referred to herein as the &ldquo;<U>Cash
Collateral</U>&rdquo;. In case, pursuant to the recapitalization or reclassification of the capital of the issuer thereof or
pursuant to the reorganization thereof, any distribution of capital shall be made on or in respect of any of the Securities or any
property shall be distributed upon or with respect to any of the Securities, the property so distributed shall be delivered to the
Secured Party, to be held by it as security for the Obligations. Except to the limited extent provided in &sect;6, all sums of money
and property paid or distributed in respect of the Securities, whether as a dividend or upon such a liquidation, dissolution,
recapitalization or reclassification or otherwise, that are received by the Company shall, until paid or delivered to the Secured
Party, be held in trust for the Secured Party as security for the payment and performance in full of all of the Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5. <U>Warranty of Title;
Authority</U>.</B> The Company hereby represents and warrants that: (a) the Company has good and marketable title to, and is the sole
record and beneficial owner of, the Securities described in &sect;1, subject to no pledges, liens, security interests, charges, options,
restrictions or other encumbrances except the pledge and security interest created by the Security Agreement and this Agreement and Permitted
Liens, (b) all of the Securities described in &sect;1 is validly issued, fully paid and non-assessable, (c) the Company has full power,
authority and legal right to execute, deliver and perform its obligations under this Agreement and to pledge and grant a security interest
in all of the Securities Collateral pursuant to this Agreement, and the execution, delivery and performance hereof and the pledge of
and granting of a security interest in the Securities Collateral hereunder have been duly authorized by all necessary corporate or other
action and do not contravene any law, rule or regulation or any provision of the Company&rsquo;s or each Subsidiary&rsquo;s charter documents
or by-laws or of any judgment, decree or order of any tribunal or of any agreement or instrument to which the Company or each Subsidiary
is a party or by which it or any of its property is bound or affected or constitute a default thereunder, and (d) the information set
forth in <U>Annex</U>&nbsp;<U>A</U> hereto relating to the Securities is true, correct and complete in all respects. The Company covenants
that it will defend the rights of the Secured Party and security interest of the Secured Party in such Securities against the claims
and demands of all other Persons whomsoever. The Company further covenants that it will have the like title to and right to pledge and
grant a security interest in the Securities Collateral hereafter pledged or in which a security interest is granted to the Secured Party
hereunder and will likewise defend the rights, pledge and security interest thereof and therein of the Secured Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6. <U>Dividends,
Voting, etc., Prior to Maturity</U>. </B>So long as no Event of Default shall have occurred and be continuing, the Company shall be
entitled to receive and retain all cash dividends paid in respect of the Securities, to vote the Securities and to give consents,
waivers and ratifications in respect of the Securities; <U>provided</U>, <U>however</U>, that no vote shall be cast or consent,
waiver or ratification given by the Company if the effect thereof would in the judgment of the Secured Party impair any of the
Securities Collateral or be inconsistent with or result in any violation of any of the provisions of the SPA, the Note, the Security
Agreement or the other Transaction Documents. All such rights of the Company to receive cash dividends shall cease in case an Event
of Default shall have occurred and be continuing. All such rights of the Company to vote and give consents, waivers and
ratifications with respect to the Securities shall, at the Secured Party&rsquo;s option, as evidenced by the Secured Party&rsquo;s
notifying the Company of such election, cease in case an Event of Default shall have occurred and be continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7. <U>Remedies</U>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>7.1. <U>In
General</U>. </B>If an Event of Default shall have occurred and be continuing, the Secured Party shall thereafter have the following
rights and remedies (to the extent permitted by applicable law) in addition to the rights and remedies of a secured party under the
NV UCC, all such rights and remedies being cumulative, not exclusive, and enforceable alternatively, successively or concurrently,
at such time or times as the Secured Party deems expedient:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(a)   &nbsp;if
the Secured Party so elects and gives written notice of such election to the Company, the Secured Party may vote any or all shares of
the Securities (whether or not the same shall have been transferred into its name or the name of its nominee or nominees) for any lawful
purpose, including, without limitation, if the Secured Party so elects, for the liquidation of the assets of the issuer thereof, and give
all consents, waivers and ratifications in respect of the Securities and otherwise act with respect thereto as though it were the outright
owner thereof (the Company hereby irrevocably constituting and appointing the Secured Party the proxy and attorney-in-fact of the Company,
with full power of substitution, to do so);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(b)   &nbsp;the
Secured Party may demand, sue for, collect or make any compromise or settlement the Secured Party deems suitable in respect of any Securities
Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(c)   &nbsp;the
Secured Party may sell, resell, assign and deliver, or otherwise dispose of any or all of the Securities Collateral, for cash or credit
or both and upon such terms at such place or places, at such time or times and to such Persons as the Secured Party thinks expedient,
all without demand for performance by the Company or any notice or advertisement whatsoever except as expressly provided herein or as
may otherwise be required by law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(d)   &nbsp;the
Secured Party may cause all or any part of the Securities held by it to be transferred into its name or the name of its nominee or nominees;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(e)   &nbsp;the
Secured Party may set off or otherwise apply or credit against the Obligations any and all sums deposited with it or held by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>7.2. <U>Sale
of Securities Collateral</U>. </B>In the event of any sale or other disposition of the Securities Collateral as provided in clause
(c) of &sect;7.1 and to the extent that any notice thereof is required to be given by law, the Secured Party shall give to the
Company at least ten (10) Business Days&rsquo; prior notice of the time and place of any public sale or other disposition of the
Securities Collateral or of the time after which any private sale or any other intended disposition is to be made. The Company
hereby acknowledges that ten (10) Business Days&rsquo; prior notice of such sale or other disposition or sales or other dispositions
shall be reasonable notice. The Secured Party may enforce its rights hereunder without any other notice and without compliance with
any other condition precedent now or hereunder imposed by statute, rule of law or otherwise (all of which are hereby expressly
waived by the Company, to the fullest extent permitted by law). The Secured Party may buy or otherwise acquire any part or all of
the Securities Collateral at any public sale or other disposition and if any part or all of the Securities Collateral is of a type
customarily sold or otherwise disposed of in a recognized market or is of the type which is the subject of widely-distributed
standard price quotations, the Secured Party may buy or otherwise acquire at private sale or other disposition and may make payments
thereof by any means. The Secured Party may apply the cash proceeds actually received from any sale or other disposition to the
reasonable expenses of retaking, holding, preparing for sale, selling and the like, to reasonable attorneys&rsquo; fees, travel and
all other expenses which may be incurred by the Secured Party in attempting to collect the Obligations or to enforce this Agreement
or in the prosecution or defense of any action or proceeding related to the subject matter of this Agreement, and then to the
Obligations pursuant to the terms of the Transaction Documents. Only after such applications, and after payment by the Secured Party
of any amount required by &sect;9-608(a)(1)(C) or &sect;9-615(a)(3) of the NV UCC, need the Secured Party account to the Company for
any surplus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>7.3. <U>Private
Sales</U>.</B> The Company recognizes that the Secured Party may be unable to effect a public sale or other disposition of the Securities
by reason of certain prohibitions contained in the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), federal
banking laws, and other applicable laws, but may be compelled to resort to one or more private sales thereof to a restricted group of
purchasers. The Company agrees that any such private sales may be at prices and other terms less favorable to the seller than if sold
at public sales and that such private sales shall not by reason thereof be deemed not to have been made in a commercially reasonable
manner. The Secured Party shall be under no obligation to delay a sale of any of the Securities for the period of time necessary to permit
the issuer of such securities to register such securities for public sale under the Securities Act, or such other federal banking or
other applicable laws, even if the issuer would agree to do so. Subject to the foregoing, the Secured Party agrees that any sale of the
Securities shall be made in a commercially reasonable manner, and the Company agrees to use its best efforts to cause the issuer or issuers
of the Securities contemplated to be sold, to execute and deliver, and cause the directors and officers of such issuer to execute and
deliver, all at the Company&rsquo;s expense, all such instruments and documents, and to do or cause to be done all such other acts and
things as may be necessary or, in the reasonable opinion of the Secured Party, advisable to exempt such Securities from registration
under the provisions of the Securities Act, and to make all amendments to such instruments and documents which, in the opinion of the
Secured Party, are necessary or advisable, all in conformity with the requirements of the Securities Act and the rules and regulations
of the Securities and Exchange Commission applicable thereto. The Company further agrees to use its best efforts to cause such issuer
or issuers to comply with the provisions of the securities or &ldquo;Blue Sky&rdquo; laws of any jurisdiction which the Secured Party
shall designate and, if required, to cause such issuer or issuers to make available to its security holders, as soon as practicable,
an earnings statement (which need not be audited) which will satisfy the provisions of Section 11(a) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>7.4. <U>Company&rsquo;s
Agreements, etc</U>.</B> The Company further agrees to do or cause to be done all such other acts and things as may be reasonably necessary
to make any sales of any portion or all of the Securities pursuant to this &sect;7 valid and binding and in compliance with any and all
applicable laws (including, without limitation, the Securities Act, the Securities Exchange Act of 1934, as amended, the rules and regulations
of the Securities and Exchange Commission applicable thereto and all applicable state securities or &ldquo;Blue Sky&rdquo; laws), regulations,
orders, writs, injunctions, decrees or awards of any and all courts, arbitrators or governmental instrumentalities, domestic or foreign,
having jurisdiction over any such sale or sales, all at the Company&rsquo;s expense. The Company further agrees that a breach of any
of the covenants contained in this &sect;7 will cause irreparable injury to the Secured Party, that the Secured Party has no adequate
remedy at law in respect of such breach and, as a consequence, agrees that each and every covenant contained in this &sect;7 shall be
specifically enforceable against the Company by the Secured Party and the Company hereby waives and agrees not to assert any defenses
against an action for specific performance of such covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8. <U>Marshalling</U>.
</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>The Secured Party shall not be required to
marshal any present or future collateral security for (including but not limited to this Agreement and the Securities Collateral), or
other assurances of payment of, the Obligations or any of them, or to resort to such collateral security or other assurances of payment
in any particular order. All of the Secured Party&rsquo;s rights hereunder and in respect of such collateral security and other assurances
of payment shall be cumulative and in addition to all other rights, however existing or arising. To the extent that it lawfully may,
the Company hereby agrees that it will not invoke any law relating to the marshalling of collateral that might cause delay in or impede
the enforcement of the Secured Party&rsquo;s rights under this Agreement or under any other instrument evidencing any of the Obligations
or under which any of the Obligations is outstanding or by which any of the Obligations is secured or payment thereof is otherwise assured,
and to the extent that it lawfully may the Company hereby irrevocably waives the benefits of all such laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9. <U>Company&rsquo;s
Obligations Not Affected</U>.</B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>The obligations
of the Company hereunder shall remain in full force and effect without regard to, and shall not be impaired by (a) any exercise or nonexercise,
or any waiver, by the Secured Party of any right, remedy, power or privilege under or in respect of any of the Obligations or any security
thereof (including this Agreement); (b) any amendment to or modification of the Transactions Documents or any of the Obligations; (c)
any amendment to or modification of any instrument (other than this Agreement) securing any of the Obligations, including, without limitation,
the Security Agreement and the other Transaction Documents; or (d) the taking of additional security for, or any other assurances of
payment of, any of the Obligations or the release or discharge or termination of any security or other assurances of payment or performance
for any of the Obligations; whether or not the Company shall have notice or knowledge of any of the foregoing, the Company hereby generally
waiving all suretyship defenses to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10. <U>Transfer, etc.,
by Company</U>.</B> Without the prior written consent of the Secured Party, the Company will not sell, assign, transfer or otherwise dispose
of, grant any option with respect to, or pledge or grant any security interest in or otherwise encumber or restrict any of the Securities
Collateral or any interest therein, except for the pledge thereof and security interest therein provided for in this Agreement and any
Permitted Liens so long as the holder of such lien has not taken any action to foreclose or otherwise realize on the Securities Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11. <U>Further Assurances</U>.
</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>The Company will do all such acts, and will
furnish to the Secured Party all such financing statements, certificates and other documents and will obtain all such governmental consents
and corporate approvals and will do or cause to be done all such other things as the Secured Party may reasonably request from time to
time in order to give full effect to this Agreement and to secure the rights of the Secured Party hereunder, all without any cost or
expense to the Secured Party. The Company hereby irrevocably authorizes the Secured Party at any time and from time to time to file in
any filing office which the Secured Party deems necessary in any Uniform Commercial Code jurisdiction any initial financing statements
and amendments thereto that (a) indicate the Collateral as the Securities Collateral or words of similar effect, or as being of equal
or lesser scope or in greater detail, and (b) contain any other information required by part 5 of Article 9 of the Uniform Commercial
Code of the jurisdiction of the filing office for the sufficiency or filing office acceptance of any financing statement or amendment,
including whether the Company is an organization, the type of organization and any organization identification number issued to the Company.
The Company agrees to furnish any such information to the Secured Party promptly upon request. The Company also ratifies its authorization
for the Secured Party to have filed in any Uniform Commercial Code jurisdiction any like initial financing statements or amendments thereto
if filed prior to the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12. <U>Secured
Party&rsquo;s Exoneration</U>. </B>Under no circumstances shall the Secured Party be deemed to assume any responsibility for
or obligation or duty with respect to any part or all of the Securities Collateral of any nature or kind or any matter or
proceedings arising out of or relating thereto, other than (a) to exercise reasonable care in the physical custody of the Securities
Collateral and (b) after an Event of Default shall have occurred and be continuing to act in a commercially reasonable manner. The
Secured Party shall not be required to take any action of any kind to collect, preserve or protect its or the Company&rsquo;s rights
in the Securities Collateral or against other parties thereto. The Secured Party&rsquo;s prior recourse to any part or all of the
Securities Collateral shall not constitute a condition of any demand, suit or proceeding for payment or collection of any of the
Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13. <U>No Waiver,
etc. </U> </B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT>Neither this Agreement nor any term
hereof may be changed, waived, discharged or terminated except by a written instrument expressly referring to this Agreement and to
the provisions so modified or limited, and executed by the Secured Party and the Company. No act, failure or delay by the Secured
Party shall constitute a waiver of its rights and remedies hereunder or otherwise. No single or partial waiver by the Secured Party
of any default or right or remedy that it may have shall operate as a waiver of any other default, right or remedy or of the same
default, right or remedy on a future occasion. The Company hereby waives presentment, notice of dishonor and protest of all
instruments, included in or evidencing any of the Obligations or the Securities Collateral, and any and all other notices and
demands whatsoever (except as expressly provided herein or in the Transaction Documents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14. <U>Notice, etc.</U></B>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT>All notices, requests and other communications
hereunder shall be made in the manner set forth in the SPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15. <U>Overdue
Amounts</U>. </B>Until paid, all amounts due and payable by the Company hereunder shall be a debt secured by the Securities
Collateral and shall bear, whether before or after judgment, interest at the rate of interest for overdue principal set forth in the
Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>16. <U>Governing Law;
Consent to Jurisdiction</U>. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">This
Agreement IS A contract UNDER the laws of the state of NEVADA and shall for all purposes be construed in accordance with and
governed by the laws of SAID state of NEW YORK. The Company and THE SECURED PARTY EACH agree that any suit for the enforcement of
this agreement or any other action brought by SUCH PERSON arising hereunder or in any way related to this agreement </FONT></B><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHALL
BE BROUGHT IN THE COURTS OF THE STATE OF NEW YORK IN THE BOROUGH OF MANHATTAN OR ANY FEDERAL COURT SITTING THEREIN AND CONSENTS TO
THE NONEXCLUSIVE JURISDICTION OF SUCH COURT AND SERVICE OF PROCESS IN ANY SUCH SUIT BEING MADE UPON SUCH PERSON BY MAIL AT THE
ADDRESS SPECIFIED ON THE SIGNATURE PAGE OF EACH PARTY HERETO. <FONT STYLE="text-transform: uppercase">the Company and the secured
party each hereby waives any objection that it may now or hereafter have to the venue of any suit BROUGHT IN the state of new york
or any court SITTING THEREIN or that A suit BROUGHT THEREIN is brought in an inconvenient court</FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>17. <U>Waiver of Jury
Trial</U>. THE COMPANY AND THE SECURED PARTY WAIVES ITS RIGHT TO A JURY TRIAL WITH RESPECT TO ANY ACTION OR CLAIM ARISING OUT OF ANY
DISPUTE IN CONNECTION WITH THIS AGREEMENT, ANY RIGHTS OR OBLIGATIONS HEREUNDER OR THE PERFORMANCE OR ENFORCEMENT OF ANY SUCH RIGHTS OR
OBLIGATIONS</B>. Except as prohibited by law, the Company waives any right which it may have to claim or recover in any litigation referred
to in the preceding sentence any special, exemplary, punitive or consequential damages or any damages other than, or in addition to,
actual damages. The Company (a) certifies that neither the Secured Party nor any representative, agent or attorney of the Secured Party
has represented, expressly or otherwise, that the Secured Party would not, in the event of litigation, seek to enforce the foregoing
waivers or other waivers contained in this Agreement and (b) acknowledges that, in entering into this Agreement and any other Transaction
Document to which the Secured Party is a party, the Secured Party is relying upon, among other things, the waivers and certifications
contained in this &sect;17<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>18. <U>Miscellaneous</U>.
</B>The headings of each section of this Agreement are for convenience only and shall not define or limit the provisions thereof. This
Agreement and all rights and obligations hereunder shall be binding upon the Company and its respective successors and assigns, and shall
inure to the benefit of the Secured Party and its respective successors and assigns. If any term of this Agreement shall be held to be
invalid, illegal or unenforceable, the validity of all other terms hereof shall be in no way affected thereby, and this Agreement shall
be construed and be enforceable as if such invalid, illegal or unenforceable term had not been included herein. The Company acknowledges
receipt of a copy of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF</B>, intending to be legally bound, the Company and the Secured Party have caused this Agreement to be executed as of
the date first above written</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3"><B>ABVC BIOPHARMA, INC.</B>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 31%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">44370 Old Warm Springs Blvd</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Fremont, CA 94538</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIND GLOBAL FUND II LP</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>By: Lind Global Partners II LLC, its general partner</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff Easton, Managing Member</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each undersigned Subsidiary
hereby joins in the above Agreement for the sole purpose of consenting to and being bound by the provisions of &sect;&sect;1.2, 4.1, 6
and 7 thereof, the undersigned hereby agreeing to cooperate fully and in good faith with the Secured Party and the Company in carrying
out such provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>AMERICAN BRIVISION CORPORATION</B>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44370 Old Warm
Springs Blvd. Fremont,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">CA 94538</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>BIOKEY, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44370 Old Warm Springs Blvd. Fremont, <BR>
CA 94538</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>BIOLITE HOLDING, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44370 Old Warm Springs Blvd. Fremont, <BR>
CA 94538</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>BIOLITE BVI, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44370 Old Warm Springs Blvd. Fremont, <BR>
CA 94538</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U STYLE="text-decoration: none">&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ANNEX&nbsp;A TO PLEDGE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the issuers has any
authorized, issued or outstanding shares of its equity interests of any class or any commitments to issue any shares of its equity interests
of any class or any securities convertible into or exchangeable for any shares of its equity interests of any class except as otherwise
stated in this <U>Annex</U>&nbsp;<U>A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Issuer</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Record <BR>Owner</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Class of <BR>Shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Percentage Ownership</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 27%; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 27%; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 27%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 2%; text-align: left"></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>










</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>14
<FILENAME>ea174178ex99-1_abvcbio.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABVC BioPharma Receives $3.175 Million Investment
from The Lind Partners to Continue Clinical Trials</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fremont, CA (February 23, 2023) &ndash; ABVC BioPharma,
Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology,
today announced it has closed a funding agreement for gross proceeds of $3.175 million (the &ldquo;Investment&rdquo;) with Lind Global Fund
II, LP, an investment fund managed by The Lind Partners (together &ldquo;Investor&rdquo; or &ldquo;Lind&rdquo;), a New York-based institutional
fund manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are pleased to have The Lind Partners
as an investor,&rdquo; said Howard Doong CEO of ABVC BioPharma. &ldquo;The proceeds from this investment will be primarily allocated to
continuing Phase II clinical trials for Vitargus, our medical device that helps the eye maintain a round shape and keeps the retina in
place during and after retinal re-attachment surgery and Phase II, Part 2 clinical trials for ABV-1505 our drug for the treatment of ADHD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are pleased to invest in ABVC to support
their vision and growth initiatives,&rdquo; said Phillip Valliere, Managing Director at The Lind Partners. &ldquo;We believe 2023 will be
an exciting year for ABVC as their drug pipeline meets expected key milestones.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Investment is in the form of a securities
purchase agreement (the &ldquo;<B>Purchase Agreement</B>&rdquo;) whereby the Investor has purchased from the Company and the Company has
issued and sold to the Investor (a) a $3.704 million senior convertible note that is convertible into shares of the Company&rsquo;s common
stock at an initial conversion price of $1.05 per share, subject to adjustment (the &ldquo;<B>Note</B>&rdquo;) and (b) a common stock purchase
warrant (the &ldquo;<B>Warrant</B>&rdquo;) which entitles the holder to acquire up to 5,291,667 shares of common stock of the Company at
an initial exercise price of $1.05 per share, subject to adjustment (each, a &ldquo;<B>Warrant Share</B>&rdquo;). Gross proceeds to the
Company from the sale of the Note were $3,175,000 after deducting the original issue discount to the investor but before fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Note does not carry any
interest. Beginning with the date that is six months from the issuance date of the Note and on each one (1) month anniversary thereafter,
the Company shall pay Lind an amount equal to $308,680.58, until the outstanding principal amount of the Note has been paid in full prior
to or on the Maturity Date or, if earlier, upon acceleration, conversion or redemption of the Note in accordance with the terms thereof
(the &ldquo;Monthly Payments&rdquo;). At the Company&rsquo;s discretion, the Monthly Payments shall be made in (i) cash, (ii) shares of
the Company&rsquo;s common stock, or (iii) a combination of cash and Shares; if made in shares, the number of shares shall be determined
by dividing (x) the principal amount being paid in shares by (y) 90% of the average of the 5 lowest daily VWAPs during the 20 trading
days prior to the applicable payment date. The Notes sets forth certain conditions that must be satisfied before the Company may make
any Monthly Payments in shares of common stock. If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash
premium of 5% of such Monthly Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities being offered and sold pursuant
to the Purchase Agreement have not been registered under the United States Securities Act of 1933, as amended (the &ldquo;U.S. Securities
Act&rdquo;) and are being offered and sold pursuant to an exemption from the registration requirements of the U.S. Securities Act provided
by Rule 506(b) of Regulation D and applicable U.S. state securities laws, and such securities will be issued as &ldquo;restricted securities&rdquo;
as such term is defined in Rule 144(a)(3) under the U.S. Securities Act. This Press Release is not an offer to sell or the solicitation
of an offer to buy the securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer
to buy nor shall there be any sales of the Company&rsquo;s securities in any state in which such offer, solicitation or sale would be
unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About The Lind Partners</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Lind Partners manages institutional funds
that are leaders in providing growth capital to small- and mid-cap companies publicly traded in the US, Canada, Australia and the UK.
Lind&rsquo;s funds make direct investments ranging from US$1 to US$30 million, invest in syndicated equity offerings and selectively buy on
market. Having completed more than 150 direct investments totaling over US$1.5 Billion in transaction value, Lind&rsquo;s funds have been flexible
and supportive capital partners to investee companies since 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ABVC BioPharma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC BioPharma is a clinical-stage biopharmaceutical
company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is
focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at
world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center).
For Vitargus, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements.&rdquo; Such statements may be preceded by the words &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;plans,&rdquo;
&ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo; &ldquo;estimates,&rdquo; &ldquo;aims,&rdquo;
&ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;potential,&rdquo; or similar words. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of
which are beyond the Company&rsquo;s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration
with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of
our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed
to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking statements is set forth in the Company&rsquo;s filings with the Securities
and Exchange Commission (SEC), including the Company&rsquo;s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors
are urged to read these documents free of charge on the SEC&rsquo;s website at&nbsp;<B>http://www.sec.gov</B>. The Company assumes no
obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leeds Chow, CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: leedschow@ambrivis.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.75pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-top: Black 0.75pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>abvc-20230224.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWaSLyaPtyJ1xOYkxuG98fZk67ysuMyWdSCyleiLGId4F -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:ABVC="http://abvcpharma.com/20230224" elementFormDefault="qualified" targetNamespace="http://abvcpharma.com/20230224">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://abvcpharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="abvc-20230224_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abvc-20230224_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>abvc-20230224_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>abvc-20230224_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abvcpharma.com/role/Cover" xlink:href="abvc-20230224.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abvcpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140511889210080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 24,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">333-91436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0014658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44370 Old Warm Springs Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">668-0881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ea174178-8k_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abvc-20230224.xsd" xlink:type="simple"/>
    <context id="From2023-02-24to2023-02-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-02-24</startDate>
            <endDate>2023-02-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-02-24to2023-02-24">0001173313</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-02-24to2023-02-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-02-24to2023-02-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-02-24to2023-02-24">2023-02-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-02-24to2023-02-24">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-02-24to2023-02-24">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-02-24to2023-02-24">333-91436</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-02-24to2023-02-24">26-0014658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-02-24to2023-02-24">44370 Old Warm Springs Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-02-24to2023-02-24">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-02-24to2023-02-24">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-02-24to2023-02-24">94538</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-02-24to2023-02-24">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-02-24to2023-02-24">668-0881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-02-24to2023-02-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-02-24to2023-02-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-02-24to2023-02-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-02-24to2023-02-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-02-24to2023-02-24">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-02-24to2023-02-24">ABVC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-02-24to2023-02-24">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-02-24to2023-02-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>20
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG1L9O9Z1G"FR84G!R8_>!315DL/GZC53*/;!1@"W["?%8EM^\_=T(1N+KT7
M+I4PDMKP?=R</S)&;MZB-<M6_.C:K47H?C3_-/H=8ZJ=WC_)Z6]2KE8V2[^!
M@EE;!\E9UCRV_W-/X![L*>W^_([9-VJ2\"4(>1>7X-IJM^7=G1B9E]O,A32P
M:2T/UYS!7+ /P/VEE.;CQ.Y<JW\\#/\%4$L#!!0    ( ,F#6%:?H!OPL0(
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( ,F#6%8'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ R8-85EGT
MC%7N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ R8-85IE<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #)@UA6ZN,Z%E $  "$
M$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ R8-85I^@&_"Q @  X@P   T              ( !DPP
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #)@UA6EXJ[',     3 @  "P
M            @ %O#P  7W)E;',O+G)E;'-02P$"% ,4    " #)@UA6JL0B
M%C,!   B @  #P              @ %8$   >&PO=V]R:V)O;VLN>&UL4$L!
M A0#%     @ R8-85B0>FZ*M    ^ $  !H              ( !N!$  'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ R8-85F60>9(9
M 0  SP,  !,              ( !G1(  %M#;VYT96YT7U1Y<&5S72YX;6Q0
52P4&      D "0 ^ @  YQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea174178-8k_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abvcpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea174178-8k_abvcbio.htm">ea174178-8k_abvcbio.htm</File>
    <File>abvc-20230224.xsd</File>
    <File>abvc-20230224_lab.xml</File>
    <File>abvc-20230224_pre.xml</File>
    <File>ea174178ex10-10_abvcbio.htm</File>
    <File>ea174178ex10-11_abvcbio.htm</File>
    <File>ea174178ex10-1_abvcbio.htm</File>
    <File>ea174178ex10-2_abvcbio.htm</File>
    <File>ea174178ex10-3_abvcbio.htm</File>
    <File>ea174178ex10-4_abvcbio.htm</File>
    <File>ea174178ex10-5_abvcbio.htm</File>
    <File>ea174178ex10-6_abvcbio.htm</File>
    <File>ea174178ex10-7_abvcbio.htm</File>
    <File>ea174178ex10-8_abvcbio.htm</File>
    <File>ea174178ex10-9_abvcbio.htm</File>
    <File>ea174178ex4-1_abvcbio.htm</File>
    <File>ea174178ex99-1_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>25
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea174178-8k_abvcbio.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea174178-8k_abvcbio.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20230224_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20230224_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abvc-20230224.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ABVC",
   "nsuri": "http://abvcpharma.com/20230224",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea174178-8k_abvcbio.htm",
      "contextRef": "From2023-02-24to2023-02-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://abvcpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea174178-8k_abvcbio.htm",
      "contextRef": "From2023-02-24to2023-02-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0001213900-23-014358-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-014358-xbrl.zip
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M._&" 1(C9/K2X"H:>J2GB^(19NJ&B]$U[J&0ZE3&(:*D1[!O 85$'RO3:#)
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M8(*(V*94FW5MGNR\OA0T #AK*(&F46[O?Z><?Q9R(4:4:"EH4ESJA^[P>XM
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M%B=[FYSD;3#)9XQ45<)>+^F^O7O+@*MA!O#_E@4TG#:!."XUVY;.)J=L>JN
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M4CF%QC7AACK))1$XYOPZ+GD$> ZTR^A=064@IH"?(_"- ZNEP$($%@*+R)$
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M[(S_'.\\\&\WBGDFR?'_4$L#!!0    ( ,F#6%8>7F%*00\  "U@   ;
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M?DRQN["(,190JI! /H[3,2I#BL"=(DA/AM(%4^.A@6E,O]QO@9H8=R_9FAV
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M,).>.M1>CHV7NSSIQIK,:#-Q0),Q&0B@%#F,"H<>MEB/:TR3\-R'D]8%6 C
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MD0]S+F<7_[E_.J) _TW _P%02P,$%     @ R8-85OMLO@FS+@  9_8  !L
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M7G0[->;A$LPZ!8L0EW"02>3BQL-9"Z=XFGCC\<3)QK?V@QB%C >ZG6HM<\Z
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MMZA<JIZUGHL;SN@=1-224TFZPV#L5_+&8:E4^K# %+L<?4HS.>8!F1+&Z60
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M8-Q) 8]P25;(I V+:3 9O 5A4EI43OV*DRX#RKP9YNY^+J8,4O;)M')W1-C
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M;,=5HA\;57:5S;%"QZ_)O$>UMWTSSK--J+4UX%M4M>6_OJI=&^2MK&[[_Z#
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M!<M[%F;IIY$D;.F9(A;Z/5L'VJ)&S/P]Q$.J)2%.85&GX4Q(DJ)"_+OV^QM
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MMBIK8X2CZ-R/\(YKMO:KY*D.-WDJR5,=;O)47^U.5E*L2F?) XD#1H\N9=_
MH%I2WSH4Z03I="PGE:+=.%<U'1<,AL1(&=_&TRE)I,8@UM$XS>'&'($*N@)I
M3(A61SN'J(TVU?[^FOX]"GXSHUTS2CB;SW2 #M?;8 HFL9T49W%39Y_ S-AZ
ML;N-S/"USD91TR:,<L*4MZ!GK>9P!I'&$0"L3$PE(@\ZU!4\48@1*S@,P4-T
MJ8M[KFQQC^$LTX4E&/8 L^EWQ>CLUQ5Q+1'W2I.C%'148J:#?@\3#A4''0D=
MJO(]5R%**$_ND9$S2C$X#+^0$BSJKQ:5LZR0["FF,.HT#^MML"R/PAJ<%B!J
M.&9.&W&=(T?S;5I$Y2X8[=X%UUMWSQ[V=UW#WLDQ*OQ/5\[R=4@(WU#XIXLS
M?1V36([2% VOST6#OECW^:,6VR!3KYV@[VPRI14!BVPB:^6&PP\,[3!_+DR3
M$@Z:JVS3/*_9*T<%=L.?4O]+ @#0E>;"[37K5XA)?,I,CM-A8W,3I6';>99G
MQ4>O&CC:LE!<2U6@T@W;-DO0*EF/_<R GQ3 ,Q,3XL%4FI+.1X,&UZA*1VEV
MEZJJ=[76_U[5N(' =M'M6O[<A=S[0LM(ST7P6 (&5Z)*XA$3)G9AW$UA4"6-
M8JWE"GJ3=AXFV >(D=4$9KAC"(-472,4@F$<8JQ,YA@WPY,[IF0BW0W7B7)%
ML#J-8+9PF1=P%S#U\?JLV1^^:,I@'J;<;ABU$2)>,$TG:\2&OD4W@$V+U'ZJ
M7-ZU<5U!(M W-D.OB:,F?O=91/K!F-#@)^B-3\U@Q =&)6"\XEK 9. +CH,&
ME=M_^D[Y\F)Z*&):$TR@TZ0*YG&];"&]UJ%,E"*)W2IEL*4'PV3U>5-9[A@I
MJQ?81BB&D3[&, MHU<!2@W:#$PCN*6'+T"+B/L;$R3Y)[LJ*_1]F9\>"?QH1
M Z9H2]I18:T_D3Q,LJINGO:V_^ %_'.VR3<_4/579:&IC:/=\R;=%E3[.#X$
MM#7/8#F>P;,^IHW_HZW!]<_,?R+'/T=0,GF^\/NL,34VQ?@9'$VY9HSN>3:<
M,_N_;64>FP;RQACP-C%^EY=H]]TF=[AQ$\<S2%[T#H;(4.W8N"=#::6E.M]]
M";[(4) 8\5;'NMN!@D8@.1)\J6B"&!?AT>M(2$3$W36KN^AGGD)DS$@3[(*
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M\2?Z+2C41V6LKG 0_@XG,/9WOGUWCD0R[YRT6T3;%Z:9VD 5Z3.F!MS:^_;
MDF:WB+*]XD(B:PEH6GST<(XI,XN0N'1S0F$B25M8 6.K$_ESK! GX;4(G6M&
MLE$=3SS/SX/S?)46&9H Y[9%J&@/TSMB/N+"!.--.<U01A0%XFY%00]2@<!;
MQT'M'+2^5#]2'VL?%MNV;VI.H-49-;T!&?\V I]^ B\##_%I@01?Z9B3:/![
MP\SF/74G^C KF0'G?087C'6IF$=7H+=>UW$;LCQI<B:,$NJO..*8%&<T->,3
M5B#+$<YJYF PUAD)N 3I.ON]@$:'6[=[[Q;2A#$DW/9P,XQG#%L(6V<Y4GWO
M"'?RYO=[UH_^&D[DUQ0B>_) GQ@W.^B*FUV>7%R>7)V<70^N3\_/KBA2)E&R
MTY,K$T0[.O_Y8G#VFW'$K14V8^:'&9(>&H=)-4$+3"F*\L"98-)!"R=2QF+2
M2.Y>^P7'E,/'/H,S^CKK,!:.LQK=0W33&+$A-J#NOA",ACE K"<BS2;9?AAS
MLQKGHBVZ@<%M@0L6C-<SE\-X06NXVITQJ3]K[=@)%IFG9IDJ[XCS;Y[*!%<5
M]B!>'U+/94="]OV>O_$__'"NL\4X;?\%<BN;P&(Y%::W>%93S,_548WGY/O2
M762GW,$=QO"I51XFLVJ%("'C>'&Q\:/=/E1+"7^<I7?).*&;F>0A%?G4X"S9
MIX/%5-Y+X,/47S[8?IQP[%P'<Z-&1[!7",>+7P]M*6R":(![.2BX@^>8$&Z]
M.+WJ7WE^^!B,R\@A2[CLL_6N6UC(%GP&SZ S3#-4.S[)W^=55H\S"E50+CRE
MH(C^V.>;AE?EME,$O'+O_& L0HG8R 3;P=J71#<O0\K3CVG-1N)?]09 A ;6
M0B75@Q4\'3V-)4&?$^EF2<9$J6:J1"'4GAGN((XX#'(L%C9?_@*FZ1<[PBLD
M-U]MDIN2W'RUULG-KW@7/ZZ(]D-%-)"J6Q([;Z*3 I:'/:8W)(,U"=HY^28,
M3A6T>:BGGJ@V"& JT&^'16V7QUK"?I=?6Q1JM_X79W-BZ\JE%65[4%IK_TWI
MQ$=K<W$,)J83%N,*2HWSB8%YJ+U GJ_N,+R-J'>.)(3OFC>WU<)A*D(QB+1F
MQ;T4+FTY;YC=0K0/+V&=5G>))C-=M4T0.=M"!IT5/+J8M0U3/:!&UR:+JOWV
M7])4E/=[;\ND(H:-XPSMRU+"M44)#ZH8MH9$#TP^E>A=S1W5;:VR[SKB=FC?
MFC]7E,&U>*2P0O0L;E@9U"?@-RE.)Z]Q]R(NF05; ^';_>UEQ[Z4< JS!H\-
M_9H)8S-6\(O#$V!,\ $GGT 'IJV]541A[R3X.JN,]XXL&K3'C5U"9APW0#*W
MIMZ9IDK<D*; 6PCIBHE,"C^ XYI7[@H2A53S63/")2I ,=XAFA+SKQIG&2LB
M$7!:<A?[T+R.9.H2)SBC,#D-Q?1X\(&E@HDEG&HEH*.^ABTA.]$P2W-I.^8)
M_FR*HJ]=Q1R$*@:,!A <$UA:K3&L!(Q=%I(2@2RG#?W!9TM#P6(\EIFU!4,<
M_T*K& $6(QDPGX"2MO\\;YA^_RXK\T N+J2_P)R_]MO@5F\?L.-8C$@%7D;O
M8;'T33#'.W'TC.-TDN @I-<L!]O)*1&B:LDL(%51,A,8(D;X,4 *)A5>1K:_
MM'!OWWH[$J8'N,4-'?62(Y)"L4GY![RK(Z2*';\DEX[DJ7O5$:Y$;B<K9L)H
M^U1;_^7!),(@H-%FJ@":_6'J#,3D'*/ML',<N%8J5\\\L'5DV/#)\/!2U+P4
MT7-.5/,2IX97W([8Q# IU)K<FR$BW07O$D-VL8#K0HDX'F>_M\+;HB/W(!/D
MKLDJ[6I30*@F1#QHW6$)"^GD''K5 S@84V.])(@?2$;F5@Z98O=P&//IF"SN
M:<EDI4^8^ZA[ZGGF^SWL:P-:W3'=A.K<!*JM3B?H%,Z+Z\>,F\O&)BP:/S8+
MA% I[OTT>:8^LMV;C9K7':B""E=_8;<7E2IJ*I>%0LC\+0]5U8VDZ0,2&2^G
ML+68.:;;8@NY-Y>-2_V$;<(% &=!7F69"+157SQNV[#+QTU;]>F#7S1NE_/X
M!%/<. R>QR6,-_:B,UXCRGZO@TS8,.NJXUZ';2?1+%DGRV&%$,OK38A%0BRO
M-R&6KW,7/V[_'H;VKY @Z&B_3^;R9]?>['VQVIN]QY.(3-LILW>-\EX%![Q>
M?V'.&(UFBNO#YWN[N_$N__\"!"U!! R ,2]9-]A /7H:*7B!2"!WL(>DW?M8
MN7ZP'[]Z_C(^V'^]")=[GU:IYEA3B)PW N?$@]R^N>BOJIS?W#IX8@<NTS,:
M;Y/:/&U__R ^W-N+=)>NI6_>,0;J*5@H.G*X;#]^_?)U_&+_L'4[[*-@ZBL7
M%T*9?I&FK9=3EP-IR8-O?IF2@H37V-U[8?HQ@>N$:(0[XAU 4(%IIKP?/W_U
M,M[;-6/J]VC>=6O)9-$[XM,.7N_'>R]V.^8*WX4C7T(_8L)8QD!IG,=HC)X(
M]D/\?'^7P+E=FZ)U4WNW]FPIS()-9),U::^24E?L:DHLIVBT_&4?K>J_'*#[
M+,-H!V8IX&3'P>BIE_'N\^?Q\\5 \_9PE]A?K:> =42/V=N%%3N(#P[:NVCA
M<Q95T\E[!08B^+:*&3\8J VLTD@7QK@DL+6H][E08[:>L\BZ;#^'K&CW(&-^
MF@ @WS0F,OP'!I-RC+-XAKY=+3L;^YH@#IK]'@*6?\+QY5DJR?D1C!A;W@:X
MFR! TC#D )NM/:7'*FUGY?'-4#3-Z)A*<,RXLN3.F#"<_QV/%3TM,&SFTV%%
M;=K@MJZQ_ R##$W3BH!Z&WL%RE&<$(ZYH%C'!B F6']U<N0"S"?'/PXN07X/
M*6W1A6F _\ZRQ9.TT@@2\J2E5WP+:H+TT$W:RH!C5 I^Y<6=I&D9=QLQ:>C%
M0[!QIXVIH4V-H34U,!R!54!SI#UQ-'A$4R!@SC&E!P0E+G_4CAHI,$>V\#?8
M-O<Q<C[>87G.T743AWZ4^6];JE)L_.@>F4=X6(0-L8/$6RH:V0!+9]K*2AP^
M0\\F%3.*7MN-FB2%(H-"<<])$:6UY+:L]6.GQ.R#,I= [*B3HE2">@:F$31:
M&3O/BO8%DR^K0'C@HT=H!( HE=R'1)DD9_B@Q!L>DP4S8*T.F8&=Z,1_?XM&
M60Z\(4!W!_*&<<4"O,%Q>  3^(P"W_3'ZNB5R >O&"T,ZXW,"28+^\= =J(%
MB)WU$BD8;#[C=@N6QHY.8"&ZS=\P'(J5-I,NXNTZT].?[8.0$:36V\^F^I V
MDFI/Y357[>BHB/JD8IU6E)Z)J7[7C<#M"D?S^# PF4A\'#0VF0!D:3F5[[IA
M6:/*#0-_7R4CS+"/;#D-_$'C-P.L@WFJ72"\8[!NXK'9$'[*24C*=O ZT"QB
M!U:R, R\FT2$[6W=.1%:"JXTG9Z@XS@N3!<W-&JR9^,LGX>92M4]C/!=QCYL
MP':ZT;G@KN"JWTTE1+M+,Y5^3W9N],C&%=$N(A*#\>DHD^BG->1$1\UNX8E@
MBM*UED '>^D&)'^&Z)M?M]_#:[Q+UDV2C+<C"G%T0CCT\7/[RJ8IC63P5M(J
MO05>EM5U;J<RK:<I\GS@%)UIH6T.*:+J%:R Z?^MB2]H"'*.S/!<PI3R36.<
M"-V0SSA-L7+38EL&&Y,<X5;VEON('MAYVM9LWZP22]_;W033)9B^M[N)IG^]
M>WFY@Y9:!VU0VRC.DM"H%_ ".S\9H4IW-M%3&E-88<HQK!?QB[T7\=[AJX5Q
MOJU2"U:/HX.*S%SK0BXH+JL%<GK;HO+*H;$:NEK%K%/^\/',R_,P\^*U\GNC
MN.]LY])-]F5)]D6=.+^T*#QGW%070PQ,.@ACK"664A./#08[;4M>/GXA';1%
M<W A ]^2JR1LY!0#=E'8S=11*.JTO#G2X ,=4DK>U'\V]V7TD&*UOR._#-^0
M#S(ZU_4M<BA6IL$;-MS1+W^?^-#2G"%!"@8$@Z2((]W-P(BVHRT5CT']<E-2
M*)]>FJO%#;^A'I:!%9@.OAAH0/1'*JY5QC;8Q.[S8,[MHO#E9,.-U1HL[O]K
M;L^>/_^13'!F/$25H+\?;Z:YK=)O/KA4.G:CB!?Z4^\>TIF;:S:)!SF 9NG"
MOJ4;PD3YEVH$VG!5.9WGXH2K[$\(Y?('&C, L4"N3'4SA2N7 AZ*:L$_'CAW
MR'O O@+\)C:N=LI$ZO." M->BVL%Y4.>%K+S.7A.Z\+@D_"BX,A) LXL-=S"
M%B'A%5BKQ($'MZGD6J+4R"TX$&.,.C!G,/;6;Y=7Q7+AF)R%:5;G*>G>C2SN
M#D\[6>P?%W5..H]]$,RP\B(KEIVMA(IGN5["/V885.1SQGM4G0+,=<V+MB0V
M!\U1ZCYZY/R\%<LJI&Z#[6/?$JPP]YH.53]#4@GAYPJS?!399=@JS)(S!RZM
M"KE"WS*IQA*P2N9C UY/D*A[RG$90I].*;$,IUS^98DG\#5',N-H!@[<O)R3
MHXOGA&L.!+( KX"E $3R/8ZC\;RRS"&D=U RWR$&?AQMN3)D =B3(KW/D 4/
M _ZC1$AU:V^VO#TA-8IEXS0!1@$L+1I6;./KS LS 905R*;J+G&K(#&E8'V_
M!R/$/0;;IVSX&3801S'CM*@YP5?/IU,4+NZF'+]&SF',?S+^=*&@YZ&6!;FA
M]-;N;6>@-1N=^+4P<;O/Z.1$C2J[;MV/8Q@V7(\Q<E4![5T*4P:SG9?WCH/:
MK!W\N\ T)QZ[+<F;+IGJ8(H+S GD9+(\2\V65/&4>INR,FQ.&8J9K'"I!,/6
M0FWZF$Y[F-XF^224#1U<_UV(UA92V$91EZ$Q):9-N4QEMBP00Z3NZJ=J.Q):
MHNHT:)NN:>DRMN06*#/*U"Q2:.).*G5&5-C51JNMIM5&/KY+5W"8KI6MG,,4
M-@2G&Z+Z 23FE XER_-<JQZ*6)8Y0PFR42;5!7(*(DLFC@BA>EX)IB=I&'CN
M=99)JM359'6H$YBQA-,2]BR8$B>4;B"D$#+LH]>Q[B/K>A X(QAI&W-9O-ZL
MC(,0Q6;S_YV2G8\LGGV,>M @?QP,+DQ2STUB3>0L/&M2L$4#@Y&Y&>*D!4TF
MQ8<GH*Q1:ZDZ [B7,/<1%NIN6^QN?I?@"=R0F7\L7'NDJ:UHL<P%Y@F--QI:
M[KLD9_%+!0+@*]%Q'YE"/^18+%JX%^:MF8@WLX%=!Z'BO4VHV(2*]S:AXJ]S
M'S\>_GL1AO_>@PEXXQ!8EZ[0YZ(JI2N'JTAT&5U7GS82D3WB7CQH>HRXZ*V>
M9Y2YSI,,@ULS=T.B7T;WQV:!T5ZR!;E;/M1'\^ZI,2E28Z'>XAHPQCG/JR9F
M=VH$APY$<JQ*GTRM$X("_/*FL$7)L!R#E9U*T7!E+?J/17F?I^.;5.7JL%;S
MCCAOLY$T''\<*8!^*9P,L$A)KTFYL5=]NQKDP(8<O4RF2T!:GK!NY+6+LGOA
MNVYX8QR,H]5%O6H-S]0&N]FI!(B%9>IL3F:524=D:>V*IF& 3YUW-:A8(!5D
M5XNNY&@.>))W;-BX2_"EA@DXG*R("3>"8W [;YT4X^,"Y65')?.'8LS46;#+
MB%X/QO$^8P-'#OPQS'Q>SA1#!OR.BG6QU-E^1_6QVJO 2#KQ.@O^E7%>,8%D
M/WN',/F!:Z #1C+2X F@B&FDS;-XNV "@,N$U>^&J?XIC6<Y>1!5Y0ZW;<%Q
M&&QTLQC4<;>"JT')''>)T@5Z*A#4$3W5E?]8V]"&6@0#$&??!_ 3[!O=O=N$
MX;@<:R(13--:@)T[^M.A<%_Y 7K5*H4*&&5@0=L<,DO]0-IUCD:+'('*?B(:
MQ0^1&O1B2OD2"7+2&!9&ECBTZ1=PTN8SSWO*?18F&33=BVY<C UX)<;GB&1P
M+TKZ)H*9C<-#CILRN9>>7/@91CT<5N_Q\XRABLB<:Y(M<I GS-!0:WVMZC9,
MS6S88Q!!988.R#$U$I\HYS&0K<"6U+(+WI&$1T<112*%2%TQ-(W%L!"@AD=%
M)H/<'$)]"%^'A_ $)K!\2)'46#:B:*G5D(&9BD8+_'->X!+FR9#LGGJ&O!5%
MET$9AF-C8Y9PCT+YJ3,:GS(HX8,P[KXSL\'FJ6X,]-(B#?N]L[*M/D-6V$L\
M;L]W][8FEEC:H&JWC2X06D(=2;VU70[DMABZ*,841X%S=N>!]EP)2DHK8T%Z
M&-2WFSSU;FBM4?X)Z3XK;+Y(3[RO_1CL[8;G +-!M$<0W'AA"!R)B;R#V<QJ
M);7KL.2"<,0E56>AA!\C W&C*Z% ?V#&@]9^3KV*L&(+.X5B6T5T;?#?U$<&
M41)I=8=P1_E._^D9/>H[^25*<C)'^1\R DP>SQ[,O]$7+?CG2)?$ XLMUT8=
M=U)HV,@ECQ0,LBKU4!R9GDE+A2E3L-#A/;VPD^W<7<5\*53OJ->7*753E* (
M1,]4TMTJ9?NXU9'NL%84 IYQITKBJIME[(R[<XGGCGP\K,G;.M@6>(E5C-UH
MM2>(-C1;)I@2I#88TZQVH4_VW)6XD!HQ0ID_^.\<XG7)+Z$ !DDRLF@Q\"H=
M1)E<S?F&!*F7:$'<R1W6'CML]?2&S8;DL6M)KZSXFOV>>T_*22U[S]ASLD-W
MWNHFM%A8QO*<P//<RW.#9:.6;#6#2UXLML "-\^89%/*+MUPU62=&K6U: !M
M8=3>K&RY40 <*RH0:$@M<E3.PQ8Y3.&S><52"6:YD40['VYDRL$\0H8B%NZ!
M/Y!")VX Z]!+U!TV/&'KI'E6B:_O;^+K)KZ^OXFO?YW[> 4+JL5B?E+<955I
MK 5TD-EN8O^5$NED,B'(@0CI'?7T,%T2EEH>6HI]#&:7+.0FB2T_G=UZ^4V7
M>Z]C103A8,DH*=?;.4QW=)LF.=T&F[$ED[2QQ)%V,B)R??^65.-RS@'C\E,V
MHEIAT0$(%DAJ@F[-P#R:-Z9$EK /:%B0*8<1-)H,Y3B/(P2!T_ Y,ZQM.5?@
M8VTZ%WECB3TU(3:X 6D;>O-5;2U,\XX6S:W8METM-44ET@-YV+&QC(7Z<P-H
M;Y^X%EWS-;9FP<4:4(:\VTWI#II1,3%^S=W<&;AJ;B>[J29@G".SOR\$-T3[
MQF)XK,;G8[)HM_@"@#DK:%N "UP9,X*(()"75K% ,/\MGO5Z)QI0W$@-BX&U
M8%R9F/LM"&S9U'#GNAW1;=NE5:I_107<,=?R"P !O3U%E4OWE7@>D]V2B.,H
M7E)+YK!1J4,"5@MS WR&T /GH8,?R,URB/$4WHLBX1P9I\]A<OBHF*4@?M]Y
MEG-1;!<E<+CJFZ/D':46+>UI(?"?)T:@$R&U%L@__Y/S+HA[N6%>  ?/P:.!
M,$_&P+@T*$<L2RM6P0OX:%L0<FZ0&A75C/4T4*/0>_6"NI3UJV4CS:KY.!5V
MR1%,7DE@RTQ8%)50]UI;+!4DY X7-S"41T)SW:%[<3*K=#*O.0B,KJU!86%K
MG@J-KAHYL!K+",V<28Z61U>>+,YZ9HVK1<5HM^#T*_#?[J6(PK9)D1$@WDF&
MD$B3&Z3Z89?,?,,1 -'J4IYE"[CM5>3\FT_-%MF<2.]$MHCR-$"#+9NGZ#=8
M!N1-BDAH\Q$6EAWX<(1U>)1L".)=?HB+58N858Y?25/$"GV&H<H@L 7^X86M
M0''&HHO0("/<<-I6E0'MAD&]"<'[8\:8Q&A6K^=O95^XK%H!3T(#&-'^=^7(
M(D:FY=BE;+1)I^;736\PNX[3R?:TF9@ZJY77Q]ZC36[E9)CJB4.VLG,[_!28
MCNSA'HJ),N<N&\^EM; M7S>$>+%R2_J]]>V7L\+Q;E5CGI5VZF!RS=P=.1J0
MDV;T>":J2[-D[/ I3C+* -TF6+L7XV$R/4BL>Y3#<I)N;JI,(%WR@-_GXYNI
M@#5&:++B;RH'^)8M82Y;"!,R> R"=504QK7[S;2?9V[!E<$4K1073YU'H?&D
M4?9[RK"0@3Z"_7A\M)MSX)V#%BSQ&MGZ5M1L9(7>)M):$^DH$>#"/0*2>>@T
MV*]1:?DMKB?I&('IK.#X"#@O+OD$ZPU;$1TQJ> 5'VR4)Z;D1=>Y\CE1Y%4!
M:Y$YB8:-BJD,#5,A:S@>A)]OHC2:JQHS-(;<E[%2R9S,=/R,0V"1:<&=T5<W
M237.I;\H&'/T2&U;<X:GOD4B+$Q>IYS6<3"E.9$%TD\>G2+7JNT6^60M2Q;,
MOQQZ\L%!.X'B&CYH!'N_IQ"D7 155FY*;P4*DM18PV!8N<KR8ZTX '4\S:0A
M;2V2-&D5IYN785)6MD@)?5\*QC86;&;KESQJMM8LT+2I?8(V>\B1-"]H6?BQ
M84\%:=U*20\]\>"CL)L+/R.?W!'Z3UH[<)V$SBHIAX--RL&D' XV*8=_U7[@
MH%Y?A@W!I5<4*5@PT8FDX :,>I @XA!:X@APAV"H;?RGA/Y1'JL\OE>R]5A;
MCF2[V]["VE:"G5) PB94,PKSD/N'.B3ELE$C&CTRN"Y]Q\Y55EAW:(%1ZA@J
ML?6VAG#D"L.L>HI@=IQJRO!7^&+JNFVA>R!1#G8L,YG:KD;X?$'NN>K8$+^.
MRN:&U;(-CMJ9UZMBK%+I1\XTZ[24INM7:K+2;B[!$*+E;[@?#7'P2$D:IW\T
M!-)4>#1<E:N:)86EA,D#_UK"<UV3CV/ *581)!O-JSK7<(>9X,S[CLNTMM'C
M0GKF(%B;%VZ8/F#'9WI5*:Z3D3&2CE?76YYHJVL:&F:@,#%O:Q:5$UXT,\ '
MVJ_+7G6[33@.FM]#K#\*BB ,*B^K!/,PKJVB><2E,B&*E;":17=_<WQ/KI%<
MU/Z5X6+]"HR)?VXA_"H*8^M8\S0E:U(V1&=/:]C@',4R\)DB&DR0 88A4_B=
M 8QE]I9<.(I2C9DF+?XJ151+H3I/=0R#J%_@Z[W7A[O<(YV;$*R3_;B"T]H"
M#1^E%46Z52\^\6'/)52#?2-J5=?15=IOZI7:%+!:N<8>XRO%_ )2V&':W&,F
MH1O&AQ+)KQX3OG>$!=X2&(QD'14%<Y56;)&Z6 QC -*-D$.8SE.L*OD.K),?
MK6[1;%6G6+9^N'N(8[QT%%%7S_[3XQ@2>P0G+BNZK8AWR,RRMPL_+(DU]I,B
MT4"_S7#&<<E+4A0(S)RF:2.'@YA:I;/I9N?KG;_?@@F#%_&C5/6#;0EF '?$
M6QBIC'6HDDCYC42KW5<S84SEDA7CT!,M1TRJ4[)L5+%":A-7'&YH" 9J-13J
MUBB?)V.B'"3.L*UNR:BVWO'"OG4E%LL3C4&2IW[[# DIM!HNDUGM05PW.TOO
MK!9\:C RUA&=VTN*5H7]I:WM?K$"S4I+R=I?MWL<(UZTEE2+U"^XKM2N,*FC
M\VJK:9]F+5XTM!A+3].QV>O$/ \SB(!BTL\I^D*N6-M$XEQU$)NJA"U:/KK*
M9_D00J$ _VL2[60CPD2[O@=MRB QM#VA&5HR%,6PUG7@#8J%8]J'TW2E>6Z6
M6D,-S-0QGL.<L;LR1QJ-*I..T88=-(6C6TZS$5)&I77=ML!OD[&>9DE[H.D/
M ["\1NCBW99,-%BE=QF<C6!^^SU_^4',$&A9>VB=G%U>A-ON=YL\A1FJW>HZ
MZJ':B$:0<VGN4 N6T96L=ECKJ=WA.8A,&(%A(ZHZF]\L;;^YV,''MQF:$#T6
MJNFLJQUU*-R-W!^WR9/4&^(A5' 1FED"%W!&"KX:ST?28,2K^NOWMM@94YSJ
MEO)VN_7Z*QYND>XK]2TU5>2MOJ5=L[?1!IXV:$'[P,YX6Y4?4]MJ/$:&NK'[
M&Z>;C>T![Y&'Z%W*2!2LR(05<T;YXQ6DV H-'CGD1\;]WH0?IBCB94LEYFD3
M>=K(/<U&I4R$X%'HG>.QZ* S1'146G3D]A=N23\KW&Z@^TB@;ITVY2II@\--
MVL"D#0XW:8-_W8C5_D$0L3I_-SB2E(&N'EP%?=)9Z=PB:NF,-L2$'T,\E(0<
M8F<U&*R3[R=V4S>"8OZV&_-%@$NV-UP9?0"4\9$"-<A8R>2.P0"GAD/HB(ID
M/Z>1XP#>P1:'51(H.@-Y2LMJ[=_T&+GKO/X?UQ55H#U$6ZXBE!?!%8.^"3&?
MR.TLF,[N1F>$K"8;S"01+.C-YG&,#4;V%5B-8R98KK+A7"&$J)J2.(^3NP3T
MX-"0>)L[4YX\##4)+)36Q)E_6$6'92*_EQD:\_ GQN-Q1@IVLEEOR6)C!$I^
M0.SAA?A8#Y&+@6(6/69>562RI#?F%']-EJ/P1,%;/41N&RW< ;(F;ND[%U'O
M!U2EN%R;4/D3!<]A%)I]%,ZCDW145IBKB"XP*(I-7@U]4%L@+<=9+^H#^!TE
M)@U82#56IK-E3P'!X2QD!-.G$SJWDSER&'#(D<L2[/[!_!@B/FWLE#!I!G("
MEW05EG=#.8A!6*Q7=Q1=-] 60]#[Y/Z-@<A)5<5#I%_& N8P?CPVN!@A4&-1
MS+4J[-11N1K2E5-/8>?HJ1FA/^?53/I&"T1\V?3=XZIDW&W)AHUA'HG)WVN+
M'.R&?L]N!TY>+&MDLH"KOM1-$RT ,JO]=J)5FJ=WZ-=YT"["M%/..+$N@1$?
MTZ1I.JGPU39MB4B1Z3ZL.>!6UO>@'M<%G,=F3HE:KF'*#"7^C"*A<E\2SA0,
MB<9I#;,H9?N$P(\CQ^/D18D>/"0P9[OGJ?ZA^6RL2MZDT0#7<;C9W$C$)TK$
MYX%$'&![O)]!YH%(>I_0OH7MYT*;:JN4$R]X]FCM"N,1#56\HI%B/$!#PUU4
MUZBI[G&(4QQBE-L14CHYUL<Q5J?T9IXABU+!#^CJ_IFU>@:;\CD^L;Z,M$4[
M7(XF!H/P+5&]'5.NQ^8U51O/K67M9FGF(S?Q4M>K&"F%&D*H,)%$,&M$*QBZ
MA"$[^DQ=F1C22A*&W7J *84Z&"%;XJ.+V]<0.W:.G:3NH_:Y9;9P- ^F'M>$
M#S8G^XDG^T5PLH\Y+0H255PM'1TFP@F,[E,XV 18,V$2$UM;L76$-!^=R31&
M'QL&?"\"*WN+ T[D;)FPN"T3US3Z+0836VV'?0!8.;G*V)B:MHN%H6[C!\1=
M5MO62],4".C%&RXY/A7&PB69[=H&5:FT2E *%+4V%9&[=N-TN'1H# O7%O5_
MW8D&V$%X;%=,3V/0**#R$E>.VLOK'+QBC#T&([,JN$T("Q$4=MU>K\*I=63)
M.Z=%NE'C^[K *"47=%1PN[/].^=B.WG^5+6O;HO[A-X%J[4NH+8\U$MG04,>
M,G^;)W3EB;Z^ICR[7ZQ]P>X3VFL^WT1*3:3T^292^MB.TGJ4+B YB&KANV@^
M X,6+3;W"JPPO\367Y*YDE]TCQP4_N&.G])Z2S6])Q>7)U<G9]>#Z]/SLZMH
M<'8<_3JXO!R<79^>7$7G[Z+KGTZBT[-?3JZNSR_1+,!;L)I4"D8DN2?$ZU9*
M'TM:<NS!\]T:I74>RS4>[K2 )^<:!(LS^E]S>) I['6>EI>M!E4RI4B%Q"WK
MVVR&O:IR!B<)-PU1:9!#;:OKN>K)@/?Z/1?I,/A;\M4:H<D[3G-B45NGU-SC
M:]A*%P]T8?2;Z(3)2M *>!.%-,N<-3YU[>@[EMA0]1*2L8:%CF;E/46,QLI-
M:TKL9-4PYV.(<R$ORW:#6@ZWH+8VW& .00>NM;@*A'4"%'C8%LS X2#TK,&M
M?(B60AN"(D533>L" K29]2Y6$5))?[1@6>S/TL:F?@KB'(,5R[%$>"4) _K%
M\)FKJ.17^H/&C-%3:5FD9J;] L;A$->%?TX?#C/I"*$6Q0-48^I$D^-H+DAS
M!1O+0<,DCOH1ALO62II&"/:&7,T@_>*,S('!&X3C#!S[43;+V67!*6P>+%<(
MAV<<Z)^:<=12$A0'^/\XFF*T!=9D/HV]^H'2H1_R@!<L]OM7R*AR2P)FCR&.
M;@03GR'83K9+OR>DJ!RW!:&Y(>H)!%V+IP>,S"/PBV%MM=RR B!VAU^X.\C9
M5CB1)QVLX)2P>)%H_^-=[L(S9K.5F'89R5OP62"S!ML+$H++\+8Z=%8H:#!"
MX;8NG(.Q ]5CXL.[>RRA*W.XE=,Y3B<)/G6+1 #WI>"9B'E@AA@$M_Y,WA>6
MGAO&P*W[/9.^&)73KEMOLPB/.?5Q1W%T"M0PU7?E2'@=PC/F.@S6(B VTCRM
M[%$<X6KF=GIBSE:Y^F&G?TQ! 1%Y2)H5SGB#6&K^; C2A (2E!<S"M&G#_'-
M'MH7]#)(?,?KE KL3HW"1"3Q%=\G]QTY$1UY@HTB>0B7Q&LW5G3T,&6ENZX-
MRWDQ=G((- BQF1O:E+:R:=4.,K7-DK1<9=H(15X#H2CL*<17V1PV1JZR:BR'
M:0&V?*6C9/[>0+K^+G':(EER-5'4#A?-Q<&(]13,IMF#W3Z +)P)N'6NVT3B
MJ@@JEB)#:@&/BM@^65*GAL*H%)F(8A"QQ^4]MN#%*AJ;4.UP2&QI6.+&G]DS
MQ+5AQKI 48,_$FI_LDXLMW^R'99%A%S_;5LYYO[H1#TF,&HOUND O9A:K#*,
MB,0\%A?#[O?J<G:+CM+(^6+N>J*T<L!@8@"41W#BU=+%34UEIYWA<3K*:F>Z
M(7WUP\Q1HR$<*)EQ3>>DW\,I, !\6=PI#,(8*L1,QXAK]0A!S^,NB#N/KIVO
M*VZ_Q8G;CPR!EZBX73.NTC/#9IUFZ%?QU6S-@,#T(T-%.DP3VR[9XN%QR#8Q
MK\;,C:]($\#,DI=#+!=&RVV$AQ8>8686L2KL2U[ZL?4=E!<&=&PX1SX__FZV
M-<O^[C*$V-]B& RG@F/^3?ALM,7<H_VXT2:ZW8YNO]A$MTUT^\4FNKV);K_]
MX7DKNGU^_=/)933X\?+DY.>3LVL;S+X87&)LF^+8&\3 $Q #SW?V H7S/KW!
MMDE@**7"#;A>C=31+KNR*7KT-C']SYQ\V"V+2LS!=-$UN(G-]Q-OO&L9I/+0
M+L9J+-RP/PKA>?R[6APTA1BGQ'[-CJ24H7D58&C4*Y0Q&P1J,.**2M'9)!B,
M& "=W/W6L9;&CQK$@-&Z==LC8"@?*?I4+*7%QBTC8Q2[#<1Q (-08! )YLL(
MO$9'#5R4,LI++DO,?-(_LM&084G\>3BN\&RR_& #!%^,Z(L_+@]'_PL29B5I
M_P]8D"<__W_.3DY)0<#_7)T@F\.'RU/4"_W>V3E]JCZ+3J^N/@S>OC^)/ER<
MGT4G_WUR>70*OV*-XOT\^FGPRTGT]N3D++H\^?'TZOKD\N3X?Z/_Z;[N[/RZ
M?>VO,+!^+Q@!)F9/_OOHI\'9CR?1T?G//\.03F$L[;'J+]_![WZ#J1U<8Q(7
MGO+^='!V)*\QH#?Y^0(SO]&[R_.?9127E N./IP=GURVQW%TC;=%41!' _@;
M=.OQR7&TA=>)P^]?;G"),;X#_,_1T?GE\>G9C^]_BZ.?![_)',!-W^'KXPM=
MG;^GESVYN(XN/ES"U)]=PT#.:<1PV='U*<R=-UAZ153S/.QP3FC4E_9F$=]K
M\,O@]#TMJS\/,5X+TS6(X/9G5_!C_ ;'>?7A[?^#Q^-@8GJ&-XC+D__Z<'KI
M6QO!(' 9\<XT";04N-K1X.+B_>D1#8472_WL_>#7*YSIDU].CT_@%\?1V]]@
M:.]/?AR\!W_OXO1,EOKH_,/9U<E[?#E\,HT=YA1WR#F,_.@GF3P>.;P*/ I'
M #_]]:=3^/KJI\'[][@6ER>#J_,S&,YO.%)8!AJ9W!?VUP7LJIWVGN[W\/4^
M^^ATG)+_I1T"([IX?W+\XPG-W='YV=D)+PG/7?06QAJ]@]F!JR]_/#V#<1SA
M9%SSG7C&: +<G=?,J]2P1EWGSPF4A87^:-!P81:F&-!.P/_.+,23RMIN.*KD
MFI>9(! A&$O.3;B69$KA$03.92$%L=_=7)K1VY[- _YK007XJ<R+HEGNB&UW
M76_8YE"U9A.K3S4*PG):,$V<?0*^E F@MB:-_10L&J.Y&G-L?D1=*93"-U2N
M=!'G$<Q5&*+'[&._=T7/E8NHOL3<W.O7I&O&5*;!9KC;&/RB%,*)<I85DMOR
M&2C\\6% 5(V.C5#\"H=]FP0YC$79!=D\PWEC:S/4$"2QO.PN"4+:#1VNFPQG
M*YD<6ICN,Y>F-K7!@Z%.BY)7:[^'[?4BUPX\G+'J#OMIANV2_,[/9-%)QE\G
M_ U9K^5!,>E""337=L'3<%-00DKM(9PQ5RJ#+0%@8NH%)Z!C$[5.9>3C=F<5
M%H>Z #B633)3$1<ER33!CJ,,VQQ#^G""4XX8\SFB6/[A_B$8I-B!,_ GO*Y8
MYN@[XN3P:K/!F9H9X1735$+:V&&:%DSH6S0G#)4@2,75FOD@*\447VYBBB:F
M^'(34_QJ]S+FE);ZTV%:BR5ZB/UG?SJL49!/O=Q'ITN]_1W\=!M! @BPPN2D
M#9V PK:!'&2>LL&>KJC.5@9W<9J+J(*$J8LT1/@RVOXAH;IW>$AWL8/Q?@9C
MD=P>ELK"[&9#(6BEIQB>*M5G(U("F^Z-P(KL;ANM(Z.N4\<(:L5_J^I7!Y L
M9Y>5X6K>?X?_C+AI !QKT#8Z(05BO@!;9"2!*.28412,33*Q52=@V@<4M[SP
MU(>!\I-BU# Q -[(; 1M 1G8R4A'P<8!;XZ%@%@ERK745)TZG>4/SMSQXFAZ
M7Q$4HXYD:Y%9P:EPM+!)_^N9IJ /)<X,0J2L.G>[V63M6!"'?-KF"5AU>/^D
M,32AKE/V6Y///DX>:K5-\186UM6RLEJ!RA5F#K/<B6XSY%*$^,#P+>4DTY%Q
MN_?.'N MGDK"NNB7"(LI.8 -QW=*YO(Q/%B74L:8\69[K92.'H9!U.(V0_30
MDK?H/-&<\J^Y_:)J:>7>2;7CX->K=^ N43+FYIVVR%(RJXQ:5+08P0C]'<"'
M!)FI6Y>A 4E$V]0AI&JHIY*E\P93-IDFABJ.V('):$V+)$= %FY0JH[]RUZ\
MN[N+QS1\]2U+.8@/_N77P87R4J;(AX7FF_F>B $62S=P"82 X',VX+9:4>:O
MYATAX]'+4:H>11B2[??^\AQA"I@()X%VG#RXM]<?"MLYW*]CWV$U6I9W[Q%\
M/S<^([6-A-AA9>R7:Z)7P!TO/[*<@S\$H<<%F-@,L6*Z"$(!*K%7FRW5.J3>
MQ-+.38L<F\#XL\2MP KW^S:8P$@F!S/.FL"5<>U>F)#8EMF5E78 E-1EZ<.D
M &TF &[[HE0488=M\QK8N%1L7IH^:@C1MBMVE!/_XB9C^+2,X7Z0,7S'U:.$
MQR>)8$MO&=(VJ&UZP\=DWA=U*WBD-Z,KJ)4H%=:]H#V$0%II PGO!GO#U-8*
M(E3<0G)GQ_P3Q<NK=LM-E8P,'FE;A#2WV G8I:G)4ZL'K-U)),?DD<J<XPIY
M,) .&='VI)G(_),9&F?$4T0V&0]86Y%LU%%P35C\L=D1NOQ"SLHKUM9SC!9+
MA:<%W7"K<3IJ"XQ!B>:[H+Y<\7:0S!+;IM_3-@6Z]$LL'G-_WP1T91YV=^AV
M!0V.GT9C+I3L:,)8:(X<6.MU8= EDI@+=_:2F:+=IA:A'4<E6>68JZ1.WKQK
MER9@2<8FNTK6MCT+O8>I2,,#K]O\L*H:A_UJYK S'N-^LY&!3Y.!(9<=XGIO
M*B?T?,5MW57.LO.?QH4A*F3P*.D4.U7'E REUYRA;>7%M*]BX0ZW3B#^E]G*
M<:-/$+:*<FSN4.-$\%2D-V63";9>]1>AVYO(_U9B,;QXF5'R^V$,;SOR>N9D
M,B-BW+ H]"C..Z.45-Q0%.RW-+8'#9VW-J*AXY!87K6N!]A&:QXAW;)Q1ZL,
MFZFM&%]MS<M.LBB>7-@=8D+^3(WA.]XU5N_&MW*E->J7K#!)D+!@BP:2)]B<
MZ*>=Z#9)7&/+<TE;F'8<)W=^.:=_R&^DR3#(U>B^0N>E,&F(5DW*!&N47.>F
M<L1D@5P)A&0F^A/9./1T7O7'KN=J%[.K+!>9C]-5,-V'4,*(1VX:BVBX,)&W
M. ^UJ]Z++!CFO>,8S!2]6([N!V$'D6ZD'>4%A<>#8C<)OI:K &J1@8"[YK7
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MG#4='<LERP5GY/5WN[M1LC/=B;;PV;^!91D=$4$B/'[;F  :F[,\XFP,A=@
M!R,V,; E!_HNPL-MR5E,--?KA_IH_\HMO J7DO%I%_2(2WZ$0-)PHA"69E.#
ML<GT3LIY%6T=;CL2FG$':,]A#V*&!"!V%4$!."?4MOK5L_\,!V(^UV-0K\RN
M[6>^,U<2.PRNSS-"-$+I)Q)B;,DUY1N;LXY;U@278*,PY'7"K[QI7"KZH@62
M3QHY6,MXB& MI1[QGK=I/O9V8[\GT#H>+-D#,QO_'E<@)MV$A^D>AJ 1VQ*/
M"2XP>RWLO\*/<=TIT@5B7?G?Y)=;LLZVZ>_0L?XV+\IV]RW\(97',)F^*V*O
M.OLE4S)(#E\'[9]>GL[5Z*"Z9 29P2<[2GQT%BBGI#/%9!+6C6\,^5L$'FH6
M)I;>;!H'G"?WA(WD73%*@CZ[/(O$V*22\QU#,V@YTS/'<&EFTIY5>'9JV#8V
M'SA-/F73^=1@2US3I2&SVJ%+E*:-)+^E79!ZK$(C6WUI-RC:RVZ'(KZ.^ O4
MS__QVU1%B7 X9IN^\Z18T"HWX+@-04I^CW=3M"A=4QG) R*)6KAIJ#GKB*RB
M@)EI@^0&?Y\.D8774GSY1&#LRQ;I?3U+9H8(C$^()+0< #ZVF]X!=>)H!-H6
M-";8VR*$X:\A?%0830";1GK)\X"W3;1N88=R3N? PV^S6=1R!!1P?*"K*#M.
M3N0?G'ZOX^2T!#M(CV1J&S;(+.;E3=GJ; &6(C[ ,%*CB$$-=Q-QWP2S"YE,
MLN(V?)S_E"/MM\6SG0PO%;;"!#'W=E[L[NT]D\*TK6P[7MJQ2'EX&.;%*UUK
M2)TLO^/^D(*BZD+/!OC]F#:BG+74-BE$"Q^5"*4AZZZM8A*K'[-BS+O_P\[5
M3C1)T>_-Q5)H."-.C*!-\@G4<IHTPN8IKZ9_%77^B/'!U&_K*=H]042AL0YJ
M/5Q=!2(%&*J_,3XR*9+\ <QUP0MA9%ZW.6'%T\I5LN^A7Y/?,OF$E"3R$@AX
M+B=)Y3@(]<4H(MRE=',39_ FBBYKSQ-\<O/0'FJ5CK)9MLE]MG*?KS>Y3Y/[
M?+W)??X+N[HA@Q9&SJ>%#Q[3:H&=W"N?J,F61COV4%7HM==1@9[)8U@B4^"C
MTTXR'9"1TDMZ(&/FU"7:X*]IBCDZY&*01A.NJZ@)29$!M47_#KJ U:80?3+G
M7K:4&D2K]"[)R6LH.6.46.@-/MA63S59DW.XRS<1(CKJ)FQ*5_D(%/K(:'>!
M_]S?<C=)>&8 LM]2\.EIFA2F7L&:#<\[D)V#$>L9BWK=-1>=?!K=)@6<%H2^
M.I7K9CM:--D\EV[2^STSZ]2'V,[['S/9T>IS3=.Q?++]SJLE5^2+)1-MX4+
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M(8PX>GU\BC]]<7+T6B9Q,J1/S@[W1R?M>>R=XK#;OSY^' :P@.'K$?QN/]C
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MT*VE?83CI)/5!X<Z#'(%(!4Z$>!S1J7I]U"G:3.^NH'U7[?$A[V_251F*6P
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MJ%7Z/EC A"\J8?#P \=#$5J,FB^T93"+SH[_/#+J;[_G&W_$'-@,0I9[E63
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M>77!SM:TAKW":=!&*Z=NU#H'F")SC!99H^_$X1)*B@ _G0-'+JZJWXCCT)G
M$TMY$4YHGI8P>7^_0?+4099$%7*1M 1.N_%X:P!B[!I9-"I(?#\MD132EA([
M\]]#0L]?#TV2O"TA/4#F#$J>C<<#[>SH]_;QE<(.6!38+UW-3$ @ #\A@I$3
M2"U7DGYA0M;@O(Q0US%60C0M+I/0H450#!QF;[/S]DT">8+OT/1'6PW;=E[
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M"AYU%91*EL@\2LN 5'-*O+(0/G4;<5TH<UY@)#+"4YA><X+6;H%!4'CQ/JE
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MO]<;?BXWG/KB%-BA$Z&@LQ2M?5UC+\C0703 QJ]<V;@K_K/J;D@[1$'9-_&
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M^ZE$7^A9+>,F,%O@\+GYWAK-S9;6Y8D*\: LD\MB1B4(P.PM'"&W+\A<X7K
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MTIOT!Y.T*-*%^UD<SI&?1$F9P^A/RO/;V>(9WN:_,/^S-_O] S!9T& :X=Z
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MM@K,]DQ.8X -?L[1&TS+Q:/MY'3)3UCAY!@/*0JLO9T"JT$1C*Z5IA>H](V
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M7\_B"^63&\$4<6;B_9T ?^R"9K3?&PGF@"/(9!N#C4!!XGH9O,M- *+!J A
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MX6&T>Q#MGAY_>/ON/!H>]7OX9GO''T[/SZ+C-_R>YX/S _SCZ.!C]-OQZ?_
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MBCE**/PWC8VLU6%="*+\(/]XN'#C3J(9C39V+)@0XQYM+>>82WO^F!/9ZHM
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M@HTGP[:#-%M)3@X<@F:-%J&:I*)+*!Q* 3G/&4N<<Y&@T#I<PZFEX9$SUQ@
M#MT!+AO(DIQ/+[($5C*?HZF 8^!I)%^^M.4]"1BZX+7#?$:SB2AI@I7-\#S)
M,)H)+M:!5"5/Q"1_@/]<,O4)55%BJ(7 *-&BR%'BR1\,C7-!JG!J\P6<X>OH
M4G'"=@@R;0S/DA00[121A/B>^FOT[ENF=1FE48%&@;XOS "%01C/@AL&):/]
M)1K[)6I_.C=Q$F6Z!@6K7.+YB$NK8*#EJ #93\A;_UA0FL=<OT9FO%V/<N75
MHH!+PG$;6!95P;T0AV,GGEE$7*X9*KI$"8Q4'9<H[D$'PEE/2>[6\/)C"OMP
M[>A_/WF.1MK6BKE-T<S3;?).DG=/M\F[O];N1AO]Z9IM](&!%NSNG JVX%OX
MR[7JY)K##"ID=8\9R9@X)*MB!S_QY7ZK0>=TU<I^$[\UT&XKC,+GM^H)=! C
MXM9XD$J$/C'*$B9NGM6FC<+=B GR!K*IU O!(UD^33*E3-F#UH/TLT*CG+PS
M;R+8]Q&W+JDD19:6^%%C-.CVP0#)4+L=@CNUAR8,O*O/J=>(*F)M\]F*3F$-
MQ<'97)EQW-\MS/IRMZ=K?WC]'CU'UMT);N?MF*2*K(+V?F1_K.S^1*597_>T
M?(&74JC+I*R(*PUQ<M9;L??U;%,+L*MM02H0=#\)39V #_S4O=D%:^7N]@GH
MD/H9X!VMIQ(&7>3SRXF%(R9*ZH"P'D&,1X0'Y+$):,LW2W<[%K.M8;L'Z]GM
MF_7R$[W;&UNK.8^8WF5Y1^%]+FO9ZYA=SWEII >^]/34=8SH!"IVE]1B[%:1
MW2JPT/7NWI/'E73=&#\\E[[YPHDAYP[?@0*_&+&HBF1(N@53/#J^-#;H%IY@
M PI$KA$2Y7)JNE^I:^_K$B7)[- (,5C"V=K(YNB7'64ZGG($,8C>,7_AK823
MNYA<J^0O*O)..EZYN[.VT$EP0^2D5A 5*Y@V$[I!5&UK@&L+I03M2(KW$&AL
MKPVP2+ L9TRVC<.0E@N_1(R2##*#,@$<%-,RN4;?FKF4K>W$5W!H6-,*:R43
MK2VT-41Z @STD+;9W8%9PX=(S*<V!W;!=$JQ'GU:>PQ(%&^"3!HWQ(!:)].-
M7]:.GA8?>-@LS6BCD*YLZ'O<*'91MV&)FN/V;.VH2YV[-OQIIVYI.%(C1TFJ
MU+?RYFJU*QWI27^6$7;23=E2><-9XPV'](:<(\&=GB!B3N%(O.['6DRL)L:F
M9FTU+4"NDJ>9L A5KI;79H1^AW688T;<\TU)]Y5&EUD 6SOXZ7$5:!SP0[Z7
MF0%K0#I6V:I)&X_A55<N'22CUBG5+[$5+[>)>C[;1CTEZOEL&_7\:^UN5)[/
MUZP\^Z;T"W2%"Q4* _N5M;\86R11/9+]9^!K%/%&$7T#)SNV"IBH=&*C9.!V
M4YFPGL :-?NR-3005Y$I9Y9TT9YF+Y'RQ,J=E((F)30]%235Y2%/E3JJX,FC
MQX;/0\4T-&?^SV%W4+DBL5"_3?,A&CNX%L<:DRM 9(40RY!9J:30XO'/3="R
M<^<+-[/78V?84O/+?!7P_E<8)ZSCLMDQ6X>%T38@.CQ(J<)'G"-I0?$/HI+!
M"NW0L6,UZ(> !KUR8)CUWU!0($^%T4IF\-<'CQ\]7PWYO;MCH-\68-XQ?]HD
MZ-Y[WM'\ J-I+6EC-"8&^56C<;=Z8R@K[5N8#,_&#3KW+3N6K2A/^"4;F6Y4
MYL0_;G>SK[I WMMS@-<18+A.L$2#(S9@]+DA=RHFC6ER;K1HV0BUW#,:U*AO
M0(]!-Q?^@2Z\;W-;3'*:L]]A%E7;P=9U< ESJ=U!E%;"RV6*9KLW;L<F<N<8
M4?HXR8[GSUOKP\&!>^Y"YP/:^F'G-OD"8;J[L\*F_")!2F@W"Z&0J3;3:2#6
MO!1$6:H/V!<&9KCDQX1'.$2CV=) !^8FF.%0$DFTQ><S>@.%7[7FM7/5!N^8
MRL#G@2828[A5^\YLB8CNE:FKLT@W=HW$?^1<< ["'-DGCQX]A4?JX< C=?W2
M+SH*ZE9IY2Z+^')!'"YIQ4&$4U<VXF5Z+!U%U\$ G,&DFCO]7_3NQ 7*B#N=
MZX+PB0F% BA*F9FAL.R'FR$8IU">7%$,RE9VDL2,651B*%1+$*U Q!:HZY#=
M'5>8;CW1FJW^\YIM]2/#PW! T<K=G3.*I&ZPOM@UO3N"4PXG"!*9<"2%H69"
MY]XFA>"@&!="QIH,K@-WCUNO/@K?4T"G*6$\-$^AJ"^A#KK:6+6#<RL-:6FJ
M<T.&KP=YO21]3]4/:X,M-Q-.DL37U8$@?L=),>45IH&:!0>U9GHAZ4B8C-;"
M0;Q+8[O$,)&,_+NUE59)V),2<9)B6B4I5=M('8_82K6:5/OE&Y(F2%Q](\*M
M+MLL\(HRT:L"K_QD"6ZC@-4=8U2PIE"!I1:EH^OY>SD6IDR[=.6*-*_JXFRF
M.^DG^#BG*J<#DTXTR $T6*.0BJI,!2ZW3/'P\UG8O7XB'<(U1/>W!_(V >_G
MVX"W!+R?;P/>?ZW=C>KF'VM6-U2'CH5X[*E'!KBA";WJ)'/?@&L0;#7)%>K"
M;R-<M7G8F99<FJ'5J5A=&>Z^I30K<6:AS7R"8958H8!/,B72V_*@(%*Q5..Y
M3:*NL\:>VC>M6F3?S65D7E?W$_)1UJ.)RVCD!KT[F>J[.U)F8^FA0\W3L0JG
MBZ5$%W(7VPAT22BY.^SNP'\J)OR@JR7E[>4(*'7$2VR%#)THPW1226^ZD QI
M!"_JZDO_9&=<R@RVB:)::FK65<JE'.\2ZAL'QTHK0#UT."Y&?\?,P)V,-291
MN ;JG5GI@/JW%D*R:IL*[_W5G W^[=3(NL-LC?8DZT]Q*M-/P<2U]#HRS[HB
MVIUY&FE:_PH):A9._ BGDL(MKEAR<E7)V.'2<NPK^T"L?UMUYH(-3IS@GSIG
M+MYSNB;4V.-M-9U;@D:%O 5UDR ?4@X9Q<^BM.R C#@\,"MYO YK(WNU&KB!
M_TP3L$]*/"48G<UMZX_@E(A'-0<&@TZ=M]W=N:_<UY5W8=B+[I<E=838L3TU
MI$V^HPR+-D7I.P/[BP[54&.G:SD>8G&E)@\DNTBX-Q%(+9EH.$;,KS'X@<ZW
M#7U\O?7.><O[XST=F28.*U%$N@'@(E!1D2;P-\Z5"XCIE)F%\V.9A.B:\@3.
MZ(PZ6X+T'=;2(,T4Z)+GMVF>FGL*;4@LL_GA@Z:;H2AZOEF*HC,E;9XDRX7[
M5%C=$0EZD&-A1D;"OEVM>T0];U!\SS<9D*T;CI,(2U;85JQ1)8@-TQ7WC&JJ
M62*DS5 #%4-GHJ@ETW)J-<B!O8/A^[^/&5&, M<ZF7A^X?(W-PC""KT*TE.)
M%Z"#\]KIT4P,E9*#=^:"K+L.YB0$_W.O(K)I$H%I:,X]DN0(O/:_ ^LJX;TS
M%A8ZB'H9N(G3#?1K6K A 5NHDWIR@27=:R O5,5%?+J'AW^$;*-0S5K7*V"B
M$/Y P8TP:+ZI=[J6<L %0@''S<K,+=F8,8:I32URAY1,L2VP;(Y7'Z!/)9)U
M#$H652#..SZ1YF,T2=186_U72ACW2%U<*R)5]#]D&K'E'\4Q[-*2[F]:&</;
MJ+T:6[4EM+-+UMI4,"W.&V-I@Y@*S0+$I#3S01N%K$%5R;8AE4KJ?D)$B0I6
M)3<-@#!;BP%RG<8;MSCW=G=@VD;*"A,R'[B?;>?Z7$=EA_SX@9HC;$:;_;Q9
M;78@W8Q=Q>776HQ9^F9JR_19+ELMR+37[XIUE-\:+,'<G73^*FK7"F<J&5>X
MU>\_?K['[$/DUU#0N:(C4"&5IM_BKYTN Z'ADP(^3,7.+HF,E<5+EV216LN&
M "&[<35V3:1M9@0(R4W0+$FCN"_.%9?5:!J-E60V.QZ4\B(G11[0FAO**4K=
M>&<20\N559XL8FNTMW0=:-9\[*1A'7S0(B\U%CFK>,;6PU#OJ&!:(57P\S95
M(*F"G^]FJN"OL9-75[&__&D<1C?\U:]&WTK5ZLR"=:HX_+*Z5]5TGW2Q(U$=
ML,QEI<3/X=+.A .,^353/1@:D'J\R79--.#^,6(R*#)&KB#>C<#'U() (G$Z
MWL:AGBC&")&B]O A!:QFEM.J'<@=$2NX0.[<A#7/"Q4/UGIOEJQJ,^H"S)Z:
M1E%BX^C<K8[GD97U4*"3M7=CN1CBKD<^F=P> V1H(#F-C-\(AK5G(3,(^^.N
M-()039//!NP:LN-%'^<C4GT4@,8/BCG'M)Q^G-[ =L-=HZJ*+._H#2&S3J4#
MCNOL=: Z/=6XPW-"!F7'=;K%31NNE&<%ECA3JNE,(;+K%MY4T.5,W>8%VMZ5
M69,[:L6L+OO_\5W<JV\DY1N],FRQ:9=GU2'9=:J%BJ2DTQD::2;N!*9<DF'"
M ?MXEW7_!S,DR'R#PI.>-XLHR8O!_!$.OYERK24NN7/T\CBEBW 4;'C(_L%0
M!9])YF "'+OIZIP%5C<DY>TED*WR;?DAA9K"O#;EAR7/-(\.VXXJE?FRIUJ1
ME_IHKTYW<QMW%171C1I.(%R$!$."#E^5UE!Y=#CZJ@TEWGKEF[5S/2?&.IJ:
M(M_/&7E!FZVA8_?"]O3S2+E/.K\JQFBC2_10*U(53E^V6,&QX;09?J,5L0OC
MHZLELPTZ!6\FP]-35UK\FQ@5'<LP:AR<8!Q=Y84_<9JW"5?$B.$)V-TY(LO%
M\^ZX][C]8V@2A33?9,.$S.4S'K.-I?Y(RLI=EYJQQ 89+]20R7*X7Z*\8MU
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MH*]\\K,D6S*">Z][Q.FEXA??ZH'K?;VG.&=+GP<'Y6AP?!B\/3K9[QT%;S[
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M6&(#KF^M2V_*,>I1HNJ?9!R.7I7[*]E]JT:"DG8P,$^W$^EE5F 'Q2W)BJ.
M#1:08C,9TV;(2X9DUL//D;7]D,:3/,-J48@^:;LIH:9JHT\N.:P.-]F!7A
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MHYJ/_K/62XL.JH&2JBAL1T[)P(4X"%T8P*KT+0NY#TK$/62-_[=6UCAQG2#
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M/GB=25MT%<DHF.;HV["IQ-1+U=6CNND_J(^C\9]PGDN3XBF.$\I7@.??A2E
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MU LU[A\?]??YQ^%'T#XF@]%0P3#[A[W!.]4;#XX'PS=J=#)!F8^/' R.CTY
M!0!=!12789_?H,%J&D] 3]/4QSC@:.]P\*:'#P-$".3)\* _QE]0JSGJCU^/
MQN]([Y&)X)_C$UA:ZQ @"+]@:U*YX/@LGL8WM^7RI"19_J9=F<A((Q)M!T?I
M*F/D.UYQ(@$I$LXYVV*FXHJN&??=VRQ.38*Q_D*7S.>7 :9?QQ)<8W4$^0]Z
M/[J=*%R$I]JV\; ?R6@!T9L&TK'2=/,C[VC(V=SR](J2@(W$Y)H,HQFF8@=Y
M5E1JFP))=]@08<14<I-<"KI<EF--72/@&A;N)2H_LCF\]=A9\X8J[H0%1IV]
M\D>;\C*':W34Z\^U'IKU:(+T?B3]C+MP^<E%7%6'SBL4*JRGNJO=O_+*;4S7
M7JGYH/OFR9YL)D[G.KDTT9H *[8PV"!HYQM[*&/ @]]=9L+.!3CLH;LQU):_
M  >['ZSVWHF&];8!>Q<7,S1-4IU5:W5=U<.'R&.H0EX78@66U'#.1<I6*O":
M 7G\>8%5F[GOUF$7%<=A6BJK[-6UUJ>%%8UPF*AU]KFV26[6 +->7U.;9=^4
MJY_:VQL%<GI;8Z:8TN%Q2^]]_W:_+&^MI+#MG5K*>">45D W#4F KFJT>;/E
MMRDG4BRP?6&A9[:>H+5E5V8*)]DX\\9?'3VF>T,6IK;#ULOMJ/UPZ:I(K?T?
MB@_<69?VML'6V>4>8;-^[+QYCEDH_DR3,^^^8:D<,C<=NWN,+0MS]0TNQO%7
M1;Y/SPU@VI'!H!7V\Z8LTZ3"S<&#:_T1/(%,M^&*Z^&*ZVV5L^^U[%@K4ZPY
MH.J!-[Q/CN5X2U,/O+?&*\ Z!;9S2A&NA7^GH$FEN*;>VL7';8]!UW&;DG2Y
M08&K?V[70_SKXP&!>S)SC^!!%)H[Y/W;<GP_O6F?VNTTVA;P??)A<7;M[;/N
MX&)N0L)ZL-&6*7SI)1MZMSVUU.<C9(Q?"TN@8$W 8/ VHA!7$UP5OZ#6>39C
MJX:%VC80-%Y*A0-)V$R98?&PC-#MM R!"SYU\K$-*T:#M*U.3-H=HL432"Z,
M@Y<>I'S%@*372]VC>![]MHM%!AM$V3^[@A\2C(P?]O::B@$1Q6Y/O,EK#2QP
MSD]@C AIFCZ\AB9,C1W6/G*D'0ES#D(D1A;=['@AE'--YXO[P>[N'7M>;VUS
MWR0@8*>*=?+G [[H4;0FEXGE H;H<EM5F^!TSL,97?PAZ6+2CEP:J6IRMG.^
MDCHZ>(UV+# $OD!V)<V"PIR1#PIVK6#]Q((DW94H@8*#"\VTVMN8DTXO]]5R
MD]D+@)#%:#(U4!T&_2OT Y0F18I5<P%%DJ<P3TQ+HH1I/8Y=OV.P/9SJS!H[
M"1R3T$N);5SV+&GX=)'L+6;^D0?<^5*_^U&]A?/]^<;Y;ISOSS?.]Y^8EO=>
M#<B;.^P?'ZL/Z*<=O0Z0T[//J][Z>Q:295=GQU)!8%@EM:YB=HJ?K.I$-P7+
M'?53;,4GO&;G)V >D][>85_M]P\/CX]Z^X/AFW\]>/R /A_U#@[,YZ^&[B*.
MRC-\]/$O]BB3TV%9 $F;_ST@2GPY&9L)L(,W)@>9E0"Y/S#4.CDP3\G@SW'L
M%>%JUC<YN/+%WUM?O$--8N]5[UU_/-CO#=7>>/!^<(QQ@_W1^&@T)I]^3>$"
M0.&O,:/B$>W'J[OJJ/1T?1V;/&%PGVBHE3[N<._W+E_X.^M(<'^$V!G^Z\$3
MBXJ;19P'K*.1;S\NMSL=MWOLV2]W>618<K9CKC[OT]]^^2_QTDX":Z:+"3H/
MVDGCNZWFIB_O:'*?U.\0@SW.'?H:'-X=-_V;R<W;BLD[EHI[@]&?_8^!&@SW
M=[Z'#+QS]7(C]#9";R/T-D)O(_1^>I[W,PF]P\&DK]Z.#A%%[=)/P-ELXD9P
M;0371G!M!-<_E^?]=()K[_W@APNMC>&VD7\;^;>1?QOY]WW9Y[51\;9P^NUR
M!/[852/.V7VA#L.B_#LE"ORQ&MN_*M .2'JT-SKXB'O^Z.WDW>&K_P=02P,$
M%     @ R8-85H839JF $   SU4  !H   !E83$W-#$W.&5X,3 M-U]A8G9C
M8FEO+FAT;>U<_T\;.1;_/5+^!Q]25R %:*'MGB"+%""EN:,!)6&KU>E^<&:<
MQ+N3<=:>(<W^]??>LSU?DH&D+=#>TEV)9F8\]OO^/N_92?/]X,/E2;W6?-]N
MG<._#/]K#CJ#R_9)<]_^"T_WW>/FZ=7Y;ZP_^.VR_<O62,7)$7OU<I:P@9P*
MP[IBSGIJRN.&O=%@?:'E: M>A%>O/_>]8S;E>BSC(X9#7QZS1'Q*=GDDQW!+
MR_$DV3IIGIZT/TWD4"8PX=[/S?U3(/OZ,18,1)P(O77R4SPTL^.O7V0W43-:
M*+LQ5$FBINY>U=+ ;//F9-!KG;<_M'K_9OWVV4VO,_B-M2YZ[?:'=G? FOLW
M)X\HA-]3D\C1XN&D</\J@XDT[%Y^MQ,<\E,4_IFJ8Q2.YJ& J?^HU_HB2+5,
M%JPUUD),088HG)\T#=UA\!J)581,QHEBW# U8N_$4*=<+]C!88,=O#PX9,,%
MXW'(AB*9"Q&SYKLK6-9Q2T0GFL=FI#1H+IW-A ZX$:2KUNFO9^RT<W7]OM7[
MT&K4:YWNV1XJI]'<QUE.& ?QW/*0LT#IF=(\D2IFVSDW.$.1Z :#:7MC$0MV
MEK]!4S*<9#KC\0+8\=,!;VD<"LV2B6 1GQ.+ R[G/*[7"NO0E(6%D.,&2]18
MP(N:S64R84A+@PD>3& I]^H%L)XH77@K>ZE!:Y;'F9P/' J\7':ZY_7:Q>75
M:>N2O;OIGK-.AUU>,V1INS !T'@ID).B-/;^#D;N;DI@#B=]N?=&QF0]']^W
M>^U6WRIWEFJ3@@Q!O/5:,N$).Q,ZX3)FSLHE4'&=ZF "QI<;/ O)!JQIHSCQ
MFH%V!%PO&38^=GJRBH1K*W.V#1/P*7X.Z1$L*T8C$23UVDBK*4N 9Z",_BWI
M'=36OVZ5W,Y.#0P$&0.QA"7/5'P+=^0P$NP:)I7&*'##KDJ$XV*9?KMT3G6]
M!K.-^"U,YKA=1SY;2STN7W; PKP3G!=%C58/JOY#>*9 +C+F<2!YQ'@ ?CE5
M(;DJO'#+9<212URR(/."BND^A*:I(7H#%8?2OIU8WLG5OI%=>J=X[!RSF6/D
MZ@#U&XA4423C<:8/?'RG*I84 -J<:74KT4P@G*.9X&,PX,P?T!P:;)@F3,71
M L*]LF,R#4%@FZIX7*\IU)1I6%,OKF(F/(K =&X%$Y_ =Q-GE*&(Y"UE(T>6
M,[(E7UE.:8W[7!QB/-Q?,7+O# VFA4GP]4;)/_*[!A):1.O (_0KY&HN(<2
M%.5(XI@E=[\WZ7ZK6/I]V>Q2,!>5:BW:# 8:T$,X=@H:X_T52^',^'DD 1N3
M>!O.4!&$V2@"W6KP!K2-4(!WB+!>&XI(S7>^65SY?C(M2 R\.8;L .Y<KQ'T
MV51'>3)PKEWT;$9(-=?$ZH2XMM+D] J<$$"<C3I>K9C@G%ZK+2 C]B:6^+2/
M;@RX /["[$A+OOS5:"0#\6P=LGOU$69#Q;^[ZK6]ZNLUT+V!#."@N NI,RT
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M*JC7O*SH'9C71JJ5K AV0MTZD)E,(/[18)O(O!B<&!UM(PBQ<'6G/"R#WMT
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MEVLM@AWVLT,<-N%UREU%*SHUI ,F>>>.=G> U$%A\\B5S@5#6J]-FAX 2YH
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ME@.XI>5@F&X<-TZ.6Y^&LB=3F'#GE\;N"9!]M8X%0Y&D0F\<OTAZ9GRTYD6
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MS:.D\9J!W@1<SU@\/G8:M"J&:ZL.M@D3\!'^'M$C6%;T^R),Z[6^5B.6 L]
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M3&&MO]#)"(GY$1X6S+LO*B\SA1U0DL>Q(\$31"4#B .)\]D1F=OBF798UP'
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M8J_7O'QH-,QE8]-<'@3;H 8=R$FF$/%HL$U=GG4G.D=/'X(J7-TI \N4=S"
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M"ZN">$YQS5O$O^P.@ +ID+3.^61ID_!ZLMNR@0-R,).9XA:>&6<VI87<-O4
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MN(^1N=B]J=M7M2^_9+5_BWZ?M;A)\>\R/;S8SVLJH;\P%;+[<OQGS_V>)WR
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M!8&.0OP'A4S&T<U[KI, +)$GM.+1BIN"D^&+74U"&( E4CE,!@?%MT@2ATO
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M[2@\</D8EC&C@$Y,Y#;@A#1D1^1N$=Z6#P<6^=EH1#6#SBI'!+99ET-U7]O
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M,U!/5&J@J:_DC3? 40#6S; C6/0;CPN?2]0)"L1@S4''U5D)QM_##<\M/T@
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M$IY!)1Y8"H$)R%8^O-&P7O6H%%PG&(65,SY;3:G+ )=KBQ,)#83Q%!4*K"K
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M &Q3A;TM8BZ5 ]^G!(?KC@6C39T QQI(K10Y8TQM$1*G"%8+!Z7.< 8LZX!
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MI&2ZR7U^G.05GG*8Z\VN<I:T01PJ\%TP<TQ)-%\0#)=B>>U<U_0I0/%%N1G
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MV_O,<IJ9OGVSA'UL-04VY\[Z4],US+*X$43-ILJ9;H&GSUU5XTK9'%JMN._
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M!C;5/SETW//<'(FR<F<NA^)PG0U:(M 5(IFLWL8<;KUW#6M,[=!1#1J==GO
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MQ_LG!Y_>X%_>C=\?O?G_4$L#!!0    ( ,F#6%9#EKA.;@X  ( M   :
M96$Q-S0Q-SAE>#DY+3%?86)V8V)I;RYH=&W=6FUO&S<2_BY _X$->H$-K&3)
MJ9/&]AGGU\9HDKJQDZ(?N;N4Q'JUW)!<R^JOOV>&7&DEV3@4J(.KBP:R=ODR
M',X\\\R,#M_=?'A_U.T<OCL_/L.GH/\.;RYOWI\?'>Z$3[S=B:\/3WXY^UU<
MW_S^_OS?+T:F]/MB.*B\N-%3Y<1'-1.?S%2627B0B&ME]>@%)F+JU5^==R"F
MTHYUN2]HZ.! >'7O>[+08SRR>CSQ+XX.3X[.[R<ZU5Z\?=L?OBQ35QT<[IQ
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MR2=I,I<MKW3Z7A"IG[CE]=$%R#*+(]OWR%0:B ^CP:<26\/M,)NHM":?I(R
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M4""'<DJ"X+>1T(DMYC<@E>#O):)E3GR>JP5^GK3^ICU/<4\84A)\>7$-%5_
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M=F-B:6\N:'1M4$L! A0#%     @ R8-85OMLO@FS+@  9_8  !L
M     ( !*4(  &5A,3<T,3<X97@Q,"TQ,5]A8G9C8FEO+FAT;5!+ 0(4 Q0
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M8G9C8FEO+FAT;5!+ 0(4 Q0    ( ,F#6%8&!UV%0D,  !.' 0 :
M      "  8?P 0!E83$W-#$W.&5X,3 M-5]A8G9C8FEO+FAT;5!+ 0(4 Q0
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M8G9C8FEO+FAT;5!+ 0(4 Q0    ( ,F#6%9/,AM-4D8  !]M 0 9
M      "  ;.) @!E83$W-#$W.&5X-"TQ7V%B=F-B:6\N:'1M4$L! A0#%
M  @ R8-85D.6N$YN#@  @"T  !H              ( !/- " &5A,3<T,3<X
H97@Y.2TQ7V%B=F-B:6\N:'1M4$L%!@     1 !$ LP0  .+> @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
